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Summary 
Human tissue transglutaminase (TG2) catalyses transamidation and deamidation reactions 
through a nucleophilic cysteine residue (CYS277). TG2 activity was found to increase in 
celiac disease, cystic fibrosis, neurodegenerative disorders and cancer. For this, TG2 has 
received much focus as a target for drug discovery and many inhibitors have been designed 
and tested. The most important of these have an electrophilic warhead that reacts covalently 
with CYS277 resulting in an irreversible inhibition of TG2. The work presented in this thesis 
aimed at the development of computational methods that could aid in the design and testing 
of potential TG2 inhibitors. 3-D models of TG2 active site were developed starting from 
published X-ray crystal structures by means of docking experiments with known irreversible 
inhibitors followed by molecular dynamics (MD) simulations. The models were validated by 
additional docking runs and MD simulations involving a larger set of compounds with a range 
of activities against TG2. The models performed reasonably well in the validation process 
and were, therefore, chosen as active site models of TG2. No straightforward correlation 
could be found to rank the compounds based on their activities. This was the rationale for 
the next stage of the work, where the mechanism of inhibition of TG2 by two classes of 
inhibitors was studied. The covalent-bond-forming events for the inhibitors bearing 
acrylamide warheads were followed by applying quantum mechanics/molecular mechanics 
(QM/MM) umbrella sampling MD simulations to the reaction. The produced activation 
energies correlated well with the biological activities for the inhibitors and a mechanism with 
an oxyanion intermediate was proposed. The mechanism of inhibition by compounds having 
sulfonium ion warheads was investigated using reaction path experiments, where a 
transition state was first identified and verified and was used as a starting point for the 
reaction path. The activation energies again produced a reasonable correlation with 
biological activity and an SN2 mechanism was suggested for this inhibition. 
On a different level, two allosteric inhibitors proposed in the literature were docked into an 
allosteric site in TG2 predicted by a collaborator from the University of Strathclyde, and 
docking complexes were subjected to accelerated MD (aMD) to inspect whether the binding 
would induce significant conformational changes in TG2. The binding of one inhibitor in the 
predicted site caused bending in TG2 structure that could be a starting event for complete 
TG2 inactivation. The other inhibitor seemed to produce a similar effect when bound to the 
original GDP binding site. An even more profound conformational change was reported due 
to the binding of GDP in its original binding site. aMD, for the simulation times used (400-
1000 nanoseconds), was able to represent some large conformational changes in TG2 
brought about by the binding of allosteric inhibitors. To sum up, the work presented in this 
thesis was successful in applying various computational approaches to the analysis of 
inhibition of TG2 with irreversible and allosteric inhibitors. 
Key words: docking, molecular dynamics, umbrella sampling, allosteric inhibition. 
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1 General Introduction 
This chapter of the thesis gives an introduction to the transglutaminase enzyme family, 
human tissue transglutaminase, its biological functions, regulation and role in disease states, 
the available classes of inhibitors and their mechanisms with example structures, and the 
different computational techniques applied throughout the course of this work including 
molecular dynamics and docking. 
1.1 Transglutaminases 
Human tissue transglutaminase (TG2) belongs to the family of transglutaminases (Martin et 
al. 2013). The family has an EC code of 2.3.2.13 and the other names given to the enzymes 
include protein-glutamine gamma-glutamyltransferase, fibrinoligase, glutaminylpeptide 
gamma-glutamyltransferase, polyamine transglutaminase and TGase (Gasteiger et al. 2003) 
(http://enzyme.expasy.org). The enzymes, in general, are involved in the post-translational 
modifications of proteins (Martin et al. 2013). 
Transglutaminases act as aminoacyltransferases, where they catalyse the calcium ion-
dependent transamidation and deamidation reactions of the side chain of a peptidyl 
glutamine residue (Siegel & Khosla 2007). The amide group of a glutamine side chain acts 
as an acyl donor (electrophile) and a primary amine from another protein acts as an acyl 
acceptor (nucleophile) in transamidation reactions leading to the formation of an isopeptide 
bond between the side chains of the two residues on the two proteins. In deamidation 
reactions, water acts as the nucleophile and the result is the conversion of glutamine to 
glutamate. Both reactions proceed with the liberation of ammonia and the formation of an 
intermediate thio-ester bond between glutamine amide and an active site cysteine residue of 
the transglutaminase. The intermediate acts the initial electrophile (Figure 1-1). This catalytic 
activity is inhibited by GTP (Badarau, Collighan, et al. 2013; Siegel & Khosla 2007). 
Cross-linked proteins resulting from transglutaminase catalysis strengthen the tissues 
against degradation by chemicals and by proteolytic enzymes, since the bond that forms 
during transamidation reaction is an iso-peptide bond, rather than a peptide bond that is 
sensitive to proteolysis. The structures are also insoluble (Pinkas et al. 2007; Candi et al. 
1998). Therefore, the resultant proteins contribute to the stabilisation of hair, skin and blood 
clots (Badarau, Collighan, et al. 2013). 
The members of the transglutaminase family are distributed in various tissues of the body 
and within these tissues, they may be located inside the nuclei, in the cytoplasm or in the 
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extracellular space. Their deficiency or increase may be associated with various pathological 
conditions. A summary of the locations, biological functions and the associated pathological 
conditions for the transglutaminases is presented in Table 1-1. 
 
Figure 1-1: Reactions catalysed by transglutaminases. 
All the enzymes mentioned in Table 1-1 are involved in catalysing the formation of complex 
protein structures through transamidation reaction shown in Figure 1-1, with the exception of 
band 4.2. The latter is located in the membrane of the erythrocytes and has an alanine 
residue instead of the active site cysteine, making it useless with this type of catalysis. Band 
4.2 contributes to maintaining the shape of erythrocytes through mechanical support (Odii & 
Coussons 2014). Another point to mention regarding Factor XIIIA is that this is the active 
form of Factor XIII. The activation occurs in response to high calcium ion concentrations 
(Muszbek et al. 2011). 
1.2 Tissue Transglutaminase 
Tissue transglutaminase or TG2 is probably the most important member of the 
transglutaminase family due to its widespread distribution in the tissues of human body and 
its involvement in a variety of disease states (Badarau, Collighan, et al. 2013). This is the 
reason why TG2 was the focus of this thesis. The following sections will include more 
detailed information about TG2, its biological functions and substrates, its biochemical 
structure, its role in disease states and some of its established inhibitors. 
 
Protein-1
TGase
+ Ca2+
- GTP
+ NH3
Protein-2
H2O
Lys
Protein-1
TGase
Protein-2
Protein-1
TGase
Protein-1
TGase
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Transglutaminase Other names Location Biological 
function 
Associated 
pathology 
TG1 
Keratinocyte TG, 
particulate TG, 
TGK 
Keratinocytes 
and squamous 
epithelia. 
Cytosolic and 
membrane 
Cell envelop in 
squamous 
epithelia and 
differentiating 
keratinocyte 
Mutations cause 
Lamellar ichthyosis 
(Odii & Coussons 
2014; Candi et al. 
1998) 
TG2 
Liver TG, tissue 
TG, endothelial 
TG, erythrocyte 
TG 
In many tissues, 
in the membrane, 
cytoplasm, 
nucleus, 
extracellular 
Apoptosis, cell 
survival 
signalling, cell 
differentiation, 
matrix 
stabilization, 
endocytosis 
Increased activity 
causes 
Neurodegenerative, 
autoimmune, 
malignant diseases 
(Facchiano et al. 
2006; Odii & 
Coussons 2014) 
TG3 
Epidermal TG, 
hair follicle TG 
Keratinocytes, 
corneocytes, hair 
follicles, 
cytoplasm 
Differentiation of 
hair follicles 
Loss may cause 
thinner hair (John 
et al. 2012; Odii & 
Coussons 2014) 
TG4 
Prostate TG, 
TGP 
Prostate gland, 
extracellular 
Reproduction 
and fertility in 
rodents (Cho et 
al. 2010) 
Increased activity 
recorded in 
prostatic cancer 
(Jiang et al. 2013) 
TG5 TGX, type 5 TG 
Mainly in female 
reproductive 
system, 
keratinocytes, 
cytoplasm 
Keratinocyte 
differentiation 
Increased activity in 
hyperkeratotic 
ichthyosis and in 
psoriasis (Odii & 
Coussons 2014; 
Candi et al. 2002) 
TG6 TGY, type 6 TG 
Testis, lungs, 
brain, unknown 
cellular 
distribution 
CNS 
development, 
motor function 
Spinocerebellar 
ataxias, 
polyglutamine 
diseases (Odii & 
Coussons 2014; 
Wang et al. 2010; 
Guan et al. 2013) 
TG7 TGZ, type 7 TG 
Mainly testis and 
lungs 
Unknown 
Unknown 
(Kuramoto et al. 
2013; Odii & 
Coussons 2014) 
FXIIIA 
Factor XIII A, 
fibrin stabilising 
factor, 
fibrinoligase, 
plasm TG 
Platelets, 
placenta, 
astrocytes, 
macrophages, 
heart 
Wound healing, 
bone growth, 
maintaining 
pregnancy, 
improving 
vascular 
permeability 
(Muszbek et al. 
2011; Odii & 
Coussons 2014) 
Deficiency causes 
impaired wound 
healing, abortion 
and severe 
bleeding tendency 
(Muszbek et al. 
2011; Odii & 
Coussons 2014) 
Band 4.2 
Erythrocyte 
membrane 
protein band 4.2, 
B4.2, ATP-
binding 
erythrocyte 
membrane 
protein band 4.2 
Surface of 
erythrocyte 
membranes, 
bone marrow, 
foetal liver, 
spleen, found in 
membranes 
Key component 
of erythrocyte 
skeletal network 
maintains 
erythrocyte 
shape and 
mechanical 
properties 
Spherocytic 
elliptocytosis (Odii 
& Coussons 2014) 
Table 1-1: Members of the transglutaminase family of enzymes (Odii & Coussons 2014). 
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1.2.1 Biological functions of TG2 
Despite the widespread distribution of TG2 in tissues, it was found that mice, with genetically 
removed TG2, led normal lives in terms of anatomy, development and reproduction; 
indicating that TG2 is not a vital enzyme (Nanda et al. 2001; De Laurenzi & Melino 2001). 
Regarding the non-vital functions that TG2 is involved in, they can be broadly categorised 
into those that are calcium-dependent (transamidation and deamidation post-translational 
modifications), and functions that are independent of calcium and do not involve reactions at 
the active site cysteine residue (Odii & Coussons 2014). 
1.2.1.1 Calcium-dependent functions of TG2 
The Ca2+-dependent actions of TG2 are the same as those for other members of the family, 
where TG2 catalyses transamidation and deamidation reactions through an active site 
cysteine residue (CYS277). Transamidation leads to the formation of insoluble protein-like 
structures, whereas deamidation leads to the conversion of glutamine to glutamate (Pinkas 
et al. 2007; Candi et al. 1998). The specific functions, or role in diseases, of transamidation-
resultant structures depend on the location of their substrate and TG2. 
TG2 located in the extracellular matrix (ECM) can catalyse the crosslinking of ECM proteins 
such as fibronectin, fibrin, collagen, vitronectin and osteopontin and the crosslinked proteins 
contribute to the stabilisation of ECM (Aeschlimann & Thomazy 2000; Belkin 2011). Within 
the cells, in the intracellular space whether in the nucleus or in the cytoplasm, TG2 
crosslinking potential is activated in the event of necrosis. The result is the formation of the 
proteinaceous structures that prevent the release of inflammatory materials outside the 
apoptotic cells. A variety of intracellular proteins and enzymes could act as substrates for 
TG2 (Nicholas et al. 2003). 
Besides transamidation crosslinking, TG2 also catalyses deamidation reactions in which 
water acts as the nucleophile and the result is the conversion of a glutamine residue in the 
protein to a glutamate (Figure 1-1). Of the glutamine-containing proteins susceptible to 
deamidation are lens β-crystallins (eye lens proteins responsible for lens integrity and 
reactivity), where age-related deamidation of glutamine residues in the N-terminal arms of 
the crsytallins can be mediated by TG2, thereby facilitating cataract formation (Boros et al. 
2008). Probably the most important deamidation reaction catalysed by TG2 is that affecting 
the wheat protein gliadin, resulting in epitopes that activate T cells and elicit immune 
response in celiac disease (Nurminskaya & Belkin 2013). This will be discussed in more 
detail in the section of diseases associated with TG2. 
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It has been reported that deamidation is favoured at low concentrations of TG2, at low pH 
and with poor substrates (Nurminskaya & Belkin 2013). Furthermore, deamidation and 
transamidation were found to be substrate specific; TG2 deamidates or transamidates 
specific and different glutamine residues (Boros et al. 2006). 
1.2.1.2 Calcium-independent functions of TG2 
Studies performed with the active site cysteine of TG2 (CYS277) mutated to serine have 
found that TG2 was still performing some biological functions, indicating that such functions 
are not related to TG2 calcium-dependent transamidating and deamidating activities (Siegel 
& Khosla 2007). One of those functions is the ability of TG2 to bind and hydrolyse GTP 
(guanosine triphosphate) converting it to GDP (guanosine diphosphate). This type of ability 
allows TG2 to function as a G-protein and transfer signals into the cells (Gundemir et al. 
2012). In this fashion, TG2 was found to transport signals from α1-adrenoceptor to 
phospholipase C (Hwang et al. 1995). Other receptors to which TG2 was shown to act as a 
G-protein are oxytocin receptor (Baek et al. 1996) and thromboxane receptor (Vezza et al. 
1999). G-protein action of TG2 is not only Ca2+-independent, but also inhibits the Ca2+-
dependent transamidating and deamidating activities (Gundemir et al. 2012). 
The ability of acting as a protein kinase (ability to phosphorylate proteins) is another calcium-
independent action of TG2. TG2 was found to be able to phosphorylate a variety of proteins, 
including insulin-like growth factor-binding protein-3 (IGFBP-3), histones, p53 and 
retinoblastoma protein (Mishra & Murphy 2004; Mishra et al. 2006; Mishra & Murphy 2006; 
Mishra et al. 2007). This activity of TG2 was in vitro only, and whether TG2 can act as a 
kinase in vivo is still unknown (Gundemir et al. 2012). TG2 can also act as protein disulphide 
isomerase (PDI), aiding in the formation and breakage of disulphide bonds between cysteine 
residues. This action was shown to occur both in vivo and in vitro (Gundemir et al. 2012). 
In addition to crosslinking the proteins of ECM, TG2 was found to facilitate the adhesion of 
ECM to cell surfaces by non-covalent binding to fibronectin (Akimov et al. 2000). TG2 has 
high affinity to fibronectin and they both bind independent of Ca2+ or G-protein or kinase 
activities of TG2 (Odii & Coussons 2014). The result is improved cellular adhesion which can 
contribute to wound healing and embryogenesis (Akimov & Belkin 2001). 
1.2.2 Regulation of TG2 activity 
TG2 is normally latent with regard to its crosslinking and deamidating activities, which 
usually require the lack of GTP or GDP and high concentrations of Ca2+. GTP and GDP 
normally bind to TG2 and induce a large conformational change in the enzyme that renders 
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TG2 inactive. In stressful conditions that involve cell injury, calcium homeostasis is 
disturbed, increasing Ca2+ concentration, and activating TG2 by releasing the bound GDP or 
GTP. This is true for intracellular TG2. Outside the cells, TG2 is also normally inactive, but 
not because of GTP binding. Instead, the majority of the enzyme is non-covalently bound to 
fibronectin making it inactive. When cells are injured, activated intracellular TG2 is released 
to the extracellular space causing detachment and activation of the extracellular TG2 (Wang 
& Griffin 2012; Siegel et al. 2008). 
1.2.3 Structure of TG2 
The PDB structure of TG2 that was used as the basis for this work had the code 2Q3Z 
(Pinkas et al. 2007). TG2 in this structure is in the form of active enzyme that is not bound to 
GTP or GDP. Active TG2 has an “open” conformation, in contrast to a “closed” conformation 
when the enzyme is bound to GTP or GDP (for example PDB code 1KV3 (Liu et al. 2002)). 
In both cases, TG2 is composed of 4 distinct regions; an N-terminal β-sandwich (green in 
Figure 1-2), a catalytic core (red in Figure 1-2) and two C-terminal β-barrels (yellow and 
cyan in Figure 1-2). The N-terminal β-sandwich is the part of TG2 that binds to fibronectin, 
and the catalytic core contains the active site cysteine residue and represents the site at 
which transamidation and deamidation reactions take place. In active TG2, the 4 major 
components are in the form of a line exposing the catalytic core and CYS277 to substrates. 
In the inactive closed conformation, the two C-terminal barrels fold on the catalytic core, 
blocking the access of substrates to CYS277 and inhibiting the transamidating and 
deamidating actions. A cleft between the catalytic core and the first β-barrel in the closed 
conformation holds the site at which GTP/GDP bind (Pinkas et al. 2007; Jang et al. 2014; Liu 
et al. 2002) (Figure 1-2). 
1.3 Role of TG2 in Disease States 
As mentioned earlier, TG2-knocked out mice could lead normal lives, indicating that TG2 is 
not vital to mammalian life, despite its various functions. However, it is the involvement of 
TG2 in a variety of disease states that makes the enzyme an attractive target in the process 
of drug discovery and development. The enzyme has been linked to a number of 
pathological conditions, including autoimmune and inflammatory diseases, 
neurodegenerative diseases, certain tumours and some metabolic disorders such as 
diabetes mellitus (Griffin et al. 2002; Facchiano et al. 2006). The exact role of TG2 in these 
conditions is still not entirely clear, but from the proteinaceous materials detected, it is 
believed that it is the Ca2+-dependent catalysis of TG2 that is important (Badarau, Collighan, 
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et al. 2013). In the following sections, a brief description of the role of TG2 in each of the 
disease states will be presented. 
 
Figure 1-2: TG2 in open (upper) and closed (lower) conformations.CYS277 is shown in both in the space 
filling form. β-sandwich is coloured green, catalytic core is red, 1st β-barrel is yellow and the 2nd β-barrel 
is cyan. In the open conformation, there is a covalent inhibitor bound to CYS277 and shown in the stick 
form. In the closed conformation, GTP is shown also in the stick form. The open conformation is PDB 
2Q3Z, while the closed conformation is PDB 4PYG (Jang et al. 2014). 
1.3.1 Celiac disease 
Celiac disease (coeliac disease or CD), also called celiac sprue and gluten-sensitive 
enteropathy, is an autoimmune disease in which TG2 plays a very distinct role. CD is 
characterised by sensitivity to gluten in wheat and other cereals. Gluten contains the 
glutamine-rich peptide, gliadin. TG2 can deamidate some of the glutamine residues on 
gliadin producing negatively charged glutamate residues. CD affected patients express 
human leukocyte antigen (HLA) molecules DQ2 and DQ8. Glutamate residues in 
deamidated gliadin can specifically bind to these antigenic molecules inducing an 
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inflammatory T-cell response that results in the flattening of the intestinal mucosa. 
Subsequently, nutrient absorption from the small intestine is impaired and if gluten ingestion 
is continued, symptoms would include chronic diarrhoea, malabsorption, anaemia, failure to 
thrive and weight loss (Facchiano et al. 2006; Sakly et al. 2006; Rauhavirta et al. 2013). 
TG2-autoantibodies are found in the serum of CD patients, further confirming the role of TG2 
in CD (Dieterich et al. 1997). These antibodies provide a diagnostic tool for CD and can be 
found in the intestinal mucosa even before their appearance in the serum, making their 
detection in the intestine a useful tool for confirming CD in potential patients (Tosco et al. 
2013). 
The only available standard treatment for CD is dietary gluten restriction, which is almost 
impossible to achieve successfully. This is due the cost of the gluten free diet, the difficulty of 
obtaining gluten free diet in many regions of the world and the fact that many gluten-free 
diets still contain trace amounts of gluten that can induce a response in some patients 
(Schuppan et al. 2009). Therefore, TG2 inhibition has been suggested as a promising 
treatment for CD (Sollid & Khosla 2011). In a proof-of-concept study by Rauhavirta et al. 
(2013), the authors found that treating cells and CD-patients’ intestinal biopsies with gliadin 
in the presence and absence of TG2 inhibitors resulted in reduction of gliadin toxic effects in 
the inhibitors-treated cells and biopsies. A reduction in the immune response has also been 
observed. 
1.3.2 Inflammatory disorders 
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding for cystic 
fibrosis transmembrane regulator (CFTR) and is characterised by chronic lung inflammation 
and infection. It can affect other organs of the body causing pancreatic insufficiency, biliary 
disorders and male infertility (Ratjen & Döring 2003). Peroxisome proliferator-activated-
receptor-γ (PPAR-γ) is an inflammatory regulator whose ability to prevent or reduce CF 
pulmonary inflammation was proven through its regulation of the nuclear factor-B (NF-κB), 
one of the inflammatory mediators involved in CF (Maiur et al. 2008; Perez et al. 2008). 
Defects in CFTR genes responsible for CF were found to be associated with increased 
levels and activity of TG2. It was also shown that increased TG2 activity was linked to 
reduced PPAR-γ levels; where TG2 would crosslink PPAR-γ into aggregates reducing its 
anti-inflammatory action. In addition, inhibiting TG2 irreversibly was found to restore the 
normal levels of PPAR-γ in cells (Maiur et al. 2008). 
NF-κB indirect activation by TG2 has also been linked to rheumatoid arthritis (RA), in which 
increased levels of TG2 in the synovial fluid have been reported. Increased TG2 activity was 
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linked to up-regulation of neutrophil gelatinase-associated lipocalin (NGAL) protein in RA 
patients (Katano et al. 2009). The role of TG2 in inflammation is not always harmful, where 
inflammation is a defence mechanism by which the body can fight back external injurious 
stimuli. In response to cutaneous injury, inflammation participates in the process of wound 
healing and TG2 activity is increased in response to some inflammatory mediators [for 
example, transforming growth factor (TGF)-β], and TG2 itself activates other mediators with 
the ultimate purpose of enhancing wound healing (Mehta et al. 2010). 
1.3.3 Neurodegenerative diseases 
TG2 is thought to be involved in the pathogenesis of some neurodegenerative disorders 
such as Alzheimer’s, Huntington’s and Parkinson’s diseases. The mechanism is probably 
related to the formation of insoluble protein aggregates through calcium-dependent catalysis 
(Siegel & Khosla 2007; Facchiano et al. 2006). In Alzheimer’s disease (AD), the most 
important pathological legions are extracellular senile plaques (SP) and intracellular 
neurofibrillary tangles (NFT). SPs are mainly composed of amyloid beta (Aβ) peptides, 
whereas NFTs mainly contain hyper-phosphorylated tau. Both Aβ and tau have been shown 
to act as substrates for TG2 (Wang et al. 2008). By its crosslinking activity, TG2 was shown 
to be involved in the formation of the AD lesions (SPs and NFTs), where it was found that 
TG2 catalyses the crosslinking between Aβ peptides in SPs and between tau peptides in 
NFTs (Wilhelmus et al. 2009). In addition, many of the risk factors for AD, such as head 
trauma, ischemia and brain stress, have been shown to increase the activity of TG2 (Wang 
et al. 2008). 
Huntington’s disease (HD) is a neurodegenerative disorder characterised clinically by motor, 
psychological and cognitive anomalies. It is caused by a defect in the gene encoding for the 
huntingtin (HTT) protein. The defect includes an expansion of CAG repeats resulting in an 
extended polyglutamine tract at the N-terminal of HTT (Munoz-Sanjuan & Bates 2011). The 
polyglutamine tract gets separated from the defective HTT and forms aggregates with itself 
and with other proteins. The resultant macromolecular structures eventually lead to neuronal 
death. TG2 may catalyse the formation of these aggregates (Dedeoglu et al. 2002). Lesort et 
al. (1999) found that TG2 activity is increased in the brains of HD patients and this increase 
is directly proportional to the severity of the disease. Inhibition of TG2 with cystamine 
(reversible TG2 inhibitor) was shown to reduce polyglutamine aggregates and improve motor 
function and survival in HD mice (Dedeoglu et al. 2002). Similar outcomes were obtained by 
crossing HD mice with TG2 knock-out mice (Mastroberardino et al. 2002). 
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Parkinson’s disease (PD) is another neurodegenerative disorder affecting dopaminergic 
neurons and is characterised by motor and non-motor dysfunctions (Jankovic 2008). The 
defective neurons in PD patients contain inclusions called Lewy bodies. Lewy bodies are 
insoluble aggregates containing a protein called α-synuclein which is very prone to form 
aggregates in pathological conditions including PD and Lewy body dementia. It has been 
proven that TG2 is involved in the crosslinking of α-synuclein with other proteins producing 
Lewy bodies in vitro and in cell lines (Nemes et al. 2009; Junn et al. 2003). 
1.3.4 Cancer 
Siegel & Khosla (2007) reviewed a number of studies that showed increased levels of TG2 
in more than one type of cancer including glioblastomas, malignant melanomas and 
pancreatic ductal adenocarcinomas (PDAC). Verma et al. (2006) found that high TG2 levels 
in PDAC were associated with nodal metastasis and resistance to chemotherapy. The ability 
of TG2 to induce invasion was related to its potential to activate FAK (focal adhesion 
kinase), an enzyme involved in metastasis by promoting anti-apoptosis. The authors showed 
that this role of TG2 is not related to its transamidating or deamidating actions, by mutating 
the active site cysteine residue into serine residue and still obtaining comparable results 
(Verma et al. 2006). Similar results regarding the association between increased levels of 
TG2 and resistance to chemotherapy and metastasis were reported for breast cancer 
(Mehta et al. 2004). In addition to inducing metastasis and resistance to chemotherapy, 
increased TG2 levels in malignant cells was linked to their ability to survive and defy 
apoptosis (Mangala et al. 2007). 
Park et al. (2011) proposed another mechanism by which TG2 can induce metastasis in 
pancreatic cancer cells. Their work examined sphingosylphosphorylcholine (SPC)-induced 
keratin 8 reorganisation in pancreatic cells as a possible pathway to metastasis by improving 
viscoelasticity and the migration properties of the malignant cells. The authors found that 
TG2 is activated by SPC, and the activated TG2 induces keratin 8 reorganisation by SPC. 
They also found that inhibiting TG2 by cystamine or genetically silencing TG2 would block 
the pathway resulting in reduced metastasis (Park et al. 2011). By a similar approach (gene 
silencing and cystamine inhibition), the research group, in another study, proved the 
inductive effect of TG2 on the metastasis in lung cancer cells, which is initiated through 
epithelial-mesenchymal-transition with the conversion of E-cadherin to N-cadherin (Park et 
al. 2013). 
The relationship between TG2 and cancer is not simple. There are studies that showed an 
important role for TG2 in resisting cancer. For example, it was noted that TG2 inhibits 
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angiogenesis in an in vitro assay, independently of its transamidating activity, and that TG2 
inhibits tumour growth and improves survival in mice melanoma models, compared to the 
same model from which TG2 was genetically removed (Jones et al. 2006). Therefore, 
inhibiting TG2 can be useful in certain types of cancers but the concept should not be 
generalised to all cancer cases. 
1.3.5 TG2 and metabolic disorders 
Many of the enzymes that are involved in the production of energy within the body can be 
modified by TG2; they can act as substrates for isopeptide bond formation catalysed by 
TG2. Examples include glyceraldehyde 3-phosphate dehydrogenase, alpha-ketoglutarate 
dehydrogenase, phosphoglycerate dehydrogenase and fatty acid synthase. The same 
applies for hormones and receptors involved in metabolism (Facchiano et al. 2006). In 
diabetes mellitus, TG2 is believed to have a beneficial role where it was found that TG2-
knocked out mice are intolerant to glucose and their glucose-stimulated insulin secretion 
(GSIS) is compromised. In addition, three TG2 point mutations were found in patients with 
type 2 diabetes mellitus (Bernassola et al. 2002). Salter et al. (2012) investigated the effects 
of these mutations on insulin secretion and found a positive correlation between the 
mutations and the impaired GSIS. They linked the defect in insulin secretion to a reduction in 
the transamidating action of TG2 initially and then to defective binding to GTP as a result of 
the mutations. 
The association of TG2 in the above-mentioned wide range of pathologies provides the 
opportunity for a new therapeutic target, where inhibiting TG2 may offer possible 
pharmacological solutions to one or more of the pathological conditions linked to increased 
TG2 activity. An imperative characteristic of TG2 as a therapeutic drug target is the fact that 
TG2 has been shown to be non-vital to mice, reducing the possibilities of serious side effects 
arising from its inhibition. Because the role of TG2 in many pathologies has not yet been fully 
understood, TG2 potential inhibitors, in this stage of TG2-related research, can be used to 
provide a better appreciation of the mechanism by which TG2 can be involved (by inhibiting 
TG2 and monitoring the effects on the pathological condition). This concept has actually 
been employed in more than one of the studies discussed above. Different classes of tested 
TG2 inhibitors will be presented in the next section. 
1.4 Inhibitors of TG2 
Two central themes should be considered when discussing TG2 inhibitors. The first is that 
the exact mechanism by which TG2 is involved in the various diseases is not fully 
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understood; it has been shown that sometimes it is the transamidating activity that is 
increased (as in celiac disease) and sometimes Ca2+-independent actions are detected 
(some types of cancer). Therefore, it should not be expected from an inhibitor that interacts 
with CYS277 to be effective in suppressing all the pathologies associated with TG2. 
Secondly, the other members of the transglutaminase enzyme family share similar actions, 
especially those that are Ca2+-dependent, which means that inhibiting TG2 may inhibit these 
enzymes as well. This is especially important for FXIIIA, whose inhibition may result in 
uncontrolled bleeding; and inhibition of TG1 which may lead to ichthyosis (Table 1-1). Thus, 
selectivity of potential inhibitors to TG2 should be verified before moving further in the 
process of the validation of the inhibitors. 
TG2 inhibitors can be classified into two broad categories, reversible inhibitors and 
irreversible inhibitors. Reversible inhibitors either compete with substrate lysine residues to 
bind to the thio-estered glutamine residue inhibiting the formation of the isopeptide bond, or 
they act in a similar fashion to GTP, where they bind somewhere in TG2, other than the 
transamidating active site, and induce a conformational change in the entire enzyme that 
blocks the access of substrates to CYS277. Irreversible inhibitors act by covalently binding 
to TG2 CYS277, and therefore inhibiting the enzyme in a suicidal manner (Badarau, 
Collighan, et al. 2013; Siegel & Khosla 2007). 
1.4.1 Reversible inhibitors 
The net result from these inhibitors is either the formation of the isopeptide bond with the 
wrong amine (competitive inhibitors) or a temporary loss of TG2 action as a result of a large 
conformational change induced through an allosteric inhibition (non-competitive inhibitors). 
1.4.1.1 Competitive reversible inhibitors 
This class of TG2 inhibitors is characterised by a structure having a saturated aliphatic chain 
and a terminal primary amine. They act as substrates for the 2nd step in TG2-catalysed 
transamidation and deamidation reaction and the result is still an isopeptide bond but with 
the amine inhibitor instead of being with the natural amine substrate or with water. Examples 
of these inhibitors include putrescine, cadaverine derivatives (Lorand & Conrad 1984; 
Badarau, Collighan, et al. 2013) and cystamine (Jeitner et al. 2005) (Figure 1-3). Putrescine 
has been used by many for assays of TG2 activity and examples for putrescine use include 
the work by Schaertl et al. (2010) and Ohtake et al. (2006). Cadaverine derivatives were also 
used for the same purpose and examples include van den Akker et al. (2012), Olsen et al. 
(2011) and Sarang et al. (2007). 
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Figure 1-3: Chemical structures of the amine reversible inhibitors of TG2. 
Cystamine is actually composed of 2 molecules of cysteamine [β-mercaptoethanolamine 
(MEA), NH2–(CH2)2–SH] connected by a disulphide bond. Two mechanisms have been 
proposed, by which cystamine can inhibit TG2. The first involves the intracellular reduction of 
cystamine to 2 molecules of MEA by glutathione (GSH). MEA then acts as a substrate for 
the 2nd step of transamidation, and an isopeptide bond forms between MEA and the 1st 
protein glutamine residue (Jeitner et al. 2005). This has been proven by the finding that it 
requires twice the molar equivalents of MEA to inhibit TG2 than what is required of 
cystamine (Cooper et al. 2002). 
Jeitner et al. (2005) have shown that the inhibition of TG2 by MEA is concentration-
dependent confirming that the inhibition is reversible. The authors suggested that the MEA 
thiolate group, by having an electron-withdrawing effect, would help in positioning MEA 
perfectly to be involved in the formation of the isopeptide bond through interacting with some 
positively charged moiety in the active site of TG2 due to its negative charge. The 
neutralisation of the negative charge by this interaction would also increase the 
nucleophilicity of MEA amine, thus increasing the chance for the formation of the bond. 
The second mechanism by which cystamine may inhibit TG2 is the formation of disulphide 
link with CYS277 causing irreversible inhibition of TG2. This mechanism was supported by 
the evidence that cystamine inhibited TG2 in a time-dependent manner (Lorand & Conrad 
1984; Lorand 1998; Siegel & Khosla 2007). Jeitner et al. (2005) reported that if cystamine 
was reduced intracellularly to MEA, then the disulphide bond formation will be an unlikely 
event, implying that cystamine will act as an irreversible inhibitor only in the absence of 
intracellular GSH. 
In addition to TG2, cystamine has been found to inhibit caspase 3 (an enzyme whose 
activation was linked with Huntington’s disease progression). Inhibition of caspase 3 may 
contribute to the beneficial effects cystamine has in Huntington’s disease besides inhibiting 
TG2 (Lesort et al. 2003). The authors indicated that caspase inhibition is independent of 
TG2 inhibition. 
Problems associated with inhibition by cystamine include the formation of proteinaceous 
structures resulting from the use of MEA as the amine source in transamidation reactions. 
These structures may elicit an immune response for being unrecognisable by the body. 
Putrescine Cadaverine Cystamine
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Another problem with cystamine is its lack of selectivity; cystamine was shown to inhibit 
caspase 3 and can inhibit other members of transglutaminase family, and this could result in 
undesirable effects (Badarau, Collighan, et al. 2013). Nevertheless, cystamine can still be 
used in research on cells overexpressing TG2 as an indicator of the beneficial effects arising 
from TG2 inhibition, and it has been used for this purpose as indicated earlier in HD and in 
cancer. 
Other competitve TG2 inhibitors were proposed by Sohn et al. (2003) who synthesised 
recombinant peptides with dual inhibitory effect against phospholipase A2 (PLA2) and TG2. 
The former is one of the enzymes involved in inflammatory processes and is activated by 
TG2 through the formation of intramolecular crosslinks between glutamine and lysine 
residues in PLA2. The inhibitory peptides were derived from TG2 substrates lipocortin-1 and 
pro-elafin and contained glutamine and/or lysine residues, making them suitable substrates 
for either step of the transamidation reaction, and hence the reversible action. The 
synthesised peptides were able to inhibit PLA2 alone, TG2 alone and PLA2 activated by TG2. 
Their results showed improved allergic conjunctivitis in a guinea pig model treated with these 
peptides (Sohn et al. 2003). The study did not examine the selectivity of these inhibitors 
against other members of the transglutaminase family. 
Another group of reversible inhibitors was studied by Pardin, Pelletier, et al. (2008). The 
researchers synthesised a series of cinnamoyl derivatives and tested them against TG2. 
Their findings showed two classes of potent reversible inhibitors of TG2 that compete with 
the acyl donor substrate during transamidation reactions, the cinnamoyl benzotriazolyl 
amides and 3-(substituted cinnamoyl) pyridines. The most active of their compounds (i1) 
was a benzotriazolyl derivative with a TG2 IC50 of 18 µM (Figure 1-4). 
 
Figure 1-4: Compound i1 from the work 
by Pardin, Pelletier, et al. (2008) with an 
IC50 against TG2 of 18 µM. 
From structure activity relationship studies, the authors proposed the importance of 
hydrogen bond acceptors in the inhibitor structures for better activity. They also proposed 
that non-planar rings can reduce the inhibitory effect due to steric hindrance at the 
transamidation active site in TG2. The most active compounds were also tested against 
FXIIIA and caspase 3. There was very little or no activity against these enzymes inferring 
selectivity against TG2  (Pardin, Pelletier, et al. 2008). It is worth mentioning here that the 
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researchers used guinea pig liver TG2 for testing for its ease of attaining and its 80% 
structure similarity with human TG2. 
The same research group followed on their work and synthesised a new series of 
compounds based on their most active compounds, keeping the cinnamoyl and the triazole 
groups and modifying the aromatic ring to enhance the inhibitor binding within TG2 active 
site (Pardin, Roy, et al. 2008). Their most active compound (i2) (Figure 1-5) in this group had 
an IC50 against guinea pig liver TG2 of 2.1 µM, compared to 18 µM from their previous 
research. The authors showed that a similar mechanism was followed by this group of 
inhibitors in being reversible and competitive TG2 inhibitors (Pardin, Roy, et al. 2008). No 
report of examining the selectivity of this inhibitor group was mentioned in the paper. 
 
Figure 1-5: Compound i2 from the 
work by Pardin, Roy, et al. (2008). 
1.4.1.2 Non-competitive reversible inhibitors 
It has been mentioned earlier that TG2 activity is dependent on calcium ions. This activity 
can be inhibited by the binding of guanine nucleotides such as GTP and GDP. These natural 
inhibitors bind to an allosteric site in TG2 other than the transamidation active site and 
induce conformational changes that result in the loss of enzyme activity. This inhibition can 
be reversed by high concentrations of calcium ions (Liu et al. 2002). The conformational 
change has been introduced previously and the literature showed that the site at which GTP 
and GDP bind in TG2 is distinct from the transamidation active site. In theory, it is therefore 
possible to inhibit TG2 reversibly using compounds that would induce the conformational 
change triggered by the natural TG2 inactivators, GTP and GDP. 
Case and Stein (2007), after screening a library of 110,000 drug-like molecules, were able to 
find one compound that inhibited TG2 reversibly in a manner similar to that of GTP. The IC50 
of this compound (i3, Figure 1-6) was recorded to be 0.6 µM and a selectivity study showed 
no effect of the compound on FXIIIA and caspase. 
The authors proposed an allosteric inhibition mechanism through proving that the inhibitor 
blocks the activation of TG2 by Ca2+ by a steady state velocity analysis. They could not, 
however, prove that the inhibitor binds to GTP binding site, so they suggested that the 
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inhibitor could bind to the GTP binding site or to a different site in TG2 that regulates the 
binding of GTP, but not at the transamidating site. They have also shown that the inhibitory 
effect of their compound is dependent on the structure of the substrate used in the assay, 
suggesting a competitive mechanism. The authors explained this by the fact that the 
allosteric inhibitors can bind not only to the active free enzyme, but also to enzyme-substrate 
complexes and in the latter case, the structure of the substrate is relevant (Case & Stein 
2007). 
 
Figure 1-6: TG2 allosteric inhibitor (i3) by Case and Stein (2007). 
Caron et al. (2012) used Förster resonance energy transfer (FRET) as an alternative method 
to X-ray crystallography for elucidating the changes in conformation of TG2 in response to 
activation. They used the peptide inhibitor that was bound to TG2 in the crystal structure with 
the PDB entry 2Q3Z by Pinkas et al. (2007) and proved that this compound inhibits TG2 by 
covalently binding to the active site cysteine residue locking TG2 in the open conformation. 
They also used the most potent inhibitor from the work by Pardin, Roy, et al. (2008) 
(compound i2 Figure 1-5) and showed that i2 inhibits TG2 by maintaining the closed 
conformation of the enzyme and blocking the transamidating activity. This may contradict the 
results reported by Pardin, Roy, et al. (2008), but the closing of TG2 conformation may occur 
after binding of the inhibitor. 
Both types of reversible inhibitors have the potential to inhibit other members of the 
transglutaminase family, indicating a lack of selectivity. In addition, amine competitive 
inhibitors may induce an immune reaction resulting from the formation of non-native 
structures, which could limit their applications. These limitations, besides the moderate 
potencies of the reversible inhibitors and the availability of the active site nucleophilic 
cysteine residue, were probably the reasons for studying irreversible inhibitors. 
1.4.2 Irreversible inhibitors 
These TG2 inhibitors usually have an electrophilic warhead that can easily react with the 
nucleophilic sulphur atom of CYS277 by forming a covalent bond. Since the nucleophilic 
cysteine residue is essential for TG2 activity, the result of the reaction with these inhibitors is 
complete loss of TG2 activity. The design of such inhibitors is usually based on the 
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glutamine-bearing substrates of TG2, where small similar peptides are designed, to which an 
electrophilic warhead is incorporated to achieve the irreversible inhibition (Badarau, 
Collighan, et al. 2013). 
The simplest compound that has been used as an irreversible inhibitor is iodoacetamide 
[NH2-CO-CH2-I] which is a known blocker of biochemical thiols, including the thiol group of 
cysteine residues (Reisz et al. 2013). Iodoacetamide has been used to inactivate TG2 during 
tests of the activity of the enzyme. Examples of such uses include the work performed by 
Dørum et al. (2010) and de Macédo et al. (2000). Iodine in the structure of iodoacetamide 
serves as a good leaving group increasing the electrophilicity of the terminal methyl group. 
However, the small size and high reactivity makes it possible for iodoacetamide to interact 
with other thiols within TG2 or within other thiol bearing enzymes. This probably limits the 
use of the compound to testing the activity of TG2 (Siegel & Khosla 2007). 
1.4.2.1 Peptide based inhibitors 
In addition to the electrophilic warhead and the amino acids, peptide-based inhibitors should 
have in their structure a hydrophobic group on the opposite side from the warhead to 
improve the positioning of the inhibitor within the active site of TG2, which has a hydrophobic 
loop (Pinkas et al. 2007) (more details on this will follow in the relevant Results sections). 
Among the peptide-based inhibitors, the dihydroisoxazole derivatives received the most 
attention and were validated extensively. They are derived from acivicin which is an isoster 
of glutamine. These inhibitors are characterised by a 3-halo-4,5-dihydroisoxazole derivative 
warhead attached to an amino acid by a peptide bond, with an aromatic group to increase 
specificity to TG2 active site (Choi et al. 2005; Watts et al. 2006). 
One of the best members of this group was discovered by Choi et al. (2005). The compound 
(i4) (Figure 1-7) has tyrosine as the amino acid and benzyloxycarbonyl (Cbz) group as the 
hydrophobic group. i4 was found to be very active as a TG2 inhibitor and, when tested on 
human colonic cancer cell line, it sensitised the cells to epothilone C, a tubulin binding 
anticancer agent. Similar results were obtained when compound i4 was injected into mice 
with glioblastoma. The compound also showed good oral bioavailability and low toxicity 
when administered to mice. The compound was not tested against other transglutaminases 
but it was incubated with GSH as a sulphur containing electrophile and GSH was not 
affected. GSH was chosen because it represents the most abundant physiological thiol. 
Structure activity relationship (SAR) studies showed that a bulky group such as the Cbz was 
important for activity as was the amide group connecting the dihydroisoxazole group to the 
remainder of the inhibitor molecule (Choi et al. 2005). 
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The same group followed on the work on the same chemical class (Watts et al. 2006). They 
first proved that these inhibitors act by covalently binding to CYS277 of TG2. This was 
performed using mass spectrometry and it was found that the mass of the cysteine residue 
increases by a factor corresponding to the mass of the inhibitor minus that of bromine.  
Then, the authors synthesised a different series of compounds, changing the hydrophobic 
part and the amino acid from their previous set to enhance the activity. Their most active 
compound (i5 Figure 1-7) was about 50-fold more potent than compound i4. i5 had 
tryptophan as the amino acid and a quinoline group for the hydrophobic part. 
  
Figure 1-7: 3-Bromo-4,5-dihydroisoxazole derivatives, left is compound i4 by Choi et al. (2005) and right 
is compound i5 by Watts et al. (2006). 
In addition, the authors have set the criteria for a dihydroisoxazole derivative to have 
increased activity against TG2. The criteria are (S)-stereochemistry at position 5 of the 
dihydroisoxazole moiety, the presence of a heteroatom in the side chain of the amino acid 
and the presence of hydrogen bond acceptor in the hydrophobic part of the inhibitor. 
Although the article stated that the inhibitors were selective, no measures were taken in the 
study to ascertain this (Watts et al. 2006). 
Another study came out from the same laboratory (Klock et al. 2014) in which a library of 
published dihydroisoxazole TG2 inhibitors that includes around 60 compounds was tested 
for the selectivity of the inhibitors against TG1, TG3 and FXIIIA. It was found that many 
compounds were inactive against TG3 or FXIIIA, but were active in inhibiting TG1. The 
authors attributed TG1 activity to the presence of aromatic amino acids in the structures of 
the inhibitors. Consequently, they designed and tested a series of dihydroisoxazole 
derivatives containing substituted proline instead of tyrosine or tryptophan. Their most active 
compound was about 5 times more potent against TG2 than against TG1 (i6 Figure 1-8). 
The compound has a quinoline group and a nicotinamide substituted proline residue (Klock 
et al. 2014). 
For other peptide-based irreversible TG2 inhibitors, Chica et al. (2004) were able to define 
the possible structure of small peptide-based acyl donor substrates for TG2. Understanding 
how these substrates bind to TG2 would help in the design of related irreversible inhibitors. 
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They concluded that for best results, the peptide must contain in its structure a Cbz 
protective group with glutamine and glycine residues (Cbz-Gln-Gly) (carbobenzyloxy-L-
glutaminylglycine). They also showed that tert-butyloxycarbonyl protective group (t-Boc) in 
the structure would make it unsuitable as a substrate. This is consistent with the finding from 
Choi et al. (2005) regarding the importance of the Cbz group and the requirement for the 
presence of glutamine residue in the structure. 
 
Figure 1-8: Compound i6 by Klock et al. (2014). 
Even though the researchers used the crystal structure of red sea bream TG2, which has 
about 50% structure similarity in the active site with guinea pig TG2, their basic substrate 
was the basis for non-dihydroisoxazole inhibitors designed by others (Chica et al. 2004).  
Different functional groups have been attached to the glutamine residue in the above 
substrate by different researchers to produce various groups of irreversible TG2 inhibitors. 
Examples of these functional groups are maleimides, epoxides and α,β-unsaturated amides. 
Maleimide warhead inhibitors (Figure 1-9), based on the above scaffold, have been studied 
by Halim et al. (2007) who have shown that such inhibitors demonstrated time-dependent 
irreversible inhibition, suggesting reaction with the active site cysteine residue of TG2. Their 
compounds were not very effective when compared to other warheads, such as acrylamides. 
The authors attributed this to the physical size of the maleimides warhead group and the 
difficulty of its approach to CYS277 (Halim et al. 2007). 
Based on the same scaffold, de Macédo et al. (2002) synthesised a series of compounds 
containing α,β-unsaturated amides and their corresponding epoxides as the warhead (Figure 
1-9). They did not test the compounds for their activity against TG2 but they proposed that 
they would be potential inhibitors for the enzyme. 
Pardin et al. (2006) synthesised and tested a series of peptide based inhibitors. They used 
the scaffold by Choi et al. (2005) as the basis for their peptide but replaced tyrosine by 
phenylalanine. Their primary peptide structure composed of a Cbz protective group, 
phenylalanine, an aliphatic spacer and an electrophile. The electrophile was one of three 
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types, an acrylamide (α,β-unsaturated amide), a chloroacetamide or a maleimide (compound 
i7, Figure 1-10). 
 
Figure 1-9: Different warheads attached to the scaffold Cbz-Gln-Gly (R is the scaffold). 
 
Figure 1-10: Compound i7, the basic scaffold used by Pardin et al. (2006) with the different warheads. 
The acrylamide and chloroacetamide compounds showed good inhibitory activity against 
TG2, with inhibitory efficiencies that were 4-50 times higher than the dihydroisoxazole 
compound, i4, by Choi et al. (2005). It was also found that this activity is related to the length 
of the aliphatic spacer, where the activity increases with increasing the length of the spacer 
(n ranged between 2 and 8). The relation of the activity of the inhibitors with the length of the 
spacer was explained based on the shape of the active site in TG2. The authors suggested 
that a reasonable distance should separate the warhead from the hydrophobic Cbz group 
because the warhead is supposed to react with CYS277 and the hydrophobic group should 
accommodate itself in a hydrophobic region of TG2 active site; and CYS277 and the 
hydrophobic region of the active site are distant from each other, hence the requirement for 
the separation of the warhead from the Cbz group (Pardin et al. 2006). 
The activity of the maleimide compounds was much lower than that of the other warheads, 
and that was attributed to the size of the warhead and the ease of access to the active site. 
All the inhibitors showed time-dependent inactivation of TG2. Irreversibility was further 
confirmed by removing the excess of the inhibitors from the reaction medium and noticing 
that TG2 activity was not restored. The authors also examined the specificity of the inhibitors 
Maleimide EpoxideUnsaturated amide
R=
Acrylamide
Chloroacetamide
Maleimide
(  )n
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to TG2 by testing them against glutathione as a physiological thiol-containing nucleophile. 
The results showed that glutathione consumed only 10% of the inhibitor after 24 hours, 
compared to the fast reaction with TG2 (Pardin et al. 2006). 
Dimethyl-sulfonium ketone is another warhead that has been used in a class of peptide-
based inhibitors. Inhibitors containing the sulfonium warhead were derived from 6-diazo-5-
oxo-L-norleucine (DON), using Cbz, Fmoc (fluorenylmethyloxycarbonyl) or t-BOC as the 
protective group with various amino acids by Griffin et al. (2008) (i8 Figure 1-11). An extra 
carboxyl group was added to the inhibitors to enhance water solubility and activity against 
TG2. 
 
Figure 1-11: Peptide-based inhibitors derived from DON by Griffin et al. (2008) (i8). 
The compounds showed good irreversible inhibitory effect with a TG2 IC50 of as low as 5 µM. 
The Fmoc and t-Boc protective groups increased the IC50 to more than 30 µM, again to 
signify the importance of the Cbz group for the activity against TG2. The enhanced water 
solubility would be useful in reducing toxicity as the compounds would be less likely to cross 
cell membranes. The study, however, did not include any attempt to examine the selectivity 
of the inhibitors for TG2. In addition to the sulfonium ion warhead, an imidazolium based 
warhead was also tried using the same peptide scaffold and was found to be more active 
than the sulfonium group with an IC50 of 3 µM (Griffin et al. 2008). Consequently, the 
research group continued working by synthesising a new series with modifications of the 
imidazolium warhead (Badarau, Mongeot, et al. 2013). 
The new study came up with some active TG2 inhibitors with IC50 values of as low as 1 µM. 
Their main result was that the activity was lost by increasing the size of substitution at the 
imidazolium ring nitrogen atoms (Figure 1-12). The same observation was reported 
regarding the sulfonium warhead in the previous paper (Griffin et al. 2008). Another finding 
from this group was that the sulfonium warhead offered more specificity for TG2 over FXIIIA 
compared to imidazolium warhead (Badarau, Mongeot, et al. 2013). 
R AA
Cbz Proline
PhCh2Ch2OC(=O) Glycine
Fmoc Phenylalanine
t-BOC Tryptophan
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Figure 1-12: Examples of modifications to the imidazolium warhead by Badarau, Mongeot, et al. (2013) 
and their effect as TG2 inhibitors. 
The relatively large size of the imidazolium group can be compared to that of maleimide. 
Some of the imidazolium compounds were active and the authors have attributed this to the 
higher chemical reactivity of the imidazolium group, when compared to other chemical 
groups such as maleimide. 
1.4.2.2 Inhibitors discovered by screening of compound libraries 
Several irreversible inhibitors were reported by Prime, Andersen, et al. (2012) who screened 
a library of 283,000 compounds for activity against TG2 and 4 chemotypic hits emerged. 
Three of these hits were excluded from further investigation because of high molecular 
weight or lack of selectivity. The 4th hit (4-bromophenylacrylamide, i9, Figure 1-13) showed 
good activity against TG2 with an IC50 of 3.3 µM and promising selectivity characteristic 
when tested against TG1, TG3, FXIIIA and caspase 3. Therefore this hit was used as a 
starting point for the synthesis of different groups of related compounds that were analysed 
in vitro and by a docking study (Prime, Andersen, et al. 2012). 
The first modification involved the simple additions on the phenyl group. Only one compound 
of this group (sulphonamide modification, i10, Figure 1-13) was found to be active and 
showed a TG2 IC50 of 1.9 µM. A docking study on i10 suggested that forming hydrogen 
bonds with residues TRP241 and GLN276 is important for a good pose. There was a 
possibility for another hydrogen bond between the sulphonamide group of the active 
compound and ASN333. Based on this assumption, the researchers prepared another series 
of compounds by extending the sulphonamide part to improve the chance of forming such 
hydrogen bond. 
All the 16 compounds in this new series showed very good activity against TG2 with little or 
no effect on TG1, TG3 and FXIIIA (i11 is an example with a Cbz group and an IC50 of 0.12 
µM, Figure 1-13). The next step involved modifications in the acrylamide moiety of the latter 
active series. The alterations in the warhead lead to significant reductions in the activity with 
complete loss of selectivity; epoxides, esters, ketones and nitriles as substituents of the 
 Active                  Inactive                               Inactive                   Active 
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acrylamide warhead all resulted in inactive inhibitors of TG2. The same applied to 
substitutions at the α- and β-carbons of the acrylamide double bond with the exception of 
substituted chlorine. The same results (few active and none selective compounds) were 
reported for another series in which the modifications involved the phenyl group linking the 
acrylamide warhead to the sulphonamide part. 
One final series of compounds was prepared by modifications to the Cbz protecting group, 
such as adding halo and alkyl substituents to the terminal phenyl group, or entirely replacing 
Cbz with urethanes and amides. Many of those modifications enhanced the activity and 
selectivity profiles for the inhibitors, and one compound in this series (i12, Figure 1-13), in 
which Cbz was replaced by an admantyl amide, showed the best activity and selectivity in 
this study with a TG2 IC50 of 0.01 µM and an 18-fold higher activity against TG2 than FXIIIA, 
and even higher selectivity against TG1 and TG3 (Prime, Andersen, et al. 2012). The results 
from the final series imply that the lipophilic parts of irreversible TG2 inhibitors represent a 
good area for development and modifications, in contrast to the warhead groups which can 
only be restricted to few classes of chemical groups. 
 
Figure 1-13: Four compounds representing different series of TG2 inhibitors from the work by Prime, 
Andersen, et al. (2012). 
1.4.2.3 TG2 inhibitors used in this project 
The structures of a total of 21 active TG2 inhibitors and 8 proven inactive compounds have 
been used during the course of this project in the various stages. These compounds were in-
house compounds; designed, synthesised and tested for their activity and selectivity against 
TG2 in the laboratories of the School of Life and Health Sciences in Aston University, 
Birmingham with the participation of researchers from chemical and biological backgrounds. 
All the compounds have been patented (Griffin et al. 2014) and the most important of them 
were published (Badarau et al. 2015). The basis for the design of the new set of compounds 
i9 i10
i11 i12
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was molecular dynamic simulations applied on docking complexes for a sulfonium ion and 
an imidazolium inhibitors from previous work (compound i7, Figure 1-10) (Griffin et al. 2008; 
Badarau, Mongeot, et al. 2013). The simulations showed that the dihedral angle between the 
nitrogen from Cbz group, and the alpha carbon, the carboxylic carbon and the amine 
nitrogen of the central amino acid stabilised around 0°. 
The value of the dihedral angle inferred stability around that region, therefore, that part was 
replaced by a more rigid piperazine ring. The resultant inhibitor (compound i13, Figure 1-14), 
which had glycine as the amino acid and a dimethyl sulfonium as the warhead, had a TG2 
IC50 value of 1.4 µM and showed an irreversible inhibition mechanism with minimal cellular 
toxicity. It was used as a prototype, from which several other compounds were derived. 
Changing the warhead to diethyl sulfonium retained the activity, while replacing it with an 
imidazolium group caused loss of activity. These same changes to diethyl sulfonium and 
imidazolium warheads produced the opposite effects on activity against TG2 in the previous 
set of compounds (Griffin et al. 2008), implying that the 2 sets, though related, cannot be 
compared to each other as they exhibited different activities. 
 
Figure 1-14: Compound i13, which 
was the basis for the compounds 
designed by Badarau et al. (2015). 
Lipophilic warheads were also tried; vinyl sulphonamide and acrylamide, with the aim of 
producing TG2 inhibitors with enhanced cellular permeability to specifically target 
intracellular TG2. Both warheads were active with the sulphonamide being slightly better 
(IC50 for vinyl sulphonamide was 1.725 µM and for the acrylamide 5.925 µM). Next, the 
emphasis was turned on modifying the carbamate moiety in compound i13 and combining 
this with various warheads. The rationale this time was to enhance the binding within the 
hydrophobic region of TG2 active site. Different sized aromatic and other hydrophobic 
groups were tried, with the best results obtained when the adamantyl hydrophobic part was 
combined with an acrylamide warhead (compound 1a, Table 3-1, with a TG2 IC50 of 0.125 
µM), and when a tert-butyl part was used with a dimethyl sulfonium warhead (compound 1b, 
Table 3-1, with and IC50 of 0.273 µM). A naphthalene group for the lipophilic part with an 
acrylamide warhead also gave good activity against TG2 (compound 1c, Table 3-1). 
Amino acids other than glycine have also been tried. Changing to a bulky group such as 
phenylalanine resulted in complete loss of activity, while changing to alanine with the 
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dimethyl sulfonium warhead improved TG2 inhibition over that obtained with compound i13 
(compound 1d, Table 3-1, with an IC50 of 0.7 µM). 
The final alteration involved applying a fluorescent tag on the lipophilic part of the inhibitors 
and the goal was to track the inhibition within the cells and to test that the inhibitor is 
physically bound to TG2. Two compounds having a dansyl group in their lipophilic end were 
synthesised and tested; the first had an acrylamide warhead (compound 1e, Table 3-1) and 
produced the best inhibitory effect against TG2 with an IC50 of 0.0061 µM. The second 
compound was designed with a dimethyl sulfonium warhead and showed descent TG2 
inhibitory activity with an IC50 of 0.38 µM (compound 1f, Table 3-1). 
An additional test was applied to confirm that these inhibitors act on the active “open” form of 
TG2. Two versions of TG2 were incubated for 30 minutes, once with TG2 activator Ca2+ and 
one with the TG2 inactivator GTP. Each TG2 version was then incubated with the inhibitors 
1e and 1f for 30 minutes and the excess inhibitor removed. TG2 activity was measured and 
it was found that TG2 incubated with Ca2+ lost its activity upon the addition of the inhibitors 
while TG2 incubated with GTP retained its activity. This indicates that for these inhibitors to 
work, Ca2+ must be available to induce the open conformation of TG2 to give them access to 
CYS277. 
To examine the selectivity of the inhibitors to TG2, the activity of compounds 1e and 1f 
against caspase 3 and 7 was measured and the compounds were found to be inactive 
against these enzymes. In addition, all the active compounds showed very good selectivity 
towards TG2 when tested against TG1, TG3 and FXIIIA and this was especially true for the 
dansyl compounds. Next, the toxicities of the active inhibitors were determined using XTT-
base assay. The toxic concentrations for the compounds ranged between 25-100 µM, with 
some halogenated inhibitors having the highest toxicities, whereas the water soluble 
compounds with sulfonium warheads were the best tolerated. The toxic concentrations were 
much higher than TG2 IC50 values. It should be noted that the toxicity from the halogenated 
compounds was not unexpected, and they were never intended to be used as potential 
drugs; rather, they served as intermediates during the syntheses and were tested for their 
activity as TG2 inhibitors. 
Compound 1e with the dansyl fluorescent group was used to confirm the covalent inhibitory 
mechanism by incubating TG2 with the compound and Ca2+ for 3 hours. The same was 
applied for a mutant version of TG2 in which a serine residue replaced the active site 
cysteine residue. After incubation, the enzyme was separated from the remaining inhibitor 
and fluorescent bands were checked under the microscope. Wild type TG2 incubated with 
1e showed bands for the dansyl group while the mutant TG2 did not show any bands, 
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indicating the covalent binding of the inhibitor to the active site cysteine. When cellular 
permeability was tested on a subset of inhibitors, it was observed that the acrylamide-based 
inhibitors could penetrate cells and inhibit intracellular TG2 better than the sulfonium ion 
compounds. This is consistent with the water solubility profiles for both types of warheads 
(Badarau et al. 2015). 
The version of TG2 that was used in the majority of studies for testing the inhibitors was the 
guinea pig liver TG2 (Sohn et al. 2003; Pardin et al. 2006; Pardin, Pelletier, et al. 2008; 
Griffin et al. 2008). Although this can be justified by the fact that this version of TG2 has 80% 
resemblance to the human version (Pardin, Pelletier, et al. 2008), testing the inhibitors 
against human TG2 will certainly produce more relevant results. The human version of the 
enzyme has been used in the studies by Choi et al. (2005), Watts et al. (2006), Prime, 
Andersen, et al. (2012), Badarau, Mongeot, et al. (2013) and Badarau et al. (2015). Griffin et 
al. (2008) used guinea pig TG2, but in addition they tested two of their compounds against 
human TG2 and found comparable results. 
1.5 Computational Techniques 
Computational chemistry is a general term which describes chemical events that can be 
represented by mathematical terms developed enough to be automated to make use of the 
rapidly increasing powers of computers (Young 2001). The term has been used 
interchangeably with molecular modelling and theoretical chemistry (Cramer 2013). Two 
main computational or modelling techniques have been used throughout this thesis; 
molecular dynamics (MD) and protein-ligand docking. Within each, several sub-techniques 
have been applied; with MD, for example, conventional MD was the major techniques used, 
in addition to enhanced sampling techniques with quantum mechanical treatment and 
covalent MD. With docking, flexible and rigid receptor approaches have been applied using 
more than one scoring function as well as rescoring a docked conformation and covalent 
docking. Both of these methods rely heavily on the principles of energy minimisation or 
geometry optimisation. In the following sections, brief descriptions for the various 
computational approaches will be presented. 
1.5.1 Energy minimisation 
The potential energy of any chemical system is a function of its atomic coordinates giving 
rise to the potential energy surface (PES), which is a multidimensional shape showing how 
the energy changes with the coordinates of the atoms. The surface is composed of hills, 
corresponding to high energy conformations, and valleys for the lower energy structures. 
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When building a computer model of a chemical system, the structure produced may not 
reflect the most stable conformation for that molecule. This results from the fact that the 
drawn structure will most probably be located outside the deepest valley in the PES (global 
minimum), which represents the most stable conformation for that system. The structure will 
have a higher chance of being within one of the local minima. The process of optimising the 
geometry of the chemical system to minimise its energy to the lowest possible value is called 
energy minimisation (Leach 2001). 
Several minimisation methods are available. Examples include the Newton-Raphson 
method, which is the most computationally expensive because it calculates the first (slope) 
and second (curvature) derivatives of energy at each geometry point. Another example is the 
steepest descent method which calculates the first derivative only and assumes that the 
second derivative is a constant. Steepest descent is the fastest minimisation method and 
moves the system in the direction of the largest slope (steepest gradient). Conjugate 
gradient method is another minimisation method that is similar to the steepest descent, but 
the new search direction contains some information from the previous search direction 
(Höltje & Folkers 2008). All these are mathematical methods that optimise the geometry to 
minimise the energy. Energy is calculated at each step of the optimisation using one of two 
major methods. These are discussed in the next sections. 
1.5.1.1 Molecular mechanics (MM) 
Molecular mechanics or force field methods make use of classical mechanics to handle 
chemical systems and treat molecules as being composed of atoms connected by bonds. 
Therefore, to model a new molecule, one can use the bond connecting parameters from 
known molecules (Hinchliffe 2003). Databases for those parameters can be obtained from 
experiments or from higher level calculations (Boeyens & Comba 2001). The force field 
refers to the energy terms investigated within a molecule, together with the parameters for 
those terms. The energy terms are generally divided into bonded terms (bond length, bond 
angle and dihedral angle) and non-bonded terms (van der Waals and electrostatic 
interactions). The total energy of the system is taken as the sum of these energy terms 
(Leach 2001). 
1.5.1.1.1 Bonded terms 
The energy associated with bond length is calculated based on Hook’s law, in which the 
energy is related to the difference between the actual bond length and some value that 
represents the ideal or equilibrium length for that bond (Leach 2001). Bond angle term is 
also handled according to Hook’s law as in bond length. However, its contribution to the total 
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energy of the system is less than that from bond length (Leach 2001). The angle between 
the 2 planes defining 4 successively bound atoms (the dihedral angle) is another bonded 
term in the force field. The energy of dihedral angle is calculated depending on the number 
of possible rotations around the angle. Its contribution to total energy is the least, but this 
should not make the angle less important than the previous term, because it means that it 
can be distorted very easily resulting in non-realistic conformations (Vinter & Gardner 1994). 
1.5.1.1.2 Non-bonded terms 
The terms describe the interactions between each atom pair that are not connected by a 
covalent bond and are of two types. Attraction or repulsion between non-bonded atoms, that 
are not caused by charges are represented by van der Waals forces. The contribution from 
this interaction is calculated by the Lennard-Jones 6-12 potential, where the energy will have 
a minimum at certain distance separating the atom pair. Electrostatic interactions arise from 
attraction and repulsion resulting from the charges on the various atoms in the system. The 
energy of the interaction between 2 atoms depends on the distance between them and the 
partial charges they are carrying and is calculated by Coulomb law (Vinter & Gardner 1994). 
Non-bonded interactions tend to fade at higher distances, but in theory they extend infinitely. 
To save computer time, cut-off distances are introduced, which are distance limits beyond 
which the non-bonded energy will not be calculated for atom pairs. Force field methods 
perform the minimisation process by iteratively changing the parameters and calculating the 
energy at each step, until reaching the lowest possible energy for the system or the 
maximum number of iterations (Vinter & Gardner 1994). 
Molecular mechanics methods are computationally very efficient, making them suitable to 
handle large systems including biological macromolecules. The force fields are transferrable, 
so they can be applied to a variety of systems (Leach 2001). On the other hand, their 
accuracy is not the best among the energy calculation techniques, and the lack of 
representation of electrons in the force fields means that they cannot be used to simulate 
chemical reactions (Vinter & Gardner 1994). 
1.5.1.2 Quantum mechanics (QM) 
These methods use the principles of quantum chemistry to describe a chemical system and 
calculate its energy. They handle molecules as being composed nuclei and electrons moving 
around them (Vinter & Gardner 1994). Quantum mechanical methods estimate the energy of 
a system by finding the appropriate wave function to describe the system. The wave function 
is a probability function for the movement of the electrons around the nuclei (orbitals). An 
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exact wave function can only be found for systems containing one electron only by solving 
the Schrödinger equation, and this is only be applicable to hydrogen atom (Leach 2001). For 
poly-atomic systems, the energy of the electrons has more than one component; a core 
component (interaction between electron and nucleus), an exchange component (electrons 
on different orbitals) and a Coulomb component (electrons on the same orbital). Therefore, 
the Schrödinger equation cannot be solved exactly and the result is multiple wave functions 
to describe the system. Based on the variation principle, the best wave function is the one 
that gives the lowest energy to the system (Leach 2001; Vinter & Gardner 1994). Depending 
on the level of approximation, QM methods are of 2 major types. 
1.5.1.2.1 Ab initio methods 
Ab initio is the Latin term for “from scratch”, which means that these methods do not use 
approximations or parameters from experiments, and perform optimisation by handling every 
single electron in the system (Dorsett & White 2000). Some approximations are, however, 
inevitable to make the calculations possible; one example is the use of the linear 
combination of atomic orbitals (LCAO) to represent the molecular orbital of the system in 
which the wave functions corresponding to the individual atomic orbitals are added together 
to give a wave function for the molecule, and the wave function with the lowest energy is the 
minimum for that molecule (Vinter & Gardner 1994). 
Ab initio methods are defined by a choice of a method and a basis set. The method is a 
mathematical representation for the calculation of the wave function of the molecular orbital 
from the individual atomic orbitals. Hartree-Fock (HF) is an example of ab initio methods that 
deals with single-electron wave functions (Dorsett & White 2000) and density functional 
theory (DFT) which performs the calculations based on electron density, rather than single 
electrons (Koskinen & Mäkinen 2009). The basis set is an analytical term used to represent 
the atomic orbitals (Vinter & Gardner 1994). 
Ab initio methods are highly accurate when compared to other means of geometry 
optimisation, and because they do not rely on parameters, they can be used for newly 
designed systems for which no experimental data exist. They can be used to derive 
parameters for other methods, such as force fields and semi-empirical methods (Dorsett & 
White 2000; Leach 2001). Their major disadvantage is that they are very computationally 
expensive, especially with the use of more complicated methods and basis sets, making 
them applicable only to small systems (Vinter & Gardner 1994). 
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1.5.1.2.2 Semi-empirical methods 
They are methods that also deal with electrons and nuclei but they involve approximations 
that allow them to be much faster than ab initio methods (Hinchliffe 2003). The 
approximations include neglecting the integrals of overlaps between atomic orbitals (Leach 
2001), substituting some integrals by parameters from experiments and performing the 
calculations on valence shell electrons only (Höltje & Folkers 2008). Depending on the level 
of neglect involved in the method, there are several types of semi-empirical methods, such 
as CNDO (complete neglect of differential overlap), MNDO (modified neglect of diatomic 
overlap) and PM3 (parameterisation method 3) (Leach 2001). Semi-empirical methods are 
faster than ab initio methods and their results are more reproducible, being based in part on 
parameters. They are less accurate, however, especially when applied on systems larger 
than the systems from which the parameters were derived (Vinter & Gardner 1994; Seabra 
et al. 2009). 
1.5.2 Molecular dynamics 
X-ray crystallography is probably the best technique that can be used to elucidate the 3-
dimensional (3D) structure of biological macromolecules. The main drawback of this 
technique, among others, is that the structures produced are static and do not represent the 
entire conformational space the macromolecule can adopt. NMR spectroscopy is another 
technique that can give more insight on the flexibility of a biological system, through 
uncovering the structure of the macromolecule as an ensemble of conformations. 
Nonetheless, the technique remains extremely difficult to apply and time consuming (Mortier 
et al. 2015). 
The static structures from X-ray crystallography and the ensembles from NMR spectroscopy 
have succeeded in providing essential information about biological macromolecules and 
their spatial arrangements. However, the inflexibility of the structures renders them less 
useful in recounting events that involve dynamics of the biological system. Example events 
include the continuous motion of proteins in biological solutions, the conformational changes 
in proteins brought about by binding of ligands, whether natural substrates or exogenous 
molecules, and the allosteric regulation of enzymes that signifies an important regulatory 
mechanism for many enzymes and usually involves a large conformational modification of 
the enzyme that alters its activity. Similar examples can be found within nucleic acids, where 
the binding of DNA to transcription factors is regulated by base sequence as well as the 
potential of the DNA molecule to accommodate the transcription factor (Hospital et al. 2015). 
Molecular dynamics (MD) is a computational method that could be used to predict the 
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possible conformational space a biological macromolecule can explore, as well as the paths 
taken by the biological system during this exploration. When applied to the static structures, 
MD can extend the level of flexibility of the system (Mortier et al. 2015). 
Advances in computational powers witnessed in the last few years have enabled the 
application of MD on larger and larger systems. At the same time, these advances have 
allowed for extended simulation times; simulations on large proteins, receptors, membrane 
proteins, phospholipids, nucleic acids and other macromolecules for microseconds are now 
routinely conducted (Mortier et al. 2015). 
1.5.2.1 Basic principle 
MD simulations operate on the basis of solving Newton’s equations of motion: 
𝒇𝒊 = 𝒎𝒊𝒂𝒊 
where 𝒎𝒊 is the mass of atom i and 𝒂𝒊 is the acceleration of atom i and 𝒇𝒊 is the force acting 
on the atom. The force is a function of the potential energy of the system and the latter is 
dependent on the positions of all atoms in the system. The result from MD is a time series of 
conformations that represent the dynamic spatial configuration of the biological system, and 
from which, thermodynamic properties can be calculated. The application of MD requires 4 
basic fundamentals; the resolution of the system, description of the interactions within the 
system, production of the time series conformations and solvation (Mortier et al. 2015). 
1.5.2.1.1 System resolution 
The resolution describes how the elementary particles of the system are given. The particles 
can be presented as nuclei and electrons, as atoms or as coarse-grained (CG) particles, 
each composed of several atoms. Nuclei and electrons description is utilised when there is 
QM treatment and the description gives the most accurate results, but is very slow that it 
would be impractical to apply to large systems. QM treatment is, therefore, reserved for the 
study of enzymatic reactions and reaction pathways where only a small fraction of the 
system is treated by QM while the remainder is handled conventionally. CG description is 
the other extreme where the number of particles in the system is reduced significantly 
allowing more space to be explored more rapidly, at the expense of the accuracy of the 
information obtained. Particles treated as atoms represents the best compromise between 
speed and accuracy and is the most popular approach in conventional MD (Mortier et al. 
2015). Within the system resolution also lies the solvation of the system. This will be 
discussed in a separate section. 
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1.5.2.1.2 Force field 
The potential energy function used within MD simulations describes the interactions within 
the system particles and is generally termed ‘force field’. Force fields, as mentioned 
previously, commonly use two main terms to define the interactions between atoms; bonded 
interactions term and non-bonded interactions term (Mortier et al. 2015). Force fields, with 
their parameters, allow the calculation of the forces acting on each atom in the system, 
which in turn permit the prediction of the velocities and accelerations of these atoms and 
consequently the new atomic positions according to Newton’s equations of motion. Due to 
the method of integration used in the calculation of the forces, a short time step must be 
used. The term ‘short’ means that the time step should be shorter than the fastest atomic 
motion and therefore, time steps are generally in the order of 1-2 femtoseconds. The use of 
larger time steps can significantly improve computation time and this is possible with CG 
representation of the system but on the expense of the accuracy of the information obtained 
(Hospital et al. 2015). 
The parameters embedded in the force fields are derived from higher level computational 
methods or from experiments. Because biological macromolecules are composed of a finite 
set of building units (for example, amino acids for proteins and nucleotides for nucleic acids), 
the use of force fields would sound reasonable as those contain information on this finite set 
of building blocks. For organic, drug-like molecules or ligands, no building blocks can be 
used for the representations because of the diversity in the structures of these ligands. 
Separate force fields are used to describe these atoms which have the information for 
bonded and non-bonded terms taken from the general force fields while the partial atomic 
charges are derived from higher level QM calculations (Mortier et al. 2015). 
Multiple reliable force fields exist today, and examples include the AMBER (assisted model 
building with energy refinement) force field (Hornak et al. 2006) used with the AMBER MD 
package (Case et al. 2012), CHARMM (Chemistry at HARvard Macromolecular Mechanics) 
(MacKerell et al. 1998) with the CHARMM program (Brooks et al. 2009) and GROMOS 
(Groningen Molecular Simulation) (Oostenbrink et al. 2004) with the GROMACS 
(GROningen MAchine for Chemical Simulations) program (Hess et al. 2008). Those force 
fields differ mainly in the methods used for their parameterisation and the sources of the 
parameters; the force fields cannot be used interchangeably, but the trajectories resulting 
from them are comparable (Hospital et al. 2015). 
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1.5.2.1.3 Production of the time series 
After the forces acting on atoms are calculated and the new atomic positions are predicted, 
the new conformation is recorded and is used as the starting point for the next time step 
force calculation. The ultimate result of the MD simulation is a time series of the new 
conformations that would represent a trajectory for the dynamics of the biological 
macromolecule as predicted by Newton’s equations of motion (Mortier et al. 2015). As stated 
earlier, the calculation of the new atomic positions requires integrating the equation of 
motion. An analytical integration is not possible due to the complexity of the equation. A 
numerical integration is used instead. Several numerical algorithms are available such as 
Verlet algorithm and the leap frog algorithm (Paquet & Viktor 2015). 
1.5.2.1.4 Solvation and periodic boundary conditions 
Biological macromolecules are found in solutions in biological system, and this should be 
considered when applying MD simulations. Two main solvation models exist; implicit 
solvation and explicit solvation. In the implicit solvation model, solvent, usually water, 
molecules are not added physically to the simulated system. Instead, they are replaced by a 
potential that is used to simulate the effect of the presence of the actual solvent molecules. 
This model is computationally fast because the number of the atoms of the system is not 
increased. In addition, the model allows for infinite representation of the solvent, which is the 
case in bulk liquid. On the other hand, there is the fundamental compromise in computation 
between speed and accuracy due to the absence of water molecules, and thereby the 
absence of the effects that could result from their presence such as hydrogen bonds and 
ligand solvation effects (Paquet & Viktor 2015; Onufriev 2008). 
In the explicit solvation model, water molecules are added physically to solvate the biological 
system. Although water molecules in bulk solution are in the form of an infinite solvation box, 
only a finite number of water molecules can be added during MD due to the limited capacity 
of the computer memory. Solvation boxes are used for this purpose and these can take the 
shape of cubes, dodecahedrons or truncated octahedrons. The larger the solvation box, the 
more accurate the simulation would be, but this will have a great effect on the speed of the 
simulation. In fact, much of the computation time is spent on dealing with the solvent 
molecules as they usually constitute the majority of the components in the test system 
(Tuckerman & Martyna 2000; Paquet & Viktor 2015). 
Because solvation boxes are finite, periodic boundary conditions are employed to make the 
representation more realistic. Periodic boundaries work by generating replicate translational 
images for the system in all the dimensions and the true system is in the centre of those 
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replicates. When a water molecule reaches the boundary of the box and eventually leaves it, 
its copy will replace it from the corresponding image. The representation is more realistic 
than the implicit solvent but explicit solvent with periodic boundary is computationally 
expensive due to the requirement to handle long distance electrostatic interactions between 
the atoms from various images. One approach around this is the use of the particle mesh 
Ewald method. This approach works by dividing the Columbic potential into a shot-range 
component (calculated by conventional means) and a long-range component whose 
contribution is calculated through a Fourier transform (the potential is calculated in the 
reciprocal space) (Tuckerman & Martyna 2000; Paquet & Viktor 2015). 
1.5.2.2 Stages of MD 
According to the authors of the CHARMM MD program (Stote et al. 1999), conventional MD 
is ideally performed in 5 stages. The first stage involves preparing the initial coordinates of 
the system to be simulated. These can be from a crystal structure from the Protein Data 
Bank, a homology model for a protein whose 3D structure has not been yet elucidated or a 
docking complex generated by one of the docking programs. The type of solvation should be 
chosen at this stage, whether implicit or explicit, as well as the force field that will be applied 
to define the atoms and the interactions. The second stage is performing energy 
minimisation on the system. The objective is to remove any bad clashes from the original 
crystal structure, and therefore, local optimisation would be sufficient where the goal is not to 
find a global minimum. Another objective for minimisation is to allow water molecules added 
during solvation to accommodate themselves to the biological system without any overlap. 
The third step comprises heating the system. This is done because the system starts at a 
temperature of 0 K. During this phase, velocities are allocated to the atoms of the system at 
low temperature and MD is applied and the system is propagated over time by solving 
Newton’s equations. Periodically, new velocities are allocated to the atoms while slightly 
increasing the temperature. Heating is continued in the same way (allocating velocities while 
raising the temperature) until the desired temperature is reached. Heating is followed by 
equilibrating the system (4th step). The purpose of this stage is to run the MD on the solvated 
system while monitoring properties such as pressure, temperature and energy. This phase 
should be continued until these properties become stable over time. When the properties are 
stable, the system is said to have equilibrated and can proceed to the final phase which is 
the production of the actual MD trajectory. Production phase can be extended for any 
desired period of time, and it is the trajectory produced during the production that could be 
inspected to gather information and perform analyses about the biological system. 
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The most popular MD packages such as AMBER, CHARMM and CROMACS have made a 
great use of the computational advances. For example, they all use the messaging passing 
interface (MPI), which allows the computation to be spread over multiple cores within the 
computer, and hence greatly speeding the process. Each core will handle a section of the 
system and will perform the calculations on that section. The communication between the 
cores is reduced, since it will be reserved for those handling adjacent sections of the system, 
which will also speed the process. Graphical processing units (GPUs) are components of 
computers that were originally intended to handle different aspects of graphics. A major 
enhancement of computer abilities to perform MD simulations was made when the GPUs 
were allowed to be used as processors to run MD. With GPUs, microsecond-long MD 
simulations are now conducted routinely (Hospital et al. 2015). 
1.5.2.3 Enhanced sampling techniques 
Even with the recent advances in computational powers and the codes running MD, the 
complexity of the potential energy surface of biological macromolecules remains a major 
hurdle in the face of MD. The simulation will be trapped in an energy minimum near the 
starting conformation, without the possibility of crossing the high energy barriers separating it 
from the global minimum. Enhanced sampling techniques are methods developed to 
overcome the high energy barriers in the potential energy surface allowing more accessible 
exploration of conformational space. In addition, these techniques enable the sampling of 
events that accompany such high energy barriers, such as protein folding and bond breaking 
or formation (Hospital et al. 2015), keeping in mind that bond breaking and formation 
requires in addition QM treatment. Examples of those techniques are presented in the 
following sections, with a more detailed description of those used in this work. 
1.5.2.3.1 Replica exchange molecular dynamics 
This method of enhanced sampling involves simulating multiple copies or replicas of the 
biological system at the same time but at different temperatures. A swap is performed 
between the replicas every predefined number of steps, so that a replica starting at low 
temperature will be allowed to sample at a higher temperature and vice versa. A weighting 
analysis is performed to give the conformational space that was sampled during the method, 
which would be much wider than that sampled by conventional MD, since the simulations of 
replicas at higher temperature will overcome some of the high hills present in the potential 
energy surface of the molecule (Mitsutake et al. 2001). A major disadvantage of this 
approach, arising from the fact that multiple simulations are run at the same time, is its 
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computational cost (Michel & Essex 2010). The method has, however, proven superior to 
classical MD in predicting events such as protein folding (Bernardi et al. 2015). 
1.5.2.3.2 Umbrella sampling 
The basic idea behind umbrella sampling is that a MD simulation is performed while adding 
a biasing potential to push the system to sample a predefined coordinate over a certain 
range of values. These values are defined by a restraint added to the coordinate. A record is 
kept for the manner in which the coordinate has changed over the simulation. The process is 
repeated by moving the minimum of the restraint governing the predefined coordinate to 
some higher or lower value. Each of the resultant trajectories is called a window. The 
individual windows must have some degree of overlap. This means that each recorded value 
of the coordinate must have been sampled in more than one window. The change in the 
coordinate between the windows must be small enough to ensure a quasi-static process. At 
the end, the biasing potential is removed and the potential of mean force (PMF) can be 
calculated, which represents the free energy change as a function of the coordinate 
(Lonsdale et al. 2012; Kästner 2011). Umbrella sampling can be used to calculate the free 
energy difference between two states (defined by the coordinate) through calculating PMF. 
That is why it was used in this work to simulate the reaction between some irreversible 
inhibitors and TG2. The elements of umbrella sampling are presented in the next sections. 
1.5.2.3.2.1 The coordinate 
Several system parameters can be used as the coordinate, or reaction coordinate (RC) for 
umbrella sampling simulations. The chosen RC should have the ability to represent the 
change between the initial and final stages of the system during the sampling simulations. It 
should also be possible to calculate the RC as a function of the atomic coordinates of the 
system being simulated. Accordingly, parameters such as distances, bond lengths, angles, 
dihedral angles, hydrogen bond lengths and root-mean-squared deviation (RMSD) from 
some reference structure, can all be used as reaction coordinates (Spiwok et al. 2015). 
1.5.2.3.2.2 The biasing potential 
During umbrella sampling, the RC is set to change from one value to another, where each of 
the 2 values characterises a definitive state of the system. As mentioned earlier, the change 
in RC between these 2 values is supposed to proceed over small steps, or windows and 
during each window a biasing potential is added to bring the desirable change. Usually, the 
biasing potential is applied in the form of a harmonic potential. The potential produced from 
applying the harmonic restraint is added to the energy of the system at that value of reaction 
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coordinate. This can then be removed to calculate PMF. The strength of the restraint is a 
criterion that requires attention; too low restraints will not be enough to push the system to 
cross the high energy barriers in the potential energy surface, and too high restraints will 
result in a very narrow distribution of RC with the subsequent lack of overlapping between 
the windows. Trying several values of the restraint, starting from the lowest possible and 
moving up until the change is observed with reasonable overlap indicates that the chosen 
restraint is suitable. This can be performed beforehand using smaller windows, but it will still 
be expensive in terms of computational time. The use of experimental values, if available, 
would produce more promising results (Kästner 2011; Mills & Andricioaei 2008). 
1.5.2.3.2.3 Potential of mean force 
The result from umbrella sampling is usually expressed as a graph of the free energy 
change in the system along the sampled reaction coordinate. This is the definition of PMF 
(potential of mean force). The free energy or the PMF is obtained from the time series of the 
changes in the reaction coordinate in each window under the influence of the biasing 
potential. The weighted histogram analysis method (WHAM) (Souaille & Roux 2001) is used 
to remove the effect of the biasing potential and calculate PMF based on the probability of 
the distribution of the reaction coordinate over the windows. For the best PMF results, 
WHAM requires that umbrella sampling windows are overlapping (Kästner 2011; Baştuğ et 
al. 2008). 
1.5.2.3.3 Steered molecular dynamics 
The concept of steered molecular dynamics (SMD) also involves the application of an 
external force or perturbation to drive a particular process in the desired direction, and thus 
would reduce the time needed to observe the final outcome. The work involved in the 
process could then be converted to binding free energy using the Jarzynski’s equality 
(Jarzynski 1997b; Isralewitz et al. 2001; Park et al. 2003; Suan Li & Khanh Mai 2012). 
Jarzynski’s equality (Jarzynski 1997a; Jarzynski 1997b) is a mathematical expression that is 
used to convert the work performed in non-equilibrium processes to a free energy. The basic 
equation is: 
𝑒
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𝑘𝐵𝑇
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𝑘𝐵𝑇
)
〉 
where 𝜟𝑮 is the free energy of the system, 𝑾 is the work performed in the process, 𝒌𝑩 is 
Boltzmann constant and 𝑻 is the temperature of the system. The angled brackets indicate an 
average of the work over a number of the non-equilibrium processes. 
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The main drawback in Jarzynski’s relationship lies in its very definition, where it applies only 
when the work is averaged over an infinite number of the non-equilibrium processes and 
when a finite number is used, correction must be applied to account for this bias (Dodson et 
al. 2012). Gore et al. (2003) have devised equations for the bias correction as well as the 
calculation of mean square errors associated with the bias correction. The equations involve 
calculating and correcting the dissipated work to ultimately calculate the bias-corrected 
Jarzynski’s average. 
1.5.2.3.4 Accelerated molecular dynamics 
This is another enhanced sampling method that is aimed at improving the exploration of the 
potential energy surface of the studied biological systems by allowing the biological systems 
to break free from the local energy minima in which they are trapped. A major difference 
between accelerated MD (aMD) and umbrella sampling is that the latter requires a 
knowledge of the system to define the coordinate along which to apply the biasing potential. 
In aMD, a biasing potential is added such that it would be used every time the system is 
trapped in a local minimum, and if the system is next to a barrier or a hill on the energy 
surface then the biasing potential will not be used. In this way, prior knowledge of the system 
is not an absolute requirement. As in umbrella sampling, the effect of the biasing potential 
can be removed at the end of the simulation. aMD has enabled access to milliseconds of 
simulation information by performing nanoseconds of simulations (Pierce et al. 2012; 
Hamelberg et al. 2004). 
The bias is added when the true potential of the system falls below a predefined value (E), 
which is an indication that the system is in a local minimum. The bias addition is done in 
such a way to keep the shape of the minimum; in other words, the bias will help in raising the 
minimum and smoothing the associated well rather than making it flat. The predefined value 
of the true potential (E), below which the bias will start acting, must be larger than the 
minimum potential of the system in its starting conformation; otherwise, the result would be 
conventional MD. The recommendation is to apply conventional MD for a short period and to 
calculate the average potential energy of the system at the end of this period. The average 
potential energy can then be used to define E (Pierce et al. 2012; Hamelberg et al. 2004). It 
is possible to obtain the original potential energy surface of the simulated system by 
reweighting the aMD simulation using exponential averaging and Boltzmann factor (Miao et 
al. 2014). 
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1.5.2.4 Quantum mechanical treatment 
As mentioned in the sections covering system resolution and force fields, conventional force 
fields mostly used in MD handle the systems as being composed of atoms connected by 
strings and have special terms to account for non-bonded interactions. In some situations, 
the system involves a chemical reaction between 2 or more molecules and there is bond 
formation and/or breakage during the reaction. Classical force fields cannot simulate such 
types of system, regardless of the simulation time allowed. 
QM methods deal with electronic structures; they account for electrons when handling the 
systems and hence can simulate chemical reactions. The main problem with these methods 
is their computational cost; because they deal with electrons, their simulations can take very 
long times. One way around the problem is to apply a combined quantum 
mechanics/molecular mechanics (QM/MM) method. In a QM/MM treatment, the reaction 
centre (for example and inhibitor and an active site residue) is treated by a QM method, 
while the rest of the system is treated by a classical force field using a MM method. The 
relatively small QM region will allow the simulation to be performed within an accessible time 
scale. The MM treatment enables the inclusion of the effect of the environment (remainder of 
protein structure, for example) on the reaction as well as any conformational changes 
associated with or resulting from the reaction (Ranaghan & Mulholland 2010). 
Two approaches for calculating the total energy of the system in QM/MM have been 
proposed. The first is the additive approach, in which the QM region is only treated by a QM 
method and the total energy of the system would be simply the sum of that of the QM region, 
the MM region and the energy of the interaction between the 2 regions (van der Kamp & 
Mulholland 2013). The 2nd approach is a subtractive method, in which the energy of the total 
system (including the QM region) is calculated by MM, and the energy of the QM region is 
calculated additionally by the QM method. The energy of the system is then taken as the 
sum of the total energy calculated by MM for the whole system and the energy of the QM 
region calculated by QM, and from this sum the energy of the QM region calculated by MM 
method is taken away (Vreven et al. 2006). 
If the QM region is covalently bound to the rest of the system (MM region), then additional 
atoms are added to the QM region at the positions of the covalent bonds linking the 2 
regions. They are called link atoms and are usually hydrogen atom. They are treated as 
being a part of the QM region and their main purpose is to satisfy the valence of the atoms at 
the interface between the 2 regions (Walker et al. 2008). Many QM methods are available to 
be used for QM/MM simulations. Semi-empirical methods such as AM1, PM3, PM6 and 
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SCC-DFTB are reasonable choices, considering that higher level methods such as ab initio 
methods are much more computationally expensive. It should be noted that it is the QM 
method and the treatment of the QM region that will determine the speed at which the 
simulation is performed (van der Kamp & Mulholland 2013). 
Two semi-empirical QM methods were used in QM/MM simulations in this work; PM3 and 
SCC-DFTB. Semi-empirical methods deal with electrons and molecular orbitals in their 
attempts to optimise or minimise molecular systems. They differ from the higher level ab 
initio methods in that certain aspects of the calculations have been simplified by 
parametrisation. PM3 (parameterisation method 3) belongs to a class of the semi-empirical 
methods called Modified Neglect of Diatomic Differential Overlap (MNDO) that is based on 
parametrising all two-electron integrals to avoid involving them in the calculations and 
therefore to save computational time. PM3 has been parametrised to reproduce large 
number of molecular properties. The method includes terms to handle hydrogen bonds, and 
many important elements were incorporated in the parameter set (Stewart 1989; Stewart 
2007). 
SCC-DFTB (self-consistent charge density functional tight-binding) is an approximation for 
the density functional theory (DFT) method, which is one of the ab initio methods (Elstner 
2006). The Hartree-Fock method handles single electrons, and when an electron is being 
treated, the other electrons in the system are fixed. DFT moves around this approximation 
by dealing with the electron density. With the latter, it is possible to represent the density of 
all the electrons by 3 variables, rather than 3 variables for each electron in the system. The 
energy is then taken as a functional (function of a function) of the electron density, and by 
minimising the density, the geometry is optimised (Orio et al. 2009). 
Tight binding is a semi-empirical approximation to DFT, which assumes that the electrons 
are tightly bound to the atoms and have limited interactions with the surrounding 
environment (Goringe et al. 1997). This allows introducing an approximation to the electron 
density by splitting it into a tightly bound reference region and an external region on which 
the calculation is performed (Foulkes & Haydock 1989). SCC-DFTB is a variation of DFTB in 
which the charge fluctuation is taken into account by decomposing the electron density into 
atomic-like contributions which fade as the distance from the atoms is increased (Elfturi 
2014). 
1.5.2.5 Principal component analysis 
Principal component analysis (PCA) is a statistical method used to reduce the complexity of 
large data sets, such as MD trajectories. PCA extracts from the trajectories principal 
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components (PCs), each of which corresponds to a distinct molecular motion mode within 
the trajectory. Each PC is an eigenvector that has an eigenvalue, where the latter can 
numerically describe the contribution of that particular PC to the total motion within the MD 
trajectory. By comparing the PCs and their eigenvalues, it is possible to discriminate 
between important modes of motion from those that are not very influential. This will greatly 
facilitate the analysis of large MD trajectories, by giving the opportunity to focus the analysis 
on the major modes of motion observed during a given MD simulation (Ng et al. 2013; 
Skjaerven et al. 2011; David & Jacobs 2014). 
1.5.2.6 AMBER overview 
AMBER 12 (Case et al. 2012) was the version of AMBER that was used to run various MD 
simulations in this work. AMBER refers to a collection of force fields designed to handle 
various biological molecules including proteins, nucleic acids and lipids in addition to small 
organic molecules. The term AMBER also applies to a package of programs and codes 
designed to perform various functions related to MD. The most important of these programs 
are presented below (Salomon-Ferrer, Case, et al. 2013). 
1.5.2.6.1 sander 
Sander (simulated annealing with NMR-derived energy restraints) is the main program within 
AMBER involved in running MD. It is also responsible for running replica exchange and 
QM/MM simulations. 
1.5.2.6.2 pmemd 
This program is similar to sander but is applicable to a narrower range of MD simulations. It 
is faster than sander and performs better on parallel cores. It also includes the GPU 
acceleration recently introduced to AMBER (Salomon-Ferrer, Götz, et al. 2013). 
1.5.2.6.3 LEaP 
This is the program used to generate the parameter-topology and coordinate files that can 
be read by sander and pmemd to run MD. It can read PDB files and it can add hydrogen 
atoms, water molecules and neutralising ions. 
1.5.2.6.4 antechamber 
This program is similar to LEaP but is used to generate the input files for small organic 
molecules that are not included in the standard AMBER force fields. Its output files are then 
Chapter 1   General Introduction 
55 
 
loaded into LEaP to be used with the files for the biological molecule (Wang et al. 2006; 
Wang et al. 2004). 
1.5.2.6.5 CPPTRAJ 
This program is used for the analysis of the trajectories generated from various MD runs. It 
can calculate a wide range of information including distances between specific atoms, 
hydrogen bonds, root-mean-squared deviations from a reference structure, atomic 
fluctuations of the individual residues during a simulation, principal component analysis and 
many more (Roe & Cheatham 2013). 
1.5.2.6.6 MMPBSA.py 
This is another program that is used for post-processing purposes where it can be applied 
following a simulation of a complex between two molecules (ligand and protein for example) 
to calculate an estimate of the binding energy between the 2 molecules (Srinivasan et al. 
1998; Miller et al. 2012). 
AMBER programs and force fields are very popular MD tools. AMBER as a software has 
been cited more than 4,000 times until 2013 whereas AMBER force fields have been cited 
more than 9,000 times to that year (Salomon-Ferrer, Case, et al. 2013). 
1.5.3 Molecular docking 
Molecular docking, or docking for short, is another computational method used to predict the 
interaction between two molecules, usually a ligand and a receptor. This prediction involves 
posing the ligand within a binding site in the receptor. An accurate guess of the binding 
mode is an important goal for docking, and together with correct estimation of the binding 
affinity that reflects biological activity of the ligand, represents the major sites of development 
of docking softwares. For posing the ligand in the binding site, the software uses a docking 
method to find the most plausible mode for ligand binding. This is not a straightforward task 
due to the large number of conformations a ligand molecule can adopt. For the prediction of 
the binding affinity, a scoring function is applied on the poses generated by the docking 
method to score the poses based on the interactions between the ligand and the receptor 
(Kitchen et al. 2004). 
1.5.3.1 The docking method 
The docking method or the search algorithm attempts to reproduce the experimental binding 
mode for a ligand in the binding site of a receptor, or to predict the binding mode if no 
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experimental one is identified. The algorithm accomplishes that by exploring the degrees of 
freedom of the ligand, and sometimes, of the receptor active site. Ideally, all the degrees of 
freedom of the involved residues should be tested and the resultant binding modes 
examined, but this approach is not applicable as it would be computationally very expensive. 
Therefore, approximations are applied to make the process more computationally 
accessible; restraints and constraints are applied to the ligand to limit its degrees of freedom, 
and the binding site of the receptor is treated as rigid body or partially flexible (Meng et al. 
2011; Taylor et al. 2002). How the docking methods or the searching algorithms differ in the 
handling of the flexibility of the ligand and the receptor represents the major determinant of 
the method category. 
1.5.3.1.1 Docking methods handling ligand flexibility 
These docking methods were designed mainly to find a way of posing the ligand within the 
binding site of the receptor. They are more concerned about handling the flexibility of the 
ligand than that of the receptor. 
1.5.3.1.1.1 Shape-matching search algorithms 
The basis of these docking algorithms is that they generate binding modes by fitting the 
ligand within the binding site of the receptor, such that the molecular surface of the ligand 
complements the molecular surface of the receptor binding site. They are the simplest of the 
docking methods and the most efficient in terms of computational time required to perform a 
docking task. Their accuracy, however, is limited by the rigid treatment of the ligand. The 
shape-matching methods are usually applied during virtual screening of libraries of 
thousands of compounds to identify hits, that could then be tested using more rigorous 
search methods (Meng et al. 2011; Huang & Zou 2010). 
1.5.3.1.1.2 Systematic search algorithms 
Two type of search algorithms fall under this category, the exhaustive search and 
fragmentation methods. In exhaustive search algorithms, ideally, all of the ligand’s degrees 
of freedom are explored and since this is not computationally practical, some constraints are 
added to the ligand to reduce the number of rotatable bonds and hasten the searching 
process (Huang & Zou 2010; Friesner et al. 2004). The fragmentation method is also called 
incremental construction and involves breaking the ligand into small pieces at its rotatable 
bonds, and then rebuilding the ligand within the binding site piece by piece. Usually, a 
nucleus from the ligand is selected to be docked first (anchor). This, typically, is the largest 
core in the ligand and/or is responsible for important interactions with the binding site. The 
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remainder of the ligand is added incrementally to the anchor. The final outcome is the 
generation of several possible orientations of the ligand with better handling of its flexibility 
(Meng et al. 2011; Cross 2005). 
1.5.3.1.1.3 Stochastic or random searching algorithms 
These methods produce random changes to the ligand within the binding site to generate a 
binding mode. The changes are accepted or rejected after being judged by a predefined 
probability function. Different random algorithms have been proposed based on the criteria 
for accepting or rejecting the random changes (Sousa et al. 2006). Monte Carlo is an 
example of random searching method that utilises a Boltzmann-based probability function to 
judge the quality of the random alterations on the ligand. The function takes the decision 
based on the energy scores of the ligand before and after the alteration. Monte Carlo 
methods are computationally efficient when compared to MD methods, as the energy 
function is simpler and due to the ability of Monte Carlo methods to cross high energy 
barriers (Sousa et al. 2006; Meng et al. 2011). Tabu searching is another random algorithm, 
which performs docking by randomly changing the pose of the ligand within the binding site. 
The decision to accept or reject a new pose is based on comparing the RMSD of the new 
pose to all the previously generated poses. The algorithm also prevents the generation of 
previously explored poses by keeping a record of them (Kitchen et al. 2004; Sousa et al. 
2006). 
Another type of the random searching methods is the genetic algorithm. As the name 
suggests, these algorithms use the principles of genetics and evolution to perform docking. 
The ligand’s degrees of freedom; its rotation, orientation and translation, are encoded into 
chromosomes as genes. Therefore, the chromosome would be composed of genes that 
define the states of the ligand (genotype) while the atomic coordinates resulting from the 
genotype represent the actual pose of the ligand within the binding site (phenotype). The 
chromosomes are altered randomly by applying genetic operations, namely mutations and 
crossovers to produce new chromosomes, and thereby, new poses for the ligand. Mutations 
involve making random changes to the genes constituting the chromosomes, and crossover 
operations exchange genes between chromosomes. Any new pose generated by the genetic 
operations is scored by a fitness or a scoring function; if the score is better than the that of 
the previous genotype, the resultant pose is retained and subjected to further alterations, 
and if the score was worse, the pose is rejected and the previous pose is altered differently. 
The process is repeated until a predefined number of operations is reached (Meng et al. 
2011; Sousa et al. 2006; Jones et al. 1995). 
Chapter 1   General Introduction 
58 
 
1.5.3.1.2 Docking methods handling receptor flexibility 
Receptors, usually proteins, are dynamic molecules that are in continuous motion within the 
biological system. This is complicated by the conformational changes induced in the receptor 
by the binding of the ligand (ligand-induced fit). In order to simulate the docking process 
more realistically, the protein potential to move should be taken into consideration. However, 
because of the huge magnitude of the degrees of freedom of the protein, this is not usually a 
straightforward task (Huang & Zou 2010). The following methods have been used as 
approaches to tackle the issue of receptor flexibility in docking. 
1.5.3.1.2.1 Soft docking 
Using soft potentials in docking is the easiest and fastest method to handle protein flexibility. 
The method involves softening the van der Waals component of the scoring functions. The 
result is allowing or tolerating some clashes or overlaps between the ligand atoms and those 
from the receptor. Being fast and computationally efficient is the major advantage of the 
method. However, it can only handle minor side chain movements in the protein and cannot 
represent backbone dynamics (B-Rao et al. 2009; CCDC Software Limited 2013). 
1.5.3.1.2.2 Rotamer libraries 
Rotamer libraries represent a database for the most commonly observed conformations or 
rotamers for the side chains of the amino acids. Implementing such databases in the docking 
software allows the program to perform a survey of the possible conformations the side 
chain of a particular amino acid can adopt during docking to produce the most favourable 
complex for the ligand and the receptor. The computational cost is highly dependent on the 
size of the library. The method only handles side chains and cannot produce conformations 
that are not included in the library (B-Rao et al. 2009; Alberts et al. 2005). An example of 
rotamer libraries is the Penultimate library (Lovell et al. 2000) that is used by the docking 
program GOLD (Genetic Optimisation for Ligand Docking) (CCDC Software Limited 2013). 
1.5.3.1.2.3 Docking into multiple protein structures 
This approach is similar in concept to applying rotamer libraries and involves performing the 
docking task of the same ligand more than once into different conformations of the same 
receptor while treating each receptor conformation as a rigid body. Depending on the 
number of receptor structures used, the method can be computationally expensive but it will 
be able to handle side chain and backbone motions in the receptor. It should be noted that 
the chosen structures may not represent the entire conformational space of the receptor 
(Huang & Zou 2007; B-Rao et al. 2009). The multiple structures of the protein can be 
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obtained from a variety of sources including NMR structures, multiple X-ray structures of the 
same protein or conformations of the protein generated from a MD simulation on an initial 
structure (Carlson 2002). 
Ensemble docking is a variation of docking into multiple protein structures, in which an 
average grid structure for the receptor is generated from the multiple conformations before 
docking, and a rigid docking is performed on the single average structure. The approach is 
more efficient in terms of the computational time required, but the drawbacks include that not 
all the features in the structures can be averaged, and the resultant structure may produce 
non-realistic ‘artificial’ complexes with the ligands (Cozzini et al. 2008). 
1.5.3.1.2.4 Molecular relaxation 
This approach involves firstly docking the ligand into the binding site of the receptor without 
any account for receptor flexibility. Then, the generated complex is relaxed as a whole or just 
the part that involves the ligand and the neighbouring receptor residues. The relaxation is 
performed through MD simulations. These methods allow for the exploration of a wider 
space of the conformational universe of the protein, including its backbone. They also give 
the possibility of testing the stability of the docking generated poses of the ligands; in other 
words, the methods enable the monitoring of the ability of the ligand to maintain its pose for 
any given period of simulations time. The main drawback of relaxation methods, however, is 
that they are computationally very expensive. MD can also be used on the receptor on its 
own to generate multiple conformations that could be used separately (Hospital et al. 2015; 
B-Rao et al. 2009; Huang & Zou 2010). 
1.5.3.2 The scoring function 
A scoring function is the second half of any docking protocol besides the searching 
algorithm. Scoring functions are responsible for estimating the binding free energy of the 
complexes generated by the searching algorithm. They are included in the docking process 
for several purposes; to distinguish between a correct binding mode of the ligand within the 
binding site from an incorrect one, to rank the generated poses of the ligand based on their 
binding affinities, to discriminate between active compounds and non-binders, and to rank 
several active compounds according to their biological activities toward the receptor. An 
ideal scoring function would be able to do all that, but this will be computationally impractical. 
Therefore, scoring functions are developed with approximations to achieve reliable results 
within feasible computation time (Meng et al. 2011; Sousa et al. 2006). The types of most 
widely used scoring functions are presented below. 
Chapter 1   General Introduction 
60 
 
1.5.3.2.1 Force field-based scoring functions 
Force field functions attempt to estimate the binding energy between the ligand and the 
receptor by calculating two terms, the ligand internal energy and the energy of the non-
bonded interactions between the ligand and the receptor. The non-bonded interactions 
involved are of two types, van der Waals interactions, which are calculated by a Lennard-
Jones potential, and electrostatic interactions estimated through a Columbic formula (Sousa 
et al. 2006). Classical functions of this kind do not account for hydrogen bonds and solvation 
and entropic effects and include a cut-off distance for handling long range non-bonded 
interactions. Some newer functions based on force fields do include terms for hydrogen 
bonds or solvation (Meng et al. 2011). An example is the GoldScore function used within the 
GOLD docking program (CCDC Software Limited 2013; Verdonk et al. 2003). 
1.5.3.2.2 Empirical scoring functions 
The binding free energy between the ligand and the receptor in this type of functions is 
decomposed into several terms that describe hydrogen bonding, van der Walls interactions, 
metal ligation, hydrophobic effects, entropy, solvation and electrostatic interactions. 
Parameters for those terms are included in the scoring function for the calculation of the 
binding energy. The parameters are derived from a defined set of protein-ligand complexes, 
usually from the Protein Data Bank. Empirical scoring functions are more efficient than the 
force field functions because of their simpler energy terms. Nonetheless, their performance 
is highly dependent on the training set used to derive the parameters and may not function 
with the same efficiency between different protein-ligand systems (Meng et al. 2011; Huang 
& Zou 2010). 
1.5.3.2.3 Knowledge-based scoring functions 
Knowledge-based scoring functions estimate the score of a particular pose for the ligand 
within the binding site by calculating the sum of interaction energies between each atom pair 
from the ligand and the protein, within a predefined cut-off sphere. The interaction energies 
for the atom pairs are obtained from a statistical analysis of different ligand-receptor atom 
pairs in crystal structures, after converting them into distance dependent pairwise potential 
(potential of mean force or PMF). This type of scoring functions provides a compromise 
between speed and accuracy and is a middle ground between the previously mentioned 
scoring functions (Moitessier et al. 2008; Huang & Zou 2010). 
Consensus and clustering scorings are scoring techniques designed to improve the scores 
obtained from the various scoring functions. In the former, the scoring information from 
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multiple scoring functions is merged to obtain better, consensus score. In clustering scoring, 
the generated binding modes for the ligand are clustered and the entropic contribution to 
scoring can be estimated by examining the clusters, thereby, adding entropic impact to the 
docking score (Huang & Zou 2010). 
1.5.3.3 GOLD overview 
GOLD (Genetic Optimisation for Ligand Docking) program version 5.2.2 (CCDC Software 
Limited 2013; Jones et al. 1997; Jones et al. 1995; Nissink et al. 2002; Verdonk et al. 2003; 
Cole et al. 2005; Verdonk et al. 2005; Hartshorn et al. 2007) was the main docking software 
used during the course of this thesis. The docking method used in the program is genetic 
algorithm that provides flexible treatment of the ligand and optional flexible handling of the 
side chains of up to 10 residues of the receptor active site. The flexible treatment of the 
receptor is achieved through one of 3 options; either allowing the side chain to rotate freely, 
choosing rotamers for the side chain from the Penultimate rotamer library (Lovell et al. 2000) 
or choosing the rotamers for the side chain that are specified in the PDB file for the protein. 
In addition to rotamers, the program offers the possibility of docking with soft potentials for 
any number of active site residues. GOLD is equipped with 4 different scoring functions; the 
Astex Statistical Potential (ASP) scoring function (Mooij & Verdonk 2005) (knowledge-
based), ChemScore (Eldridge et al. 1997; Baxter et al. 1998) (empirical), CHEMPLP (Korb et 
al. 2009) (empirical) and GoldScore (Verdonk et al. 2003) (force field). Detailed description 
and comparisons between the scoring functions is presented in section 3.6. 
Besides standard docking, GOLD provides some non-standard docking functions. Examples 
are the possibility of including up to 25 water molecules within the active site to test the 
effects of the presence of water on the docking in terms of water displacement and using 
water to mediate interactions with the protein. Another function is the use of hydrogen 
bonding constraints during docking. This utility forces the formation of a hydrogen bond 
between predefined atoms from the ligand and the protein and is used to reproduce certain 
structural hydrogen bonds during the docking. The third example involves docking with a 
distance constraint, which is similar to the hydrogen bond constraint in specifying a ligand 
atom and a protein atom and forcing them during the docking process to lie within a 
predefined distance range. The final example is the possibility of covalent docking, in which 
GOLD forces the formation of a covalent bond between predefined atoms from the ligand 
and the protein, and poses the rest of the ligand accordingly. In the biased docking methods 
(hydrogen bond and distance constraint), a penalty is added to the score if the specified 
conditions are not met. 
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1.6 Computational Chemistry and TG2 Inhibitors 
Very few studies used computational chemistry techniques to aid in the design and testing of 
TG2 inhibitors. One of the earliest studies was by Iwata et al. (2000) and involved docking a 
series of in vitro tested compounds with a cyclopropenone ring against FXIIIA. Their results 
showed that the cyclopropenone ring should come close to the catalytic cysteine for activity. 
They also pointed the importance of a neighbouring tryptophan residue through forming a 
hydrogen bond with the inhibitor. The tryptophan residue (TRP279) is located at the top of 
the tunnel in which the catalytic cysteine is located and corresponds to residue TRP241 in 
TG2 (more details in section 3.1). Additionally, they showed that the terminal phenyl ring of 
the inhibitor would position in the hydrophobic region of the enzyme active site. 
Chica et al. (2004) performed molecular modelling experiments involving their proposed 
peptide substrates of TG2 (section 1.4.2.1) to aid in the understanding of the mode of 
binding of the substrate. The researchers performed docking and molecular dynamics (MD) 
studies using the coordinates for red sea bream TG2. Their most significant findings were 
the role of TRP329 (TRP332 in human version) in acting as a gate to the active site, where 
its side chain moves to open and close the active site, possibly depending on calcium ion 
concentration. They also recorded a hydrophobic interaction with the substrate involving 
TRP236 (TRP241 in human TG2) that is important for positioning the glutamine residue to 
the catalytic cysteine. 
Another study was performed by Tagami et al. (2009) to investigate the binding mode of a 
peptide substrate (Cbz-Gln-Gly) to microbial transglutaminase using a docking study and 
MD. They were able to conclude that a distance of around 4 Å between the side chain of 
glutamine residue in the substrate and the catalytic cysteine sulphur atom is important for 
activity along with some pi-interactions between the substrate and some active site residues 
such as leucine, isoleucine, phenylalanine and tyrosine. 
Prime, Andersen, et al. (2012) conducted GOLD covalent docking experiments on 
compound i10 (the initial sulphonamide modification, Figure 1-13). Their results identified the 
key residues of TG2 which are involved in forming interactions with the inhibitors. Examples 
of these interactions included hydrogen bonds between the warhead acrylamide CONH 
groups and TRP241 and GLN276. The generated poses also suggested the possibility of 
hydrogen bonding involving the central sulphonamide group and ASN333. This potential 
hydrogen bond would facilitate the interactions of the lipophilic part of the inhibitor within the 
hydrophobic loop of TG2 active site. That was the basis for their next series of modifications 
(section 1.4.2.2). 
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The study published by Badarau, Mongeot, et al. (2013) also included docking and MD. Two 
inhibitors with sulfonium ion and imidazolium warheads were docked into TG2 active site 
and MD simulation was applied on the docked complexes to examine the change in pose 
with time. The docking and MD results showed that the inhibitors adopt a bent conformation 
to facilitate the access of the warhead to the catalytic cysteine residue. The bent 
conformation involves posing the warhead deep in the catalytic tunnel. A hydrogen bond with 
residue TRP241 was seen to stabilise the bent conformation during MD simulation, in 
addition to interactions with TRP332 (the other bridging tryptophan residue). These 
interactions were mostly evident with the imidazolium warhead, and the authors suggested 
that they are responsible for the lower selectivity towards FXIIIA because these residues are 
conserved in FXIIIA (Badarau, Mongeot, et al. 2013). 
No studies are available that include docking of larger sets of compounds or examination of 
the interactions within TG2 active site in more details. Furthermore, MD simulations, which 
are very powerful tools in computational chemistry, have not been used extensively with 
regard to TG2. 
1.7 Aim and Objectives 
The project involved computational analysis of TG2 enzyme and its inhibitors with the 
ultimate aim of developing modelling methodologies that could aid in the design and testing 
of new potential inhibitors for the enzyme. Towards this aim, a series of computational 
objectives have been sought. These included: 
 Docking a small set of known TG2 inhibitors into the enzyme active site. 
 Application of MD to the docked complexes. 
 Development of TG2 active site models from the MD trajectories. 
 Validation of the TG2 models by docking of additional known TG2 inhibitors, MD 
simulations, covalent docking and binding free energy calculations, with a view to 
establishing a correlation between the experimentally-determined biological activities 
and calculated molecular properties such as docking scores and binding free 
energies. 
 Investigation of the mechanism of covalent inhibition of TG2 by the use of QM 
methods with the aid of techniques such as umbrella sampling and reaction path 
experiments, with a view to establishing a correlation between experimentally-
determined biological activities and activation energies and reaction energies. 
 Attempting to validate predicted allosteric sites of inhibition in TG2 for known 
allosteric inhibitors by means of docking and MD simulations. 
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2 Materials and Methods 
A general description of the methods followed during the course of this thesis is presented in 
this chapter, proceeded by a listing of the computers and the programs used to carry out the 
simulations. Some specifics for certain calculations are mentioned in the relevant results 
chapters. 
2.1 Materials 
2.1.1 Computers 
For Microsoft Windows XP® Professional Version 2002 Service Pack 3, a desktop computer 
with the following specifications was used: Intel(R) Core(TM) i7-2600, CPU 3.4 GHz, RAM 
2.94 GB. A Windows 7 Enterprise® 64-bit computer with the following specifications was 
also used; Intel(R) Core(TM) i5, CPU 3.4 GHz, RAM of 6.00 GB. Ubuntu 12.04 operating 
system was used to run the AMBER Package on an Intel(R) Core(TM) i7-3820 with a CPU 
of 3.6 GHz and a RAM 6 GB desktop computer. The latter computer is also equipped with 
two GeForce® GTX TITAN GPU cards from NVIDIA®, each with 6 GB of memory and 2688 
CUDA cores. This was the main PC used for AMBER. In addition, AMBER was run on a 
number of other PCs and Aston University servers. The PCs were similar to the main Ubuntu 
PC but with GeForce® GTX 780 GPU cards, also from NVIDIA®. The servers had 
GeForce® GTX 780 and GeForce® GTX 780 Ti and their CPUs were Intel(R) Xeon(R) and 
varying memories. All the PCs and servers are the property of Aston University. 
2.1.2 Programs 
1. AMBER (Assisted Model Building and Energy Refinement) Package, Version 12 
(Case et al. 2012), was used for the minimisation of the protein and later on for the 
MD simulation. This version of AMBER supports GPU acceleration through CUDA 
(CUDART driver version 5.5 and CUDA Runtime version 5.0) (Salomon-Ferrer, Götz, 
et al. 2013). 
2. AmberTools 13 (Salomon-Ferrer, Case, et al. 2013) is a package of supporting 
programs developed by AMBER group for the preparation of input and analysis of 
AMBER MD trajectories. Example programs used in this work include LEaP which 
was used for the generation of input files for MD, antechamber which was used for 
the generation of parameter and topology files of non-standard residues, CPPTRAJ 
was used to perform the post-MD analysis on the trajectories including calculating 
root-mean-square deviation (RMSD), hydrogen bond profiles and others, and 
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MMPBSA.py used for the calculation of the binding free energy between ligands and 
protein after a MD simulation (section 1.5.2.6). 
3. GOLD Suite (Genetic Optimisation for Ligand Docking) Version 5.2.2 (CCDC 
Software Limited 2013; Jones et al. 1997; Jones et al. 1995; Nissink et al. 2002; 
Verdonk et al. 2003; Cole et al. 2005; Verdonk et al. 2005; Hartshorn et al. 2007) was 
used for various types of docking applied in the course of this work, for instance, 
flexible active site, covalent and water dockings. 
4. CAChe (Computer-Aided Chemistry) WorkSystem Pro Version 7.5 (Fujitsu Limited 
2006) was used for the drawing and minimisation of test compounds, docking and 
preparing the enzyme for MD. CAChe was also used to perform reaction path 
experiments on the sulfonium ion TG2 inhibitors. 
5. Accelrys Discovery Studio (DS) Visualizer Version 3.5 and 4.0 (Accelrys Software 
Incorporation 2012; Accelrys Software Incorporation 2013) was used for visualisation 
of the docked complexes and analysis of the interactions between the compounds 
and the active site. It was also used to generate the 3-dimensional pictures presented 
in this work. 
6. VMD (Visual Molecular Dynamics) Version 1.9 (Humphrey et al. 1996) was used for 
visual inspection of MD trajectories as well as for performing analysis on the 
trajectories including hydrogen bonding and RMSD. 
7. GAMESS (General Atomic and Molecular Electronic Structure System) version 13-64 
(Schmidt et al. 1993) was used to calculate the electrostatic potential for ligands 
during covalent docking and MD. 
8. pyPcazip (Shkurti et al. 2016) was the program used to perform the principal 
component analysis (PCA) for the MD simulations. 
AMBER, CPPTRAJ and pyPcazip were run under Ubuntu. The others were run on Windows 
(7 and XP). VMD was run on both. 
2.1.3 Compounds 
A range of active and inactive TG2 inhibitors were used in this work for the testing and 
validation of the various active site models and for the subsequent experiments. The details 
of the structures of the used compounds are in the relevant results chapters. The 
compounds were mainly adopted from the work by Badarau et al. (2015) and the associated 
patent (Griffin et al. 2014). 
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2.2 Methods 
2.2.1 Chapter 3 methods (model development and validation) 
2.2.1.1 MD simulation on empty TG2  
2.2.1.1.1 Preparation of TG2 for molecular dynamics 
The crystal structure of TG2 was downloaded from the Protein Data Bank (www.rcsb.org) 
(Berman et al. 2000) as the PDB entry 2Q3Z (Pinkas et al. 2007). Human TG2 contains 687 
amino acid residues; in the crystal structure 2Q3Z, 32 of these residues were missing. In 
addition, the structure contains a covalently bound inhibitor, Ac-P(DON)LPF-NH2, in the 
active site that is connected to CYS277 by a covalent linkage. The structure also contains 5 
sulphate ions and 261 water molecules. The names and numbers of the missing residues 
are (Pinkas et al. 2007): 
GLN307, ASN308, GLU319, PHE320, GLY321, GLU322, ILE323, GLN324, GLY325, 
ASP326, LYS327, GLN407, ASP408, ASP409, GLY410, SER411, VAL412, HIS413, 
LEU462, ASN463, LYS464, LEU465, ALA466, GLU467, LYS468, GLU469, GLU470, 
THR471, ILE684, GLY685, PRO686, ALA687  
All the missing residues were added using CAChe Workspace’s ‘Insert Residue’ function. 
Hydrogen atoms were added to the structure and water molecules and sulphate ions 
deleted. The whole protein was then locked (atoms’ X, Y and Z coordinates frozen) with the 
exception of the added residues and an MM2 energy minimisation (Allinger 1977) was 
applied to relax these added residues. Residues 1-154 and 586-687 were deleted being far 
from the active site (Badarau, Mongeot, et al. 2013) to reduce computational cost. The 
remaining residues represent the catalytic core in TG2, while the deleted residues represent 
the N-terminal β-sandwich and the C-terminal β-barrels (section 1.2.3). 
At this point the active site was defined. It was taken as a sphere of radius 8 Å working 
outwards from residues TRP241 and TRP332 (bridging residues of the active site tunnel, 
more detail in Chapter 3). The inhibitor was deleted and the residues forming the active site 
were recorded. CAChe Workspace was used for this. This is a list of these active site 
residues: 
GLY170, SER171, ALA172, ASN229, LEU237, LEU238, GLY239, ARG240, TRP241, 
ASP242, ASN243, ASN244, TYR245, SER250, PRO251, MET252, TYR274, GLY275, 
GLN276, CYS277, TRP278, VAL279, PHE280, THR299, ASN300, TYR301, ASN302, 
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SER303, ALA304, PHE316, ARG317, ASP326, LYS327, SER328, GLU329, MET330, 
ILE331, TRP332, ASN333, PHE334, HIS335, CYS336, TRP337, ASP358, PRO359, 
THR360, PRO361, GLN362, ALA395, GLU396, LEU420, ILE421, VAL422, GLY423, 
LEU424. 
Hydrogen atoms were deleted and a PDB file was saved as the starting point for the MD run. 
CYS277 was converted to CYM for AMBER to handle it as deprotonated and HIS335 to HIP 
to be treated as protonated. 
The file was loaded into the LEaP program of the AMBER package to prepare the 
parameter-topology (PRMTOP) and coordinate (INPCRD) files using the AMBER force field 
ff99SB (Hornak et al. 2006). Before that 10 sodium ions were added to neutralise the charge 
of the protein. The latter was then solvated in a truncated octahedron of TIP3P (transferable 
intermolecular potential 3P) (Jorgensen et al. 1983) water molecules that extended for 8 Å 
from the protein surface. The total number of water molecules that were added was 7486. 
Finally, the PRMTOP and INPCRD files were generated and saved. 
2.2.1.1.2 Applying energy minimisation 
The PMEMD (Particle Mesh Ewald Molecular Dynamics) program of the AMBER package 
was used to run the minimisation on TG2. The minimisation was run for 2,000 cycles 
(maxcyc = 2000) using steepest descent for the first 1,000 cycles and conjugate gradient for 
the second 1,000 cycles (ncyc = 1000). The cut-off distance for treating non-bonded 
interactions was taken as 12 Å. Also, the minimisation was run at a constant volume (ntb = 
1) with no pressure scaling, and using an explicit water model (igb = 0). 
2.2.1.1.3 Initial MD simulation (MD1), heating up the system 
The minimisation output file was used as the starting point for this stage of the MD 
simulation (ntx = 1). The heating stage of MD was also run under constant volume (ntb = 1) 
using a cut-off distance of 12 Å without any restraints (ntr = 0). An explicit water model was 
used (igb = 0) and the temperature of the system was taken from 0-300 K using Langevin 
dynamics (ntt = 3) at a collision frequency of 1 ps-1 (gamma_in = 1). The simulation was run 
for 20,000 steps (nstlim = 20000) at 0.001 ps time step for a total of 20 ps. The random 
number generator (ig = -1) was used during this stage. 
2.2.1.1.4 Second MD simulation (MD2), equilibrating the system 
The restart file obtained at the end of MD1 was used as the starting structure for this stage 
of the MD simulation. MD2 was run at constant temperature of 300 K for 5 nanoseconds 
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(5,000,000 steps of 0.001 picoseconds). The simulation was run under constant pressure 
periodic boundaries (ntb = 2) using isotropic position scaling (ntp = 1). Updating output files 
was done every 10,000 steps. The remaining criteria were the same as those of MD1. The 
random number generator was also applied during the equilibration phase. 
2.2.1.1.5 Third MD simulation (MD2_fast), production phase 
Again, the restart file of MD2 was used to start this stage of MD. The simulation was run for 
30 ns (15,000,000 steps of 0.002 ps). In this stage, constant volume periodic boundaries 
were applied with no pressure scaling (ntb = 1, ntp = 0). The run was also performed at 
constant temperature (300 K) but this time using the weak coupling algorithm with zero 
collision frequency (gamma_in = 0). The SHAKE algorithm was applied to restrain bonds 
involving hydrogen atoms (ntc = 2, ntf = 2). The wrapping function (iwrap = 1) was used in 
this stage so that the coordinates written to the output files were to be wrapped into the 
primary box to make the trajectory more realistic. The output files were updated every 
12,500 steps. 
During the heating phase (MD1), using constant pressure will result in an unstable system 
as the system is cold at the start. However, constant pressure must be used during the 
equilibration phase (MD2) to allow for the density of the system, and water molecules in 
particular, to equilibrate. The weak coupling algorithm (ntt=1) was used in the production 
phase (MD2_fast) to hasten the calculation. This algorithm does not ensure even distribution 
of the temperature and therefore should only be used after equilibrating the system (Walker 
& Cheatham 2010). 
The minimisation and the three stages of MD simulation were applied using the CUDA 
version of commands for AMBER 12 that involves the use of GPUs rather than CPUs to run 
AMBER calculations (Götz et al. 2012; Le Grand et al. 2013; Salomon-Ferrer, Götz, et al. 
2013). 
The production run was continued by applying new simulations at the end of every 30-ns 
simulation using the restart file from the last simulation as the starting structure for the new 
one. To take the system to a simulation time of 515 nanoseconds, MD2_fast was repeated 
17 times (5 ns from equilibration plus 30ns*17 for each production run). The CPPTRAJ 
program of the AmberTools was used with each resulting trajectory from MD2_fast to centre 
the protein in the solvent box. CPPTRAJ was also used to generate a single trajectory 
combining all the individual trajectories to be used later by the same program for the 
generation of RMSD and atomic fluctuation charts. A PERL script was used to extract 
temperature and energy data from the OUT files for the analysis of the resulting trajectories. 
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2.2.1.1.6 Extracting models from MD trajectory 
The VMD program was used for the extraction of conformations from the production phase 
trajectories. The conformations used for the initial docking were taken at every 5 ns starting 
from the tenth to the 100th nanosecond. The models were named by the nanosecond at 
which they were taken. These conformations were edited in a text editor to remove water 
molecules and sodium ions and to convert CYM and HIP to CYS and HIS respectively. Each 
of the conformations was checked for structural plausibility by means of a Ramachandran 
plot (Ramachandran & Sasisekharan 1968) using DS Visualizer. 
2.2.1.2 Preparation of the compounds 
All the test compounds used in this work were drawn and corrected for bond lengths, bond 
angles and atom valence and hybridisation states using CAChe Workspace. They were then 
energy minimised using a molecular mechanics force field (MM2) (Allinger 1977) and a 
semi-empirical quantum mechanics with PM3 parameter set (Stewart 1989; Stewart 2002) 
methods. CONFLEX conformational search (Gotō & Ōsawa 1993) was also applied to the 
rotatable bonds within the individual compounds prior to the PM3 energy minimisation. The 
energy minimisation and the CONFLEX search were performed using the CAChe 
Workspace. 
2.2.1.3 Docking 
At this stage of docking, the objective was to obtain some valid complexes to run MD on. For 
this reason, only six active test compounds were used. 
2.2.1.3.1 CAChe docking 
The FastDock program within CAChe Project Leader was used to perform the docking study. 
The following specifications were used for the docking: 
Type of docking: Flexible active site side chains and flexible ligands. 
Docking method: Lamarckian genetic algorithm 
Scoring Function: PMF (potential of mean force) 
Calculation Type: Dock (Use Grids) 
Use Amber van der Waals: Grid Spacing (Å) 0.30000 
Pop Size: 50 
Crossover Rate: 0.80000 
Elitism: 5 
Maximum Generations: 3000 
Mutation Rate: 0.20000 
Convergence: 1.0000 
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Four dockings were performed for each compound to increase the probability of finding the 
correct binding mode. All the complexes of the docking results were converted to PDB files 
to be viewed by DS Visualizer for analysis of the docking pose. Typically, the run time for a 
single docking was in the region of 4 hours. 
2.2.1.3.2 GOLD docking 
Hermes 1.6 of the GOLD Suite 5.2 was used to set up and run the dockings. The protein 
was loaded into Hermes as a PDB file and the active site was defined using the “List of 
atoms or residues” method of defining the binding site in Hermes. The compounds were then 
added to Hermes as MOL2 files. The number of GA (genetic algorithm) Run (corresponding 
to the number of docking solutions) for each compound was set to 20. GoldScore (Verdonk 
et al. 2003) was used as the primary scoring function for docking. Each docking was also 
rescored using the CHEMPLP (Korb et al. 2009) scoring function. 
Early termination (a function in GOLD that terminates the docking if the top ranked solutions 
are very similar) was turned off to allow for complete exploration of the binding possibilities. 
“Genetic algorithm search options” was set to ‘Automatic' where search efficiency was set to 
200% (Very Flexible) with 10,000 operations to be performed as a minimum. Ten residues 
were selected from the active site residues to be treated as flexible during docking. The 
flexibility was applied using the “Library” option in “GOLD”. The “Library” option produces 
rotamers for the side chain that are consistent with the Penultimate Rotamer Library (Lovell 
et al. 2000) which includes the most commonly observed side chain conformations for the 
natural amino acids. Molecule Explorer in Hermes and DS Visualizer were both used for the 
analysis of the docked complexes. 
2.2.1.4 AMBER MD simulations on docked complexes 
A good docking complex for each of the six compounds was chosen to be taken into further 
MD simulation. The criteria chosen to define a “good docking complex” are presented in 
section 3.1 of the results. Each complex was first edited by removing the hydrogen atoms 
from the protein but not from the ligand and changing CYS277 to CYM and HIS335 to HIP. A 
separate file containing the ligand’s coordinates only was also saved. 
The antechamber programme in the AMBER package was used to generate the parameter 
and topology files (PREPIN and FRCMOD files) for the ligand using the general AMBER 
force field (GAFF) (Wang et al. 2006; Wang et al. 2004). The generated files were loaded in 
the LEaP program of the AMBER package together with the complex PDB file to prepare the 
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parameter-topology (PRMTOP) and coordinate (INPCRD) files after neutralising the complex 
with sodium ions and adding an 8-Å truncated octahedron of TIP3P water molecules. 
Minimisation and 3-stage MD simulation were then applied to the protein using the same 
settings as those used for empty TG2. The simulation in this case was allowed to continue 
for 275 nanoseconds for each ligand-protein complex. CPPTRAJ was also used here as for 
the empty TG2 to combine all the trajectories in one trajectory and to generate RMSD and 
atomic fluctuation charts. In addition, CPPTRAJ was used to generate, from the original 
combined trajectory, a new trajectory in which all the water molecules were deleted except 
25 molecules that were closest to CYS277. 
The trajectory obtained from each MD run was analysed thoroughly using VMD especially 
looking for hydrogen bonds between the ligand and active site residues. Also the distance 
between the warhead and the sulphur atom of the catalytic cysteine residue was measured 
over the whole trajectory. RMSD for the individual ligands and that of TG2 and the atomic 
fluctuation data were all computed for all the simulations. 
2.2.1.5 Docking into models from MD trajectories of complexes 
Models of the active site were extracted from these trajectories at 30-nanosecond intervals 
to perform docking experiments and to select valid models. GOLD was the main docking 
program used at this stage with settings similar to those used previously with the exception 
of turning on ‘Early Termination’ and using default settings for docking speed. Valid models 
were TG2 active site models which gave good docking results (section 3.1 for a definition of 
“good”). These valid models were further validated by the docking of additional active and 
inactive compounds, docking with changed GOLD settings (docking with water molecules in 
the active site and covalent docking) and applying 5-ns MD simulations on different docked 
complexes. 
2.2.1.5.1 Binding free energy calculations 
Binding free energy calculations were applied to the trajectories obtained from the 5-ns MD 
simulations (section 3.4.5), where the trajectories were first subjected to post-MD treatment 
with CPPTRAJ (Roe & Cheatham 2013) that involved auto-imaging. This was followed by 
the generation a specific set of parameter and topology files for the ligand, the protein and 
the complex with LEaP program to be used in the calculation of the binding free energy. The 
complex was prepared by combining the PDB files of the ligand and the protein. Parameter-
topology and coordinate files were additionally prepared for the complex after neutralising 
and solvating it with an 8 Å octahedron of TIP3P water molecules. 
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The binding free energy was calculated with Poisson Boltzmann (PB) and Generalized Born 
(GB) models using the MMPBSA.py program of the AMBER package (Srinivasan et al. 
1998; Miller et al. 2012). In addition, QM treatment was also applied to the ligand and the 
active site cysteine residue during separate calculations with the GB model. The QM 
methods used were PM3 (Stewart 1989) and DFTB (Seabra et al. 2007; Elstner et al. 1998). 
For the GB calculations, igb=5 [GB-OBC model (Onufriev et al. 2004)] was used for the 
normal and QM calculations. A value of 0.1 M was used for the salt concentration. For the 
PB model (Srinivasan et al. 1998), the default settings were used except for the ionic 
strength which was set to 0.1 M. The calculations were performed on all the 200 frames in 
each simulation (5 ns and saving every 0.025 ns) without omitting any frame. 
2.2.1.6 Covalent docking and MD 
2.2.1.6.1 Docking 
The GOLD software offers the possibility of performing docking experiments that involve the 
formation of a covalent bond between predefined atoms from the ligand and the receptor. 
The function requires that the same linking atom be present on both molecules, the protein 
and the ligand (CCDC Software Limited 2013). The protein atom selected was the SG atom 
of CYS277. A sulphur atom was added to the ligand as a linking atom. It was added to the 
electrophilic carbon atom of the acrylamide warhead. Other GOLD settings were similar to 
those used in the first validation experiment (20 solutions per ligand, GoldScore for primary 
scoring and CHEMPLP for rescoring and default docking speed settings). 
2.2.1.6.2 Molecular dynamics 
Since there is a covalent bond in the complex to be used as the starting structure in MD, a 
new residue should be defined for AMBER to recognise the ligand. This was performed over 
multiple steps. 
2.2.1.6.2.1 Capping the ligand 
The ligand was extracted from the complex file obtained after GOLD covalent docking and 
the connecting sulphur atom was deleted. A cap was introduced to account for the missing 
valence in the electrophilic carbon of the ligand. The cap chosen was -SCH3. The cap was 
added using CAChe Workspace. The whole molecule was then minimised by MM2. A 
CONFLEX (Gotō & Ōsawa 1993) search with MM2 was applied followed by a PM3 
minimisation on the lowest energy conformation produced by CONFLEX. The ligand was 
then saved as a PDB file and taken to GAMESS program to calculate its charge. 
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2.2.1.6.2.2 GAMESS calculation 
The GAMESS program (Schmidt et al. 1993) was used to perform an energy minimisation 
with a high level method and to calculate the electrostatic potential of the molecule. The 
latter was then used to assign charges to the individual atoms of the ligand. Molby program 
(Nagata 2014) was used to prepare the input files of the various ligands for GAMESS 
calculations. The settings involved running an optimisation (RUNTYP=OPTIMIZE) for 100 
cycles (NSTEP=100) using 6 3-1G* method (GBASIS=N31 NGAUSS=6 NDFUNC=1). The 
electrostatic potential calculation was requested using IEPOT=1. 
2.2.1.6.2.3 RESP fitting 
RESP (restrained electrostatic potential) (Bayly et al. 1993) is a free program incorporated 
into AMBER and can be used to assign charges to the atoms of a molecule whose 
electrostatic potential has been calculated. A script written by Hans de Winter (Rega Institute 
for Medical Research, Belgium) was used to convert the electrostatic potential grid produced 
by GAMESS into a format that is readable by RESP. Charge fitting was performed over 2 
stages. In the first stage, the charges of the cap atoms were fixed to the values of the 
charges of atoms SD, CE, HE1, HE2 and HE3 of the side chain of methionine residue in the 
AMBER force field. 
The second stage involved restraining all non-carbon, non-hydrogen atoms to the charges 
fitted in the first stage. Carbon and hydrogen atoms that are not parts of methyl or methylene 
(CH2- or CH3-) were also restrained to the charges of the first stage. Methyl and methylene 
carbon atoms and the first hydrogen atom attached to them were fitted freely while the 2nd 
and/or 3rd hydrogen atoms were assigned the same charge as the first hydrogen of that 
group. 
2.2.1.6.2.4 Library building 
The antechamber program of the AMBER package was used to assign atom types for the 
atoms of the capped ligands based on the GAFF force field (Wang et al. 2006; Wang et al. 
2004). The Parmchk2 program of the AMBER package was used on the file generated by 
antechamber to check the parameters produced. Antechamber and Parmchk2 were used on 
the capped ligand to account for the types and parameters of the ligand atoms involved in 
forming the covalent bond. A PDB file of the original ligand without the cap and after 
removing the connecting sulphur atom was loaded into LEaP program of AMBER package to 
generate a library file of the ligand. Atom types and charges were assigned manually for 
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individual atoms from antechamber and RESP respectively using LEaP, and a library file 
was saved. 
2.2.1.6.2.5 Parameter-topology and coordinate files 
All the above stages were applied on individual ligands once and the library file produced 
from LEaP and frcmod file from Parmchk2 were used to build parameter and coordinate files 
for all the complexes involving that specific ligand. The complex PDB file was loaded into 
LEaP program of AMBER package together with the library and frcmod files. CYS277 was 
converted to CYX. A covalent bond was added explicitly between SG of CYS277 and the 
electrophilic carbon of the ligand using LEaP. The complex was then neutralised with sodium 
ions and solvated with an 8 Å octahedron of TIP3P water molecules and parameter and 
coordinate files were saved. 
2.2.1.6.2.6 Molecular dynamics 
After the generation of parameter and coordinate files, conventional MD was applied as 
before. The process started with a 2,000-cycle minimisation, followed by 20 ps of heating 
MD under constant volume, equilibration under constant pressure for 5 ns and production 
under constant volume for 15 ns. Only the production phase was analysed. The analysis 
included measuring the RMSD of the ligand using the “RMSD Trajectory tool” of VMD 
program as an indicator for the ligand behaviour during the simulation. Hydrogen bond 
analysis was also performed using the CPPTRAJ program of the AmberTools package. 
2.2.2 Chapter 4 methods (QM work) 
2.2.2.1 AMBER umbrella sampling simulations 
These experiments were applied to 6 active compounds, all having acrylamide warheads. 
Their structures as well as biological activities are presented in Chapter 3. The starting 
structures were either docked complexes taken from the various validation processes or 
snapshots from the 5-ns MD simulations. For each compound, the structure selected was 
the one that had the lowest distance between SG from CYS277 and the compound’s 
electrophilic carbon (the beta carbon of the acrylamide double bond Cβ or EC). Good 
docking rank and favourable interactions with active site residues were also considered in 
the selection process. 
The starting structures were loaded in the LEaP program of the AMBER package to 
generate the parameter and coordinate files after generating those files for the compounds 
with antechamber with ff99sb and GAFF force fields respectively, neutralising and solvating 
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the complexes with in an 8-Å truncated octahedron of TIP3P water molecules. The systems 
were then minimised for 2,000 cycles and heated under constant volume from 0 K to 300 K 
over 20 picoseconds (ps) using Langevin dynamics. The heating was followed by 
equilibrating the system for 5 ns under constant pressure also using the Langevin dynamics. 
NMR restraints were used during MD to restrain the distances involved in the reaction at 
their starting values. The force constant used was 500 kcal/mol.Å2. The distances fixed were 
the one between SG of CYS277 and EC of the compound (D1 in Figure 2-1) and the 
distance between HD1 from HIS335 and the alpha carbon of the double bond of the 
acrylamide (Cα or C2) (D2 in Figure 2-1). 
 
Figure 2-1: Restrained distances in umbrella sampling simulations. 
2.2.2.1.1 QM/MM 
Umbrella sampling (US) was performed using quantum mechanical treatment (Walker et al. 
2008) of the region involved in the chemical reaction. The rest of the system was treated 
molecular mechanically using the ff99SB force field (Hornak et al. 2006). The QM region was 
composed of the acrylamide compound and the side chain of CYS277 (the negatively 
charged sulphur, SG and the connecting carbon with its 2 hydrogen atoms) and the 
imidazole ring of HIS335.  PM3 (Stewart 1989) and SCC-DFTB (Elstner et al. 1998; Seabra 
et al. 2007) were the methods used to calculate the energy of the QM region in this work. 
PM3 was applied with a 12-Å cut-off distance. The same cut-off was used with SCC-DFTB 
along with an electronic temperature of 100 K. 
2.2.2.1.2. Umbrella sampling (US) 
For each compound and for each QM method, 2 US experiments were performed. The first 
simulation assumed that the reaction occurs over a single stage and the second simulation 
CYS277
φ
D1
D2
D3
HIS335
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involved two stages to drive the reaction to completion. All the simulations were performed 
under constant pressure. Before starting US, a 100-ps MD under constant pressure was 
applied on the structure resulting from the equilibration step. This MD was run with QM 
treatment of the reaction centre while fixing the distances between SG and EC and between 
HD1 and C2 to their starting values with a force constant of 250 kcal/mol.Å2. Each US 
simulation used the restart file from the 100-ps QM relaxation as the starting structure. The 
simulations were divided into windows along the reaction coordinate (RC); the number of 
these windows depended upon the starting value of the RC and the method used (1 or 2 
stages). Each window was run over 5 ps. RC was controlled by a flat well restraint potential 
in all the US experiments. 
2.2.2.1.1.1 Single-stage US simulations 
The reaction coordinate in this case was taken as a “generalised distance coordinate” 
involving the summation of 2 distances; the SG-EC distance (D1 in Figure 2-1) and the HD1-
C2 distance (D2 in Figure 2-1). The RC for the 1-stage simulations was set to change over 
the windows from its starting value to 4.5 Å by 0.2-Å reductions and 50 kcal/mol.Å2 force 
constant. After that, the reductions were 0.1 Å per window and the force constant was 
increased to 100 kcal/mol.Å2. The end value for the RC was set to 2.8 Å (≈1.8 Å for SG-EC 
bond and ≈1 Å for HD1-C2 bond). The same changes in the RC and the same number of 
windows were used for each compound with PM3 and SCC-DFTB. The number of windows 
ranged from 38 to 62 depending on the value of RC in the starting structure. 
2.2.2.1.1.2 Two-stage US simulations 
The RC for the first stage of the 2-stage US simulation was a simple distance coordinate 
involving the distance between SG and EC. This was set to change from its original value to 
1.6 Å over 0.1-Å reductions using a force constant of 250 kcal/mol.Å2; between RC values of 
2.1 and 1.9 Å the reductions were set to 0.05 Å. These settings were used with PM3 and 
SCC-DFTB. The number of windows ranged from 19 to 43, also depending on the starting 
value of RC in the individual compounds. 
For the 2nd stage of the 2-stage simulations, RC was defined as a “generalised distance 
coordinate” sampling the difference between the HD1-C2 distance (D2 in Figure 2-1) and 
HD1-ND1 distance (D3 in Figure 2-1). RC was set to change over 0.4-Å reductions using a 
force constant of 250 kcal/mol.Å2 up to a value of 2.0 Å when the change was 0.2 Å per 
window with the same value for the force constant. The end point was set at -2.0 Å. The 
restart file generated from the last window of the 1st stage was used as the starting structure 
for this stage. 
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2.2.2.1.2 PMF calculations 
The weighted histogram analysis method (Souaille & Roux 2001) was used to calculate the 
PMF profiles for the US simulations. The WHAM program (Grossfield 2013) was employed 
to construct the PMF graph along the reaction coordinate from the time series files 
generated during the US simulations. The number of bins for the 1-stage and the 2nd stage 
of the 2–stage simulations corresponded to how many 0.1-Å reductions were there during 
each simulation. There was 1 bin for each 0.1-Å reduction in the 1-stage experiments, while 
there were 4 bins for each 0.1-Å reduction for the 1st stage of the 2-stage simulations and 
there were 2.5 bins for each 0.1-Å reduction for the 2nd stage of the 2-stage simulations. The 
convergence tolerance used was 0.00001 in all the simulations. 
2.2.2.2 CAChe reaction path experiments 
QM reaction path experiments were applied on a set of 8 active compounds all having 
sulfonium ion warheads. The method used for the generation of the reaction path and the 
calculation of the activation energy was the same for all the compounds. The differences 
were in the choice of the starting conformation and whether it was energy minimised or not. 
The sources of the starting structures were MD frames or docking complexes (section 
4.2.1.2, Table 4-6). 
2.2.2.2.1 Map reaction experiment 
Minimisation within CAChe was applied to most of the starting structures using MM2. The 
process was applied on the compound and the cysteine residue while everything else in the 
system was locked. This was followed by deleting the entire system with the exception of the 
ligand and CYS277. Hydrogen atoms were added to CYS277 to complete its valence. Two 
reaction coordinates were chosen to map the reaction between the warheads containing the 
sulfonium ion and the negatively charged sulphur (SG) of CYS277. These were the distance 
between the electrophilic carbon (EC) of the ligand and SG of CYS277, and the angle 
between SG of CYS277, EC and the positively charged sulphur (S+) of the sulfonium ion in 
the ligand. In all the cases, the distance was allowed to change from its original value to 1 Å 
while the angle was changed from its original value to 180°. Both changes were applied over 
20 steps. The QM method used with all the compounds was PM3. 
2.2.2.2.2 Transition state (TS) choice, refinement and verification 
A map reaction experiment typically produces a 3-dimensional potential energy surface 
(PES) such as the one in Figure 2-2, when applied with 2 reaction coordinates. The axes 
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represent the reaction coordinates (distance and angle) and the energy of the system as a 
whole calculated by PM3. TS structures were chosen from the saddle points immediately 
next to the minimum having the same value for the angle as the minimum but with a different 
value for the distance (one step backwards). 
 
Figure 2-2: PES produced by map reaction. 
Refinement of the chosen TS was performed using a PM3 gradient minimisation. The refined 
TS was then verified again using a PM3 calculation of vibrational frequencies through the 
FORCE program of the CAChe package. Only TS structures that gave one, and only one, 
negative vibration in the verification process were considered. 
2.2.2.2.3 Reaction path experiment 
The refined and verified TS structure from each system was used as the starting point for the 
final experiment, the reaction path. The QM method used was also PM3 that was run for 200 
cycles using the intrinsic reaction coordinate (IRC) method. 
2.2.3 Chapter 5 methods (allosteric inhibition) 
Methods for this chapter are presented in the chapter itself (section 5.2) for their involvement 
of a technique that was detailed within Chapter 5.  
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3 Development and Validation of TG2 Active Site 
Models 
This chapter of the thesis covers the work that involved preparing models for the active site 
of TG2 which could be used for testing potential inhibitors for the enzyme by docking. The 
active site models were generated by an approach that combines MD simulations with 
docking. MD was applied initially on an empty version of TG2, and selected docking 
complexes were subjected to MD, and from the resultant trajectories, conformations were 
selected and tested for their ability to dock already tested inhibitors of TG2. The produced 
models were then validated by a series of docking experiments in which additional test 
compounds were introduced, some of them were inactive. Other docking experiments were 
also applied, that involved docking with water molecules in the active site, inflexible docking 
and covalent docking. Short MD simulations were also employed to judge the quality of the 
docking complexes produced in the various experiments. Binding free energy was calculated 
and correlated to biological activity. The behaviour of TG2 during various MD simulations 
was also discussed in this chapter. 
3.1 Results of Initial Docking 
The main purpose of the MD simulation performed initially on empty TG2 was to supply 
some conformations that could be used as models for the active site. Two reasons lie behind 
this justification for requiring more than one conformation of the enzyme for docking 
purposes. The first is that it has been around 40 years since the introduction of MD to 
biological macromolecules (McCammon et al. 1977) and the beginning of an era that started 
to consider proteins as molecules that are in continuous motion and cannot be represented 
by a single physical conformation (Karplus & McCammon 2002). The second reason is that 
a number of residues were missing from the original crystal structure and were added before 
the start of MD. These added residues needed to relax and accommodate themselves to 
their locations to improve the process of their integration into the protein, and molecular 
dynamics is an approach that could be used in this respect (Hospital et al. 2015). 
The behaviour of TG2 during this simulation is discussed in detail in a separate section of 
this chapter (3.9). For the purposes of this section of the work, it will be mentioned that the 
simulation was stable as indicated by the changes in the temperature and energy of the 
system with time as well as the change in the root-mean-square-deviation (RMSD) which are 
all presented in section 3.9. 
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3.1.1 TG2 active site 
The crystal structure that was used as the basis for this work (PDB 2Q3Z) had TG2 in an 
“open conformation”, in contrast to a GDP-bound “closed conformation” (PDB code 1KV3 
(Liu et al. 2002)). In 1KV3, the two C-terminal barrels are bent towards the active site giving 
the “closed” shape (Figure 3-1, (Pinkas et al. 2007)). The crystal structure, 2Q3Z has a 
gluten-like pentapeptide inhibitor, Ac-P(DON)LPF-NH2 covalently bound to CYS277. 
The catalytic cysteine residue (CYS277) is located in a tunnel (Figure 3-2) bridged by two 
tryptophan residues (TRP241 and TRP332) and there is a threonine residue (THR360) at 
the edge of the tunnel. The inhibitor in the crystal structure exhibited a network of 
interactions with active site residues including hydrogen bonds and hydrophobic interactions. 
The hydrogen bonds were between the inhibitor and residues TRP241, GLN276, CYS277 
and ASN333. In addition, there was the covalent bond with CYS277 (Figure 3-3). 
As it can be seen from Figure 3-3, the inhibitor assumes a bent conformation in the active 
site with the warhead in the catalytic tunnel and the other end, which is mainly aromatic, 
embedded in a hydrophobic region or loop (Figure 3-2) (Badarau, Mongeot, et al. 2013; 
Pinkas et al. 2007). This hydrophobic region is mainly composed of the following residues; 
ALA304, LEU312, ILE313, PHE316, ILE331 and LEU420. Four of these residues, ALA304, 
ILE313, ILE331 and LEU420, form pi-alkyl interactions with the terminal phenyl ring of the 
inhibitor stabilising this part in the hydrophobic region (Figure 3-4). 
 
Figure 3-1: TG2 closed and open 
conformations. The closed 
conformation bound to GDP (left), 
and the open conformation bound 
to a covalent inhibitor (right). 
Adopted from Pinkas et al. (2007). 
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Figure 3-2: Active site tunnel and the hydrophobic loop in TG2.The surface is coloured by hydrophobicity 
and the inhibitor by element. 
 
Figure 3-3: H-bonds 
between the inhibitor and 
TG2 in the original crystal 
structure.
The residues selected to be treated as flexible when using the GOLD docking program were 
based on the above information (residues involved in hydrogen bonds and lipophilic 
interactions with the inhibitor). These were TRP241, GLN276, CYS277, TRP278, TRP332, 
ASN333, PHE334, HIS335, THR360 and LEU420. Hydrogen bonds will be shown as green 
dotted lines and pi interactions as dotted light pink (pi-alkyl), dotted dark pink (pi-pi) or dotted 
Hydrophobic loop
Catalytic Tunnel
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orange (pi-cation) lines. This summary of the interactions was introduced to be used as a 
guidance during the analysis of the subsequent docking and MD trajectories. 
 
Figure 3-4: Hydrophobic 
interactions between the 
inhibitor and TG2. 
3.1.2 Initial docking 
Six active TG2 inhibitors (Badarau et al. 2015) were used for initial docking. Compounds 1a-
1f are listed in Table 3-1 along with their structures and IC50 values against human TG2. The 
goal at this stage was to obtain good poses for the active inhibitors within the active site of 
TG2 for the complexes to be taken to MD simulation. Therefore, a distance of less than 4 Å 
between the electrophilic carbon of the compound’s warhead and the sulphur atom of 
CYS277 was used as the sole criterion for selecting a good complex at this stage. 
Table 3-2 shows the six complexes selected with the distance between the warhead and the 
sulphur atom of CYS277, and the docking software used. The complexes were named in the 
form [inhibitor name-model name (ns at which the model was taken)-docking attempt]. 
Figure 3-5 shows the poses of the selected complexes. It has been mentioned earlier that a 
good pose for an inhibitor in the TG2 active site is in the form of a bent conformation with the 
lipophilic part of the inhibitor embedded in the hydrophobic loop of TG2 (Pinkas et al. 2007; 
Badarau, Mongeot, et al. 2013). However, this could not be achieved with all the compounds 
at this stage. Consequently, the selected complexes for compounds 1c, 1d and 1f had the 
lipophilic part of the inhibitor outside the hydrophobic loop. 
Neither docking programs nor the ligands could be blamed for the docking results obtained 
at this stage. The settings used during the dockings ensured that a most extensive search 
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was performed combined with flexible treatment of (the most important) active site residues. 
The ligands used were proven to be active and their IC50 values show that they are amongst 
the most active TG2 inhibitors (Badarau et al. 2015), and their structures, although sharing a 
similar core, have different lipophilic parts and two different warheads. This leaves two 
possible causes for the failure; either the active site itself is not fit to accommodate the 
ligands, or the fact that the inhibitors are irreversible and act through forming a covalent 
bond with CYS277, and the formation of the bond, although unlikely, may need to be the first 
event for the compound to position itself correctly within the active site of TG2. Molecular 
dynamics applied to these 6 docking complexes was a possible solution to the first cause of 
failure in docking at this stage by allowing the active site residues to move freely with the 
ligand within to accommodate it better by changing the conformations of the side chains or 
even the backbone structure to allow for better positioning of the ligands. Dealing with the 
bond is more complicated and requires quantum mechanical treatment or covalent docking. 
These techniques have been applied during the course of this work and are presented in the 
relevant Results sections. 
Compound name Structure IC50 (µM) 
1a 
 
0.125 
1b 
 
0.273 
1c 
 
0.440 
1d 
 
0.700 
1e 
 
0.0061 
1f 
 
0.380 
Table 3-1: Structures and IC50 for compounds 1a-1f. 
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Complex Name Distance (Å) Docking Program 
1a-85ns-3 3.4 CACHe 
1b-30ns-2 3.3 CACHe 
1c-30ns-14 3.7 GOLD 
1d-95ns-9 3.7 GOLD 
1e-40ns-10 3.0 GOLD 
1f-80ns-6 5.6 GOLD 
Table 3-2: Good complexes from initial docking. 
When the active site of TG2 to be used for docking was investigated, different centres for the 
sphere used in the definition were tried. These included the sulphur atom of CYS277, the 
whole CYS277 residue, each of the bridging tryptophan residues (TRP241 and TRP332) on 
its own and finally both the bridging residues at the same time. With each one of these 
centres, an 8-Å sphere of residues was used as the active site and a test docking was 
performed. The best results were obtained with the last definition, signifying the importance 
of these bridging residues in correctly posing TG2 inhibitors in the active site. That is why 
this active site definition was used throughout this work. 
3.2 Analysis of MD Trajectories of Initial Docking 
The main reason for performing MD simulations on docked complexes of TG2 inhibitors is to 
obtain better TG2 active site models. Taking 19 conformations of TG2 from a 100-ns 
simulation to be used for docking of 6 proven active inhibitors produced only 3 valid 
complexes with the correct proposed conformation of the inhibitor and 3 more complexes 
were assumed to be correct. Therefore, MD was applied to those complexes in an attempt to 
refine the active site by allowing for the inhibitors to adjust themselves correctly within the 
active site and at the same time permitting the active site residues to accommodate the 
inhibitors. Only the trajectories of compounds 1a and 1b will be discussed in details as they 
gave valid models in the subsequent docking. The other 4 trajectories will be discussed 
briefly. 
3.2.1 Trajectory of 1a-85ns-3  
In the starting conformation for this run, there were no hydrogen bonds between 1a and the 
protein. However, there were pi-interactions between the residues in the hydrophobic loop 
and the adamantyl part of the ligand and a pi-interaction involving TRP332 and the 
piperazine ring of 1a (Figure 3-6). Also in the starting conformation, the bridging tryptophan 
residues were very close to each other that the tunnel was almost closed (Figure 3-7). 
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Figure 3-5: Docking complexes for the 6 compounds selected to be taken to molecular dynamics. 
 
 
 
1a-85ns-3 
1b-30ns-2 
1c-30ns-14 1d-95ns-9 
1e-40ns-10 1f-80ns-6 
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Figure 3-6: Hydrophobic interactions 
between TG2 and 1a. 
 
Figure 3-7: The tunnel in the starting conformation of 1a trajectory. A: Surface view. B: space filling view 
of the bridging tryptophans. 
3.2.1.1 Warhead position 
The acrylamide warhead of compound 1a left the tunnel and moved away from CYS277 
early in the simulation. This happened at 12.475 nanoseconds. In the frame immediately 
before this time point, the warhead was about 7.6 Å away from CYS277 sulphur atom but 
was essentially within the tunnel. The distance then started to increase to more than 20 Å 
(Figure 3-8). It has also been noted that at the same frame at which the warhead left, 
CYS277 has moved towards the bridging tryptophan residues causing the tunnel to close. 
The movement of the warhead at this time was also evident from the RMSD measured for 
1a alone during the trajectory and is shown along with the distance in Figure 3-8. By 
comparing the 2 traces, it is obvious that both have started to increase at the same time. 
3.2.1.2 Hydrogen bonds 
VMD program was used for hydrogen bond analysis using the default settings; 3.0 Å donor-
acceptor distance and 20° angle cut-off. Very few hydrogen bonds were found during this 
A B
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simulation, but there was a bond with ASN333 at the beginning that lasted to approximately 
the same time as the presence of the warhead within the catalytic tunnel. Figure 3-9 shows a 
graph for the distance between O38 of 1a and H of ASN333 along with the bond itself. Both 
the closure of the tunnel and the disappearance of the H-bond with ASN333 may have 
contributed to the movement of the warhead of 1a away from the catalytic tunnel. 
 
Figure 3-8: Graph of the distance between the acrylamide warhead and SG atom of CYS277 in the 1a 
trajectory along with RMSD for 1a alone. 
  
Figure 3-9: Distance of the H-bond between ASN333 and 1a (left) and the bond itself (right). 
3.2.1.3 The lipophilic part 
The distance between C43 of 1a and alpha carbon of SER309 (Figure 3-10 right) was used 
as a reference for the position of the lipophilic part. SER309 was chosen as a reference 
because of its position at the top of the hydrophobic loop, where it oversees the lipophilic 
part of 1a. Figure 3-10 shows a graph of this distance with the position of the lipophilic part 
within the hydrophobic region. In the starting conformation, the distance was 13.6 Å and 
from the graph it is clear that the adamntyl group did not move that much during the 
simulation. The reason behind this is the persistence of the hydrophobic interactions with the 
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adamntayl part during the simulation. An analysis of 9 conformations taken at 30 ns intervals 
from the entire simulation revealed that there were at least two residues forming pi-alkyl 
interactions with the adamntyal group of 1a in each conformation. Figure 3-11 shows one of 
these conformations. 
 
Figure 3-10: Distance between the lipophilic part and SER309 during the simulation. 
 
Figure 3-11: Hydrophobic interactions 
stabilising the adamantyl group in the 
hydrophobic loop in 1a trajectory, 
even following the leaving of the 
warhead. The frame is from 200 ns of 
the trajectory. 
3.2.1.4 TG2 
The presence of 1a did not trigger noticeable conformational change on the time scale of the 
simulation. This was observed from measuring the RMSD for the protein and comparing it to 
a measurement done on a trajectory of the same length for the MD simulation on empty 
TG2. Figure 3-12 shows the 2 RMSD measurements and indicates that no large differences 
occurred upon the introduction of 1a into TG2. 
The atomic fluctuation scores for TG2 residues in this simulation are presented in Figure 
3-13. Only the peak with red points has residues that are close to the active site. The peak 
belongs to a helix and the high fluctuation is the result if coiling and uncoiling events. The 
helix is shown in Figure 3-14. It was missing in the original crystal structure. The helix was 
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not very stable possibly due to the presence of 2 glutamate residues (GLU319 and GLU322) 
that may be repelling each other causing the un-coiling of the helix. There is also a glycine 
residue in this helix which allows greater flexibility (Lehninger et al. 2000). 
 
Figure 3-12: RMSD for TG2 in the presence and absence of compound 1a. 
 
Figure 3-13: Atomic fluctuation for TG2 residues in the trajectory of 1a. 
 
Figure 3-14: The high 
fluctuating helix from 1a 
trajectory, coloured red, 
while the rest of TG2 is 
green and showing CYS277 
to appreciate the location of 
the helix. 
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3.2.1.5 Temperature and energy 
The stability of the simulation was reflected in the changes in the temperature and total 
energy of the system. These two quantities were almost constant throughout the simulation 
after the initial relaxation and are shown in Figure 3-15. 
  
Figure 3-15: Changes in temperature and total energy during the simulation of 1a. 
3.2.2 Trajectory of 1b-30ns-2 
In the starting conformation, there was a hydrogen bond between ASN333 side chain and 1b 
and the distance between SG of CYS277 and the electrophilic carbon of 1b was 3.3 Å. 
There were no hydrophobic interactions involving the lipophilic part of 1b. 
3.2.2.1 Warhead position 
The warhead of 1b remained in the tunnel close to the sulphur atom of CYS277 for the entire 
simulation. The distance between the two averaged at 5.7 Å. Figure 3-16 shows a plot of this 
distance with time. The graph also shows the RMSD for 1b in this simulation, and its low 
values also indicate that there was no significant motion involving compound 1b during the 
simulation. 
 
Figure 3-16: A graph of the distance between the warhead carbon of 1b and SG of CYS277, with the 
RMSD for 1b during the MD simulation. 
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3.2.2.2 Hydrogen bonds 
Again, default VMD settings were used for hydrogen bond analysis and hydrogen bonds with 
3 residues were found, ARG317 (side chain), ASN333 (side chain and backbone) and 
PHE334 (backbone) (Figure 3-17). In total, bonds with these residues were present for about 
33% of simulation time. A deeper look into the time-dependent behaviour of these bonds 
showed that the ones with ASN333 and PHE334 (which were present for 28% of the 
simulation according to VMD) were probably responsible for keeping the warhead close to 
CYS277. When the hydrogen bond with ARG317 forms, a pocket in TG2 is formed that 
closes on the lipophilic part of 1b (Figure 3-18). This bond persisted for 7% of the simulation 
time and was most evident between 75 and 160 nanoseconds of the simulation. 
  
Figure 3-17: Hydrogen bonds in 1b trajectory with ASN333 (A), PHE334 (B) and ARG317 (C) showing the 
acceptor atoms on 1b. 
 
Figure 3-18: Pocket formed when there is H-bonding with ARG317 (right) and absence of the pocket when 
the interaction is not present (left). 
A B 
C 
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3.2.2.3 The lipophilic part 
The reference atom of 1b that was used as an indication for the position of the tertiary butyl 
lipophilic part of 1b within the hydrophobic region was C42 (Figure 3-19B). SER303 was 
used instead of SER309 as the counter protein reference part because SER309 showed 
more movement during the simulation than SER303, and thus it could not be used as a 
reference. This is evident from the atomic fluctuation values for the two residues; SER303 
had a value of 0.77 Å while SER309 showed atomic fluctuation of 1.73 Å. 
In the starting conformation, the distance between C42 of 1b and CA of SER303 was 7.8 Å. 
In the simulation, it averaged around 4.9 Å. Figure 3-19A shows a graph of the change of 
this distance with time during the simulation and it can be seen that the distance has 
decreased after the start of the simulation indicating that the tertiary butyl group moved more 
inside the hydrophobic loop during the simulation. Figure 3-20 shows a comparison between 
the position of the tertiary butyl group between the starting conformation (A) and 
conformation at 65 nanoseconds (B). 
 
Figure 3-19: A: distance between C42 of 1b and SER303 in the 1b trajectory. B: the same distance on a 
PDB structure. 
An analysis of 9 conformations taken at 30 nanoseconds intervals showed at least 2 
hydrophobic interactions between residues from the hydrophobic loop within TG2 and at 
least one of the methyl groups of the tertiary butyl lipophilic part of 1b in 8 of the 
conformations. These interactions together with the hydrogen bond with ARG317 and the 
subsequent formation of the closed pocket around the tertiary butyl group are the likely 
reasons behind the persistence of the lipophilic part within the hydrophobic loop (Figure 
3-21). 
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Figure 3-20: How the tertiary butyl group of 1b moved further into the hydrophobic loop from the starting 
conformation (A) to the conformation at 65 ns (B). 
 
Figure 3-21: Example of 
hydrophobic interactions involving 
the tertiary butyl part of 1b in the 
hydrophobic loop of TG2. 
Pi-cation interactions were noticed to exist, which involved the positively charged sulfonium 
ion of 1b warhead. The most prevalent of these was the one with the benzene ring PHE334. 
Because the VMD program cannot measure the distance between an atom and the centre of 
a ring, distances were measured between the positively charged sulphur atom of 1b and C1 
of the benzene ring of PHE334 (CZ) and then with C4 (CG) of the same ring and an average 
was calculated (Figure 3-22). Although this could not be used as an ultimate judgement for 
the presence of the bond as it does not take into account the orientation of sulphur atom with 
respect to the ring, it does give an insight on the possibility of the formation of this interaction 
based on distance. 
The distance between the positively charged sulphur of 1b and the benzene ring of PHE334 
averaged around 5.1 Å (Figure 3-23). This bond with PHE334 was present in 7 of the 9 
conformations taken at every 30 nanoseconds. In the remaining 2 conformations, there was 
instead a pi-sulphur interaction involving TRP241 and/or TRP332 (Figure 3-24). Therefore, it 
A B 
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can be said that there was always a pi-sulphur interaction that, along with hydrogen bonds 
with ASN333 and PHE334, has contributed to the stabilisation of the warhead within the 
catalytic tunnel. Ringer et al. (2007) studied the optimum conditions for favourable pi-sulphur 
interactions by mining in the data of the Protein Data Bank. Their observations were 
dependent on the orientation of hydrogen atoms attached to the sulphur and in one of the 
favourable configurations, they found that the optimum distance between the sulphur atom 
and the centre of the benzene ring is 5.5 Å. This further confirms the persistence of the 
interaction with PHE334 based on the graph in Figure 3-23. 
 
Figure 3-22: Pi-cation interaction between 1b and PHE334, 
showing CG and CZ atoms used to define a distance between 1b 
and the benzene ring. 
 
Figure 3-23: Plot of 
the distance between 
sulphur atom of 1b 
and benzene ring of 
PHE180. 
 
3.2.2.4 TG2 
As in 1a trajectory, the presence of 1b within TG2 active site in this simulation did not cause 
significant changes in the enzyme itself. This was confirmed by comparing the RMSD values 
of this run to those of the simulation applied on TG2 alone for the same simulation time 
(Figure 3-25). In fact, RMSD plots show that the presence of the compound stiffens the 
enzyme and limits its overall conformational changes. This also applies to compound 1a 
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(Figure 3-12). This is consistent with the data that suggest that the covalent inhibitors of TG2 
when bind to the enzyme lock it in its open conformation (Pinkas et al. 2007). Atomic 
fluctuation analysis did not show any significant peaks with all residues having values less 
than 3 Å, with the exception of 3 residues that were a part of a loop located on the other side 
of the active site. 
 
Figure 3-24: Example of pi-sulphur interactions 
involving TRP332 and PHE334 with the positively 
charged sulphur atom of 1b. 
 
Figure 3-25: RMSD of TG2 alone in 1b trajectory compared to that applied on an empty TG2. 
There was a loop, however, consisting of residues ASP306, GLN307, ASN308, SER309, 
ASN310 and LEU311, that showed a movement toward the back and inward to the 
hydrophobic region of the enzyme (Figure 3-26). The atomic fluctuation values for the 6 
residues were all below 2.0 Å. The hydrophobic interactions with the tertiary butyl group of 
1b and hydrogen bonds between 1b and ARG317 may be responsible for the movement of 
the loop and the subsequent enclosure of the hydrophobic loop for the tertiary butyl group of 
1b. It was therefore decided to add the residues of this loop to the definition of active site 
used in the docking experiments. 
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Figure 3-26: The loop 
between ASP152 and 
LEU157 (red) and how it 
moved from the starting 
conformation (green) 
compared to 9 
conformations taken from 
the simulation at 30 ns 
intervals. 
3.2.2.5 Temperature and total energy 
Again in this trajectory the temperature and total energy during the simulation were stable as 
shown in Figure 3-27. 
  
Figure 3-27: Temperature and total energy graphs for the trajectory of 1b. 
3.2.3 Trajectory of 1c-30ns-14 
In the starting conformation for this MD run, the distance between the warhead carbon atom 
of 1c and SG atom of CYS277 was 3.7 Å. There were hydrogen bonds with CYS277 
(backbone) and ASN333 (side chain). There were also pi-alkyl interactions between the 
piperazine ring of 1c and TRP241, TRP332 and PHE334 (Figure 3-28). However, the 
naphthyl group, being the lipophilic part, was not in the hydrophobic region of TG2. No better 
pose for compound 1c in TG2 active site could be obtained and therefore this one was used. 
During the simulation, the lipophilic part of the inhibitor started to move in the direction of the 
hydrophobic loop of TG2 but it did not get fully inside the loop. This started to happen at 
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around 32.5 nanoseconds of the simulation. However, at approximately the same time, the 
warhead started to move away from CYS277 leaving the catalytic tunnel. The graph in 
Figure 3-29 shows the change in the warhead position relative to SG of CYS277. An 
analysis of hydrogen bonds showed that there were bonds at the beginning of the simulation 
up to the point when the warhead left the tunnel. The bonds were mainly with GLN276 and 
CYS277 (Figure 3-30). The disappearance of the bonds may be responsible for the warhead 
leaving the catalytic tunnel. 
 
Figure 3-28: Interactions between 
1c and TG2 active site in the 
starting conformation. 
 
Figure 3-29: Time plot for the distance between warhead of 1c and sulphur atom of CYS123 showing the 
increased distance after 32 ns. 
3.2.4 Trajectory of 1d-95ns-9 
In the starting conformation, the distance between the warhead carbon atom and CYS277 
SG was 3.7 Å. No hydrogen bonds were detected but there were some pi-interactions 
between TG2 residues and piperazine ring and sulphur atom of 1d. As in the 1c starting 
conformation, the lipophilic part of 1d was not located in the hydrophobic loop of TG2. In the 
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simulation, the warhead of 1d left the catalytic tunnel and moved away during the 
equilibration phase whereupon the distance between the warhead and the sulphur atom of 
CYS277 was 8.5 Å at the first conformation of the production phase. Therefore, this 
trajectory was considered a failure. 
 
Figure 3-30: Number of hydrogen bonds with 1c showing their disappearance after 32 ns. 
3.2.5 Trajectory of 1e-40ns-10 
In the starting conformation, the distance between the warhead and CYS277 was about 3 Å. 
There was a single hydrogen bond with GLN276 side chain and a pi-alkyl interaction 
involving the adamantyl group of 1e with ARG317 (Figure 3-31). 
The warhead remained in the catalytic tunnel close to CYS277 for about 187 of the 275 
nanoseconds of the simulation time (Figure 3-32). Analysing the hydrogen bonds in the 
trajectory showed that a bond with GLN276 was present up to the time at which the warhead 
left the tunnel. Figure 3-33 is a graph representing the frequency of this hydrogen bond. The 
disappearance of this bond may have been the reason for causing the warhead to leave the 
active site tunnel. 
3.2.6 Trajectory of 1f-80ns-6 
In the starting conformation, the distance between the warhead and the sulphur atom of 
CYS277 was 5.7 Å. There were 2 hydrogen bonds with CYS277 side chain and GLN324 
side chain. There were also pi-alkyl interactions between the piperazine ring of 1f and 
TRP214 and TRP332. However, the lipophilic part (dansyl group) was not in the hydrophobic 
region of TG2. During the simulation, the warhead moved further away from CYS277 and 
the dansyl group failed to enter inside the hydrophobic loop of TG2. 
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Figure 3-31: Interactions between 
1e and TG2 active site in the 
starting conformation. 
 
Figure 3-32: Graph for the 
distance between warhead of 
1e and sulphur of CYS123 
showing the increased 
distance after 187 ns. 
 
Figure 3-33: Frequency of 
the H-bond between 1e and 
GLN276 showing the 
disappearance of the bond 
after 187 ns. 
The temperature and total energy for the last four simulations (compounds 1c, 1d, 1e and 
1f) were stable throughout and very similar to graphs presented in figures Figure 3-15 and 
Figure 3-27. Also, none of these compounds caused any large scale changes in TG2. This 
was evident from the RMSD measured for TG2 only in each of the 4 simulations and 
compared to that from the simulation on empty TG2 for the same simulation time (Figure 
3-34). The atomic fluctuations for TG2 residues in the 6 simulations have also been 
compared. They also showed that there were similar modes of motions in the 6 simulations. 
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Figure 3-35 contains the atomic fluctuation values for the 6 simulations and it can be seen 
the locations of the peaks are matching. 
 
Figure 3-34: RMSD graphs for TG2 in the simulations for compounds 1c, 1d, 1e and 1f compared to the 
simulation of empty TG2. A detailed description of empty TG2 MD is presented later in section 3.9 of this 
chapter.  
 
Figure 3-35: Atomic fluctuations for TG2 residues in the 6 MD simulations. 
Several observations can be drawn from looking at the trajectories of the complexes. 
Hydrogen bonds are essential in keeping the warhead in the catalytic tunnel close to SG of 
CYS277. This was very clear with the trajectories of 1a and 1c where discontinuation of a 
hydrogen bond was associated with the warhead leaving the tunnel. ASN333 is probably the 
most important residue in this respect, being positioned conveniently to bond with the 
central, or linker, part of the inhibitors leading the warhead to the tunnel. GLN276 is another 
example, being close to CYS277, where a hydrogen bond with this residue may provide a 
means for keeping the warhead in the catalytic tunnel (trajectories for 1c and 1e are 
examples for the significance of this residue). Pi-cation interactions involving the positively 
charged sulphur atom of the inhibitors containing sulfonium ion warheads and the aromatic 
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rings of the residues close to CYS277, especially PHE334, also played significant role in 
maintaining the pose of compound 1b. 
Although the warhead left the catalytic tunnel in compounds 1a and 1e, both of which were 
appropriately posed at the start of their simulations, the lipophilic parts of the 2 compounds 
remained in the hydrophobic loop of TG2 active site. This indicates that the preservation of 
the lipophilic part in its starting location is easier than preserving the warhead. The reasons 
may include the magnitude of lipophilic interactions in the region and the shape of the 
hydrophobic loop and its ability to enclose the lipophilic part of the inhibitors. This enclosure 
was particularly evident with the tertiary butyl lipophilic part of compound 1b (Figure 3-20). 
3.3 Docking into TG2 Models from MD Trajectories of 
Complexes 
Models of the active site were extracted at 30-nanosecond intervals from the six MD 
trajectories of the complexes from the initial docking to perform docking experiments starting 
from the 35th nanosecond. A total of 9 active site models were generated from each of the 6 
trajectories to perform dockings on. Again, only the 6 active compounds from Badarau et al. 
(2015) were used at this stage. CAChe docking was used with models from the trajectories 
of 1b, 1c and 1e but no good results were obtained with any model. As a result, CAChe was 
not used on models from the other trajectories. Instead, GOLD was used with models from 
all the trajectories. The GOLD settings were the same as those used for the first stage with 
the following modifications: early termination was allowed and default settings for docking 
speed with 100% efficiency were applied. 
The results of docking on models from each of the six trajectories will be presented 
separately based on the trajectory. Within the individual trajectories, only results from 
models that have shown good docking will be presented, except when there are no good 
results. The complexes were named as in the initial docking. Figures will show the pose of 
the compounds within the active site with the distance between the warhead and the sulphur 
atom (SG) of CYS277 as a red solid line. The compounds will be in a stick form except the 
warhead atom which will be shown as a ball. Hydrogen bonds will be shown as green dotted 
lines and pi interactions as dotted light pink (pi-alkyl), dotted dark pink (pi-pi) or dotted 
orange (pi-cation) lines. 
During the analysis certain criteria had been set to define a good docking complex and from 
which to select valid active site models. These criteria included: 
Chapter 3   Model Development and Validation 
104 
 
1. An appropriate bent pose within the active site for the active compounds with the 
warhead in the catalytic tunnel containing the active site cysteine residue (CYS277) 
and the lipophilic part in the hydrophobic region of the active site (Badarau, Mongeot, 
et al. 2013; Prime, Brookfield, et al. 2012). 
2. A ranking in the top 4 places out of the 20 solutions generated for that compound 
based on GoldScore scoring function first and then the CHEMPLP function. In both 
scoring functions, the higher (more positive) the score, the better is the complex 
because the score is taken as the negative of the sum of multiple energy terms 
(CCDC Software Limited 2013). 
3. The presence of hydrogen bonds between the ligand and some key residues in the 
active site especially TRP241, GLN276, TRP332, ASN333 and PHE334. 
3.3.1 Docking into TG2 models from the 1a complex trajectory 
The warhead of the different active compounds was close to CYS277 in many cases for 
dockings on models from 1a trajectory. However, the lipophilic part of the active compounds 
was not under the hydrophobic loop of TG2 in the majority of these cases. Figure 3-36 
shows an example of such pose for compound 1b in the model taken at 65 ns from this 
trajectory. 
 
Figure 3-36: Example pose of 1b with the 
lipophilic part outside the hydrophobic 
loop (coloured red). 
The model taken at 95 nanoseconds (95ns) gave good results in terms of poses and scores 
and was therefore selected as a valid model to be taken for further investigation. Table 3-3 
shows the docking results of the 6 active compounds on 95ns model. Figure 3-37 presents 
the pose of compound 1b as an example of complexes generated in this model. From Table 
3-3, it can be seen that a hydrogen bond with ASN333 was present in 1b and 1e complexes. 
In all the compounds, there were hydrophobic interactions stabilising the lipophilic part in the 
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hydrophobic loop. In case of the sulfonium ion warhead (1b and 1f), there were pi-cation 
interactions with TRP241 and/or PHE334. 
Complex 
Distance 
(Å) 
H-bonds GoldScore* Rank CHEMPLP* Rank 
1b-95ns-9 6.1 ASN333 49 2nd 38 14th 
1b-95ns-18 6.3 ASN333 47 3rd 52 3rd 
1c-95ns-2 5.5 HIS335 56 2nd 46 11th 
1c-95ns-12 4.3 
CYS277 
PHE334 
47 4th 61 4th 
1e-95ns-1 4.3 
GLN276 
ASN318 
ASN333 
57.07 1st 49 4th 
1e-95ns-4 3.7 
GLN276 
ASN318 
PHE334 
57.03 2nd 39 12th 
1f-95ns-13 4.5 
GLN276 
ASN318 
52 9th 31 12th 
Table 3-3: Docking results for active compounds into the 95ns model. *GOLD scoring functions are 
unitless (Yang 2008).  
 
Figure 3-37: Poses of 1b in the 95ns model showing interactions with TG2 residues. 
ASN333 was the only residue among those in Table 3-3 to from hydrogen bonds with its side 
chain atoms as well as backbone atoms (Figure 3-37). The remaining 3 residues participated 
in either side chain or backbone atoms in hydrogen bonds with the compounds, but not both; 
GLN276 side chain, ASN318 backbone and PHE334 backbone. As a result of the good 
docking results obtained with model 95ns, two additional models were selected from this 
trajectory which are close to 95ns and were taken at 90 (90ns model) and 100 (100ns 
model) nanoseconds. The docking results on these two models are presented in Table 3-4 
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and Table 3-5. Figure 3-38 gives examples for the poses in 90ns model and Figure 3-39 
examples for 100 ns model. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
1a-90ns-8 3.5 None 47 2nd 46 13th 
1a-90ns-14 3.5 TRP241 46 4th 55 6th 
1b-90ns-6 7.4 ASN333 41 16th 47 2nd 
1d-90ns-8 5.2 None 57 1st 62 1st 
1d-90ns-20 6.5 PHE334 55 2nd 0.33 19th 
1e-90ns-11 4.1 ASN333 48 1st 32 13th 
1e-90ns-17 3.1 
GLN276 
ASN318 
PHE334 
47 2nd 23 18th 
Table 3-4: Docking results for active compounds into the 90ns model. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
1a-100ns-1 5.2 None 46 1st 49 9th 
1a-100ns-4 4.9 None 45 2nd 53 3rd 
1b-100ns-3 5.9 
ASN333 
PHE334 
46 4th 58 1st 
1e-100ns-1 3.5 GLN276 60 1st 46 4th 
1e-100ns-8 3.7 GLN276 55 3rd 56 1st 
1e-100ns-9 3. 6 None 59 2nd 50 2nd 
1f-100ns-4 5.1 
GLN276 
ASN318 
54 4th 51 3rd 
Table 3-5: Docking results for active compounds into the 100ns model. 
In 90ns and 100ns models, again there were hydrogen bonds with ASN333 (side chain and 
backbone) and PHE334 (backbone), in addition to TRP241 (side chain), GLN276 (side 
chain) and ASN318 (side chain). With the exception of ASN318, all the other mentioned 
residues are important in stabilising the warhead within the catalytic tunnel (Badarau, 
Mongeot, et al. 2013; Pinkas et al. 2007). In 1b and 1d complexes, the pi-cation interaction 
was also present between the sulfonium ion sulphur and the phenyl group of PHE334, 
TRP241 or TRP332 (Figure 3-38 and Figure 3-39). Hydrophobic interactions involving 
different lipophilic parts were also present. The residues participated the most were ALA304, 
ILE313, ILE331 and LEU420. In the 100ns model, there were pi-pi interactions between the 
dansyl group of 1e and 1f and the side chain of PHE316 (Figure 3-38 and Figure 3-39). 
The 95ns model gave some good results when tried first with the original definition of the 
active site. The results presented above were obtained when the active site definition of 1b 
trajectory was used. The same definition was also used for dockings on 90ns and 100ns 
models. The better docking results using this definition may give an indication to the 
significance of the 306-311 residue region (the hydrophobic loop of the active site) of TG2 
for the activity of inhibitors. They also emphasise the importance of the lipophilic part of the 
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inhibitors and its pose within the hydrophobic loop of TG2 active site for an appropriate 
docking complex. 
 
Figure 3-38: Poses of 1a, 1b, 1d and 1e in the 90ns model showing interactions with TG2 residues. 
3.3.2 Docking into TG2 models from the 1b complex trajectory 
Residues 306-311 were added to active site definition used in models of the 1b trajectory. 
CAChe was used for docking on models from this trajectory, but out of the 216 docking 
attempts (4 dockings per compound for 6 compounds in 9 active site models), only 7 
plausible poses were obtained. Figure 3-40 shows 2 of these 7 good poses for compounds 
1d and 1c in the models taken at 65 ns and 95 ns respectively. 
When GOLD was used, 3 models for the active site taken from this trajectory produced good 
docking results and were considered valid. These were 65ns, 155ns and 245ns. Their 
results will be presented separately. The other models also produced some good results but 
not as much. In all cases, the best results were obtained for compound 1b. 
 
1a-90ns-14 
1b-90ns-6 
 
1d-90ns-8 
 
1e-90ns-11 
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Figure 3-39: Poses of 1a, 1b, 1e and 1f in the 100ns model of the 1a trajectory showing interactions. 
 
Figure 3-40: Poses of 1d and 1c in 65ns and 95ns models of the 1b trajectory after CAChe docking. 
3.3.2.1 65ns model from the 1b trajectory 
Table 3-6 represents a summary of the good docking results obtained with this model. The 
poses for these results are presented in Figure 3-41. 
It can be seen from Table 3-6 and Figure 3-41 that a hydrogen bond with ASN333 is 
important for a good ligand pose. Pi interactions between residues from the hydrophobic 
loop of TG2 and the lipophilic parts of the various ligands were also evident. Finally, 
regarding the sulfonium ion warhead in 1b and 1d, pi-cation interactions were also noticed 
 
1a-100ns-4 1b-100ns-3 
1e-100ns-1 1f-100ns-4 
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between TRP332 and HIS335 from TG2 and 1b and between PHE280 and HIS335 of TG2 
and 1d. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
1b-65ns-13 5.9 ASN333 66.32 1st 51 12th 
1b-65ns-18 6.3 
ASN333 
PHE334 
66.3 2nd 50 13th 
1d-65ns-12 4.2 
CYS277 
HIS335 
63 8th 40 17th 
1e-65ns-20 4.5 
GLN276 
ASN333 
PHE334 
68 2nd 78 1st 
Table 3-6: Docking results for active compounds into the 65ns model. 
3.3.2.2 155ns model from the 1b trajectory 
The results obtained from docking on this model are presented in Table 3-7 and Figure 3-42. 
Hydrogen bonds were not very frequent in this model but there were pi-interactions between 
the piperazine ring of the compounds with TRP241 (for 1c, 1e and 1f) and with PHE334 (for 
1f). These interactions may have served the function of keeping the warhead within the 
catalytic tunnel close to CYS277. 
  
 
Figure 3-41: Poses for 1b, 1c and 1e in the 65ns 
model showing interactions with TG2 residues. 
 
1b-65ns-13 
1d-65ns-12 
1e-65ns-20 
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Complex Distance H-bonds GoldScore Rank CHEMPLP Rank 
1c-155ns-16 4.9 
GLN276 
ASN333 
73 3rd 86 1st 
1d-155ns-19 6.4 None 66 4th 23 19th 
1e-155ns-2 4.4 None 70 3rd 67 4th 
1f-155ns-6 4.2 CYS277 76 1st 83 1st 
Table 3-7: Docking results for active compounds into the 155ns model. 
 
Figure 3-42: Poses for 1c, 1d, 1e and 1f in the 155ns model showing interactions with TG2 residues. 
3.3.2.3 245ns model from the 1b trajectory 
The results for the docking of the 6 active compounds on 245ns model are summarised in 
Table 3-8 and Figure 3-43. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
1b-245ns-9 6.8 
ARG317 
ASN333 
PHE334 
63 2nd 73 1st 
1b-245ns-2 6.6 ASN333 69 1st 62 5th 
1c-245ns-4 5.5 
CYS277 
ASN333 
PHE334 
HIS335 
70 1st 70 7th 
1d-245ns-16 6.4 
ASN333 
PHE334 
67 2nd 71 2nd 
1e-245ns-11 5.1 None 67 1st 73 1st 
Table 3-8: Docking results for active compounds into the 245ns model. 
  
  
1c-155ns-16 1d-155ns-19 
1e-155ns-2 1f-155ns-6 
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Figure 3-43: Poses for 1b, 1c, 1d and 1e in the 245ns model showing interactions with TG2 residues. 
Again, hydrogen bonds and pi-interactions were present and participating in positioning both 
the warhead and the lipophilic part of the active compounds. It can be seen from Figure 3-43 
that the lipophilic part of 1d was not located under the hydrophobic loop of TG2. In fact, this 
conformation has been adopted by compounds 1a and 1d in many cases of the dockings on 
the valid models. In this particular case of 1d in the 245ns model, the conformation was 
ranked second in both scoring functions and the warhead was somewhat close to CYS277. 
No hydrophobic interactions were detected between the terminal phenyl group of 1d and 
TG2 residues where it was docked but it seems that the pi-interaction with TRP332 with the 
piperazine ring of 1d was responsible for positioning the lipophilic part. 
3.3.3 Docking into TG2 models from the 1c complex trajectory 
CAChe and GOLD were used for docking on models from this trajectory. Both programs 
were unable to produce plausible poses for the active compounds in the TG2 active site. 
This was true for the pose of the warhead and the lipophilic part of the ligands. The same 
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poor results were obtained after using the definition of the active site adopted from the 
trajectory of 1b. 
3.3.4 Docking into TG2 models from the 1d complex trajectory 
GOLD was used for docking into models from the 1d trajectory using the original definition 
for the active site. No good results were obtained. Both the warhead and the lipophilic part of 
the active compounds failed to dock into their appropriate places in TG2.  Active site 
definition from the 1b trajectory was then tried in models 35ns, 95ns, 155ns, 215ns and 
275ns as representatives for models from 1d trajectory. Again, no good results were 
obtained. 
3.3.5 Docking into TG2 models from the 1e complex trajectory 
CAChe was used for docking into models from this trajectory but no good results were 
obtained. In very few cases, the lipophilic part was able to position itself in the hydrophobic 
region but the warheads of the 6 compounds failed to dock close to the sulphur atom of 
CYS277. Figure 3-44 is an example for compound 1b in the model taken at 155 
nanoseconds, where the distance between the warhead and SG of CYS277 was about 9 Å. 
 
Figure 3-44: Pose of 1b in the 155ns model of 
1e trajectory after CAChe docking. 
For GOLD dockings, the results were similar to those obtained on models from the 1a 
trajectory in that the warhead managed to get close to CYS277 but the lipophilic part failed 
to be positioned under the hydrophobic loop. The lipophilic part was pointing out of the 
protein in the majority of cases. In Figure 3-45, a representative of docking on models from 
this trajectory is shown; compound 1d is docked into the 125ns model where the warhead 
was about 4.8 Å away from CYS277 but the lipophilic part is not in place. The conformation 
of TRP332 is shown as a possible cause for this. 
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Figure 3-45: The pose of 1d 
in the 125ns model of 1e 
trajectory showing the 
distance with CYS277 (4.8 Å) 
and the conformation of 
TRP332. 
The conformation of TRP332 changed during the MD simulation in such a way as to block 
the hydrophobic loop in TG2 and prevent the access of the lipophilic part of the 6 active 
compounds to this region (Figure 3-46). Although TRP332 was one of the residues that were 
selected to be treated as flexible during the docking, it appears that a movement to allow the 
lipophilic part to dock well was outside the range of the flexibility offered by GOLD. This 
flexibility was based upon The Penultimate Rotamer Library (Lovell et al. 2000) which 
includes the most commonly observed side chain conformations for the natural amino acids. 
Therefore, this orientation of TRP332 was responsible for the inappropriate poses for the 
active compounds. 
3.3.6 Docking into TG2 models from the 1f complex trajectory 
Again, no good results were obtained for the 6 active compounds when docked into the 
models taken from this trajectory. In some cases, the warhead was able to dock to a position 
that is close to CYS277, but the lipophilic part was never in the hydrophobic region of TG2. 
The reason behind this seems to be the orientation of TRP332. This residue, as in the 
models taken from 1e trajectory, was blocking the approach of the lipophilic part to the 
hydrophobic loop of TG2. Figure 3-47 presents an example of the poses on models from 1f 
trajectory. The figure shows the pose of 1d in the 245ns model with the conformation of 
TRP332. 
Chapter 3   Model Development and Validation 
114 
 
 
Figure 3-46: Orientation of TRP332 in the 1e trajectory compared to the starting conformation (top left). 
The other conformations were taken at 30 ns intervals from the trajectory. TRP332 is shown in yellow as 
ball and stick. 
 
Figure 3-47: The pose of 1d in the 
245ns model of 1f trajectory. The 
distance with CYS277 is shown (3.3 
Å) along with the conformation of 
TRP332 to show a possible cause 
for the pose of the lipophilic part. 
The criteria set at the start of this section (3.3) for the definition of an acceptable docking 
complex have been confirmed with the results obtained from the 6 models of the first two 
trajectories. Hydrogen bonds involving the central region (the linker) of the inhibitor 
molecules are important for generating the required bent conformation of the ligand, as are 
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the lipophilic interactions at the hydrophobic loop of TG2. It has also been noted that pi-
cation interactions involving the sulfonium ion of compounds 1b, 1d and 1f may be able to 
compensate for the lack of hydrogen bonding to the linker region in positioning the warhead 
to CYS277. This role has also been played by lipophilic pi interaction involving the 
piperazine ring of some compounds. Those observations are consistent with the ones made 
during the analysis of the MD trajectories on the docked complexes in section 3.2. 
Compound 1e was the only compound that has managed a good pose in all the selected 
valid models in this stage of docking. This should not be surprising, knowing that 1e is the 
most potent compound within the group. The compound failed, however, to exhibit the 
formation of hydrogen bonds with TG2 residues in 2 models; 155ns and 245ns. The second 
best performance in terms of the correct poses was achieved by compound 1b, which 
docked appropriately in all the models with the exception of 155ns. That was combined with 
passing the other criteria as well, including the formation of hydrogen bonds and the good 
ranking. Since all the compounds share the same linker region, and each 3 compounds 
share the same warhead, it can be said that the lipophilic part of the inhibitor in this group of 
compounds was responsible for the different docking results. Therefore, a combination of a 
dansyl group with an acrylamide warhead (compound 1e), and a combination of a tertiary 
butyl group and a sulfonium ion warhead (compound 1b) (Table 3-1) may offer superiority to 
the potential of the compounds to dock well in the active site of TG2. 
Due to the significance of the lipophilic interactions in the docking complexes that proved to 
be valid, the presence of such an interaction has been added to the criteria defining a good 
docking complex; besides the appropriate bent conformation, the good rank with one or both 
of the used scoring functions and the presence of hydrogen bonds with the key residues in 
the active site of TG2. 
Despite the good results obtained with the 6 models and from 6 different compounds with 2 
types of warheads, the models need to be tested on a larger set of compounds, and some 
inactive compounds should be tested as well, in order to determine if the models could 
discriminate between potent and inactive compounds. This was the rationale of the next 
stage of this work. 
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3.4 Validation of Active Site Models 
The six active site TG2 models selected from the previous stage were validated by docking 
experiments and short MD simulations. The validation process included: 
1. Performing a docking experiment with GOLD that is similar to the previous one with 
turning off early termination and adding 3 inactive compounds to the test set. 
2. Performing a docking experiment with GOLD similar to the one described in step 1 
with the same test compounds but with having 25 water molecules within the active 
site of TG2. 
3. Applying a GOLD docking experiment identical to that in step 1 with a new set of 15 
active and 5 inactive TG2 inhibitors. 
4. Applying docking experiment using GOLD on the 6 models with settings similar to 
those in step 1 on a set of compounds that includes the original 6 active compounds, 
the 3 inactive compounds introduced in step 1 and the 20 active and inactive 
compounds from step 3. This experiment was repeated 3 times. 
5. Performing 5-nanosecond MD simulations on selected docking complexes of the 6 
valid models from the above experiments and the previous docking results. 
6. Performing docking with GOLD using settings as those in experiment 1 on a set of 3 
active compounds (different chemical type to the initial set) from the work by Prime, 
Andersen et al. (2012). 
3.4.1 Validation process 1 (3 inactive compounds) 
A valid model should not only dock active compounds in a good manner, but it should also 
give bad docking results for inactive compounds. This was the rationale behind adding three 
inactive compounds to the test set [compounds 2a, 2b and 2c (Table 3-9) (Badarau et al. 
2015; Griffin et al. 2014)]. The results will be presented by models. 
3.4.1.1 Models from the 1a trajectory 
The results of docking the 6 active compounds and the 3 inactive ones into models 90ns, 
95ns and 100ns from the 1a trajectory are summarised in Table 3-10. An analysis of the 
docking complexes from this trajectory showed that, although some complexes in models 
90ns and 100ns did not contain any hydrogen bonds, the hydrophobic interactions involving 
the lipophilic part in the hydrophobic loop of TG2 were evident in all the complexes except 
that of 1e in the 90ns model. Probably that is why the complex of 1e (1e-90ns-17) failed to 
achieve a good rank in the two scoring functions. 
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Compound Structure IC50 (µM) 
2a 
 
400 
2b 
 
> 100 
2c 
 
> 100 
Table 3-9: Inactive compounds used in validation process 1. 
There were also pi-interactions with the piperazine ring of all the compounds in models 95ns 
and 100ns except for 1e and 1f in 95ns and 1f in 100ns model. In those two compounds, 
there were pi-sulphur interactions between the sulphur atom of the sulphonamide group and 
the phenyl group of TRP332 or a hydrogen bond between the sulphonamide group and 
ASN318. Other pi-sulphur interactions were recorded involving the sulfonium ion of 1b, 1d 
and 1f in the 3 models. 
Compound 2c achieved a good pose in the 3 models with good GoldScore ranking in the 
95ns and 100ns models. The good rank is probably offset by the lack of hydrogen bonds in 
the 2 complexes. The GoldScore scoring function is the sum of multiple energy terms, one of 
which is van der Waals interactions between the ligand and the protein. Given the large size 
of 2c molecule, the van der Waals component contributed much to the score giving rise to 
the high scores associated with 2c. For 2b complex in the 90ns model, however, a rank of 4 
out of 20 would mean a favourable pose. This was the only pose for an inactive compound 
that achieved all the criteria for an acceptable docking complex. 
3.4.1.2 Models from the 1b trajectory 
The results of docking of the 9 test compounds on models 65ns, 155ns and 245ns of the 1b 
trajectory are presented in Table 3-11. It can be clearly seen from this table that the 
hydrogen bonding profile for all the models is much better than in the models from the 1a 
trajectory. This may contribute to the generally better scores for the active compounds in 
models from the 1b trajectory than from the 1a trajectory. Only one inactive compound 
achieved a good pose and score, 2b-245ns-4, but in this complex, no interactions involving 
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the lipophilic part of the molecule were recorded. This may indicate that the pose of the 
lipophilic part may change easily. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
1a-90ns-1 3.7 None 49 2nd 19 19th 
1a-90ns-7 3.5 None 47 7th 57 1st 
1b-90ns-2 6.6 ASN333 51 1st 53 3rd 
1b-90ns-1 6.4 None 49 2nd 42 10th 
1d-90ns-5 5.3 None 58 1st 60 1st 
1d-90ns-3 5.9 None 53 4th 60 2nd 
1e-90ns-17 3.3 
ASB318 
ASN333 
PHE334 
43 12th 39 8th 
2b-90ns-8 3.3 TRP241 54 4th 64 8th 
2c-90ns-8 6.3 ASN318 46 19th 15 20th 
1a-95ns-14 5.2 TRP332 50.5 2nd 50 6th 
1a-95ns-15 4.3 TRP332 50 3rd 50 5th 
1b-95ns-6 5.9 
TRP332 
ASN333 
50 4th 41 7th 
1c-95ns-2 4.7 
CYS277 
PHE334 
53 2nd 50 8th 
1d-95ns-4 6.6 ASN333 47 5th 42 5th 
1e-95ns-15 3.7 
GLN276 
ASN318 
ASN333 
55 1st 48 5th 
1e-95ns-2 3.9 None 53 2nd 49 4th 
1f-95ns-20 5.8 
GLN276 
ASN318 
61 1st 43 5th 
1f-95ns-13 5.8 
ASN318 
ASN333 
53 4th 43.5 4th 
2c-95ns-3 5.6 None 61 3rd 4 20th 
1b-100ns-9 5.8 ASN333 51 1st 52 6th 
1b-100ns-15 5.7 ASN333 50 2nd 47 13th 
1c-100ns-6 4.0 None 54 2nd 72 2nd 
1e-100ns-3 3.9 None 60 1st 47 1st 
1e-100ns-16 4.2 GLN276 51 7th 56 1st 
1f-100ns-16 3.2 GLN276 52 6th 82 2nd 
2c-100ns-1 5.5 None 65 1st 57 4th 
Table 3-10: Docking results for validation process 1 into models from the 1a trajectory. 
Regarding active compounds, pi-interactions involving different lipophilic parts of the ligands 
were evident in all the models. The piperazine ring of the active compounds was also 
involved in pi-interactions with active site residues, mainly TRP241 and TRP332. In models 
65ns and 245ns, the lipophilic part of compounds 1a and 1f (65ns) and 1d and 1f (245ns) 
failed to locate in the hydrophobic region of TG2 in the complexes mentioned in Table 3-11. 
As it can be seen in Figure 3-48, this may be attributed to the orientation of the side chain of 
ASN333 which may be acting as a blocker to the access to the hydrophobic loop. The 
complex of 1b is shown for comparison. 
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Complex Distance (Å) H-bonds GoldScore Rank CHEMPLP Rank 
1a-65ns-16 5.0 
GLN276 
ASN333 
PHE334 
52 12th 75 1st 
1b-65ns-7 5.8 None 57 12th 30 20th 
1c-65ns-4 4.9 
GLN276 
CYS277 
PHE334 
68 4th 92 1st 
1e-65ns-2 2.9 CYS277 60 14th 48 13th 
1f-65ns-13 5.1 
CYS277 
ASN333 
PHE334 
HIS335 
75 2nd 67 3rd 
1b-155ns-10 6.2 
ARG317 
ASN333 
PHE334 
65 3rd 69 1st 
1c-155ns-17 4.7 
ASN333 
PHE334 
76 1st 89 2nd 
1c-155ns-11 5.4 GLN276 74 3rd 94 2nd 
1d-155ns-4 5.2 
GLN276 
ASN333 
58 11th 64 6th 
1e-155ns-3 5.0 PHE334 74 1st 73 2nd 
1e-155ns-11 5.2 PHE334 73 2nd 77 1st 
1b-245ns-20 6.1 
ARG317 
ASN333 
PHE334 
63 1st 66 3rd 
1b-245ns-15 5.6 
ASN333 
PHE334 
61 3rd 63 4th 
1c-245ns-13 4.9 
TRP332 
PHE334 
66 1st 84 1st 
1d-245ns-15 3.5 
CYS277 
ASN333 
71 2nd 76 1st 
1e-245ns-20 4.8 PHE334 64 4th 61 6th 
2b-245ns-4 3.9 None 58 2nd 71 1st 
Table 3-11: Docking results for validation process 1 into models from the 1b trajectory. 
 
Figure 3-48: Poses of compounds 1a, 1b and 1f in model 65ns showing the role of ASN333 in blocking 
the hydrophobic region of TG2 active site. 1b is shown for comparison. 
 
1a 1f 1b 
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3.4.2 Validation process 2 (water docking) 
GOLD is implemented with the capability of performing a docking with the presence of water 
molecules within the active site. The program can accommodate up to 25 water molecules 
and it gives the option to turn them on or off during the docking or to allow GOLD to decide 
whether a specific water molecule is turned on or off. There is also the option of keeping 
water molecules fixed or allowing them to spin about their axes (CCDC Software Limited 
2013; Verdonk et al. 2005). For this experiment, GOLD was given the option to toggle which 
water molecules to be used. The molecules were also allowed to spin. The models were 
selected from the trajectory containing 25 closest water molecules to CYS277 at the same 
time points at which the water-free models were selected. Figure 3-49 shows model 90ns 
with the water molecules. 
 
Figure 3-49: Model 90ns 
showing the water 
molecules in the active 
site.
3.4.2.1 Models from the 1a trajectory 
Compounds 1a, 1b and 2b achieved good poses and ranks in all the 3 models, compound 
1c in the 100ns model, 1d in the 90ns and the 100ns, 1e in the 95ns and the 100ns, 1f in the 
95ns and 2c in the 95ns model. The poses in general were similar to those obtained in 
validation process 1 with all the important interactions, except for compound 2b, which either 
missed the interactions in the lipophilic region or within the catalytic tunnel. Compound 2c 
did form a network of interactions within the active site but its rank within 95ns model was 
bad. 
Surprisingly, in no complex for all the compounds were there hydrogen bonds involving 
water molecules. This happened despite the presence of a minimum of 4 water molecules 
and a maximum of 11 molecules chosen by GOLD to be involved in the docking (Figure 
3-50). However, it is been explained that a reasonable binding mode may be found by GOLD 
that does not involve any interaction with key structural water molecules (Verdonk et al. 
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2005). Keeping this fact in mind, it will not be surprising to lack hydrogen bonds considering 
that these molecules were not structural; they were added by AMBER during MD 
simulations. 
 
Figure 3-50: The seven water 
molecules chosen by GOLD for 
docking of compound 1e in the 
100ns model. None of them is close 
enough to allow for hydrogen 
bonding. 
3.4.2.2 Models from the 1b trajectory 
Similar results to what was seen with models from the 1a trajectory were obtained on these 
models in terms of good poses and ranks in addition to the lack of hydrogen bonds with 
water molecules. However, Compound 1b did form hydrogen bonds with water molecules in 
models 155ns and 245ns (Figure 3-51). Only 2c of the inactive compounds achieved a good 
pose in 155ns model but the rank was bad. There was a minimum of no water molecules in 
some complexes and a maximum of 3 molecules in other complexes in models from the 1b 
trajectory. 
 
Figure 3-51: Hydrogen bonds between compound 1b and water in models 155ns (left) and 245ns (right). 
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Although many of the 25 water molecules originally present in each of the 6 models were 
displaced during the docking, leaving between zero and 11 molecules, the displacement did 
not have a great effect on the score. In other words, there was not significant change in the 
scores of the inhibitors when there was a displacement of water molecules. The gain in 
energy upon displacement of water or the so-called desolvation effect is one of two 
mechanisms by which water can affect the docking of ligands into proteins. The other 
mechanism involves mediating hydrogen bonds with the ligands (Ladbury 1996). Since 
these 2 mechanisms did not prove to offer any advantage with the docking of TG2 inhibitors, 
the approach of water docking is probably not appropriate for TG2. This is also confirmed 
from the absence of any water molecules within the active site of TG2 in the original crystal 
structure [PDB 2Q3Z, (Pinkas et al. 2007)]. 
3.4.3 Validation process 3 (more test compounds) 
Twenty additional compounds also adopted from Badarau et al. (2015) and the associated 
patent by Griffin et al. (2014) were used for this stage of testing. 15 of these compounds 
were active with IC50 values in the range of 0.006-6.8 µM and 5 compounds were inactive 
with IC50 values above 100 µM. The compound numbers, structures and IC50 values for 
these compounds are listed in Table 3-12. 
Compound Structure IC50 (µM) 
3a 
 
1.85 
3b 
 
0.89 
3c 
 
1.4 
3d 
 
0.008 
3e 
 
4.25 
3f 
 
5.925 
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3g 
 
0.0059 
3h 
 
1.07 
3i 
 
6.8 
3j 
 
6.3 
3k 
 
3.3 
3l 
 
2.1 
3m 
 
1.5 
3n 
 
0.775 
3o 
 
1.625 
4a 
 
>100 
4b 
 
>100 
4c 
 
>100 
4d 
 
>100 
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4e 
 
>100 
Table 3-12: Active and inactive compounds used in validation process 3. 
3.4.3.1 Models from the 1a trajectory 
A summary of the results of the docking of compounds used in validation process 3 is 
presented in Table 3-13. All of the presented complexes have achieved the first criterion of a 
good docking complex which is the bent conformation within TG2 active site with the 
warhead pointing in the direction of CYS277. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank Lipo* 
3b-90ns-5 5.2 
GLN276 
ASN318 
52 1st 49 6th Yes 
3c-90ns-20 5.6 ASN333 49 4th 46 8th Yes 
3d-90ns-6 3.7 
ASN333 
PHE334 
42 3rd 49 1st Yes 
3e-90ns-1 4.0 
GLN276 
ASN318 
ASN333 
PHE334 
42 11th 52 4th Yes 
3h-90ns-10 3.7 
GLN276 
ASN333 
54 3rd 62 1st No 
3n-90ns-14 6.2 ASN333 44 19th 52 10th Yes 
3o-90 ns-3 3.8 
TRP241 
GLN276 
CYC277 
ASN318 
54 1st 57 5th Yes 
4b-90ns-8 3.0 None 50 4th 34 17th Yes 
4c-90ns-7 5.8 GLN276 63 2nd 44 17th No 
4d-90ns-18 3.4 ASN333 52 10th 39 14th Yes 
4e-90ns-1 3.4 
GLN276 
ASN333 
48 19th 39 20th Yes 
3a-95ns-19 6.6 
TRP332 
ASN333 
52 6th 38 16th Yes 
3b-95ns-12 5.7 None 57 2nd 67 1st Yes 
3d-95ns-7 6.3 
GLN276 
TRP332 
ASN333 
44 1st 33 10th Yes 
3e-95ns-16 3.6 
GLN276 
ASN333 
46 3rd 60 1st No 
3f-95ns-7 4.3 
GLN276 
ASN333 
46 1st 23 18th No 
3g-95ns-3 3.2 
GLN276 
ASN318 
PHE334 
56 2nd 23 16th Yes 
3i-95ns-10 5.7 GLN276 55 1st 30 12th Yes 
3n-95ns-6 6.3 ASN333 56 2nd 47 15th Yes 
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3o-95ns-1 4.1 
ASN276 
PHE334 
52 2nd 63 4th Yes 
4b-95ns-16 3.5 
GLN276 
ASN333 
50 1st 59 1st No 
4c-95ns-3 5.4 ASN333 57 8th 32 17th Yes 
4d-95ns-12 3.5 TRP241 48 13th 33 18th Yes 
4e-95ns-19 3.7 GLN276 56 1st 42 13th No 
3a-100ns-7 6.5 
TRP241 
ASN333 
56 1st 45 8th Yes 
3b-100ns-
16 
6.8 None 52 2nd 64 5th Yes 
3d-100ns-
10 
4.4 ASN333 42 2nd 49 3rd Yes 
3e-100ns-15 3.2 
GLN276 
TRP332 
ASN333 
PHE334 
46 2nd 46 13th Yes 
3f-100ns-13 3.4 
GLN276 
ASN332 
PHE334 
47 3rd 50 9th Yes 
3g-100ns-6 3.7 PHE334 54 2nd 59 1st Yes 
3i-100ns-20 5.6 None 59 1st 54 5th Yes 
3j-100ns-10 3.9 GLN276 42 9th 12 19th Yes 
3n-100ns-
19 
5.2 
GLN276 
ASN333 
54 2nd 75 1st Yes 
3o-100ns-7 4.4 TRP241 50 5th 74 1st Yes 
4b-100ns-6 3.4 GLN276 51 1st 52 5th Yes 
4d-100ns-7 3.1 None 43 16th 57 5th Yes 
4e-100ns-17 4.1 None 56 2nd 50 8th Yes 
Table 3-13: Docking results of validation process 3 into models from the 1a trajectory.* “Lipo” column in 
this table and the next ones determines the presence “Yes” or absence “No” of interactions between the 
lipophilic part of the inhibitors and the hydrophobic loop of TG2.  
A closer look at the distances in Table 3-13 shows that compounds with sulfonium warheads 
(3a, 3b, 3c, 3h, 3i, 3k, 3n, and 4c) achieved SG-warhead distances that are generally larger 
than 5 Å. This can be attributed to the physical size of the warhead in these compounds. For 
the 90ns model, 7 active compounds out of the 15 gave good poses, 5 of which passed the 
4 criteria for a good docking complex. Compound 3h did not have any interactions with the 
hydrophobic loop of TG2 and compound 3n failed to rank high in any of the scoring 
functions. In the same model, 4 of the 5 inactive compounds posed well in the active site but 
none of them passed the 4 criteria; 4b with no hydrogen bonds, 4c with no lipophilic 
interactions and 4d and 4e by failing to achieve high ranks in either scoring function. 
For the 95ns model, 9 active compounds achieved good poses but only 5 passed all the 
validation criteria; compound 3a was not ranked high, compounds 3e and 3f did not show 
interactions in the hydrophobic loop and compound 3b had no hydrogen bonds with TG2. 
The latter did have pi-cation interactions between the sulfonium ion and the side chains of 
TRP241 and TRP332 (Figure 3-52A). This type of interaction was also observed in 3i and 3n 
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and may further contribute to directing the warhead to CYS277. Four of the 5 inactive 
compounds had good poses but, as in 90ns model, none passed all the criteria. In the 100ns 
model, 10 active compounds had good poses within the active site of TG2 and 7 of them 
passed all the validation criteria. 3b and 3i did not have hydrogen bonds but had pi-cation 
interactions with TRP241 which leaves only 3i as a failing active compound. Only 3 inactive 
compounds posed well and only one of them managed to pass all the criteria with the other 
two missing the hydrogen bonds. Figure 3-52B is an example pose for compound 3o for this 
group of models. 
 
Figure 3-52: A: Pose of compound 3b in 95ns model showing the pi-sulphur interaction. B: Pose of 
compound 3o in 90ns model as an example. 
3.4.3.2 Models from the 1b trajectory 
A summary of docking results of all the compounds is presented in Table 3-14. Again, in all 
the complexes in the table, the compounds have achieved the criterion of the appropriate 
bent pose within the active site of TG2. The SG-warhead distances for compounds having 
sulfonium ion warheads are also generally larger than those of acrylamide compounds. For 
the 65ns model, 7 out of 15 active compounds gave good poses. Three of the 7 passed all 
the validation criteria and 4 did not, by either not having hydrogen bonds or not ranking high 
in the scoring functions. Three inactive compounds achieved good poses in this model but 
none passed the 4 criteria. In fact, all of them passed only 2 and failed with 2 criteria. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank Lipo 
3c-65ns-13 6.5 
ASN333 
PHE334 
72 1st 48 16th Yes 
3d-65ns-20 6.6 
ASN333 
PHE334 
57 2nd 45 11th Yes 
3f-65ns-1 5.3 None 62 5th 66 3rd Yes 
B A 
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3i-65ns-8 4.7 
GLN276 
CYS277 
68 5th 66 7th Yes 
3j-65ns-2 5.7 
GLN276 
CYS277 
ASN333 
82 1st 95 1st Yes 
3m-65ns-11 6.3 TRP332 65 17th 69 12th Yes 
3o-65ns-11 3.6 None 67 1st 63 6th Yes 
4a-65ns-6 3.3 
GLN276 
ASN333 
62 15th 75 5th No 
4b-65ns-16 3.2 
ASN333 
PHE334 
61 10th 67 9th Yes 
4d-65ns-5 4.9 None 69 3rd 66 9th No 
3a-155ns-8 7.1 
ARG317 
ASN333 
PHE334 
71 3rd 62 12th Yes 
3c-155ns-19 3.9 
TRP241 
HIS335 
62 7th 9 19th Yes 
3d-155ns-5 4.5 
ARG317 
ASN333 
PHE334 
58 1st 75 1st Yes 
3e-155ns-14 4.3 TRP332 57 9th 57 9th Yes 
3f-155ns-19 4.6 None 59 8th 72 2nd Yes 
3g-155ns-
12 
5.1 PHE334 73 4th 71 7th Yes 
3m-155ns-
14 
5.2 
CYS277 
ARG318 
HIS335 
76 4th 80 3rd Yes 
4b-155ns-
12 
5.0 None 68 2nd 18 20th Yes 
4d-155ns-
20 
4.9 ASN333 57 12th 65 8th Yes 
4e-155ns-2 5.2 ASN333 56 17th 41 20th No 
3d-245ns-
18 
5.2 
CYS277 
ASN333 
57 1st 60 3rd Yes 
3e-245-18 3.6 
CYS277 
ASN333 
HIS335 
61 3rd 34 17th Yes 
3f-245ns-2 4.3 PHE334 62 2nd 33 20th No 
3g-245ns-
19 
2.9 TRP241 58 11th 45 16th Yes 
3h-245ns-9 4.2 
GLN276 
PHE334 
79 2nd 70 9th Yes 
3i-245ns-2 4.6 None 63 7th 81 1st No 
3j-245ns-15 6.3 
CYS277 
TRP332 
ASN333 
HIS335 
67 2nd 65 4th Yes 
3k-245ns-5 3.4 
CYS277 
ARG317 
73 3rd 77 2nd Yes 
3o-245ns-1 3.8 PHE334 63 2nd 65 9th Yes 
4b-245ns-
18 
4.9 GLN276 61 3rd 76 1st Yes 
Table 3-14: Docking results of validation process 3 into models from the 1b trajectory. 
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In the 155ns model, 7 active compounds and 3 inactive compounds achieved the required 
pose within TG2 active site. 4 active compounds succeeded in passing the 4 criteria for a 
good docking complex and 3 active compounds passed only 3 criteria missing either the 
hydrogen bonds or the top ranking in the scoring functions. The 3 inactive compounds failed 
to pass the 4 criteria missing the hydrogen bonds, top ranks and/or the interactions involving 
the lipophilic part of the inhibitor. The performance of model 245ns was the best in this 
group, where 9 active compounds and only 1 inactive compound passed the good pose 
criterion. 6 active compounds passed the 4 criteria, 2 passed 3 criteria and one compound 
(3i) passed only 2. Compound 3i lacked interactions with the lipophilic part and hydrogen 
bonds but there was a pi-sulphur bond between the sulfonium ion and PHE280 that may 
compensate for a lack of hydrogen bonds. The only one inactive compound that posed well, 
however, has passed the 4 criteria for a good docking complex. 
It should also be mentioned that in most complexes obtained in this process, there were pi 
interactions involving the piperazine ring in the centre of the inhibitors. TG2 residues on the 
other side of these interactions were mainly the bridging tryptophan residues, TRP241 and 
TRP332 (Figure 3-53). These interactions were present in almost all the complexes except 
those from model 90ns of the 1a trajectory. These pi-interactions are weaker than the 
hydrogen bonds, but they can contribute to maintaining the bent conformation of the inhibitor 
required for its activity. 
 
Figure 3-53: Poses of compounds 3e (left) and 3i (right) in the 95ns and 245ns models respectively, 
showing the pi interactions with the piperazine ring. 
3.4.4 Validation process 4 (all compounds) 
A total of 21 active and 8 inactive compounds were docked into the 6 models using the 
default settings in GOLD with flexible treatment of the selected 10 active site residues. It was 
Chapter 3   Model Development and Validation 
129 
 
performed as a triplicate. The rationale behind this experiment was to assess the 
performance of the models in testing such a comparably large set of TG2 inhibitors. The 
performance of each of the model will not be discussed in detail as it has been presented 
previously; rather a more concise presentation will be used. The docking attempt that gave 
the best results was considered, even if that was different for each model. The best result, 
rather than the average, was considered because GOLD uses a genetic algorithm as the 
docking method (Jones et al. 1997) and this is a stochastic method that works by generating 
a set of random initial solutions, scoring them and then modifying and scoring accordingly. 
Table 3-15 contains a summary of the percentages of active and inactive compounds that 
achieved good poses and that passed the 4 validation criteria in the best docking attempt for 
each model. The same information is also presented in Figure 3-54. 
Model 
% Actives / 
good pose 
% Inactives / 
good pose 
% Actives / 4 
criteria 
% Inactives / 
4 criteria 
Docking 
Attempt 
65ns 57.14 50 38.10 12.5 3rd 
90ns 57.14 37.5 47.62 12.5 1st 
95ns 76.19 37.5 61.90 25 1st 
100ns 80.95 25 38.10 12.5 2nd 
155ns 57.14 12.5 33.33 12.5 1st 
245ns 38.10 25 28.57 0 2nd 
Table 3-15: Performance of the 6 active site models in validation process 4. Percentages are 
approximated to the nearest hundredth. 
 
Figure 3-54: A graphical presentation for information from Table 3-15. 
With the exception of 245ns, all the models scored more than 50% in capturing the bent 
conformation and it was model 95ns that performed the best in terms of achieving the 4 
criteria. This was true for active as well as inactive compounds. Although model 245ns did 
not score high for good poses, no inactive compounds passed the 4 criteria in this model. 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
65ns 90ns 95ns 100ns 155ns 245ns
Actives with good pose
Inactives with good pose
Actives with 4 criteria
Inactives with 4 criteria
Chapter 3   Model Development and Validation 
130 
 
Model 90ns had the lowest difference between the percentage of active compounds with 
good pose and those that passed the 4 criteria. This would make 90ns suitable choice for 
docking after performing some virtual screening on 95ns and 100ns models. 
The scores from GoldScore and CHEMPLP in this experiment have been analysed. The 
best score for each of the active compounds in every model for the 2 scoring functions have 
been plotted against the IC50 values for the compound. No useful correlation could be 
obtained for all the models; not when IC50 was plotted against the scores, nor when the 
logarithm of IC50 was used, nor when the scores were divided by the molecular weight (to 
normalise the pairwise interactions during the scoring process). The R2 value did not exceed 
0.1 in any case. Furthermore, the scores for the inactive compounds were not very much 
different from those of active compounds; sometimes they were even better. Table 3-16 
presents the best scores obtained for active and inactive compounds in model 95ns from this 
experiment. Figure 3-55 shows the correlation between biological activity and the scores of 
GoldScore and CHEMPLP for 95ns model active compounds as an example. 
Compound IC50 (µM) GoldScore CHEMPLP 
1a 0.125 52 57 
1b 0.273 53 46 
1c 0.44 52 60 
1d 0.7 50 11 
1e 0.0061 59 44 
1f 0.38 60 22 
3c 1.4 54 52 
3d 0.008 44 27 
3e 4.25 45 50 
3f 5.925 44 60 
3g 0.0059 59 26 
3h 1.07 50 62 
3i 6.8 60 28 
3j 2.1 50 38 
3n 0.775 64 62 
3o 1.625 56 56 
    
2c 100 64 16 
4b 100 50 51 
4d 100 42 35 
4e 100 59 13 
Table 3-16: Scores of the active and inactive compounds in model 95ns from validation process 4. 
The fact that the activity of these inhibitors requires covalent bonding with TG2 is probably 
the reason behind these poor correlations. GOLD was able to produce the bent conformation 
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and to rank the solutions of individual compounds based on this conformation along with 
hydrogen bonding and lipophilic interactions but the program was unable to rank the 
compounds based on their activities. 
  
Figure 3-55: Correlation between scores for active compounds and biological activity in 95ns model, left 
is GoldScore and right is CHEMPLP. 
3.4.5 Validation process 5 (5-ns MD simulations) 
The rationale behind this experiment was to ensure that the different poses obtained during 
various docking experiments were valid. In other words, to show whether the active 
compounds will retain their good poses and whether a good pose within the active site for 
inactive compounds will change after 5 nanoseconds of a MD simulation. 
The docking complexes used in this experiment were taken from the primary docking study 
during the selection of the valid models (section 3.3) and from validation processes 1, 2, 3 
and 4. Similar settings for the previous MD simulations were used at this stage; the 
antechamber program was used first, and then minimisation and 3-stage MD simulation 
were applied. Only the production phase (MD2_fast) was taken to investigation. The length 
of this stage was set to 5 nanoseconds. A similar approach has been used by Badarau et al. 
(2013). 
The results will be presented in the form of separate tables for each valid model. The tables 
will contain, in addition to the complex name, a code for the performance of the compound 
during the MD. 1 is a simulation for a compound in which both the warhead and the lipophilic 
part maintained their initial positions during the simulation. 2 is a simulation in which the 
warhead has left its place next to CYS277 and 3 is a simulation in which the lipophilic part 
has left the hydrophobic loop of TG2. The distance between the electrophilic carbon and SG 
of CYS277 will be presented in the starting conformation and its average during the MD 
simulation. This will not be presented for simulations in which the lipophilic part has left the 
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hydrophobic loop. Hydrogen bonds will be presented for the starting conformation and during 
the MD simulation as the interacting residues and the percentage of time for their 
persistence. 
3.4.5.1 Models from the trajectory of 1a 
Table 3-17, Table 3-18 and Table 3-19 contain the results of validation process 5 on the 3 
models from the trajectory of 1a. 
Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1a-90ns-8 2 3.5 15.4    
1b-90ns-4 1 6.7 5.7 
GLN276 
 
ASN333 
ASN318 
 
ASN333 
 
PHE334 
3.5 
 
2 
 
13 
1d-90ns-5 1 5.3 5.6 None 
ASN333 
 
PHE334 
10 
 
4 
1e-90ns-17 1 3.1 5.8 GLN276 
ARG317 
 
ASN333 
 
PHE334 
0.5 
 
1.5 
 
2 
3b-90ns-5 1 5.2 6.2 
GLN276 
 
ASN318 
ASN318 
 
ASN333 
1 
 
29 
3c-90ns-20 1 5.6 6.3 ASN333 
ASN318 
 
ASN333 
4 
 
1.5 
3d-90ns-6 1 3.5 6.1 
ASN333 
 
PHE334 
GLN276 
 
ASN333 
 
PHE334 
11 
 
11 
 
2.5 
3e-90ns-10 2 3.7 12    
3f-90ns-2 1 3.6 3.7 
GLN276 
 
ASN333 
 
PHE334 
ASN333 34 
3h-90ns-10 3      
3j-90ns-1 2 6.1 10.3    
3o-90ns-3 1 3.8 5.8 
TRP241 
 
GLN276 
 
CYS277 
 
ASN318 
ASN318 
 
ASN333 
10 
 
43 
2b-90ns-8 2 3.3 10.6    
4b-90ns-8 2 3 6.5    
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4c-90ns-2 3      
4d-90ns-19 1 3.4 6.2 ASN333 GLN276 15 
Table 3-17: Results of validation process 5 on the 90ns model of the trajectory of 1a. 
Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1a-95ns-10 1 4.6 4 TRP332 
GLN276 
 
ASN318 
18 
 
18 
1b-95ns-6 1 6 6.3 ASN333 ASN333 21 
1c-95-2 1 4.9 4.3 
CYS277 
 
PHE334 
TRP241 
 
GLN276 
 
ASN333 
 
PHE334 
9.5 
 
25 
 
1.5 
 
29 
1d-95ns-4 1 6.6 5.5 179 None  
1e-95ns-17 1 3.5 5.5 GLN276 ASN333 53 
1f-95ns-20 1 5.8 6.1 ASN318 
GLN276 
 
ASN318 
 
ASN333 
88 
 
34 
 
27 
3a-95ns-19 1 6.6 7.8 
TRP332 
 
ASN333 
ARG317 
 
ASN333 
1 
 
17 
3b-95ns-16 1 6.6 6.1 None GLN276 3.5 
3c-95ns-17 1 5.8 6.2 
GLN276 
 
ASN333 
ARG317 
 
TRP332 
 
ASN333 
9.5 
 
13 
 
5.5 
3d-95ns-1 2 6.3 
Left during 
equilibration 
   
3e-95ns-10 2 3.7 8.5    
3f-95ns-11 1 4.1 3.7 ASN333 GLN276 41 
3g-95ns-8 2 3.2 10.4    
3i-95ns-5 1 5.7 8.1 ASN333 GLN324 37 
3l-95ns-19 2 4.1 7.7    
3n-95ns-6 1 6.3 6.6 ASN333 
GLN276 
 
ARG317 
5.5 
 
11 
3o-95ns-1 1 4.1 4.6 
GLN276 
 
PHE334 
GLN276 
 
ASN318 
13 
 
8 
2c-95ns-3 1 5.6 6.5 None ARG317 1 
4b-95ns-12 2 4.0 8.7    
4e-95ns-19 2 3.7 5.8    
Table 3-18: Results of validation process 5 on the 95ns model of the trajectory of 1a. 
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Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1a-100ns-5 1 5.3 4.1 None 
GLN324 
 
ASN333 
4.5 
 
1 
1b-100ns-6 1 5.7 6.3 ASN333 
ASN318 
 
ASN333 
3.5 
 
5 
1c-100ns-6 1 4.0 3.7 GLN276 
GLN276 
 
ASN333 
5.5 
 
16 
1d-100ns-16 1 5.5 3.6 None ASN333 22 
1e-100ns-3 2 3.9 6.5    
1f-100ns-4 1 5.1 5.8 GLN276 
ARG317 
 
ASN333 
 
PHE334 
0.5 
 
1.5 
 
2 
3a-100ns-17 1 7.3 7.3 GLN324 
GLN276 
 
GLN324 
3.5 
 
2.5 
3b-100ns-19 1 5.8 5.9 GLN276 ASN318 46 
3c-100ns-1 2 6.7 8.1    
3d-100ns-7 1 4.2 6.4 
GLN276 
 
ASN333 
 
PHE334 
ASN333 46 
3e-100ns-15 1 3.2 6.1 
TRP241 
 
GLN276 
 
ASN333 
 
PHE334 
ASN333 
 
PHE334 
19 
 
6 
3f-100ns-13 1 3.4 3.9 
GLN276 
 
ASN333 
 
PHE334 
GLN276 49 
3g-100ns-6 1 3.7 3.8 PHE334 
GLN276 
 
GLN324 
 
PHE334 
17 
 
4 
 
7 
3i-100ns-10 1 5.8 6.5 GLN324 ASN333 37 
3j-100ns-10 2 3.9 12.4    
3n-100ns-19 1 5.2 5.7 
GLN276 
 
ASN333 
ASN333 
 
PHE334 
41 
 
1.5 
2c-100ns-11 3      
4b-100ns-6 1 3.4 3.8 GLN276 GLN276 60 
4e-100ns-2 2 3.7 5.5    
Table 3-19: Results of validation process 5 on the 100ns model of the trajectory of 1a. 
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In the 90ns model, a total of 16 simulations were run, 12 for active compounds and 4 for 
inactive compounds. Of those, 8 active compounds and 1 inactive compound maintained 
their initial pose by the end of the simulation. For 95ns model, there were simulations for 17 
active compounds and 3 inactive compounds from which 13 active and 1 inactive 
compounds managed to pass the simulation (performance code 1). In the 100ns model, 
there were 16 active compounds and 3 inactive compounds at the start. 13 active 
compounds and only one inactive compound finished the simulation successfully 
(performance code 1). In general, the three models performed well in terms of maintaining 
the pose of the active compounds within the active site of TG2 for 5 nanoseconds. At the 
same time, inactive compounds, for the most part, failed to stay in the active site. 
When the hydrogen bonds are considered, it was noted that ASN333 was by far the most 
common in this sense. This was seen in the 3 models from the trajectory of 1a. That only 
confirms the importance of this residue in positioning the inhibitors within TG2 active site and 
in maintaining the correct orientation. The amide group in the side chain has the ability to act 
as a hydrogen bond donor and acceptor (Johansson et al. 1974) and thereby increases the 
chance for the formation of hydrogen bonds with suitable groups on the other side. The 
location of this residue within the TG2 active site gives it an excellent opportunity to govern 
the orientation of the inhibitor (Figure 3-56). 
 
Figure 3-56: The location of residue ASN333 
relative to the active site of TG2 and 
showing a docked inhibitor and CYS277 for 
reference.
The residue is located at the bridge between the hydrophobic loop, that accommodates the 
lipophilic part of TG2 inhibitors, and the catalytic tunnel that contains CYS277 and in the 
bent conformation of the inhibitors; ASN333 will be conveniently located opposite to the 
piperazine ring in the middle of all the compounds used so far in this work. There are 2 
carbonyl groups on either side of the piperazine ring in most of the compounds (all 
compounds except 1e, 1f and 3g) and these carbonyl groups were involved in the hydrogen 
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bonds with ASN333. This did not prevent ASN333 from forming hydrogen bonds with other 
potential groups in the inhibitor molecules that are closer to the warhead. 
GLN276 and PHE334 have also been involved in high percentage of hydrogen bonds 
recorded during these simulations. GLN276 operates on the warhead end of the inhibitor 
while PHE334 formed hydrogen bonds with the central and the warhead parts of the 
inhibitors. There were also hydrogen bonds with ARG317 and ASN318 to a lesser extent. 
The latter formed hydrogen bonds mainly involving the central part of the inhibitors from the 
side of the lipophilic warhead. 
Of all the compounds, whether active or inactive, that failed to maintain their initial positions 
during the simulations, only in 3 compounds; this failure was manifested by the exit of the 
lipophilic part of the inhibitor outside the hydrophobic loop of TG2. This may indicate that, 
with the correct lipophilic parts, it is easier to keep this end of the inhibitor in place than to 
keep the warhead in the catalytic tunnel. It also indicates that for all the tested compounds, 
the various lipophilic parts were appropriate to serve the function of correctly posing TG2 
inhibitors. The fact that these inhibitors act by forming covalent bonds should not be 
forgotten; possibly if these simulations were able to account for the formation of covalent 
bonds, a different performance of the warheads may have been observed. 
3.4.5.2 Models from the trajectory of 1b 
The results of validation process 5 on models from this trajectory are presented in Table 
3-20, Table 3-21 and Table 3-22. The performance of these models was worse than the 
models of the trajectory of 1a. This was especially true for the 245ns model in which 15 
simulations were run for active compounds and only 6 maintained their initial positions after 
the simulation. The 155ns model was the 2nd worst after 245ns and the 65ns model was the 
best after 8 of the 11 tested active compounds succeeded in maintaining the orientation 
required for activity against TG2. Of the 3 inactive compounds, 2 left the active site in the 
65ns model. 
Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1b-65ns-18 1 6.0 5.8 
ASN333 
 
PHE334 
ASN333 
 
PHE334 
0.5 
 
5.5 
1c-65ns-4 1 4.9 4.7 
GLN276 
 
CYS277 
 
None  
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PHE334 
1e-65ns-20 1 4.5 5.1 
GLN276 
 
ASN333 
 
PHE334 
 
GLN376 
 
ASN333 
32 
 
16 
1f-65ns-8 1 6.2 6.3 ASN333 
ARG317 
 
ASN333 
 
PHE334 
7.5 
 
3 
 
3 
3a-65ns-8 3      
3c-65ns-13 1 6.5 6.1 
ASN333 
 
PHE334 
TRP241 
 
ASN333 
33 
 
1 
3d-65ns-4 2 7.3 8.5    
3i-65ns-8 1 4.7 5.6 
GLN276 
 
CYS277 
GNL276 
 
ARG317 
7.5 
 
5 
3j-65ns-2 1 5.7 3.8 
GLN276 
 
CYS277 
 
ASN333 
GLN276 
 
ASN333 
1.5 
 
44 
3m-65ns-2 1 6.2 6.9 
CYS277 
 
ASN333 
 
PHE334 
ASN333 
 
ARG317 
1.5 
 
0.5 
 
3o-65ns-13 2 4.8 8.6    
2a-65ns-17 2 5.4 8.7    
2c-65ns-9 1 4.2 6.4 
GLN276 
 
HIS335 
ASN333 11 
4d-65ns-5 2 4.9 6.2    
Table 3-20: Results of validation process 5 on the 65ns model of the trajectory of 1b. 
Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1b-155ns-10 1 6.2 5.7 
ARG317 
 
PHE334 
ARG317 
 
ASN333 
 
PHE334 
15 
 
9 
 
4.5 
1c-155ns-9 2 3.7 5.1    
1d-155ns-4 1 5.2 4 
GLN276 
 
ASN333 
GLN276 
 
ARG317 
 
ASN333 
 
PHE334 
35 
 
1 
 
1.5 
 
36 
1e-155ns-1 1 3.1 4.7 GLN276 GLN276 28 
1f-155ns-6 1 4.2 3.5 CYS277 
GLN276 
 
7 
 
Chapter 3   Model Development and Validation 
138 
 
CYS277 22 
3a-155ns-8 2 7.1 12    
3d-155ns-5 1 4.3 6.8 
ARG317 
 
ASN333 
 
PHE334 
ARG317 
 
ASN333 
 
PHE334 
21 
 
15 
 
4 
3e-155ns-14 1 4.3 5.7 TRP332 
ASN333 
 
PHE334 
21 
 
14 
3f-155ns-10 2      
3g-155ns-12 1 4.8 3.8 PHE334 
GLN276 
 
ASN333 
 
PHE334 
16 
 
10 
 
39 
3h-155ns-3 1 3.4 5.7 HIS335 GLN276 42 
3i-155ns-3 2 3.3 6.6    
3j-155ns-17 2 5.0 8.5    
3m-155ns-14 2 and 3 6.5     
4b-155ns-1 2  
Left during 
equilibration 
   
Table 3-21: Results of validation process 5 on the 155ns model of the trajectory of 1b. 
Complex Performance 
Warhead position (Å) Hydrogen bonds 
Starting MD average 
Starting 
conformation 
MD simulation 
Residue % 
1b-245-12 1 5.9 4.9 
ARG317 
 
ASN333 
 
PHE334 
TRP241 
 
ARG317 
 
ASN333 
 
PHE334 
18 
 
19 
 
17 
 
9 
1c-245ns-13 2 4.9 10.5    
1d-245ns-18 1 6.4 6.2 
TRP241 
 
GLN276 
 
ASN333 
ASN333 2 
1e-245ns-15 2  
Left during 
equilibration 
   
3d-245ns-18 2 3.7 6.4    
3e-245ns-8 1 3.5 3.7 TRP332 CYS277 3 
3f-245ns-9 2  
Left during 
equilibration 
   
3g-245ns-15 2  
Left during 
equilibration 
   
3h-245ns-9 2  
Left during 
equilibration 
   
3i-245ns-5 1 4.2 5.6 HIS335 ASN333 13 
3j-245ns-15 2      
3k-245ns-5 1 3.4 5.3 
CYS277 
 
ARG317 
GLN276 
 
ASN333 
1 
 
10 
3m-245ns- 1 5.0 3.8 CYS277 CYS277 40 
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17  
ASN333 
 
ASN333 
 
11 
3n-245ns-6 2 3.2 6.9    
3o-245ns-2 2 3.5 4.7    
2b-245ns-4 2 3.9 6.4    
4a-245ns-4 2 3.5 8.2    
4b-245ns-18 1 4.9 4.8 GLN276 
GLN276 
 
ASN333 
27 
 
1 
Table 3-22: Results of validation process 5 on the 245ns model of the trajectory of 1b. 
Regardless of the performance, the results of the simulations in these models were similar to 
those of the models from the trajectory of 1a. This is particularly true for the hydrogen 
bonding profile, where ASN333 was the dominant hydrogen bond forming residue with these 
models, followed by GLN276, PHE334, ARG317 and ASN318. Again, it was the warhead 
that left the catalytic tunnel more easily than the lipophilic part. This happened with all the 
complexes that failed to maintain the initial orientation in TG2 active site in models 155ns 
and 245ns. Only the lipophilic part of compound 3a left the hydrophobic loop during the 
simulation in 65ns model. 
The results of validation process 5 are summarised in Table 3-23 which shows the number 
of complexes for active and inactive compounds that the experiment started with in each 
model and the number of complexes of both active and inactive compounds that maintained 
their positions after the simulations. Figure 3-57 shows this information as a percentage for 
each of the 6 models. 
Model 
Starting number Passing number 
Actives Inactives Actives Inactives 
65ns 11 3 8 1 
90ns 12 4 8 1 
95ns 17 3 13 1 
100ns 16 3 13 1 
155ns 14 1 8 0 
245ns 15 3 6 1 
Table 3-23: Summary of the performance of the 6 models in validation process 5. 
Table 3-23 and Figure 3-57 showed that the trend followed for the performance of the 
models was similar to that observed in validation process 4 (Table 3-15 and Figure 3-54). 
Models 100ns and 95ns from the trajectory of 1a performed the best in terms of the active 
compounds, followed by 65ns and 90ns which performed almost the same and 245ns was 
the worst. With regard to the inactive compounds, all the models were similar, where no 
more than one inactive complex was able to maintain its original orientation after the 
simulation in any of the 6 models. 
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Figure 3-57: Percentages of active and inactive compounds that passed the 5-ns MD simulations without 
a significant change in their starting positions in each of the 6 active site models of TG2. 
3.4.5.3 Binding free energy calculations 
As mentioned in the ‘Methods’ section, binding energy was calculated for these trajectories, 
using 2 models offered by AMBER which are MM/GBSA (Generalized Born Surface Area) 
(Onufriev et al. 2004) and MM/PBSA (Poisson Boltzmann Surface Area) (Srinivasan et al. 
1998). This calculation was not performed on all the simulations, only the complexes that 
maintained their initial positions were considered, except for a few complexes for inactive 
compounds to investigate the effect of leaving the active site on the binding energy. The 
results will be presented as tables for each model. Different correlations with biological 
activities of the compounds, expressed as IC50, were also tried and will be presented 
following the tables. Table 3-24 and Table 3-25 show binding free energies for the models 
from 1a and 1b trajectories respectively. Complexes in the tables marked with $ are for 
inactive compounds, and those marked with $* are for inactive compounds that failed to 
maintain their starting positions at the end of the simulations. 
Complex 
Energy (kcal/mol) 
IC50 (µM) 
GB PB PM3 GB DFTB GB 
90ns Model 
1b-90ns-4 -41.05 0.20 -28.87 -37.83 0.273 
1d-90ns-5 -33.33 2.57 -21.28 -32.03 0.7 
1e-90ns-17 -50.04 2.57 -44.15 -45.61 0.0061 
3b-90ns-5 -41.05 6.77 -33.62 61.80 0.89 
3c-90ns-20 -29.05 6.53 -18.53 -28.34 1.4 
3d-90ns-6 -32.43 7.36 -27.92 
 
0.008 
3f-90ns-2 -40.42 2.04 -33.13 -37.39 5.925 
3o-90ns-3 -46.66 -6.46 -47.11 -45.71 1.625 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
65ns 90ns 95ns 100ns 155ns 245ns
%-Actives
%-Inactives
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2b-90ns-8$* -19.57 5.39 -18.01 -19.40 100 
4c-90ns-2$* -41.29 10.50 -30.96 -40.73 100 
4d-90ns-19$ -30.47 5.63 -28.49 -31.02 100 
95ns Model 
1a-95ns-10 -41.09 3.96 -37.23 -37.39 0.125 
1b-95ns-6 -30.34 8.06 -20.19 244.88 0.273 
1c-95-2 -41.79 0.11 -33.93 -39.76 0.44 
1d-95ns-4 -27.83 10.37 -22.19 -27.17 0.7 
1e-95ns-17 -36.24 5.38 6.00 -36.24 0.0061 
1f-95ns-20 -57.52 0.59 -32.08 -53.46 0.38 
3a-95ns-19 -33.54 6.32 -25.22 503.60 1.85 
3b-95ns-16 -35.65 7.84 -28.11 -33.36 0.89 
3c-95ns-17 -37.04 6.58 -25.47 -34.70 1.4 
3f-95ns-11 -31.83 7.38 -28.59 -30.67 5.925 
3i-95ns-5 -26.15 12.26 -20.57 289.11 6.8 
3n-95ns-6 -41.06 7.74 -36.00 -39.18 0.775 
3o-95ns-1 -35.69 11.77 -35.76 -33.65 1.625 
2c-95ns-3$ -30.37 19.75 -25.67 -30.98 100 
4b-95ns-12$* -23.55 9.52 -22.10 -22.66 100 
4e-95ns-19$* -28.58 7.81 -27.02 -29.07 100 
100ns Model 
1a-100ns-5 -35.68 7.62 -32.83 -32.91 0.125 
1b-100ns-6 -33.70 8.79 -25.19 -31.89 0.273 
1c-100ns-6 -33.26 3.10 -28.38 -32.24 0.44 
1d-100ns-16 -50.65 -5.41 -38.02 -52.57 0.7 
1f-100ns-4 -39.66 2.80 -26.57 -37.22 0.38 
3a-100ns-17 -33.90 9.61 -27.38 -32.49 1.85 
3b-100ns-19 -42.24 3.49 -31.71 -40.18 0.89 
3d-100ns-7 -24.97 7.16 -22.24 
 
0.008 
3e-100ns-15 -24.12 6.38 -24.01 -24.25 4.25 
3f-100ns-13 -32.96 9.45 -29.56 -30.32 5.925 
3g-100ns-6 -52.77 1.32 -36.94 
 
0.0059 
3i-100ns-10 -29.54 7.91 -20.58 78.41 6.8 
3n-100ns-19 -40.16 0.27 -32.18 168.24 0.775 
2c-100ns-11$* -38.64 7.94 -29.51 -37.55 100 
4b-100ns-6$ -36.32 7.63 -33.43 -34.96 100 
Table 3-24: Binding free energy values for the complexes in the 5-ns MD simulations in the models from 
the trajectory of 1a. 
Complex 
Energy (kcal/mol) 
IC50 (µM) 
GB PB PM3 GB DFTB GB 
65ns Model 
1b-65ns-18 -33.78 3.83 -27.71 -31.13 0.273 
1c-65ns-4 -32.22 7.03 -28.99 -31.00 0.44 
1e-65ns-20 -41.04 -2.78 -35.01 -41.31 0.0061 
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1f-65ns-8 -38.26 3.49 -26.25 93.24 0.38 
3c-65ns-13 -37.96 -3.40 -31.28 -35.91 1.4 
3i-65ns-8 -32.42 4.03 -23.81 -30.52 6.8 
3j-65ns-2 -33.87 2.72 -26.01 -30.07 6.3 
3m-65ns-2 -36.32 10.46 -24.31 96.38 1.5 
2c-65ns-9$ -25.10 7.69 -22.11 -32.00 100 
4d-65ns-5$* -38.71 0.52 -33.05 -37.53 100 
155ns Model 
1b-155ns-10 -39.37 -4.36 -27.29 -36.15 0.273 
1d-155ns-4 -38.27 1.46 -27.18 -41.67 0.7 
1e-155ns-1 -29.95 5.93 -26.24 -34.05 0.0061 
1f-155ns-6 -52.39 -0.53 -31.72 -46.37 0.38 
3d-155ns-5 -39.76 -4.19 -36.15 
 
0.008 
3g-155ns-12 -35.12 -4.36 -31.01 
 
0.0059 
3h-155ns-3 -43.17 5.84 -30.67 77.02 1.07 
245ns Model 
1b-245-12 -42.03 -5.23 -34.82 -40.45 0.273 
1d-245ns-18 -29.13 9.63 -24.65 -30.33 0.7 
3e-245ns-8 -25.35 4.58 -24.06 -23.30 0.0061 
3i-245ns-5 -30.65 -2.27 -21.11 -29.99 6.80 
3k-245ns-5 -24.09 15.42 -14.51 -23.82 3.30 
3m-245ns-17 -48.49 -1.93 -24.70 -42.65 1.5 
4b-245ns-18$ -37.94 2.01 -31.62 -34.73 100 
Table 3-25: Binding free energy values for the complexes in the 5-ns MD simulations in the models from 
the trajectory of 1b. 
A short glance at Table 3-24 and Table 3-25 shows that there is no general trend in the 
values of the energy within a single model and between the models. Inactive compounds 
have achieved binding free energy values that are better than those of many of the active 
compounds. When correlations with biological activity were investigated, the graphs in 
Figure 3-58 were produced. A correlation was tried between IC50 values and each of the 4 
energy values in Table 3-24 and Table 3-25 and the same was repeated with the logarithm 
of the IC50 vales. The correlations were only tested for the active compounds. For the 65ns 
model, the best correlation obtained was between logIC50 and GB calculated with PM3. In 
90ns model, this was the correlation between the log of IC50 and conventional GB. IC50 
against conventional PB gave the best correlation in 95ns. In 100ns, it was IC50 against 
conventional GB that gave the best correlation. 155ns was like 95ns (IC50 versus PB) and 
245ns had its best correlation between IC50 and GB PM3 (Figure 3-58). 
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Figure 3-58: Graphs for best correlation of a binding free energy value and biological activity as TG2 IC50 
for the 6 models. 
Figure 3-58 would give an indication that the models from the trajectory of 1b gave better 
correlations than the models from the trajectory of 1a. This is true if the R2 values were the 
only determinants, and they were not; the numbers of complexes for which the correlations 
were studied should also be considered (Table 3-24 and Table 3-25) and these numbers 
were higher for the models from 1a trajectory than for the second set of models. 
Another approach was considered that involved combining the scores from all the models 
and dividing the compounds according the warhead into sulfonium ions and acrylamides. 
Since more than one copy of a single compound may have been included in the 
combination, an average was taken for such compounds. This was then correlated to 
biological activity. Table 3-26 shows the average energy values for 10 sulfonium ion active 
compounds. These were correlated with IC50 and its logarithm, and the best R2 value was 
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obtained by plotting IC50 versus GB (0.43) followed by PM3-GB (0.39) (Figure 3-59). When 
the data for compound 3i were excluded from the comparisons for being the least active, R2 
increased to 0.56 for GB and 0.70 for PM3-GB. More interestingly, R2 for PB versus IC50 
jumped from 0.18 to 0.84 after removing 3i (Figure 3-60). Compound 3i is identical to 
compound 1d, one of the most active compounds used from the start, with the exception of 
the use of D-alanine instead of L-alanine in the amino acid linking between the piperazine 
ring and the acrylamide warhead resulting in about 10 times less activity against TG2 (IC50 of 
6.8 µM for 3i compared to 0.7 µM for 1d). 
Compound 
Average Energy (kcal/mol) 
IC50 (µM) 
GB PB PM3 GB DFTB GB 
1b -36.71 1.88 -27.34 11.24 0.273 
1d -35.84 3.72 -26.66 -36.75 0.70 
1f -46.96 1.59 -29.16 -10.95 0.38 
3b -39.65 6.03 -31.14 -3.91 0.89 
3c -34.68 3.24 -25.10 -32.98 1.40 
3h -43.17 5.84 -30.67 77.02 1.07 
3i -29.69 5.48 -21.52 76.75 6.80 
3k -24.09 15.42 -14.51 -23.82 3.30 
3m -42.41 4.26 -24.51 26.87 1.50 
3n -40.61 4.00 -34.09 64.53 0.78 
Table 3-26: Average binding free energy values for compounds with sulfonium ion warhead taken from 
all the 6 models. 
It can therefore be said that for sulfonium ion inhibitors of TG2 with IC50 values of less than 
3.5 µM, molecular mechanics Poisson Boltzmann surface area (MM/PBSA, or PB) as a 
method for calculating the binding free energy, would give the best affinity ranking compared 
to other models such as MM/GBSA and PM3/GBSA. Such meaningful correlations could not 
be obtained with the acrylamide based inhibitors. 
The results obtained from binding free energy calculations using MM/PBSA and MM/GBSA 
are not meaningful in all systems despite the popularity of the method in research, where 
100-200 papers have been published each year in the past five years. This may be due to a 
variety of reasons including the lack of proper representation for entropy in the calculations, 
incorrect representation of charges and lacking the effects of binding site water molecules, in 
addition to the dependency of the results on the system being studied (Genheden & Ryde 
2015). Having said that, it should also be noted that the results from these calculations could 
give useful correlations. In general, MM/PBSA is more rigorous and more computationally 
expensive than MM/GBSA but is not necessarily better in terms of results (Hou et al. 2011). 
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 Figure 3-59: IC50 versus GB (left) and PM3-GB (right) for 10 sulfonium ion compounds in Table 3-26.  
  
 
Figure 3-60: Correlations 
between IC50 and GB, PM3-
GB and PB for the sulfonium 
ion compounds from Table 
3-26 after removing the least 
active compound (3i). 
 
Changes in the conformation of the complex due to entropy can produce large fluctuations in 
MD and thereby render the calculated free energies unstable. This can be avoided or 
minimised by including as many frames from the trajectories as possible (Hou et al. 2011). 
During the calculations of binding free energy applied on the trajectories of the 5ns-MD of 
TG2 inhibitors, all the frames were included in the calculations. 
IC50 is the concentration of the inhibitor required to reduce the rate of the reaction by one 
half, and in general, it is not a very good measure of affinity. This is mainly because of its 
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great dependence on the conditions of the measurement and the concentration of the 
inhibitors (Ajay & Murcko 1995). The difference in the compounds used to obtain the above 
mentioned correlations between IC50 and binding free energy values, is that the IC50 values 
were obtained using the same experimental procedures including temperatures, 
concentrations and incubation times (Badarau et al. 2015; Wang et al. 2012). It is worth to 
mention here that the paper that was the source for the compounds used in the entire thesis 
(Badarau et al. 2015) did not contain any free energy measurements of the tested 
compounds. 
Another important point in this regard is the values of the free energies obtained; these 
should not be viewed as indicators of the affinity of any of the inhibitors as these values only 
measure the non-bonded interactions and the real activities of TG2 inhibitors involve the 
formation of a covalent bond with SG of CYS277 that was not accounted for. Therefore, the 
values would represent a measure of the affinity of the inhibitors to be inside the active site 
of TG2, making them ready to inhibit the enzyme by forming the covalent bond. 
3.4.6 Validation process 6 (more active compounds) 
Three active compounds were used in this validation process with GOLD settings identical to 
those used in validation process 1. The compounds (i10, i11 and i12) were adopted from 
Prime, Andersen et al. (2012) (section 1.4.2.2, Table 3-27). The results on all the 6 valid 
models are presented in Table 3-28. The active compounds all had acrylamide as the 
warhead. An analysis of the docked complexes showed good poses for compounds i11 and 
i12 similar to those obtained in the previous test set. Compound i10, however, could not 
have its pyrrolidine ring buried within the hydrophobic loop of TG2 in all the models. As 
shown in Figure 3-61, the compound assumed a straight conformation; possibly due to its 
short linker (the part of the molecule connecting the warhead to the lipophilic part). 
Compound Structure IC50 (µM) 
i10 
 
1.90 
i11 
 
0.120 
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i12 
 
0.010 
Table 3-27: Structures of compounds from (Prime, Andersen, et al. 2012) used in validation process 6. 
Complex 
Distance 
(Å) 
H-bonds GoldScore Rank CHEMPLP Rank 
Models of the trajectory of 1a 
i11-90ns-4 6.2 CYS277 58 3rd 37 16th 
i12-90ns-17 4.9 ASN333 53 1st 55 2nd 
i10-95ns-4 4.1 
CYS277 
PHE334 
45 1st 49 2nd 
i11-95ns-1 4.0 
TRP241 
CYS277 
53 12th 47 5th 
i12-95ns-14 4.1 
GLN276 
PHE334 
53 1st 66 1st 
i10-100ns-20 3.1 
TRP241 
GLN276 
PHE334 
44 11th 53 7th 
i11-100ns-1 3.7 
TRP241 
GLN276 
CYS277 
PHE334 
61 1st 57 4th 
i12-100ns-4 3.9 None 53 2nd 59 3rd 
Models of the trajectory of 1b 
i10-65ns-4 4.8 
TRP241 
GLN277 
PHE334 
63 2nd 2nd 58 1st 
i11-65ns-13 5.4 
GLN276 
CYS277 
70 4th 76 1st 
i12-65ns-19 3.9 None 76 1st 73 1st 
i10-155ns-11 4.7 
GLN276 
PHE334 
61 1st 62 2nd 
i10-245ns-12 4.9 
GLN276 
PHE334 
58 3rd 50 5th 
i11-245ns-13 5.2 
TRP241 
MET330 
HIS335 
64 15th 67 4th 
i12-245ns-4 4.8 
GLN276 
ASN333 
PHE334 
61 11th 76 2nd 
Table 3-28: Docking results of validation process 6 on all valid models. 
Regarding the interactions, as shown in Table 3-28, hydrogen bonds were present in all the 
models. Pi-interactions involving the lipophilic parts of the inhibitors were also evident in all 
the complexes. There were additional pi-interactions involving the piperazine and benzene 
rings in i11 and i12 and the benzene ring in i10. Figure 3-61 represents examples for 
complexes of i11 and i12. 
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This experiment was performed in order to check the validity of the models in testing 
compounds from another source. Although the selected pool of ligands is not very big, nor is 
representative for all the chemical types of TG2 inhibitors, the results of the experiment do 
show that compounds with different lipophilic parts and different linkers can still dock well 
into the active site of TG2 models developed in the course of this work. 
 
 
Figure 3-61: A: pose of i10 showing the upright 
pose of the compound. B: example pose of i11 
in 100ns and C is example pose of i12 in 95ns 
showing interactions. 
B: i11-100ns-1 A: i10-65ns-4 
C: i12-95ns-14 
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3.5 Inflexible Docking 
Another experiment was run using GOLD that involved docking the 21 active and 8 inactive 
compounds used during validation process 4 into the six valid models of TG2 active site 
using different docking settings. This time, no residues were treated as being flexible during 
the docking and the search efficiency was set to “Very Flexible”. In the previous dockings, as 
well as in this one, the genetic algorithm (GA) speed was set to automatic, where GOLD will 
determine the number of genetic operations performed for each docking based on the size 
and flexibility of the ligands. In previous dockings, the search efficiency was set to default in 
which the program will apply optimum settings for each ligand. In this docking, the search 
efficiency was set to “Very Flexible”, where the efficiency will increase to 200% of the default 
(CCDC Software Limited 2013). This was applied to compensate for the inflexible treatment 
of the active site residues. Increasing the search efficiency like that would slow the docking 
but not as much as allowing 10 residues of the active site to be flexible. Therefore, the main 
objective of this experiment was to determine whether some faster settings of the docking 
experiment will produce as reliable results as the slower settings. 
The results of this docking experiment will be presented as those for validation process 4 
and are summarised in Table 3-29 and shown in Figure 3-62. The bent conformation was 
obtained in many complexes and the hydrogen bonding profile was similar to what has been 
observed during the previous experiments with dominance from ASN333 followed by 
PHE334, GLN276 and the other active site residues seen previously forming hydrogen 
bonds with the inhibitors. If only the pose of active compounds was to be considered, then 
model 100ns would have been the best. This model performed the worst, however, in terms 
of inactive compounds achieving the 4 criteria for good docking. If this were the most 
important determinant (achieving 4 criteria), then it is model 65ns that performed the best. 
Model 
% Actives / 
good pose 
% Inactives / 
good pose 
% Actives / 4 
criteria 
% Inactives / 4 
criteria 
65ns 71.43% 50% 71.43% 12.5% 
90ns 61.90% 25% 42.86% 12.5% 
95ns 71.43% 50% 52.38% 25% 
100ns 90.48% 37.5% 61.90% 37.5% 
155ns 38.10% 0% 33.33% 0% 
245ns 52.38% 12.5% 47.62% 0% 
Table 3-29: The results of inflexible docking on the individual models showing percentages of good 
poses and passing the 4 criteria in each model. 
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Figure 3-62: Performance of the 6 models during inflexible docking showing the percentages of good 
poses and passing the 4 criteria for active and inactive compounds. 
In summary, rigid docking in a system involving TG2 and its irreversible inhibitors may be 
able to produce the correct binding mode but its ability to distinguish between active and 
inactive compounds is poor. It has been stated that treating the receptor as a rigid body has 
its disadvantages including incorrect prediction of correct binding modes and unreliable 
scores (Mohan et al. 2005). Therefore, the time saved by using inflexible docking should not 
motivate the generalisation of the method, especially that GOLD allows only for 10 residues 
to be treated as flexible which should not increase the computation time substantially. 
Particularly with TG2, flexible residues should be employed whenever possible, at least 
residue 333 (ASN333), whose conformation has been proven to be very important for 
successful achievement of the bent conformation of the inhibitors within TG2 active site 
(section 3.3.6). 
3.6 Additional Scoring Functions 
The GOLD docking program offers the possibility of using one of 4 scoring functions as the 
primary function along with one optional additional function to be used for rescoring the 
solutions obtained with the primary function (CCDC Software Limited 2013). GoldScore was 
used as the primary function and CHEMPLP as the rescoring function in all the dockings up 
to this stage. To validate the choice of GoldScore as the primary function, 3 additional 
dockings were performed using each one of the other available scoring functions as the 
primary and only scoring function. The compounds and docking settings used at this stage 
were the same as those used in the initial docking when choosing the active site models (6 
active compounds from Badarau et al. (2015) and default GOLD settings with 10 flexible 
residues and early termination). 
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3.6.1 ASP scoring function 
The Astex Statistical Potential (ASP) scoring function (Mooij & Verdonk 2005) is an atom-
atom potential which was derived from analysing existing ligand-protein complexes. It 
resembles functions such as PMF and DrugScore (Mooij & Verdonk 2005). With this scoring 
function, no acceptable pose for any of the 6 compounds was obtained in 4 models; 65ns, 
90ns, 155ns and 245ns. In the remaining 2 models, one compound in each gave only one 
acceptable pose. These were compounds 1c in 95ns model and compound 1e in 100ns 
model. They were ranked 8th and 6th respectively out of the resulting 20 solutions. A scoring 
function that estimates binding energy by examining the distances and angles between 
atoms from the ligand and the receptor active site is, therefore, not appropriate for the TG2 
system. 
3.6.2 ChemScore 
ChemScore (Eldridge et al. 1997; Baxter et al. 1998) is an empirical scoring function that 
calculates the binding energy as a sum of multiple empirical terms derived from a training set 
of 82 ligand-protein complexes from the Protein Data Bank. The terms include binding free 
energy, hydrogen bonding, metal, torsional and lipophilic terms. Only 4 compounds 
managed to achieve the bent conformation within TG2 active site using this scoring function. 
These were 1d in 90ns model, 1b in 95ns model and 1c and 1e in 100ns model. Bad results 
obtained with ChemScore scoring function may be attributed to the inherent deficiencies of 
empirical scoring functions in general. Among these are the dependence of the function on 
approximations and the lack of negative data in the training set (Eldridge et al. 1997). 
3.6.3 CHEMPLP 
CHEMPLP (Korb et al. 2009) is another empirical function that includes terms such as 
piecewise linear potential for shape complementarity, and a heavy atom clash potential for 
the ligand atoms. The function also utilises some ChemScore terms such as hydrogen and 
metal bonding and torsional terms. In the studied TG2 system, the performance of 
CHEMPLP was better than that of ASP or ChemScore but not as good as that of GoldScore. 
The performance of this function was better than the previous two with 8 complexes in the 6 
models having the right bent conformation. These were 1a and 1d in 90ns model, 1a, 1b and 
1c in 95 ns model, 1a and 1c in 100ns model and 1b in 155ns model. 
Being an empirical function is probably the reason of failure of CHEMPLP to perform as well 
as GoldScore with TG2 inhibitors. However, this function was suitable for rescoring when 
used with GoldScore as the primary function and was, in some cases, able to rank the 
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solutions of a single ligand in the same manner as GoldScore. It should also be noted that all 
the inhibitors studied here are covalently bound to TG2 and this has not been accounted for 
during the docking; all the rankings and differentiations were made on the assumptions of 
the bent conformations and the interactions involving the lipophilic part and the central part 
of the ligand. 
GoldScore (Verdonk et al. 2003) is a scoring function that is based on a force field and has 
terms for hydrogen bonds and van der Waals interactions between the ligand and the 
receptor, in addition to ligand internal van der Waals and torsional energies. The 
performance from this function was simply much better than any of the other 3 functions 
offered by GOLD. This is very obvious from the results presented so far in this work. The 
superior performance was true despite the fact that GoldScore did have flaws manifested in 
giving good scores and ranks for inactive compounds and failing to rank the compounds 
correctly based on their scores. The good performance may be due in part to the importance 
of hydrogen bonding for TG2 inhibitors, which the function was able to demonstrate for many 
of the active inhibitors during the various stages of the docking as it has a separate term for 
hydrogen bonds between the ligand and the protein. Furthermore, the ligands used 
throughout this work generally have high molecular weights ranging from 239 (1a) to 488 
(3m) and this can increase the contribution from the term describing van der Waals 
interactions between the ligand and the protein as well as the term for these interactions 
within the ligand itself during individual dockings. 
3.6.4 Rescoring 
The GOLD docking program is equipped with the ability to rescore an already docked 
conformation using any of the scoring functions available in the program. There is also the 
option of performing local minimisation on the ligand to enhance the score. The rescoring 
utility was applied on the valid models using complexes generated during different 
experiments of the validation process. Only active compounds were included in this 
experiment and the selected complexes were for compounds that achieved at least 3 of the 
criteria for a good docking complex. 
The complexes were rescored with the four scoring functions including GoldScore to 
examine the effect of local minimisation on the already generated poses and scores. 
Rescoring was performed with and without local minimisation. The minimisation process did 
not produce significant changes; in these complexes it usually produced minor changes in 
the conformation of the ligand especially involving the lipophilic part (Figure 3-63). 
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Figure 3-63: Minimised (grey carbons) and non-minimised 
(green carbons) conformations of compound 1e before 
rescoring with GOLD. 
In 4 of the 6 models (65ns, 90ns, 95ns and 245ns), no useful correlation could be found 
between the scores obtained with any function during the rescoring process and biological 
activity expressed as IC50. In many of the cases in these models, the opposite of the trend 
that should ideally be seen was produced; there was a decline in the score with the increase 
in biological activity (Figure 3-64). 
For the remaining 2 models (100ns and 155ns), the correct trend of scores was obtained but 
the correlation was not very high. The best correlation obtained for model 100ns was the 
minimised GoldScore (R2 = 0.35) and for 155ns was the non-minimised ChemScore (R2 = 
0.31) (Figure 3-65). Although these correlations are poor, they are the best correlations 
obtained so far between docking scores and IC50 values in the line of this work. GoldScore 
has already been shown to be superior to the other functions in predicting the correct binding 
mode and the hydrogen bond profile; and here it has been shown that the performance of 
GoldScore with TG2 inhibitors can be improved by applying local minimisation on the docked 
ligand conformation. This further validates the choice of GoldScore as the primary scoring 
function in the dockings performed with the selected TG2 inhibitors.  
The results from ChemScore were good without the local minimisation, therefore the 
application of the local minimisation during rescoring should not always be attempted even 
though it would sound reasonable. It can be also concluded that ChemScore, though was 
unable to predict the correct binding mode when used as the primary function (section 
3.6.2), did manage to achieve the correct trend in the scores based on the activities giving 
an indication that using ChemScore for rescoring solutions obtained with GoldScore is a 
possible approach for enhancing the ranking when it comes to docking inhibitors of TG2. 
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Figure 3-64: Correlation 
between TG2 IC50 and 
GoldScore minimised 
rescoring for model 65ns 
with the inversed trend; 
lower scores for more active 
compounds (GOLD docking 
scores are unit-less). 
  
Figure 3-65: Correlations of minimised GoldScore and non-minimised ChemScore with IC50 in models 
100ns and 155ns respectively during the rescoring process. GOLD scores are without units.  
The rescoring approach in GOLD with minimisation of the top ranked solutions has been 
found to improve the ranking of the docked ligands and the overall performance of the 
scoring functions (Perola et al. 2004). However, because rescoring did not produce reliable 
results with all the 6 models, it cannot be said that it should routinely be used for this set of 
compounds with TG2. 
3.7 Covalent Docking and MD 
3.7.1 Docking 
The functionality of covalent docking in GOLD requires setting the ligand in a special way to 
allow for the formation of the covalent bond. This includes adding a link atom to the ligand 
and the protein at the point at which the bond would be formed. The link atom used was the 
sulphur atom of the active site cysteine residue. On the compounds, a sulphur atom was 
added to the electrophilic carbon and was set as the link atom. For sulfonium ion 
compounds, this would have required removing the sulfonium ion entirely and replacing it 
R² = 0.39
0
10
20
30
40
50
60
70
80
90
0 1 2 3 4 5 6 7
G
o
ld
Sc
o
re
IC50 (µM)
R² = 0.35
0
10
20
30
40
50
60
70
0 2 4 6 8
G
o
ld
Sc
o
re
IC50 (µM)
100ns-GoldScore
R² = 0.31
0
5
10
15
20
25
30
0 1 2 3 4 5
C
h
e
m
Sc
o
re
IC50 (µM)
155ns-ChemScore
Chapter 3   Model Development and Validation 
155 
 
with a sulphur atom. Since this removal was going to change the size of the sulfonium 
compounds considerably, this compound set was not considered for this experiment. 
A total of 7 active and 4 inactive acrylamide compounds was used in this experiment. The 
results are presented in the form of percentages and column graphs as in validation process 
4 in Table 3-30 and Figure 3-66. The bent conformation (Figure 3-67) with the required 
interactions and the top ranking were achieved for many of the active compounds during the 
docking. The inactive compounds, however, managed to dock well with the bent 
conformation at higher rates than what was seen in normal docking. This cannot be 
surprising because the program is forcing the covalent bond to be formed and the bent 
conformation for the remainder of the compound structure is probably the best it can adopt if 
the covalent bond was already there. These inactive compounds, however, did not always 
succeed with regard to the other criteria and hence the low rates in the last column of Table 
3-30. This may mean that the models (except possibly 90ns) will adopt, with the right 
conformation, any potential compound having the necessary parts (the lipophilic part and a 
linker in addition to the warhead) but will be more selective towards active compounds when 
all the criteria are considered. 
Model 
% Actives / 
good pose 
% Inactives / 
good pose 
% Actives / 4 
criteria 
% Inactives / 4 
criteria 
65ns 85.71 50 42.86 25 
90ns 100.00 75 85.71 75 
95ns 85.71 75 71.43 0 
100ns 85.71 100 57.14 25 
155ns 85.71 25 71.43 0 
245ns 57.14 50 28.57 0 
Table 3-30: Results of covalent docking using acrylamide compounds on the 6 models. 
3.7.2 Molecular dynamics 
The molecular dynamic simulations applied to the covalent complexes were analysed 
visually by VMD program to investigate whether or not the bent conformation was preserved 
with time. This was confirmed by measuring the RMSD of the ligand alone. The hydrogen 
bonds formed during the simulation were also analysed using the CPPTRAJ program of the 
AmberTools package, and the default CPPTRAJ parameters for hydrogen bonds were 
employed (angle cut-off was 135º and distance cut-off of 3 Å). Two docking complexes for 
each of the 7 active compounds and 2 docking complexes for 3 of the 4 inactive compounds 
(all except 2b) were run through this stage of the experiment. 
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Figure 3-66: Performance of the 6 models in covalent docking experiment. 
 
Figure 3-67: The pose of 
compound 1e in model 155ns 
as a representative for 
covalent docking. 
In total there were 20 simulations for 10 compounds, each presented a simulation time of 15 
ns. The behaviour of the individual compounds during these simulations was very similar, 
regardless of the activity of the compound. This behaviour can be described very briefly by 
saying that everything remained the same; the ligand maintained its bent conformation within 
the active site for the length of the simulation. This was confirmed by the very similar graphs 
for RMSD, for active and inactive compounds (Figure 3-68). The exception was in one of the 
simulations for each of these 3 active compounds, 1a, 3l and 3o. The lipophilic part of the 
compounds left the hydrophobic loop of TG2 active site causing the compound to stand 
straight. This movement did not have any effect of the position of the warhead or the 
covalent bond between the warhead and CYS277 (Figure 3-69). 
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Figure 3-68: RMSD for 
the ligand only during 
the 15-ns covalent MD 
simulations for active 
(1e) and inactive (4e) 
compounds.
 
Figure 3-69: Compound 1a from one of its 
simulations in which the lipophilic part of the 
compound straightened in the active site.The 
hydrophobic loop of TG2 is coloured yellow 
while the rest of the protein is coloured by 
secondary structure. The covalent bond between 
1a and CYS277 is shown. 
 
The angle between the sulphur atom of CYS277 (SG), and the electrophilic carbon (EC) and 
the alpha carbon (Cα) of the acrylamide bond of the compounds (Figure 3-70 Right) has 
been measured for all the simulations where the lipophilic part did not leave the hydrophobic 
loop of TG2. The graph in Figure 3-70 was produced which clearly shows that the angle 
oscillated over a short range of degrees and that the oscillation was similar for all the 
simulations. The average value for the angle across all the simulations was 112.3°. This 
value is consistent with that recorded in GAFF (AMBER General Force Field for organic 
molecules) (Wang et al. 2006; Wang et al. 2004) for c3-c3-ss which is 112.690° where c3 is 
an sp3 hybridised carbon and ss is sp3 hybridised sulphur. If the angle was considered one 
of the parameters of the covalent bond, and it is, then these results can be used to confirm 
that the all the simulations preceded without any problems with the covalent bond and that 
the parameters created for the bound compounds using GAMESS and RESP worked 
properly during the simulations. 
0
0.5
1
1.5
2
0 2 4 6 8 10 12 14
R
M
SD
 (
Å
)
Time (ns)
RMSD-1e
RMSD-4e
Chapter 3   Model Development and Validation 
158 
 
 
 
Figure 3-70: Right: the angle 
measured between SG, EC and Cα 
and Left: graphs of this angle for all 
the simulations in which the 
ligands maintained their starting 
position.
The hydrogen bonding profile was not very meaningful in terms of discriminating between 
active and inactive compounds. In fact, the inactive compound 4e showed the best profile 
where in one of the 2 simulations for this compound there were hydrogen bonds with 
ASN333 for 75% of simulation time, with PHE334 for 67%, with TRP332 for 53% and with 
GLN276 for 45% of simulation time. However, in most of the cases there was an abundance 
of hydrogen bonds between the acrylamide compound and one or more of those 4 residues 
of TG2. This could be due to the presence of the covalent bond. In the previous dockings 
and MD simulations when there was no covalent bond, the objective was to get the warhead 
close to CYS277 to aid in the formation of the covalent bond and hydrogen bonds were one 
of the tools in achieving this goal. In the case of covalent MD, the covalent bond was already 
in place and therefore the compounds were in ideal positions for the formation of hydrogen 
bonds. 
Another parameter that was analysed was the radial distribution function (RDF) of water 
molecules around the covalent bond. This function measures the probability of finding water 
molecules within a predefined distance from a specified atom mask. In other words, it 
measures the density of water as a function of distance. It was measured using CPPTRAJ to 
account for all water molecules that are within 5 Å of SG of CYS277. The rationale was to 
test whether the density of water around the covalent bond would be different between 
active and inactive compounds. This is based on the assumption that water can serve as a 
proton shuttle or a source of proton during the formation of the bond. The results are shown 
in Figure 3-71 in which the RDF is presented for active (blue) and inactive (red) compounds. 
The graph shows the RDF or the probability as a function of the distance. There were no 
water molecules within the 2 Å of SG and that is reasonable as anything nearer will be within 
the van der Waals radii of the atoms, and may result in clashes. RDF starts to rise thereafter 
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with the distance without any possible distinction between active and inactive compounds. In 
any case, probability did not exceed 1 except in the simulations for 2 active compounds and 
1 inactive compound. 
 
Figure 3-71: The radial 
distribution function of water 
molecules around the 
covalent bond during the 
simulations of active and 
inactive compounds. 
When this was compared to the simulations applied initially on compounds 1b and 1e, the 
graph in Figure 3-72 was produced. The calculations for compound 1e was performed up to 
the 185th nanosecond because the warhead had left the catalytic tunnel after that and for the 
2 compounds it was performed on the SG atom as well. For the simulations containing active 
compounds within the active site, RDF was highest at 2 Å and then at 3 Å, indicating that if 
SG were free (not involved in a bond), water molecules can get very close. 
 
Figure 3-72: The same RDF 
graphs as in Figure 3-71 with 
the addition of RDF graphs 
for the initial simulations of 
compounds 1b and 1e. 
In conclusion, water molecules do not come within 2 Å of SG and EC if there was a bond 
between the 2 atoms, and after this distance, some water molecules may approach but not 
more than very few. Without the bond being there, there is much higher probability for water 
molecules to come within a 2-Å distance from SG. RDF tends to move toward unity at higher 
distances, approaching the actual density of water molecules. 
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Regarding the parameter production, the cap added to the ligand during GAMESS 
calculation was chosen because it will produce, with the acrylamide compound, a product 
that is very similar to the acrylamide-CYS277 complex built during these simulations. 
Another reason for choosing this particular cap is that it is available in the AMBER Force 
Field as a part of the side chain of the amino acid methionine and therefore the charges of 
its atoms are already available. Those charges were used during the first stage of charge 
fitting with RESP to fix the charges of the cap and distribute the rest of the electrostatic 
potential calculated by GAMESS on the atoms of the uncapped acrylamide compound. 
One simple conclusion can be drawn from the results of the covalent docking and MD. The 
difference between active and inactive TG2 inhibitors lies in their ability to place the warhead 
close to CYS277. Once these are close to each other, the covalent bond will be formed. This 
is at least true to this set of acrylamide compounds; they all had the same warhead and 
when the covalent bond was forced on the system, they all behaved in a similar way. The 
behaviour of water molecules as compared to that when there was no covalent bond may 
give an indication that water can serve as a proton source or a proton shuttle during the 
reaction but once the reaction has finished and the covalent bond was formed, then water 
molecules may leave their places next to SG. 
3.8 Analysis of the Valid Active Site Models of TG2 
The conformations that were selected from the MD trajectories as being valid models for the 
docking of TG2 inhibitors, and were then validated for this role, have been analysed to 
examine the differences between them and between the conformation of TG2 in the original 
crystal structure (2Q3Z) (Pinkas et al. 2007). The analysis involved several measurements 
which are presented in this section. 
The root-mean-squared-deviations (RMSD) of the models was measured using the structure 
of 2Q3Z as a reference. The results for the individual models are presented in Table 3-31 
which shows that the models had very comparable values for their RMSD if their source is 
considered; in other words, models from 1a trajectory (90ns, 95ns and 100ns) had an 
average RMSD of about 3.0 Å while those from the trajectory of 1b (65ns, 155ns and 245ns) 
showed a value of about 2.5 Å. These values are slightly different from the values of the 
RMSD measurement performed on the trajectories in section 3.2 (Figure 3-12 and Figure 
3-25) but this can be expected since the reference frame in the 2 measurements was not the 
same. In section 3.2, the reference was the first frame in the production phase. 
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Model RMSD (Å) 
90ns 3.1 
95ns 3.1 
100ns 2.9 
65ns 2.4 
155ns 2.5 
245ns 2.6 
Table 3-31: RMSD values of the 6 models using the original crystal structure as a reference. 
It should be noted here that the structure that was used as a reference had the missing 
residues added and minimised using CAChe only while in the models, the added residues 
would have had the time to relax and adjust themselves to their positions. This was 
especially important for the loop between residues 319 and 327, because it consisted of the 
closest missing residues to the active site. Other added residues were in locations farther 
away from the active site. In this loop, 2 distinct patterns were noticed; the behaviour in the 
models from the trajectory of 1a in which the loop moved to the inside of the active site to 
become closer to the tunnel and CYS277, and the behaviour in the models from the 
trajectory of 1b, where the loop was pointing to the outside of TG2 creating an opening in the 
active site (Figure 3-73). The different orientation of the loop between the 2 sets of models 
may be responsible for the slightly better performance of the models from the trajectory of 1a 
in posing the compounds with the correct bent conformation, for the models from the 
trajectory of 1b would have had more space to accommodate the lipophilic part; the space 
created by the added loop and the hydrophobic loop. 
 
Figure 3-73: The conformation of the loop between residues 319 and 327 in the 6 valid models compared 
to the original.The loop is coloured yellow in the “Original” picture and by secondary structure in the rest 
and CYS277 is shown to give an indication of the active site. 
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155ns 245ns Original
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This was seen during the process of selection of the valid models, one example is the results 
of docking on model 245ns in section 3.3.2.3. The justification is that in the models from 1a 
trajectory, the loop orientation will make it very difficult for the lipophilic part of the inhibitors 
to go anywhere except in the hydrophobic loop of the active site while in the models from 1b 
trajectory, there is the space created by the orientation of the added loop that can provide 
additional accommodation for the lipophilic part of the inhibitors. Although the orientation of 
the loop in the original structure is closer to the one in the models from 1b trajectory, this 
should not make the orientation more realistic, as the loop contains added residues and 
without any reference structure to compare to, there is no way of telling that the loop has 
relaxed enough to be realistic. The atomic fluctuation values for the loop residues in the 2 
trajectories from which the models were taken (Table 3-32) are comparable with the 
exception of the 1st three residues and cannot be used to judge which loop is better. 
Residue Atomic fluctuation in 1a-trajectory (Å) Atomic fluctuation in 1b-trajectory (Å) 
319 3.5835 1.4738 
320 3.4112 1.3913 
321 2.8635 1.8123 
322 2.3366 2.5744 
323 2.0198 2.2968 
324 1.7981 1.8178 
325 1.7782 1.9103 
326 1.7456 2.1469 
327 1.6844 2.046 
Table 3-32: Atomic fluctuation values of the added loop from Figure 3-73. 
One additional observation that can be easily spotted from Figure 3-73 is the orientation of 
the SG atom in the catalytic cysteine residue. In the original structure, and in the models 
from the trajectory of 1b, SG was facing to the outside of the protein while in models from 
the trajectory of 1a it was facing to the inside of the protein. This did not have any major 
effects on the dockings as manifested by the similar distances recorded in the docking tables 
between the warhead and this atom. The inclusion of CYS277 within the 10 residues to be 
treated as flexible during GOLD dockings may have minimised the effect of this difference. 
Despite the importance of residue ASN333 in the dockings of TG2 inhibitors, its 
conformation was not very different between the different models (Figure 3-74). Again it was 
one of the 10 flexible residues during GOLD docking. 
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Figure 3-74: The orientation of ASN333 in the 6 models compared to the original. 
The same cannot be said about the bridging tryptophan residues (TRP241 and TRP332) 
(Figure 3-75). In the original crystal structure, these residues formed a bridge to the catalytic 
tunnel through being stacked in the way presented in Figure 3-75, with the five-membered 
ring of the indole side chain facing each other on the 2 residues and the benzene rings are 
parallel to each other and the inhibitor is supposed to position itself between the 2 residues 
(Pinkas et al. 2007). Such orientation of the bridging tryptophan residues is more manifested 
in the models extracted from the trajectory of 1a than in those from the trajectory of 1b. This 
may contribute to the slightly better docking results in the former set of models as they offer 
more realistic representation on the approach to the active site than the second set of 
models. It should be emphasised, however, that both residues were allowed to be flexible 
during the dockings, minimising the effect of this difference. 
Finally, regarding a justification for the different docking results between the models, GOLD 
uses genetic algorithm as its docking method and this is a random searching algorithm that 
operates by generating arbitrary poses for the ligands within the active site and scoring 
them. This may result in different docking solutions for the same set of ligands being docked 
in the same protein active site models using the same settings. Such different solutions have 
actually been observed during the running of validation process 4 (section 3.4.4) when 3 
identical attempts of docking were performed on the 6 models and yet different results were 
obtained with each attempt. As a result, although the performance of the models from the 
trajectory of 1a seems slightly better than that of the models from the trajectory of 1b, all the 
90ns 95ns 100ns 65ns
155ns 245ns Original
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six models are important when it comes to testing potential compounds as inhibitors of TG2, 
if GOLD random algorithm was to be used for the docking. 
 
Figure 3-75: The orientation of the bridging tryptophan residues in the 6 models along with their 
orientation in the original crystal structure. 
3.9 Analysis of the MD Trajectory of Empty TG2 
The initial MD simulation that was applied on TG2 crystal structure to generate the initial 
models for docking was repeated twice with ig=-1 that sets the random seed for the initial 
velocity based on the current date and time. The three simulations were performed to collect 
some data on TG2 on its own, without any inhibitors during MD simulations. The results are 
presented below. The 3 runs were stable as reflected by the change in temperature and total 
energy of the system with time. Graphs of these changes are shown in Figure 3-76. 
 
Figure 3-76: Energy and temperature graphs for the 3 simulations applied to TG2 for 500 ns. 
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3.9.1 RMSD and PCA 
The stability of the simulations was also expressed by the RMSD of the runs. Figure 3-77 
shows the RMSD for the 3 runs calculated on the production phases and using the first 
frame as a reference. RMSD calculations were performed on the backbone atoms only using 
the program CPPTRAJ from the AmberTools Package (Roe & Cheatham 2013). The RMSD 
for the 1st and 3rd runs was stable between 2 and 2.5 Å. In the 2nd run there was some 
fluctuation at the start followed by stable run at RMSD between 2 and 2.5 Å until the half of 
the simulation time. After that, the RMSD was stable at values between 3 and 3.3 Å. In all 
the cases, RMSD was almost stable during the production phase. This measurement was 
followed by calculating the RMSD for the residues used in defining the active site of TG2 
during docking. Figure 3-78 shows this RMSD and it can be seen that the part of TG2 that 
constitutes the active site was moving less than the remainder of the protein. Figure 3-78 
also shows that the first 100 ns of the 1st run was almost as stable as the rest of TG2, and 
this was the part of the trajectory from which the models for the initial docking were taken 
from. 
 
Figure 3-77: RMSD curves for TG2 from the 3 runs. 
Following the RMSD calculations, principal component analysis (PCA) was performed using 
the program pyPcazip (Shkurti et al. 2016), which is a program used to compress and 
analyse MD simulations data. The analysis was applied on the trajectories after stripping 
water molecules, and included the backbone alpha carbon atoms only. The first 20 principal 
components (PCs) for the 3 runs are presented Figure 3-79. As shown from the RMSD 
graphs, it appears that the 2nd run had the highest fluctuation. This is evident in Figure 3-79 
as well. When the 1st PC was plotted versus the 2nd PC, Figure 3-80 was produced. The 
figure shows that the 3rd run was the least flexible. However, the majority of the points from 
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the 3 runs were approximately in the same region, indicating similar coverage of the 
available conformational space in the 3 runs. 
 
Figure 3-78: RMSD of the active site residues only for the 3, 500-ns runs on empty TG2. 
 
Figure 3-79: The first 20 principal components (PCs) generated by pyPcazip for the 3 MD runs with their 
eigenvalues. 
pyPcazip has the ability to derive from the principal components, a trajectory composed of 
20 frames that represents the motion of the protein in that component. This feature was used 
to investigate which parts of the protein moved the most in the 3 runs by generating such 
trajectories for the 1st PC. It was noted that in the 1st run, it was the loop between residues 
PHE320 and GLY325 that moved the most. These 6 residues were missing in the original 
crystal structure and were added before starting the simulations (Figure 3-81A). Although 
close to the active site of TG2, this loop is not involved in the inhibition mechanism at all and 
its residues are not part of the active site definition used in the docking experiments. The 
effect of this loop on the valid active site models of TG2 has been discussed in more detail in 
section 3.8. For the 2nd run, it was the loop composed of residues 449-456 that had the 
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highest motion. The loop was originally an alpha helix that opened. This loop-opening event 
has not happened in the 1st or 3rd runs. In any case, it is away from the active site (Figure 
3-81B). In the 3rd run, like the 1st run, it was an added loop originally missing from the crystal 
structure composed of residues 407-413. Again, this loop was not in the immediate vicinity of 
the active site. 
 
Figure 3-80: The first versus second PCs for the 3 runs. 
The results shown in Figure 3-81 were consistent with the atomic fluctuation data of the 
residues of TG2. This was calculated through measuring the average change in RMSD of 
the backbone atoms over time per residue. The atomic fluctuation calculation was performed 
using CPPTRAJ. The results are shown in Figure 3-82. Although the peak heights are 
different between the runs, it is obvious that the locations of the peaks are the same, 
indicating that they are the same regions of TG2 that are being more flexible than the others 
even though the extent of the flexibility is different between the runs. Also, the highest peak 
in each run corresponds to the same region in TG2 as the region observed from PCA in 
Figure 3-81. 
-80
-60
-40
-20
0
20
40
60
-100 -80 -60 -40 -20 0 20 40 60
P
C
2
PC1
1st
2nd
3rd
Chapter 3   Model Development and Validation 
168 
 
                               
 
Figure 3-81: Trajectories for the 1st PC of the 3 runs showing 
the highest moving part (red) and its location relative to the 
active site cysteine residue (yellow). A: 1st run, B: 2nd run, C: 
3rd run. 
 
Figure 3-82: Atomic fluctuation for the individual residues of TG2 for the 3 runs. 
0
1
2
3
4
5
6
7
150 200 250 300 350 400 450 500 550 600
Fl
u
ct
u
at
io
n
 (
Å
)
Residue #
1st_run
2nd_run
3rd_run
A 
B 
C 
Chapter 3   Model Development and Validation 
169 
 
3.9.2 Water behaviour 
How water molecules were moving within the active site of TG2 was investigated by using 
the “watershell” command of the CPPTRAJ program. This command calculates the number 
of water molecules in the 1st and 2nd solvation shells as a function of the frames in the 
trajectory with respect to a reference atom mask. The CPPTRAJ default dimensions of the 
shells were used, which are 3.4 Å for the 1st shell and 5 Å for the 2nd shell, and solvation 
shells were calculated with reference to the SG atom of CYS277. Table 3-33 shows the 
average number of water molecules in the 2 shells computed for the 3 runs. Again, the 1st 
and 3rd runs appear to be very similar having an average of ≈ 3.5 water molecules within 3.4 
Å and 8 water molecules within 5 Å across the simulations. Because the numbers of the 1st 
and 3rd runs were similar, those runs will be considered for comparisons. 
 1st Run 2nd Run 3rd Run 
1st Shell Average 3.5 2.6 3.4 
2nd Shell Average 8.2 4.8 8.0 
Table 3-33: Average values for the number of water molecules in the 1st and 2nd solvation shells in the 3 
MD runs applied on empty TG2. 
Figure 3-83 is graphical representation for the number of water molecules in the 1st and 2nd 
shells during the 1st MD run and it shows that within the 1st shell, there was always at least 
one water molecules within 3.4 Å of SG (this occurred in 9 frames). The maximum was 7 
residues (4 frames only), and for the majority of time, the number was between 3 and 5, 
explaining the average values shown in Table 3-33. The same applies to the graph of the 2nd 
shell. This indicates that there were always few water residues in the immediate vicinity of 
SG in the active site. To investigate how that is related to distance from SG, RDF was used. 
  
Figure 3-83: Water molecules in the 1st (left) and 2nd (right) solvation shells of the 1st MD run as 
representative of distribution of water molecules in the 3 runs. 
The radial distribution function (RDF) was used to inspect how the density of water 
molecules around SG changed as a function of distance from SG. The results of the 
calculation are presented in Figure 3-84, in which a similar pattern can be observed within 
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the 3 runs. Within 2 Å of SG, there was 5 times higher probability of finding water molecules 
than everywhere else in the 1st and 3rd runs and 4 times in the 2nd run. The probability 
decreases to about 3 within 3 Å of SG in the 3 runs. RDF goes down after 3 Å to around 1. 
This means that most of the water molecules seen in Figure 3-83 are between 2 and 3 Å and 
there are no water molecules that are less than 2 Å away from SG, due to atom radii 
restrictions. 
 
Figure 3-84: RDF of water 
molecules relative to SG 
atom of CYS277 in the 3 MD 
runs applied to empty TG2. 
 
The similar water behaviour in the 3 runs strengthens the assumption that this is how water 
molecules distribute themselves around the catalytic cysteine. The same calculation of water 
RDF was applied on the 275-ns trajectories of the active compounds. Only compound 1d 
trajectory was not considered due to the compound leaving the active site before the start of 
the production phase. Figure 3-85 shows RDF values for the 5 trajectories. It can be seen 
that the behaviour is very similar in the 2 cases, indicating that the presence of the inhibitors 
within the active site of TG2 did not affect the density of water around SG of CYS277. 
 
Figure 3-85: RDF of water 
molecules in the 275-ns 
trajectories of the active 
compounds. 
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It is true that the trajectories in Figure 3-85 had inhibitors, but it is only the one for compound 
1b that managed to finish with the inhibitor in its starting pose; in the rest, the warhead has 
left the catalytic tunnel at some point during the simulation. The compound 1e-simulation 
had the compound in its appropriate conformation for about 185 ns of the simulation time. A 
closer look at the graph in Figure 3-85 shows that within 2 Å, the probability of finding water 
was lower in the trajectories for compounds 1b and 1e. Compared to an RDF of 5 in the 1st 
and 3rd runs on empty TG2 and in the simulations for complexes in which the warhead has 
left the catalytic tunnel, this may actually mean that the presence of the inhibitor can reduce 
the density of water in the vicinity of SG, but it is until the covalent bond is formed, that all 
the water molecules within 2 Å will all be pushed away. This was shown in section 3.7 when 
discussing covalent docking and MD. 
An analysis of the number of water molecules in the 1st solvation shell was also performed 
on the trajectories of the complexes and showed that the lowest average was 1.9 molecules 
and that was for the trajectory of compound 1b and the highest was for compound 1c with 
an average of 3.6 water molecules. For the remaining 3 compounds, the averages were 3.1, 
2.9 and 3 for compounds 1a, 1e and 1f respectively. The lowest average for compound 1b is 
compatible with the RDF for the trajectory of that compound and compound 1e had the 2nd 
lowest average. Although the averages for the other simulations are not quite similar to the 
averages of the empty TG2 runs, the fact that they are higher than the averages of 
simulations in which the warhead managed to stay close to SG indicates that the presence 
of the warhead can push some water molecules away. 
The distribution of water molecules in the hydrophobic loop of TG2 has also been analysed. 
This has been calculated as RDF with reference to the alpha carbon atom of residue ILE331 
(Figure 3-86), which is one of the residues involved in the hydrophobic interactions with the 
lipophilic part of the inhibitors. The results are shown in Figure 3-87. Although residue 
ILE331 on its own does not represent the hydrophobic loop, it is one of the best choices 
available. RDF graphs for the 3 runs are very similar and show that there are no water 
molecules in the immediate vicinity of ILE331. RDF shows that water molecules start to 
appear at around 3 Å from ILE331 but at very low density when compared to SG of CYS277 
(RDF has a value of ≈ 1 at 3 Å which is the normal density of water). This was confirmed by 
calculating the numbers of water molecules residing in the 1st solvation shell which averaged 
around 0.4, 0.6 and 0.7 water molecules for the 1st, 2nd and 3rd MD runs respectively. 
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Figure 3-86: The location of ILE331 
used as reference for the RDF of 
water molecules in the hydrophobic 
loop of TG2. 
 
Figure 3-87: RDF of water 
molecules in the 3 runs in 
the hydrophobic loop of 
TG2.
The absence of water molecules from the hydrophobic loop in the simulation of the empty 
TG2 may provide an explanation for the apparent ease with which the lipophilic parts of the 
compounds maintained their positions within the hydrophobic loop, when compared to the 
warheads in the 275-ns and in the 5-ns simulations. There were much more cases for the 
leaving of the warhead than for the lipophilic part in the 5-ns simulations (section 3.4.5). In 
the 275-ns simulations, no lipophilic part left its place. 
A very similar pattern was seen when inspecting the RDF graphs for the density of water 
around ILE331 in the 5 trajectories for the compounds. The results are shown in Figure 3-88. 
The absence of water until 3 Å from ILE331 is very clear, followed by the slight increase in 
the density. Compound 1f trajectory showed the least density of water despite the fact that 
the simulation for this compound started with the lipophilic part outside the hydrophobic loop 
and continued like that for the remainder of the simulation. 
In general, the results of RDF analysis in the hydrophobic loop of TG2 show that it is highly 
unlikely for water molecules to reside underneath the loop. The presence of the lipophilic 
part of the inhibitors within the hydrophobic loop does not appear to reduce the probability of 
finding water molecules in the loop, as it would be expected from the physical occupancy, 
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since in some cases when there was a compound, the probability was actually higher than it 
was in empty TG2 (trajectory for compound 1b). 
 
Figure 3-88: RDF graphs for 
the hydrophobic loop in the 
trajectories of complexes. 
3.10 Conclusions 
The main goal of the work at this point was to derive active site models of TG2 that could be 
used to test potential inhibitors of TG2 and to validate the models. The initial MD simulation 
applied to TG2 was proven to be stable and did succeed in providing starting structures for 
MD applied on the complexes in the next stage. The MD simulations applied to the 
complexes finished appropriately only for compound 1b in terms of maintaining the initial 
pose of the compound; but in all the simulations, the importance of hydrogen bonding with 
key residues in the active site (GLN276, ASN333 and PHE334) and of the hydrophobic 
interactions involving the lipophilic parts of the inhibitors has been shown. Although the MD 
simulation of compound 1a failed to keep the compound in the active site, the trajectory 
provided 3 conformations that passed the 1st stage of testing which involved docking 6 active 
inhibitors of TG2. This supplied 3 of the 6 active site models that went to the next stage and 
the remaining 3 were extracted from the trajectory of compound 1b. The dockings at this 
stage also signified the importance of hydrogen bonding and hydrophobic interactions. 
The six models were validated next through various experiments that involved docking of 
inactive compounds, docking with water in the active site, expanding the compound test set, 
applying short MD simulations that involved calculating the binding free energies and finally 
docking of more active compounds. Even though the results were not always ideal, they 
gave the suggestion that the models can detect compounds based on their ability to inhibit 
TG2. The results also enabled the fabrication of criteria required to define a good docking 
complex for TG2 inhibitors. A positive correlation was also obtained when the binding free 
energy was related to the biological activity for compounds containing the sulfonium ion 
warhead. 
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The choice of GoldScore as the primary scoring function during the GOLD dockings 
performed was justified by testing the performance of the other functions which proved to be 
inferior to GoldScore. No scoring function, however, was able to rank the compounds based 
on their biological activity, although with GoldScore, this was slightly improved by rescoring 
after local minimisation of the docked pose. 
Covalent docking and MD proved that active and inactive inhibitors of TG2 behave similarly 
if the covalent bond was already there. They also proved that no water molecules can reside 
next to the covalent bond during MD simulations. 
The analysis performed on TG2 conformations of the 6 valid models succeeded in explaining 
the better results obtained with the models from 1a trajectory than those from 1b trajectory 
and showed that it is better to use the 6 models when trying to test some new compounds as 
inhibitors of TG2 if GOLD was to be used as the docking program. 
The behaviour of water molecules in the MD simulations has shown that there could be few 
water molecules residing very close to SG of CYS277, whether there was an inhibitor in the 
active site or not. The analysis also showed that very few to no water molecules can be in 
the hydrophobic loop of TG2 which may explain why it was easier to keep the lipophilic part 
in place than to keep the warhead. 
To conclude, the models generated during this work have been validated and proven to be 
the best available choices for testing TG2 inhibitors. More work is required to investigate the 
mechanism of inhibition to fill some of the gaps in the work so far related to the failure to 
relate some measured quantity to biological activity. This was the main rationale for the next 
chapter of the thesis. 
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4 Quantum Mechanical Experiments 
This chapter covers the results of the experiments performed with partial or total QM 
treatment to investigate the mechanism by which the various studied inhibitors react with 
TG2. Partial treatment was employed through a combined QM/MM approach with umbrella 
sampling on selected complexes of TG2 with acrylamide based inhibitors. Total QM 
treatment was applied on versions of TG2-sulfonium ion inhibitors complexes in which all the 
system was removed with the exception of the inhibitor and the catalytic cysteine residue 
and QM reaction path experiments were performed. 
4.1 Umbrella Sampling 
4.1.1 Introduction 
Umbrella sampling (US) is an enhanced sampling technique in molecular dynamics that 
permits the exploration of events which would otherwise take infinitely long time to occur. 
Candidate events would ideally involve crossing high energy barriers where conventional 
MD will only result in trapping the system in an energy minimum with no possibility of 
crossing the barrier. US applies an external biasing potential over a predefined reaction 
coordinate (RC) to drive the event to completion. The change in RC should be small to 
ensure a quasi-static process. Thus US spreads the change in RC over windows and for 
successful sampling, the windows must overlap (Kästner 2011). During the sampling, the 
change in RC in each window is recorded to represent the probability distribution along the 
reaction coordinate in that window. This distribution can then be converted to the potential of 
mean force (PMF) using the weighted histogram analysis method (WHAM) (Hub et al. 2010; 
Kumar et al. 1995). 
The next section introduces the results of the umbrella sampling applied to simulate the 
reaction between TG2 inhibitors with the acrylamide warhead and TG2 active site cysteine 
(CYS277) (Figure 4-1). The inhibitors are compounds 1a, 1c, 1e (Table 3-1, p86), 3j, 3l and 
3o (Table 3-12, p125) from the work of Badarau et al. (2015) and the associated patent 
(Griffin et al. 2014). These compounds had a range of activity expressed as IC50 from 0.006 
to 6.3 µM. 
The aim of the study is to use the US-simulated reaction to find some type of correlation with 
biological activity manifested as IC50 values for the tested acrylamide inhibitors. Since the 
formation of bonds was involved, US was performed with quantum mechanical treatment of 
the reaction centre (the acrylamide inhibitor as the electrophile, CYS277 as the nucleophile 
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and HIS335 from TG2 as the source of the proton), while the remainder of the protein and 
the water box were treated molecular mechanically. PM3 (Parametric Method Number 3) 
(Stewart 1989) and SCC-DFTB (self-consistent-charge density-functional tight-binding) 
(Elstner et al. 1998) were used as the QM methods. 
 
Figure 4-1: The reaction of inhibition of TG2 by acrylamide inhibitors. 
Two possible mechanisms for the reaction were explored; the first involves a single stage 
only during which the bond between nucleophilic sulphur of CYS277 (SG) and the 
electrophilic carbon (EC) on the acrylamide, and the bond between a proton from a nearby 
histidine residue (HD1) and the alpha carbon of the double bond of the acrylamide (C2) both 
form simultaneously. The second mechanism involved the nucleophile-electrophile reaction 
first, followed by the protonation stage. The choice of HIS335 as the proton source is 
justified in a later section of this chapter (4.1.2.4). The starting structures were frames taken 
from the 5-ns MD simulations (1a, 1c and 1e) or docking complexes from validation 
processes 3 (more test compounds) and 4 (all compounds) (3j, 3l and 3o). 
4.1.2 Results and Discussion 
The overlap between the windows of all the simulations was analysed by plotting the time 
series files where the Y-axis represented the change in RC across the simulation and the X-
axis the time of a single window in picoseconds. This was used as a measure to the success 
of the simulation. Other measures used to judge the quality of an individual simulation were 
the actual formation of the 2 bonds; SG-EC and HD1-C2, and the fact that the compound 
maintained its general pose within TG2 active site at the end of the simulation. In addition, 
RMSD of TG2 in the different simulations was measured. Figure 4-2 has been presented in 
the Methods (section 2.2.2.1) and is presented here as a reminder of the distances used to 
define reaction coordinates used in the 2 mechanisms. 
Cys277
Acrylamide inhibitor
HIS335
HIS335
CYS277
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Figure 4-2: Distances used during umbrella sampling 
for the 1-stage and 2-stage simulations. 
4.1.2.1 Single stage simulations 
In these simulations, the reaction coordinate (RC) was set as a generalised distance 
coordinate comprising the sum of D1 and D2 in Figure 4-2. This definition of the RC allows 
for the whole reaction to proceed in a single stage. SCC-DFTB was unable to drive the 
reaction to completion in compound 1c, and for the remaining 5 compounds, no useful 
correlation with the biological activity could be obtained from the US simulations. For these 
reasons, US using SCC-DFTB on acrylamide compounds assuming 1 stage for the reaction 
was not considered. Such anomalies did not occur when PM3 was set as the QM method. 
The simulations with all the compounds completed to the assigned value of the reaction 
coordinate, the 2 bonds formed, and the compounds maintained their original pose within 
TG2. In addition, a sufficient degree of overlap between the windows was observed. 
The trajectories of the simulations on individual compounds have been analysed. The 
distances involved in RC have been measured using VMD program (Humphrey et al. 1996) 
along with the SG-EC-C2 angle. The analysis showed that the 2 distances were declining 
together but the SG-EC bond would form first and that the angle would change from its 
starting value to a value between 94° and 115° at the barrier height and maintains that for 
the rest of the simulation (Table 4-1). The dihedral angle of the attack of SG on the plane of 
EC (EC, C2 and the carbonyl carbon) has also been measured. The discontinuities seen 
with compounds 1c and 3o in Table 4-1 were not flaws in the way in which the RC has 
changed during the US simulation for these compounds. Rather, the SG-EC bond was 
formed suddenly and early in the simulation, where the SG-EC distance jumped from a value 
of 2.7 Å in one frame of the trajectory for the simulation of compound 1c to a value of 1.9 Å 
in the next frame. This sudden change was accompanied by a temporary corresponding 
increase in the HD1-C2 distance from 5.9 Å to 6.6 Å to keep the change in the overall RC 
consistent. 
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Table 4-1: Distances involved in the RC for the 1-stage simulations and the corresponding angles for the SG-EC-C2 bond.X-axis is time in ps and Y-axis is in Å for 
the RC distances and degrees (°) for the angle. The black line represents the point in the simulation corresponding to the barrier height on the PMF graph. 
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As stated in the Methods section (section 2.2.2.1), PMF was calculated from the time series 
files using WHAM. The results of PMF calculations for all the compounds are presented in 
Figure 4-3. It can be seen that a similar path has been followed by all the compounds during 
their US simulations and that the barrier height was reached at a roughly similar value for the 
reaction coordinate in all the compounds. 
 
Figure 4-3: PMF graphs of the 6 acrylamide compounds generated from WHAM program.The graph starts 
from the right with the higher value from RC and ends to the left.  
The values of the parameters measured from the US MD trajectories for the structures at the 
barrier heights of the individual PMF graphs are presented in Table 4-2. The dihedral angle 
is presented in its simplest positive form to facilitate the comparisons. These structures are 
the closest one can get to transition states (TS). It can be observed from Table 4-2 that at 
the barrier, the SG-EC bond was formed only in 1a and 3o (assuming ≈1.8 Å for S-C bond) 
while HD1-C2 bond was not formed in any of the tested compounds. The value of RC 
ranged from 3.5-3.9 Å, the angle from 94-115° and the dihedral angle had values between 
56-87°. 
Compound 
TS parameters 
SG-EC (D1) 
(Å) 
HD1-C2 (D2) 
(Å) 
RC (Å) Angle (φ) (°) Dihedral (°) 
1a 1.83 2.06 3.89 98.35 56 
1c 1.94 1.61 3.54 111.51 72 
1e 2.03 1.85 3.89 94.09 80 
3j 2.15 1.71 3.85 94.47 61 
3l 1.96 1.91 3.87 114.73 87 
3o 1.83 1.63 3.46 110.71 73 
Table 4-2: RC distances and SG-EC-C2 and dihedral angles for TS structures of the 6 compounds. 
The fact that the 2 bonds have formed indicates that the chosen reaction coordinate could 
represent the reaction successfully. The end value for the RC was appropriate; the RC could 
not be pushed any further as this would have resulted in a shift in PMF scores, as there was 
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already a very slight shift at the end of the graphs (Figure 4-3). The overlap between the 
windows was checked by plotting the time series of the RC of all the windows using time 
values for the X-axis that correspond to a single window (5 ps) (Figure 4-4A). The gap seen 
in Figure 4-4A at ≈ 4 Å of overlap graph for compound 1e, has been spotted in the overlap 
graphs for other compounds. It corresponds to the barrier height as seen in Table 4-2. This 
may be expected due to the formation of the bond at this point, which could occur with a 
sudden, and rough, change in the RC. A simulation for compound 1e was run in which the 
force constant was increased from 100 to 300 kcal/mol.Å2 starting from the value of 4.1 Å for 
RC to the end of the simulation. The gap has disappeared from the overlap graph but the 
PMF graph produced was almost exactly the same (Figure 4-4C). It is for this that the default 
force constant was considered, to avoid using higher than necessary force constant. 
  
 
Figure 4-4: A: Overlap graph for 
compound 1e using the default 
values for the force constant, B: 
overlap for compound 1e using a 
force constant of 300 after RC 
reached 4.1 Å. C: PMF graphs of 
the 2 simulations. 
The reaction is expected to proceed as a Michael addition; the acrylamide double bond acts 
as the acceptor being attached to an electron withdrawing group, and SG of CYS277 being 
the donor. This can be viewed as a similar mechanism to the nucleophilic addition to carbon-
oxygen double bonds (Smith & March 2001). Hence, it may be possible to apply the Bürgi–
Dunitz angle to this reaction. This is the angle of the attack of a nucleophile (Nu) to a 
carbonyl group carbon atom (Nu-C-O angle) and its optimal value was found to be 107° 
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(Bürgi et al. 1974). The same angle has actually been proposed for any reaction that 
involves a Michael addition (Sinnott 2007). 
It is true that the angles in Table 4-2 do not all agree with the value of 107° stated in the 
literature for this angle but they are close. After the barrier height and the formation of the 
SG-EC bond, the angle keeps a value that is close to the values in Table 4-2 for the 
remaining of the simulation as can be seen from the angle graphs in Table 4-1. At this point 
the angle would represent that for an ordinary S-C-C bond. According to AMBER force field, 
such angle has a value of 108.6° in normal cysteine residue and by looking at the graphs in 
Table 4-1; it can be argued that the bond formed is behaving as a typical bond involving 
sulphur and sp3 carbon. 
Another angle was measured and that was the dihedral angle between the attacking sulphur 
and the plane of EC, C2 and the carbonyl carbon (C) (Figure 4-5). The angle assumed very 
diverse distribution among the compounds and this can be attributed to MD oscillations. The 
results for 2 compounds (1a and 3j) are presented in Figure 4-6 as examples of the diversity. 
Due to the variations, the simplest positive magnitude at the barrier height was considered 
and presented in Table 4-2. The common feature within those angles is that the 2 planes 
were virtually vertical to each other. This indicates that the attack of the nucleophilic SG of 
CYS277 was almost perpendicular to the plane containing the acrylamide warhead (Figure 
4-5) or at least not in the plane of the hydrogen atoms attached to EC. Dihedral angle values 
are therefore consistent with the values of the SG-EC-C2 angles. 
 
Figure 4-5: The dihedral angle that was measured during umbrella sampling between SG from CYS277 
and the plane of EC, C2 and C of the compounds, showing two examples for the angle with compounds 
1a and 1c.  
  
1a 
1c 
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Figure 4-6: Graphs of the dihedral angle in compounds 1a and 3j as representatives of the 6 compounds 
showing the diversity in the values of the angle. The black line vertical represents the barrier height in 
the PMF graph. X-axis is time in ps and Y-axis is dihedral angle in degrees (°).  
The RMSD for TG2 in the simulations of the 6 compounds was measured as an indicator of 
the stability of those simulations, using the 1st frame of the trajectory as a reference. The 
results are presented in Figure 4-7 and imply that TG2 was stable. The RMSD in the 6 
compounds had a maximum value of 1.25 Å. 
 
Figure 4-7: RMSD graphs for the simulations of the 6 acrylamide compounds. 
Finally, the activation energy (AE) for the reaction was calculated, and was taken as the 
difference between the barrier height and the energy of the reactants; the latter being zero in 
most cases. The reaction energy (RE) was also computed by subtracting the energy of the 
reactants from that of the products. The results for the different compounds are summarised 
in Table 4-3. When the correlation between biological activity (as TG2 IC50) and the AE was 
considered, a line with positive slope was obtained indicating an increase in AE with a 
decrease in biological activity. The line had an R2 ≈ 0.6. Interestingly, the reaction energy 
gave a similar line when plotted against the log value of the IC50 (Figure 4-8). 
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Compound IC50 (µM) AE (kcal/mol) RE (kcal/mol) 
1a 0.125 42.55 6.66 
1c 0.44 29.57 8.70 
1e 0.0061 35.66 -6.70 
3j 6.3 69.71 29.66 
3l 2.1 40.44 17.57 
3o 1.625 63.19 49.69 
Table 4-3: AE and RE (both in kcal/mol) for the 6 acrylamide compounds resulting from US simulations 
using PM3 as the QM method. 
 
Figure 4-8: left: IC50 versus AE, right: log of IC50 versus RE. 
The method was able to drive the reaction to completion and to produce AEs compatible, to 
some degree, with biological activity, with the appropriate trend; the AE was lower for the 
more active compounds. The charges of the atoms of the QM region were monitored during 
the simulations. Those of SG, C2 and the acrylamide carbonyl oxygen atom were recorded. 
The changes in these were not uniform across the compounds and could not be interpreted 
to explain a possible discrete mechanism for the reaction. In compound 3j, for example, only 
the charge of SG changed considerably during the simulation while with compound 3l, there 
was a decline in the charges of the acrylamide carbonyl oxygen and C2 around the TS 
(Figure 4-9). 
The changes in the charges for compound 3j suggest that the 2 processes (attack of the 
nucleophile and the protonation) happened at the same time with a few picoseconds during 
which SG-EC bond was there but the protonation has not happened yet. This explains the 
sharp decline in the charge of C2 at around 250 picoseconds, just before the barrier height. 
The graph of charges for compound 3l suggests differently; the SG-EC bond formed first 
accompanied by a decline in the charges of C2 and the acrylamide carbonyl oxygen that 
continued until the protonation completed. The pattern observed with 3j was observed in 1a 
and 1e, while that of 3l was seen with 1c and 3o. By looking at distance graphs in Table 4-1 
(the distances are also presented in Figure 4-9), it can be seen that the “3j charge pattern” 
was followed by the compounds in which the 2 bonds formed at the same time and the “3l 
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charge pattern” was adopted by the compounds in which the SG-EC bond was formed 
before the protonation (Figure 4-9). 
 
 
Figure 4-9: Changes in the charges (lines, left axis, Ch-O, Ch-SG and Ch-C2) of compounds 3j and 3l 
along with change in distances for the bonds to be formed (dots, left axis SG-EC and HD1-C2) during the 
PM3, single-stage US simulations.  
The charge pattern of 3j implies a simple straightforward mechanism, in which all the events 
in the reaction happen almost simultaneously without a real chance for the participating 
atoms to have their charges altered. The change in the charges of C2 and the oxygen in 
compound 3l is indicative of the formation of 1 of 2 possible intermediates, one in which the 
lack of the proton is manifested as a negative charge on C2 (Figure 4-10A) or one in which 
the broken double bond would migrate back to the carbonyl carbon with a shift of the 
carbonyl double bond to a negative charge on the oxygen (Figure 4-10B). A combination of 
the 2 intermediates is also a possibility. 
It is because the non-uniformity in the charge graphs between the compounds and the 
consequent inability to decide a possible discrete mechanism for the inhibition that the 2-
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stage simulation was tried. It should be noted, however, that a positive correlation between 
the reaction energies and biological activity (Figure 4-8) indicates that the method was able 
to predict the energies of the reactants and products correctly but was unable to predict the 
path followed accurately. 
   
Figure 4-10: Possible intermediates formed during single-stage simulation of compound 3l. 
4.1.2.2 Two-stage US simulations 
The force constant of 250 kcal/mol.Å2 used during the 2-stage simulations was higher than 
that used previously. A lower value for the constant of 50 kcal/mol.Å2, increased to 100 
kcal/mol.Å2 towards the bond, was tired initially with PM3, but the simulation failed to drive 
the reaction to completion, especially in the protonation stage. Umbrella sampling has been 
used to describe similar reactions over 2 steps with such high force constant. Silva et al. 
(2015) investigated the inhibition of mycobacterial L,D-transpeptidase 2 by carbapenems, 
where the process involves a similar electrophile-nucleophile reaction between the 
negatively charged sulphur of an active site cysteine residue and the carbonyl carbon atom 
of a carbapenem. A proton is transferred in the second step from a nearby histidine residue 
to saturate a nitrogen atom that was originally attached to the carbonyl carbon of the 
carbapenem. They used a force constant of 250 kcal/mol.Å2 in the 2 steps (Silva et al. 
2015). 
PM3 was successful in forcing the 2 steps to completion with plausible structures and no 
change in the final pose of the acrylamide compounds. The 2 bonds eventually formed in all 
the compounds. However, no meaningful correlation could be made between the biological 
activity and any of the obtained energy values. SCC-DFTB, on the other hand, gave some 
correlation. Therefore, the results for SCC-DFTB will be presented with more detail while 
those from PM3 calculations will not be considered. The results from the 2 steps will be 
presented individually. 
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4.1.2.2.1 The first step (formation of the SG-EC bond) 
The RC for this stage was the distance between SG and EC (D1 in Figure 4-2). The overlap 
between the windows for this stage of the simulation was sufficient and Figure 4-11 is an 
example. At the end of this stage, the bond between SG and EC was present in all the 
cases, and the final conformation was used as a starting point for the 2nd step. Again, WHAM 
was used to calculate the PMF and the graphs produced are shown in Figure 4-12. All the 
PMF graphs produced had what appears like a lump or a saddle somewhere around 2 Å. 
This was selected to be the structure corresponding to the TS of the 1st stage (Figure 4-12). 
 
Figure 4-11: The overlap for the 1st step during the 
2-step simulations for compound 1a as an 
indication of the degree of overlap achieved 
during this step. 
 
Figure 4-12: PMF graphs of the 6 acrylamide compounds during the 1st step of the 2-stage reaction.The 
red balls represent the TS position. The reaction proceeds from right to left.  
When the charge of SG was monitored during the simulation, it was noted that the fully 
negative charge of SG became more positive, reaching a value of around -0.5 at the saddle 
point. The structures at the saddle point also had very similar values for the SG-EC distance 
and the SG-EC-C2 angle. The dihedral angle was also recorded at the saddle point of the 1st 
step. These transition state parameters are summarised in Table 4-4 along with the values 
of PMF at that point for each compound. The latter showed reasonable correlation with IC50 
producing a straight line with an R2 of around 0.7 (Figure 4-13). 
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Compound 
SG-EC (D1) 
(Å) 
Angle (φ) (°) Dihedral (°) Charge-SG AE (kcal/mol) 
1a 2.08 114 84 -0.49 25.67 
1c 1.99 114 64 -0.40 17.45 
1e 2.11 120 63 -0.53 19.68 
3j 2.03 114 57 -0.55 32.61 
3l 2.01 124 80 -0.59 25.61 
3o 1.96 113 76 -0.48 22.95 
Table 4-4: Parameters for the structures at the saddle point of the PMF graph of the simulation of the 1st 
step of the 2-stage simulations. 
 
Figure 4-13: Correlation 
between TG2 IC50 and the 
energy at the saddle point of 
the PMF graphs of the 1st 
step of the 2-stage 
simulations for acrylamide 
compounds.
The values of the angle of the attack of the nucleophile at the structures at the saddle point 
of the 1st step (Table 4-4) are also close to the value of Bürgi–Dunitz angle (107°) which 
describes the addition to carbon-oxygen double bonds, and can be applied to any reaction 
involving a Michael addition (Bürgi et al. 1974; Sinnott 2007). The values suggest that the 
approach of SG to EC followed the proposed route, where the nucleophile is expected to 
attack from above the plane of the electrophilic centre, rather than having the reacting 
species lining up in a straight line. 
For the dihedral angle, again it was the simplest positive form (magnitude) that was 
recorded. The values are not actually right angles but they prove that the attack of the 
nucleophile was orthogonal to the plane of the acrylamide double bond rather than from the 
same plane of the bond. This further confirms that the reaction followed the appropriate 
route. It should be emphasised that during all the US simulations, saving was being 
performed every 0.5 ps and it is possible that the trajectory produced did not contain 
conformations corresponding to the cornerstone events during the simulation. In other 
words, the attack of the nucleophile may have happened at exactly the angle of Bürgi–Dunitz 
and at exactly right dihedral angle, but was missed during the saving; the saving point was 
not the same as the point of the attack. This may also explain the differences in bonds 
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lengths observed at TS structures between the compounds, both in the concerted single-
stage and 2-step mechanisms. 
4.1.2.2.2 Second step (protonation of the initial Michael addition) 
A generalised distance coordinate was used to represent the RC for this stage comprising 
the difference between D2 and D3 distances from Figure 4-2. Although the separation 
between the windows for this stage was 0.4 and 0.2 Å, the overlap achieved was reasonable 
(Figure 4-14). The graphs generated by WHAM for the PMF of this step showed some 
degree of lack of overlap in the sense that the windows were obvious in the graphs in the 
shape of curves (umbrellas) corresponding to each window (Figure 4-15). This is especially 
true for the first section of the 2nd step when the separation between the windows was 0.4 Å 
(at distances > 2 Å in Figure 4-15). The method was able to drive this stage to completion 
and the protonation of C2 was evident in all the compounds. 
 
Figure 4-14: The overlap for the 2nd step 
during the 2-step simulations for 
compound 1e as an indication of the 
degree of overlap achieved during this 
step. 
 
Figure 4-15: PMF graphs of the 6 compounds for the 2nd step of the 2-step US simulations using DFTB as 
the QM method.The red balls represent the TS. The reaction proceeds from right to left. 
There was a common trend in the path followed by all the compounds for the 2nd step and 
this is manifest from Figure 4-15. The PMF curves start at the right side of the graphs 
accompanied by an increase in the PMF with decreasing values of RC until a maximum is 
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reached, followed by a decline in PMF score. The highest point on the graph was taken to be 
the transition state or the barrier height for the 2nd step. It is represented on Figure 4-15 by 
red balls. 
TS structures did not occur at similar values of RC across the compounds. The RC assumed 
values ranging from 0.4-1.1 Å. In all the cases, the HD1-C2 bond was not formed and the 
HD1-ND1 bond (the bond connecting the proton to HIS335) was still present. The charge on 
the acrylamide carbonyl oxygen averaged around -0.7 which is more negative than its 
original charge signifying that HD1-C2 bond has not yet been formed and that the electron 
density shifting from the original double bond of the acrylamide was still on this oxygen atom. 
The charge of C2 was around -0.6 and this is much more negative than its starting value (≈ -
0.2, details are presented later). This is another indication that HD1-C2 bond was not formed 
yet. The TS parameters for the 2nd step are presented in Table 4-5. 
Compound RC (Å) 
HD1-C2 
(D2) (Å) 
HD1-ND1 
(D3) (Å) 
Charge-O Charge-C2 
AE 
(kcal/mol) 
1a 0.85 1.94 1.10 -0.72 -0.60 134.27 
1c 0.70 1.80 1.09 -0.57 -0.57 107.95 
1e 1.13 2.19 1.06 -0.65 -0.61 92.24 
3j 0.85 1.91 1.11 -0.70 -0.56 209.74 
3l 0.34 1.48 1.09 -0.62 -0.56 150.15 
3o 0.48 1.63 1.03 -0.67 -0.56 137.73 
Table 4-5: Parameters for the structures at the TS for the 2nd stage of US on acrylamides using DFTB as 
the QM method. 
The activation energy for the 2nd step correlated well with biological activity producing a 
straight line with an R2 of around 0.9 (Figure 4-16). The activation energies of the 2 steps 
during this 2-stage simulation of the reaction produced reasonable correlations with the 
biological activities for the tested compounds. 
 
Figure 4-16: Correlation 
between biological activity 
and AE for the 2nd step of 
simulations on acrylamides. 
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When the charges of the reaction atoms were monitored during the 2-step simulations (both 
1st and 2nd steps combined), the patterns of changes across the compounds were more 
comparable than what was seen in the single-stage simulations. There was a similar trend 
followed by all the compounds in terms of the charge behaviour around the reaction centre. 
For the individual compounds, the changes in charges across the individual simulations 
charges are shown in Figure 4-17. 
  
  
  
Figure 4-17: Charges of the 6 compounds during the 2-step simulations. On the X-axis is the time in ps 
and on the Y-axis is the charge of the 3 monitored atoms (SG from CYS277, and C2 and carbonyl oxygen 
from the acrylamide warhead). The black vertical line marks the end of the 1st step. 
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As it can be seen in Figure 4-17, the charges of C2 and O became more negative, while that 
of SG more positive as the 1st step progresses. At the end of the 1st step, C2 and O had their 
most negative charges. Again, this would suggest that any of the intermediates in Figure 
4-10 may be the product of the 1st step. The oxyanion intermediate (Figure 4-10B), however, 
may be the most favourable because the charge of the oxygen is more negative than that of 
C2 at the end of the 1st step. In all the compounds, the acrylamide carbonyl oxygen atom 
had a charge of -0.8, which is closer to -1.0 than the charge of C2 in the compounds, the 
latter was ranging between -0.5-(-0.6) at the end of the 1st step. 
Silva et al. (2015), in their US study for the mechanism of inhibition of L,D-transpeptidase 2 
(LDT) enzyme of mycobacteria by carbapenems, proposed a 2-stage mechanism. Their 
system and the acrylamide-inhibited TG2 are not exactly the same; LDT also has charged 
cysteine and histidine residues in the active site but the inhibitor has a beta lactam ring 
instead of the acrylamide for the electrophile. The intermediate at the end of the 1st stage, 
according to Silva et al. (2015), is an anionic stable compound bearing a negative charge on 
the N4 nitrogen atom of the beta lactam ring that was protonated during the 2nd stage. The 
PMF graph of the first stage showed that the formed intermediate has lower energy than the 
reactant or the TS of that stage, confirming it being an anion. In this study, the intermediate 
at the end of the 1st stage had higher energy than that of its TS (Figure 4-12). This, in 
addition to the charges, supports the formation of the oxyanion intermediate (Figure 4-10B). 
The possibility of the 1,2-addition should not be overlooked. In this study, the 1,4 addition 
was proposed and investigated. This is because the double bond in the acrylamide is 
attached to an electron withdrawing group and this will induce the nucleophile to attach to 
the carbon away from the electron withdrawing group (Bernasconi 1989). In 1,2-addition, the 
nucleophilic addition to the acrylamide carbonyl carbon is also a possibility. The charge of 
this atom has been monitored and it did not show any change from its original value during 
the 2-stage simulation. It is true that the US was directed to drive the reaction to EC and not 
the carbonyl carbon, but the fact that the charge of the latter remained essentially constant 
during the simulations (Figure 4-18) may indicate the higher ease for directing the 
nucleophile to EC. Therefore, the 1,4 addition may be more likely with this system. 
The changes in the distances followed very similar pattern across the compounds and were 
under the control of the reaction coordinates of the two stages at all times. Figure 4-19 is a 
representation for the distances changes during the simulations. The angle between SG-EC-
C2 (φ in Figure 4-2) did not affect the 2nd step as the bond was already present, and 
therefore the angle maintained its value of that of a S-C-C bond. 
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Figure 4-18: The change in 
the charge of the carbonyl 
carbon of the acrylamide 
warhead of compound 1e 
during the 2-step US 
experiment with DFTB. 
 
Figure 4-19: Distances 
around the reaction centre in 
the 2-step simulations for 
compound 3o as a 
representative for the 
remaining compounds. 
In the 2-stage simulations, the RMSD for the individual compounds showed a similar stable 
trend to what was seen during the 1-stage simulations with a maximum value of 1.35 Å 
(Figure 4-20). Both stages achieved good correlations with biological activity. 
 
Figure 4-20: RMSD for the simulations of the 6 acrylamide compounds with the 2-step US. 
The AE values for the 2nd stage (the protonation step) were generally higher than those from 
the 1st stage (the formation of the SG-EC bond) suggesting that the protonation is the rate 
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limiting step for this reaction. This may not be consistent with the literature kinetics for thiol 
Michael addition reaction, which states that it is the attack of the nucleophile that constitutes 
the rate limiting step (Nair et al. 2014). An explanation could be offered based on the proton 
source used for the 2nd stage in this work. It was more difficult for the US simulation to take 
the proton from HIS335 than it was for the method to form the bond in the 1st step. It is the 
relative rigidity of the location of HIS335 being part of the protein, compared to the more 
freely moving acrylamide approaching SG in the 1st step, that was possibly responsible for 
the higher AE values observed in the 2nd step. An alternative proton source may have been 
better in this regard, but the choice of HIS335 here is justified (section 4.1.2.4). 
4.1.2.3 Water behaviour 
The behaviour of water molecules around the reaction centre was investigated to examine 
the effect of desolvation on the energies of the different compounds during US simulations. 
This was performed using CPPTRAJ by measuring the number of water molecules in the 1st 
solvation shell around SG (3.4 Å from SG) and by calculating the radial distribution function 
(RDF) (section 3.7.2) of water molecules up to 5 Å around SG to inspect the change in 
density of water molecules as a function of distance. 
4.1.2.3.1 Single-stage simulations 
For the single-stage simulations, RDF graphs for the individual compounds are presented in 
Figure 4-21. The probability of finding water molecules in the vicinity of SG followed a similar 
pattern to that observed during the analysis of empty TG2 conventional MD trajectories as 
well as the trajectories for 275-ns MD applied on the complexes (section 3.9). This 
probability was highest at 2 Å from SG followed by another peak at 3 Å. No water molecules 
existed in any simulation at a distance of less than 2 Å from SG. 
 
Figure 4-21: RDF graphs for the 6 compounds during the single-stage simulations. 
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In the simulations for compounds 1c and 1e, there were no water molecules at all within 5 Å 
of SG. This has happened since the start for these 2 compounds during the generation of 
files for MD where AMBER LEaP program did not place any water molecules within 5 Å of 
SG during the solvation of the complex for the 2 compounds. The absence of water in these 
2 cases did not change with the application of initial minimisation, heating the system, 
equilibration or even QM/MM relaxation applied prior to the US simulations. 
The numbers of water molecules found in the 1st solvation shell for the individual 
compounds’ simulations are presented in the graphs in Figure 4-22. It should be noted here 
that the graphs in Figure 4-22 are continuous, so there cannot be 2 and 3 water molecules at 
the same time point, and they appear like that because there are too many time points in 
each graph. The final graph in Figure 4-22 represents the time from the 240th to the 260th 
picoseconds of the simulation of compound 3l and was presented to clarify the continuity 
issue. 
The lack of water molecules in the 1st solvation shell is very obvious for compounds 1c and 
1e (1e not presented). For compounds 1a and 3j, it can be clearly seen that there were 
some water molecules (up to 2 in compound 1a and up to 4 in compound 3j) in the initial 
stages of the simulations and that these water molecules left the solvation shell after the 
barrier height and the formation of the SG-EC bond. In compound 3l, there were between 2 
and 4 water molecules in the solvation shell, up to 3 of them stayed within the shell even 
after the formation of the SG-EC bond. A visual inspection of the trajectory of 3l showed that 
these molecules were beneath the reaction centre, deep in the catalytic tunnel and they 
were physically trapped there for the entire simulation (Figure 4-23). They did not affect the 
simulation in terms of desolvation effect as can be seen from the free energy of the reaction 
that fitted well with respect to biological activity (Figure 4-8). 
In compound 3o, solvation shell shows that there was a water molecule close to SG after the 
formation of the bond with EC. It has been confirmed that it was a single molecule and not 
multiple molecules moving in and out of the shell, by measuring the distance between SG 
and the oxygen atom of the water molecule in question over the entire simulation (Figure 
4-24). This molecule was tightly bound even after the SG-EC bond formation which occurred 
relatively early in this simulation. A closer look at the trajectory showed the involvement of 
this water molecule in hydrogen bonds with CYS277 SG in addition to hydrogen bonds with 
the bridging tryptophan residues, TRP241 and TRP332 and backbone atoms of CYS277. 
Figure 4-25 represents the last frame in the trajectory and shows hydrogen bonds binding 
the water molecule to the active site. 
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Figure 4-22: Graphs of the number of water molecules in the 1st solvation shell, as a function of simulation time all for single-stage simulations.Graph for 1e was 
identical to that of 1c and was not presented. The final graph represents 20 ps only from the original graph of 3l. The black line represents the barrier height. 
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Figure 4-23: The 3 water 
molecules (coloured blue) 
that were trapped in the 1st 
solvation shell during the 
single-stage simulation of 
compound 3l, in a frame 
after the SG-EC bond has 
been formed. 
 
Figure 4-24: Distance 
between SG of CYS277 and 
the oxygen atom of the 
problematic water molecule 
during the single-stage 
simulation for compound 3o. 
 
Figure 4-25: Hydrogen bonds 
with water molecule in 
compound 3o single-stage 
simulation.
The RDF of compound 3o shows a similar probability at 2 and 3 Å because the problematic 
water molecule stayed in its relative starting position for the entire simulation and was 
moving in the range of 2-3 Å. The failure of compound 3o active site to desolvate completely 
prior to the reaction may be the reason for the very high PMF reading for the compound 
during the single-stage simulations. The probably false high PMF value for 3o could have 
resulted from the difficulty in driving the process to completion. Since SG-EC bond was 
formed early (Table 4-2), it can be assumed that the formation of the HD1-C2 bond was the 
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difficult part. The tightly bound molecule may have contributed to an increased rigidity of the 
3o-CYS277 adduct with the subsequent difficulty in the delivery of the proton to C2. If 
compound 3o was not included in the correlation made between the activation energies 
obtained from the single-stage simulations and biological activity (Figure 4-8), then the R2 
value for that correlation would jump to around 0.9 (Figure 4-26). 
High RDF values seen at 2 Å in Figure 4-21, which indicate higher probability for finding 
water molecules at this distance, may be explained by the fact that the bond between SG 
and EC was not formed until the later stages of the simulations. Therefore, as a function of 
the entire simulation, there is higher probability to finding a water molecule within 2 Å, but if 
only the later sections of the simulations were considered in RDF analysis, then no such 
high probabilities would have been produced. This has been confirmed once for compound 
3j where the RDF was calculated for the final section of the simulation, only considering the 
frames occurring immediately before the barrier height and those after them to the end of the 
simulation (Figure 4-27). The result showed no water molecules within 4 Å, to be followed by 
an RDF approaching unity and the normal water density. This behaviour of water following 
the formation of the bond can be compared to the RDF measured during covalent MD in 
section 3.7.2 (Figure 3-71). 
 
Figure 4-26: Correlation 
between biological activity 
as IC50 and AE for the 
acrylamide compounds, 
excluding compound 3o, 
during the single-stage PM3 
US simulations. 
 
Figure 4-27: RDF graphs for 
the simulation of compound 
3j, showing the probability 
calculated for the entire 
simulation and that 
calculated for the final part 
of the simulation after the 
barrier.
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4.1.2.3.2 Two-step simulations 
For the 2-step simulations, the solvation shell graphs for the compounds are presented in 
Figure 4-28. Again, there were no water molecules within 3.4 Å of SG in compound 1c entire 
simulation (not shown). For the other compounds, the desolvation effect was not very clear. 
In compounds 3l and 3o, the simulation started with more than one water molecule in the 
solvation shell but the number decreased to only 1 molecule towards the end of the 1st step, 
showing some desolvation. This was not seen in compounds 1a and 3j, in which the number 
of molecules has remained the same or even increased after the formation of the bond. A 
possible explanation could be that at the start, SG was negatively charged and was 
attracting the water molecules and when it was neutralised through the formation of the 
bond, some water molecules left; at the same time, the charge of both C2 and the carbonyl 
oxygen on the compounds was becoming more negative before the protonation, and this 
could supply another source for the attraction of water molecules. By the end of the 2nd step, 
the protonation is established and the number of water molecules declined. 
The simulation for compound 1e started with no water molecules in the solvation shell but 
after the formation of the bond, at around the 150th picoseconds, a water molecule appeared 
in the shell and stayed there for about 75 ps. Visual inspection and hydrogen bond analysis 
with VMD showed that it was a single water molecule arriving in the vicinity of SG and that 
this molecule was involved in a hydrogen bond with the carbonyl oxygen of compound 1e for 
43% of simulation time, which makes it relatively close to CYS277. When the water molecule 
appeared in the solvation shell it was because the carbonyl oxygen of the compound moved 
closer to CYS277 during the 2nd step of the umbrella sampling and dragged the water 
molecule along. The last graph in Figure 4-28 is for the frequency of the hydrogen bond 
between the water molecule and the carbonyl oxygen of compound 1e. 
In summary, water molecules did provide some desolvation effect during the single-stage 
simulations, and to some extent in the 2-step simulations. The better desolvation effect 
observed during the single-stage simulation could be attributed to the lack of a negative 
charge in the reaction centre with the formation of the 2 bonds at relatively the same time, 
and therefore, the lack of attraction for water molecules with the subsequent desolvation. 
Capoferri et al. (2015) studied a similar system, irreversible epidermal growth factor receptor 
(EGFR) inhibition with acrylamide-based inhibitors with an approach combining steered MD 
with US at the DFTB level of theory. The inhibitors also act by alkylating an active site 
cysteine residue (CYS797). The authors proposed a single stage concerted mechanism for 
the inhibition and identified desolvation of water molecules as a key event in the process. 
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Figure 4-28: Graphs of the number of water molecules in the 1st solvation shell for 2-step simulations, 3.4 Å around SG of CYS277 as a function of simulation time 
all.The black line marks the end of the 1st step. The last graph is for hydrogen bonds in compound 5 simulation. 
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Desolvation was relatively obvious in the single-stage simulations but those simulations 
could not explain the charges of the reaction centre, which was the main reason for applying 
the 2-stage simulations. In the latter, some tightly bound water molecules remained close to 
CYS277 during the entire simulations, and it was shown that such molecules were attracted 
by negative charges either of SG or those created on the system after the formation of the 
SG-EC bond. Hydrogen bonds with some active site residues also had their role for keeping 
some water molecules tightly bound within the active site. The charges of the atoms at the 
reaction centre, however, supported the hypothesis of 2 consecutive steps for the reaction. 
4.1.2.4 Choice or proton source 
It has been stated in the literature that there is a catalytic triad in TG2 consisting of CYS277, 
HIS335 and ASP358 (Pinkas et al. 2007; Iismaa et al. 2003). CYS277 is involved in the 
transamidation and deamidation reactions through the formation of a thio-ester bond with the 
amide group from a glutamine residue (Siegel & Khosla 2007). The role of the other two 
residues remains to be clarified. One possible contribution of HIS335 was suggested by 
Iismaa et al. (2003), which involves the interaction with CYS277 to form a thiolate-
imidazolium ion pair and both residues become charged. Protonated histidine is a well-
known proton donor in proteins (Liao et al. 2013). This and the fact that HIS335 is a 
constituent of TG2 catalytic triad were the main reasons behind using this residue as the 
proton donor to saturate the α carbon of the double bond (C2) on the acrylamide 
compounds. 
Lysine and arginine residues can act as proton donors, but in TG2 there are no lysine or 
arginine residues in the vicinity of the catalytic cysteine residue, where the protonation would 
occur. The proton from such a residue is at least 9 Å apart from C2 of the acrylamide and is 
positioned inappropriately, where supplying this proton would require folding the acrylamide 
compound and most probably would not allow for the formation of the SG-EC bond (Figure 
4-29). That would make HIS335 the best option available. The latter was not always very 
close to C2 but is positioned perfectly with respect to CYS277 to allow for the protonation 
without distorting the formed SG-EC bond. 
There were water molecules within the active site that may be closer than HIS335 to C2 of 
the acrylamide (Figure 4-29), as seen during the analysis of water behaviour. However, it 
was also confirmed that they were not uniformly distributed around the reaction centre 
between the compounds, and they were entirely missing in some cases (compounds 1c and 
1e). Therefore, a single and similar reaction coordinate that involves a water molecule is not 
easy to define, but remains a possibility, either as explicit source for the proton or as a 
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proton shuttle between one of the distant protonated residues and C2 of the acrylamide 
inhibitors. 
 
Figure 4-29: The closest 
arginine (ARG317) and lysine 
(LYS176) residues to C2 of 
the acrylamide within TG2 
active site for compound 1e. 
The figure labels C2 of the 
compound along with the 
distances between the 
potential protons and C2. 
For the inhibitors bearing sulfonium ion, a single-stage US mechanism was tried using a 
generalised distance coordinate as the difference between the bond to be formed (SG-EC), 
and the bond to be broken (EC-S+, the positively charged sulphur of the inhibitor) (D1-D2 in 
Figure 4-30), with PM3 and DFTB as the QM methods. The simulations managed to produce 
the appropriate products in which the bonds formed and broke correctly, but the associated 
PMF values gave an inverse trend when correlated to IC50 values; higher PMF values for the 
more active compounds. For that, the approach was not followed any further and the 
resultant data are not presented in this work. Instead, the reaction mechanism of sulfonium 
ion inhibitors was investigated with CAChe using the intrinsic reaction coordinate (IRC). 
 
Figure 4-30: The single-
stage mechanism for the 
inhibition of TG2 with 
sulfonium ion inhibitors 
that was investigated 
with US simulation, 
showing the distances 
involved in the selected 
RC. 
D1
D2
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4.2 CAChe Reaction Path Experiments 
4.2.1 Introduction 
4.2.1.1 CAChe reaction path 
The MOPAC 2000 (Molecular Orbital PACkage) (Stewart 2002) within CAChe (Fujitsu 
Limited 2006) was used to study reaction paths. Studies were performed using quantum 
mechanical methods by having a transition state structure (TS). A “map reaction” experiment 
could be performed to identify the TS. This type of experiment within CAChe uses a semi-
empirical method (such as AM1, PM3 or PM5) to minimise the system over a predefined 
reaction coordinate (RC) (a distance or an angle). The result is a potential energy surface 
(PES) for the system as a function of the change in RC. The minimum on the PES would 
correspond to a structure of the product and the nearest saddle point (hill) would represent 
the TS structure. 
Once the TS is found, the structure needs to be refined by a conjugate gradient energy 
minimisation. This is a minimisation algorithm that operates to ensure moving down the hill 
on the PES all the time. It does so by using information obtained from the previous 
minimisation step, so that reversed progress is avoided (Höltje & Folkers 2008). The 
minimisation is followed by a verification process, which is performed by calculating the 
vibrational frequencies of the molecule through a FORCE calculation (a method that 
calculates the force matrix of the system by calculating the 2nd derivative of energy as a 
function of atomic displacements, and uses the force matrix for predicting the vibrational 
frequencies). A true TS structure would have only one negative vibration corresponding to 
only one imaginary mode of vibration. This is the vibration along the reaction coordinate 
(CAChe-Group 2006; Stewart 2002). 
After the TS structure is verified, a “reaction path” experiment is applied. This is also a QM 
based method that explores the path from a TS structure to either reactants or products. The 
method utilises an intrinsic reaction coordinate (IRC) to calculate the path of the reaction 
(CAChe-Group 2006; Stewart 2002). The IRC is a minimum energy path using the steepest 
descent energy minimisation. The characteristic of this path is that it starts from a TS 
structure and moves towards either the reactants or the products, using mass-weighted 
Cartesian coordinates (Maeda et al. 2015). IRC was first proposed for the calculation of 
reaction paths by Fukui (1970). 
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The IRC reaction path method calculates the potential energy of the system along the IRC 
and annihilates the kinetic energy. The result is a collection of structures from reactants to 
products along the IRC with the potential energies of each. Typically, this would give a graph 
in which the energy starts at certain value (reactants) and increases along the IRC until 
reaching a maximum (TS) after which the energy drops and ends with a value that is lower 
than that of the reactant (Figure 4-31) (CAChe-Group 2006; Stewart 2002). This final value 
would correspond to the product. The difference between the energies of the reactant and 
the TS is the activation energy for that reaction; which, for our system, was hoped to 
correlate to the biological activity of the individual compounds. IRC is an established method 
for the calculation of the activation energy of chemical reactions (Ikuo & Ogawa 2014; 
Yoshimura et al. 2012; Baowei et al. 2007; Yang et al. 2003; Takai et al. 1998). 
 
Figure 4-31: A typical reaction path 
between reactants (R) and products 
(P) showing the activation energy. 
In CAChe, the method is inapplicable to large systems, and there is no functionality for 
splitting the system into QM and MM regions. As such, these experiments were applied to 
smaller systems including the ligand and CYS277. The compound set involved the active 
inhibitors bearing the sulfonium ion warhead. The compromise of not including the entire 
system was made because US simulations failed to produce informative correlations when 
applied to the sulfonium ion inhibitors. 
4.2.1.2 Starting structures 
Table 4-6 shows the sources of the starting structures for each of the compounds. The table 
also shows whether the structure has been minimised or not. If minimisation was performed, 
then it would have involved only the compound and CYS277 while everything else in the 
system was constrained with CAChe locking function which freezes the coordinates of the 
locked atoms. The procedure used for the minimisation is MM2 (Allinger 1977) and was 
performed within CAChe. For the compounds whose starting structures were not minimised, 
this was because the minimised structures did not give valid map files from which to extract 
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the TS structure. It should be noted, however, that minimisation and MD must have been 
applied at one stage in acquiring these starting structures (Chapter 3). 
Compound Source of starting structure Minimisation IC50 (µM) 
1b Frame at 98.895 ns of the 275 ns MD run Yes 0.277 
1d Docking complex of 1d in 245ns model Yes 0.7 
1f 
Frame at 4.225 ns of the 5-ns MD on 1f 
in 95ns model 
No 0.38 
3b Docking complex of 3b in 95ns model Yes 0.89 
3c 
Frame at 1.775 ns of the 5 ns MD run on 
3c in 90ns model 
Yes 1.4 
3h Docking complex of 3h in 90ns model No 1.07 
3m Docking complex of 3m in 155ns model Yes 1.5 
3n 
Frame at 4.925 ns of the 5-ns MD on 3n 
in 100ns model 
Yes 0.775 
Table 4-6: Source of the starting structures of sulfonium ion compounds. Their structures have been 
presented in Table 3-1 (p86) and Table 3-12 (p125). 
After the minimisation step (or the non-minimisation), all TG2 residues were deleted with the 
exception of CYS277, leaving just the reaction centre consisting of the inhibitor with the 
sulfonium ion and the nucleophilic active site cysteine residue. Therefore, the starting 
structures used for the reaction path experiments by CAChe had the effect of the presence 
of TG2 in the sense that the initial conformation of the compounds was a one produced 
within the enzyme. A conformation taken from a MD trajectory was preferred but if this did 
not produce a reasonable PES from which to extract a TS, then a docking complex has been 
used. The starting structures were chosen as having the shortest distance between EC of 
the ligand and SG of CYS277. 
4.2.2 Results and Discussion 
The results of the experiments on compound 1b will be presented in detail while the results 
for the other compounds will be summarised. As mentioned in the methods, two reaction 
coordinates were used to generate the potential energy surface for the system; the distance 
between SG and EC, and the angle between SG, EC and the positively charged sulphur of 
the ligands (S+) (section 2.2.2.2.1). The distance of the bond to be formed (SG-EC) has 
been tried as a reaction coordinate on its own but failed to produce informative results, and 
the same applies for the two bonds to be formed and broken (SG-EC and EC-S+) (details 
are presented later in this chapter). For compound 1b, the distance and angle values in the 
starting structure after minimisation were 4.225 Å and 88.1° respectively. The generated 
map file had 441 structures. Figure 4-32 shows a graph for the energies of these structures 
as functions of the reaction coordinates (PES). 
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The structure of the minimum (the lowest energy conformation on the PES) had values of 
1.645 Å and 125° for the reaction coordinates (the Minimum in Figure 4-32) and an energy 
value of -195.133 kcal/mole. The chosen TS structure had the same value for the angle as 
the minimum but the distance was 1.80 Å and the energy -113 kcal/mole. The TS structure 
should ideally be the maximum on the potential energy surface during the movement from 
the reactants to the products. However, since the distance of the bond that is supposed to 
be formed was allowed to change from its original value to 1 Å, the highest energy 
conformation was not realistic as the distance between the two atoms forming the bond was 
very short. 
 
Figure 4-32: PES produced from map experiment on 1b with the minimum and TS. Black axis is distance 
(Å), red is angle (degrees) and blue is energy (kcal/mole). 
The chosen TS structure was refined with PM3. The refinement process produced a TS 
structure with values of 2.36 Å and 150° for the distance and angle coordinates respectively. 
In this process, the energy of the refined TS dropped to -156 kcal/mole (Figure 4-33). This 
refined TS was verified by a FORCE calculation to give only one negative vibration (Figure 
4-34) indicating a true transition state. 
When the verified TS was used as a starting point for the “reaction path” experiment, a 
typical reaction path was produced (Figure 4-35). This represents the IRC values for the 
conversion from reactants to products and going through the TS. The energy of the reactant 
was higher than that of the product but the energy of TS was the highest. The potential 
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energies of the reactant, the transition state and the product were -190.5, -156 and -214.3 
kcal/mole respectively. The TS structure from the reaction path experiment had the same 
values for the energy, distance and angle as the TS obtained previously from the map 
reaction experiment after being refined. 
 
Figure 4-33: Left: TS structure before 
refinement. Right: TS structure after 
PM3 refinement.  The dotted line is used 
by CAChe to represent weak bonds. 
 
Figure 4-34: IR spectrum of 
refined TS showing ONE 
negative vibration (red).
 
Figure 4-35: reaction path for 1b starting from reactants (left) to products (right). 
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The first set of experiments (map reaction, TS refinement and verification and reaction path) 
was then applied to the rest of the compounds and their results are presented in Table 4-7. 
The presented results include the values of the reaction coordinates in the TS structure for 
each compound along with the activation energy values. All the energy values have been 
obtained from “reaction path” experiments on TS structures that were verified by showing 
only one negative vibration in the FORCE calculation. 
Compound 
TS Coordinates Energy (kcal/mol) 
Distance (Å) Angle (°) 
TS Reactant Activation 
Start End Start End 
1d 4.99 2.33 75.7 151 -123.10 -151.18 -28.07 
1f 5.64 2.31 45.6 151 -75.70 -109.57 -33.87 
3b 4.92 2.28 67 146 -126.00 -152.82 -26.82 
3c 5.65 2.32 43 143 -117.92 -146.68 -28.76 
3h 3.68 2.34 104.4 145 -98.32 -120.14 -21.81 
3m 5.67 2.35 104.7 147 -181.76 -204.81 -23.05 
3n 4.9 2.29 81.5 148 -173.63 -202.56 -28.94 
Table 4-7: Reaction coordinates and energy values for the remaining 7 compounds. 
It can be seen from the table that the values for the reaction coordinates are very similar 
between the different compounds. This indicates that the transition state that precedes the 
formation of the product would have these values for the coordinates if the warhead was an 
electrophilic carbon attached to a sulfonium ion being attacked by a nucleophilic thiolate ion 
of a cysteine residue. It can also be deduced from the table that the structure of the 
transition state around the reacting centre is not affected by the structure of the rest of the 
ligand molecule. In addition, it can be seen that despite the wide range of the starting values 
for the angle coordinate (43-104.7°), all the TS structures had values for this coordinate in a 
range of less than 8 degrees (143.6-151°). This implies that the nucleophile and electrophile 
should get into a semi-straight line before the reaction could occur. 
The charges of the 2 sulphur atoms and the orders of the bonds to be formed and broken in 
the TS structures are donated in Table 4-8. It is evident from the table that all the ligands 
followed a similar path during reaction in terms of the charges and bond orders. Other 
quantities that were found to be very similar in all TS structures were the distance between 
SG and S+ which ranged between 4.1 and 4.2 Å and the length of the bond to be broken 
which ranged between 1.98 and 2.08 Å (Figure 4-36). 
From the information presented so far, a proposed mechanism for the reaction of inhibitors 
having sulfonium ion warheads with the positively charged sulphur of the active site cysteine 
residue of TG2 may be drawn. Such a mechanism would involve the approach of SG to S+ 
accompanied by an increase in the charge of the first and a reduction in the charge of the 
latter. At the TS, an almost isosceles triangle is formed; at its sides are the bonds to be 
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formed and broken and the base is the distance between the 2 sulphur atoms (SG and S+). 
This is followed by the neutralisation of the charges of both sulphur atoms accompanied by 
the breaking of a bond (EC-S+) and the formation of a new bond (SG-EC) (Figure 4-37). 
Compound 
Partial Charge 
TS Bond order 
Reactant TS Product 
SG S+ SG S+ SG S+ Broken Formed 
1b -0.88 0.75 -0.57 0.33 0.02 -0.02 0.53 0.38 
1d -0.69 0.71 -0.61 0.33 -0.01 -0.03 0.54 0.37 
1f -0.84 0.67 -0.59 0.32 0.00 -0.01 0.51 0.39 
3b -0.89 0.72 -0.57 0.27 -0.02 -0.01 0.47 0.43 
3c -0.89 0.69 -0.55 0.31 -0.02 0.02 0.53 0.39 
3h -0.86 0.67 -0.55 0.33 0.00 0.04 0.53 0.38 
3m -0.73 0.69 -0.57 0.33 -0.01 0.02 0.55 0.37 
3n -0.82 0.65 -0.56 0.30 -0.01 -0.03 0.51 0.39 
Table 4-8: Charges and bond orders. 
 
Figure 4-36: Distance between SG and S+ and of the bond to be broken in the 8 TSs. 
These features are consistent with an SN2 reaction mechanism, where the nucleophile (SG) 
attacks the electrophile (EC) from the opposite side of the leaving group (S+), and at the 
transition state, the three reacting groups are in a straight line with an angle of 180° (Smith & 
March 2001). The range of angles seen in Table 4-7 for the transition states of the 
compounds, although very similar, does not reflect straight lines. However, angle values and 
the way they changed from their starting standards provide evidence that the system 
attempted to render the attack of SG from the opposite side of S+. The non-180° values for 
the angles may be explained by the attraction forces between the oppositely charged 
sulphur atoms (S+ from the sulfonium ion and S- from CYS277 thiolate ion) involved in the 
reaction, causing the two sulphur atoms to try to come close to each other with a resultant 
bending in the angle to the values reported in the table. 
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Figure 4-37: Mechanism of the reaction including the change in charges and reaction coordinates 
between reactants, TS and products. 
The bond orders of the TS structures reported in Table 4-8 are also consistent with SN2 
mechanism, where such a mechanism would involve the change in the hybridization of the 
electrophilic carbon from sp3 to sp2 at the transition state with a p orbital that is shared by the 
nucleophile and the leaving group (Smith & March 2001). This would result in partially 
formed bond with the nucleophile and a partially broken bond with the leaving group. the 
bond orders shown in the table indicate that the 2 bonds are weaker than a single bond, 
confirming a TS structure of an SN2 mechanism. 
One last characteristic of an SN2 mechanism is that the three non-reacting atoms attached to 
the electrophilic carbon are nearly coplanar at the transition state to increase the chances of 
overlap between the segments of the p orbital of the electrophilic carbon with the nucleophile 
and the leaving group (Smith & March 2001). Figure 4-38 represents a different view for the 
TS of compound 1b, and it shows EC with its 3 connected atoms. All the 4 atoms appear to 
be on approximately the same plane in space, again confirming the SN2 mechanism. 
The values for the activation energy for the compounds were plotted against their IC50 
values; and a near straight line was obtained. The R2 value for the line was 0.61 (Figure 
4-39). If compounds 3c and 3m were removed from the curve, the R2 value would rise to 
0.95 (Figure 4-40). This implies that the method works best in predicting the biological 
activity if the IC50 was equal to or less than 1 µM. 
 
Reactant TS Product
CHARGES
S+ SG S+ SG S+ SG
+0.75 -0.88 +0.33 -0.57 -0.02 +0.02
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Figure 4-38: TS structure for compound 1b in the 
stick form, showing EC and the three non-
reacting atoms attached to it in the ball form to 
confirm the coplanar geometry they adopt in 
accordance with SN2 mechanism. 
 
Figure 4-39: IC50 values for the 8 compounds versus their activation energies. IC50 values are given in 
Table 4-6. 
 
Figure 4-40: Correlation with biological activity for compounds with IC50 of 1 µM or less. 
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The same protocol was also attempted on two inactive compounds (2c and 4c). In both 
cases, a reasonable PES was obtained but proper TS could not be extracted. Multiple 
conformations were taken from the PES and refined to produce TSs with acceptable 
structures in terms of the distances and the angle but they could not be verified as true 
transition states, where there always was more than one negative vibration. Most probably, 
this was due to the fact that the resultant TS structures had high energy values, in the range 
of -70 to -85 kcal/mol. 
A single label for the distance of the bond to be formed has been tried as a reaction 
coordinate for compound 1b in the map reaction experiment and a TS structure was 
extracted from the resultant PES (Figure 4-41A). The TS was refined and verified to give one 
negative vibration but it could not produce a reasonable reaction path graph (Figure 4-41B) 
and hence no relevant structures for the product or the TS could be obtained. The distances 
for the two bonds to be formed and broken have also been tried as separate reaction 
coordinates in CAChe but the PES graph from the map reaction experiment was not 
meaningful; no reasonable TS structure could be extracted. This happens because the 
breakage of the EC-S+ bond cannot be controlled by a reaction coordinate, and it takes 
place immediately and suddenly after the SG-EC bond is formally created. The two failed 
experiments with the bond to be formed on its own and the two bonds separately were the 
justification for the use of the angle with the distance as the initial reaction coordinates. 
  
Figure 4-41: PES (A) and reaction path (B) graphs for compound 1b when using 1 label as the reaction 
coordinate. 
The IRC values in the reaction path graph shown in Figure 4-35 should not be interpreted as 
any of the original coordinates used in the beginning for the generation of the initial PES. 
The IRC represents the movements of all the atom in the system in angstroms in their path 
starting from the transition state and going to the reactants and to the products (Stewart 
2002). 
It has been shown during the course of this work that the structure of the transition state for 
the reaction of the inhibition of TG2 with compounds containing sulfonium ion is the same in 
-250
-200
-150
-100
-50
0
50
100
150
1 2 3 4 5
En
e
rg
y 
(k
ca
l/
m
o
l)
Distance RC (Å)
-188
-186
-184
-182
-180
-178
-176
-174
-172
0 10 20 30 40 50
En
e
rg
y 
(k
ca
l/
m
o
l)
IRC (Å)
TS 
A B 
Chapter 4   Quantum Mechanical Experiments 
 
214 
 
the area of the reaction and is not affected by the remaining structure of the ligand. Despite 
this observation, the method used was able to produce activation energies that could be 
correlated to biological activity. This implies that the conformation of the ligand in the starting 
structure was the factor that made the difference and this conformation is related to the 
structure of the entire ligand justifying the good correlation with biological activity. Such an 
outcome would compensate for not including the entire system in the calculations. 
4.3 Conclusions 
Quantum mechanical methods are important for modelling inhibitors whose activity involves 
the formation and breakage of covalent bonds. Umbrella sampling simulations combined 
with quantum mechanical treatment of the reaction centre were able to simulate the reaction 
between inhibitors carrying the acrylamide warhead and TG2 active site cysteine residue 
using HIS335 as a source for the proton required to saturate the alpha carbon of the 
acrylamide double bond. The reaction was simulated as a single concerted stage with PM3 
level of theory and as 2 successive steps with DFTB as the QM method. The 2 mechanisms 
produced reasonable correlations with biological activities for the compounds and had 
supporting evidence. The single-stage simulations, for example, showed a more obvious 
desolvation effect happening near the formation of the bonds, when one or more water 
molecules left the active site. The charge distribution around the reaction centre, during the 
2-stage simulations, was more consistent with the reaction proceeding as 2 separate 
consecutive stages, with the formation of an oxyanion intermediate at the end of the 1st 
stage. It can therefore be concluded that the studied reaction may proceed with either 
mechanism depending on the available evidence to support one of them. 
Reaction path experiments using CAChe were able to generate typical reaction graphs for 
the transition from reactants to products and going through the transition state for inhibitors 
bearing the sulfonium ion warhead. The fact that the structures of the transition states from 
the 8 compounds were similar around the reaction centre gives these structures reliability in 
predicting the mechanism of the reaction. The latter would involve the formation of an 
isosceles triangle; at its base are SG and S+ prior to the dissociation of the sulfonium ion 
and the covalent inhibition of TG2. An SN2 reaction mechanism was proposed, and evidence 
for such mechanism in this reaction system was presented, in the form of the angles at the 
transition states, the orders for the bonds to be formed and broken and the plane involving 
the electrophilic carbon and the three atoms attached to it.  The activation energies obtained 
and their good correlation with the biological activity further validate the method. 
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5 Allosteric Inhibition of TG2 
This chapter covers the computational work that was performed with respect to the allosteric 
inhibition of TG2. This involved docking experiments using proposed allosteric inhibitors, 
followed by MD simulations on the docked complexes. Accelerated MD was applied instead 
of conventional MD, because the change in TG2 that was expected from the binding of the 
allosteric inhibitors was supposed to involve the folding of a large portion of TG2, and such 
change is unlikely to be sampled using conventional MD. 
5.1 Introduction 
As mentioned in the general introduction (sections 1.2.2 and 1.2.3), TG2 is normally inactive 
by binding to GTP or GDP. The binding of these molecules induces a conformational change 
that involves the folding of the two C-terminal β-barrels onto the catalytic core, causing the 
unavailability of CYS277 for catalysis (closed, inactive TG2 conformation). Those natural 
regulators dissociate from TG2 in conditions associated with high calcium ion 
concentrations, with unfolding of the TG2 and the exposing of CYS277 for catalysis (open, 
active TG2 conformation) (Figure 1-2) (Jang et al. 2014; Liu et al. 2002; Pinkas et al. 2007). 
The work in this chapter aimed at examining the effects of the binding of 2 proposed 
allosteric TG2 inhibitors on the TG2 open conformation, and whether this binding can induce 
the closure of the TG2 structure. This was achieved by docking the inhibitors into a predicted 
TG2 allosteric site and applying accelerated MD on the resultant complexes. 
The 2 allosteric inhibitors used in this work were compound i3 by Case & Stein (2007), which 
was proposed by the authors to bind to an allosteric site in TG2, and compound i2 by Pardin, 
Roy et al. (2008) which was proven to be allosteric by Caron et al. (2012) (Figure 5-1) 
(section 1.4.1.2). The research associated with both compounds could not prove that the 
allosteric inhibitors would bind to the same site as GTP/GDP. 
 
Figure 5-1: Compounds i3 (left) and i2 (right) which were used as allosteric inhibitors. 
The GDP binding site is located in the cleft between the catalytic core and the first β-barrel. 
In the open conformation, these two regions are distinctly separate. In the crystal structure 
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1KV3 (Liu et al. 2002), in which TG2 is in closed conformation and complexed with GDP, 
there are 31 TG2 residues within 8 Å of the GDP molecule. Of these, 7 residues are on the 
catalytic core domain of TG2 while the remaining 24 residues are on the 1st β-barrel. In the 
open conformation of TG2 (2Q3Z), the 7 residues of the catalytic core are located on a 
distant region on TG2 from the 24 residues on the β-barrel (Figure 5-2). Furthermore, the 
largest section of GDP binding site from the 1st β-barrel is located on the surface of TG2. 
Consequently, it would be difficult to define a binding site for allosteric inhibitors in the open 
form of TG2 using the binding site definition from GDP-bound closed structures. 
 
Figure 5-2: TG2 closed, inactive (top) and open, active (bottom) conformations, showing the residues that 
are within 8 Å of GDP in the closed conformation (coloured yellow and red). Yellow residues are those on 
the catalytic core while red residues are those on the 1st β-barrel. 
Since it is the open form of TG2 that requires inhibition, it may be more appropriate to use a 
binding site for allosteric inhibitors that could be defined properly in the open conformation. 
This hypothesis was strengthened by the fact that no published research for allosteric 
inhibitors, to our knowledge, proved the binding site for the inhibitors to be the same as that 
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for GTP or GDP nor suggested an alternative binding site for allosteric inhibitors. Therefore, 
an approach has been employed to predict an alternative binding site for allosteric inhibitors. 
A collaboration was initiated with Dr Blair Johnston and his PhD student Antony Vassileiou 
from the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of 
Strathclyde. They developed a computational tool for the prediction of allosteric binding sites 
in proteins. Their approach involves performing analysis on MD trajectories of the studied 
proteins; the analysis comprises residue fluctuation, accessible surface area, energy 
correlation and simple intra-sequence differences (SID). SID (Pritchard et al. 2003) is a 
bioinformatics tool built to help understand the topology of protein folding. The collaborators 
used their protocol on a training set of 40 proteins with known allosteric sites from the 
Protein Data Bank and the protocol was able to predict the allosteric site correctly in the 
majority of cases. They presented their work as a poster in the MGMS (Molecular Graphics 
and Modelling Society) Meeting in August 2014 in the University of Strathclyde. The meeting 
was held between 20th and 22nd of August, 2014 under the name Modelling Molecules and 
Materials – M3 (http://www.m3glasgow.org.uk/). 
5.2 Methods 
5.2.1 Prediction of the allosteric binding site 
A MD trajectory of the open conformation of TG2 was sent to the collaborators in the 
University of Strathclyde for the prediction of the alternative binding site of allosteric 
inhibitors. The MD trajectory comprised a run that was applied starting from the 2Q3Z 
(Pinkas et al. 2007) crystal structure after adding and minimising the missing residues, but 
this time without removing any residues from TG2; the whole protein was used. Similar 
settings to those described in section 2.2.1.1 (MD simulation on empty TG2) were used 
here; minimisation followed by heating, equilibration and finally production. The MD 
simulation was run for a total of 252.075 ns. This MD simulation was performed by Dr Dan 
Rathbone of the School of Life and Health Sciences in Aston University, using the servers 
whose details were mentioned in section 2.1.1. 
The prediction protocol found a binding site composed of 10 residues and was located in a 
pocket surrounded by 3 helices at the end of the catalytic core domain of TG2. Before it was 
used in docking, residues were added at the beginning, middle and end of the segments of 
the predicted site to raise the number of residues involved to 27 (Figure 5-3). 
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Figure 5-3: The predicted allosteric binding site by the Strathclyde protocol (top) versus the site used for 
docking purposes (bottom) after adding residues between the segments, both coloured yellow. GDP 
binding site is shown in red for comparison of the location of the 2 sites. 
5.2.2 Docking 
The GOLD program was used to run the docking experiments of compounds i3 and i2. The 
TG2 structure used as the model for docking was the last frame from the conventional 
252.075-ns MD run described previously. Similar settings to those used in the original 
dockings were used here, including the use of GoldScore as the primary scoring function 
and rescoring each pose with CHEMPLP. Early termination was turned off and 20 poses 
were generated for each of the 2 ligands. Ten residues from the core of the predicted site 
were chosen to be treated flexibly using the library option in GOLD. Default docking speed 
was used. The 27 residues from the predicted site used to define the binding site were 
(flexible residues are in bold): ARG377 ALA378 ILE379 LYS380 GLU381 PRO391 PHE392 
VAL393 PHE394 ALA395 GLU396 VAL397 ASN398 ALA399 THR442 TYR443 LYS444 
TYR445 PRO446 GLU451 GLU452 ARG453 GLU454 ALA455 PHE456 THR457 LEU462. 
5.2.3 Molecular dynamics 
Molecular dynamics was applied on the last frame from the 252.075-ns conventional MD 
without any ligands. Two docking complexes for compounds i3 and i2 in the predicted 
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allosteric site have also been subjected to MD. The aim was to examine whether the 
presence of the ligand in the predicted site would induce the closing of TG2 conformation 
into the inactive form. Since this involves a large conformational change, accelerated MD 
(aMD) was used at this stage. 
aMD was applied according to the procedure developed by Pierce et al. (2012). The systems 
were loaded into LEaP program for the preparation of the parameter and topology files after 
solvating with 8-Å octahedron of TIP3P water molecules. The systems were then minimised, 
heated and equilibrated using the same settings used previously and described in detail in 
section 2.2.1.1. The restart file from the equilibration stage was used as the starting structure 
for the aMD run. The aMD runs used the same settings used for the production runs 
previously in conventional MD with the addition of the “iamd” term which triggers aMD. The 
whole potential of the system was boosted with an additional boost for the torsions (iamd=3). 
The average potential energy obtained at the end of the equilibration phase was used to 
define the total boost (average potential energy + (0.16 kcal/mol.atom * number of atoms)) 
and the average dihedral energy was used to define the torsion boost (average dihedral 
energy + (4 kcal/mol.residue * number of the solute residues)). aMD was run over 30-ns 
trajectories to a total of 36 trajectories with a simulation time of just over 1 microsecond 
(unless otherwise specified). 
In addition to empty TG2 and the two docking complexes, 3 supplementary systems were 
subjected to aMD. These extra systems consisted of TG2 in its open form (the same 
structure used for the docking of the 2 allosteric inhibitors) around which 24 copies of each 
of the 2 allosteric inhibitors and GDP were placed at a distance of at least 7 Å from the 
protein surface. These copies were added manually using Accelrys DS Visualizer v4.0 
(Accelrys Software Incorporation 2013). Figure 5-4 shows the starting structures for these 
runs for compounds i3 and i2. 
Different analyses were performed on the resulting trajectories; mainly the RMSD and 
atomic fluctuations were measured using CPPTRAJ (Roe & Cheatham 2013), where the first 
frame of the production phase was always used as a reference and the calculations involved 
backbone atoms of TG2 residues only. Principal component analysis was also applied on 
some of the resultant trajectories. 
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Figure 5-4: The starting structures for the aMD simulations on TG2 surrounded by 24 copies of i3 (left) 
and i2 (right). 
5.2.4 Principal component analysis 
PCA was performed using the program pyPcazip (Shkurti et al. 2016). The trajectories were 
stripped of water and combined in a single trajectory for each individual simulation. The 
single trajectory was then treated with pyPcazip to calculate the principal components. 
Unless otherwise indicated, the top 2 components were considered. The program was also 
used to generate moving trajectories consisting of 20 frames each, to represent the motion 
in the protein represented by any principal component. The projections of each of the 
produced components can also be calculated by the program as a function of time. All PCA 
calculation were performed using only the alpha carbon atoms of TG2 residues. 
5.3 Results and Discussion 
5.3.1 Predicted allosteric binding site 
According to Jang et al. (2014), the catalytic core in TG2 ends with residue ASN460, and the 
1st β-barrel starts with residue GLY472. The 2 domains are connected by a strand composed 
of 11 residues, at its end the 2 C-terminal barrels fold on the catalytic core in the closed 
conformation of TG2. As shown in Figure 5-3, the location of the predicted allosteric binding 
site at the end of the catalytic core seems reasonable to handle the job of triggering the 
folding of TG2, since it is positioned just before the folding segments. GDP binds in a site 
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located at the beginning of the 1st barrel, just after the folding segment (Figure 5-5). 
Therefore, in theory, the predicted site is as close to the location of the folding event as the 
GDP binding site, and may have the potential to serve a similar function. 
 
Figure 5-5: TG2 in open conformation, showing the predicted allosteric binding site (yellow), the folding 
segment (green) and GDP binding site on the 1st β-barrel (red). 
To further confirm the prediction, the prediction protocol from the Strathclyde group was 
additionally applied on a 100-ns MD trajectory of TG2 in the closed conformation [PDB 1KV3 
(Liu et al. 2002), conventional MD run performed with the same settings used previously]. 
The aim was to examine the difference in prediction with the starting conformation of TG2. In 
this case, the predicted site was located in the N-terminal β-sandwich, far away from the 
catalytic core, the portion of TG2 that will close on the active site and the GDP binding site. 
This new site has been discarded and the one obtained from the open form of TG2 was 
used. The main evidence was based on proximity measures; the 1st predicted site was in the 
form of a pocket and was located just before the folding segments. The new predicted site, 
in addition, was on two separate regions separated by a wrapped sheet, indicating that it 
would be difficult to define a binding site (Figure 5-6). 
 
Figure 5-6: Closed 
conformation of TG2 
showing the binding site 
predicted from the 
trajectory of closed TG2 
(red) versus the original 
prediction (yellow) and 
showing GDP in its 
binding site. 
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5.3.2 Docking results 
Since the binding site used in these experiments is novel, there is no experimental or 
computational pose that could be used as a reference for an appropriate docking pose. 
Visual inspection was, thus, used to judge the 20 poses generated by GOLD, in addition to 
GoldScore ranking. One pose was selected for each compound, in which the compounds 
were more deeply embedded within the predicted allosteric site than the remaining solutions. 
Furthermore, the poses for the 2 compounds were ranked 2nd in GoldScore out of 20 
solutions. In each pose, there was a network of interactions holding the compound in place, 
mainly in the form of Pi interactions (Figure 5-7). Therefore, even though there was nothing 
to compare to, these poses were deemed to be appropriate and were considered for aMD 
simulations to test whether the presence of allosteric inhibitors in this binding site would 
trigger the conformational change brought about by the binding of GTP and GDP. 
5.3.3 Results of accelerated MD 
aMD is an enhanced sampling technique that enables the exploration of rare events which 
require passing high-energy barriers on the energy surface of the system, and the technique 
works by adding a boosting potential to the system when the energy falls below a predefined 
value (section 1.5.2.3.4) (Miao et al. 2014). It has been used to capture biomolecular events 
that involve relatively significant conformational changes such as the activation of the M2 
muscarinic receptor, a G-protein coupled receptor (GPCR) that regulates heart rate, through 
the relocation of some residues and a tilting event involving one of the alpha helices of the 
protein (Miao et al. 2013). aMD has also been used specifically to investigate allosteric 
inhibition, one example involved interleukin-1 receptor (IL-1R) allosteric inhibitors in terms of 
binding sites within IL-1R as well as the conformational changes brought about by the 
binding (Yang 2015). 
As mentioned in the ‘Methods’ section, aMD was applied on 2 docking complexes for i2 and 
i3, on empty TG2 in the open form and on open TG2 surrounded by 24 copies of the 2 
allosteric inhibitors and GDP. The results of these simulations will be presented individually. 
5.3.3.1 aMD on empty TG2 (Run 1) 
This aMD run was performed as a control for the other runs, to assess the behaviour of TG2 
in an aMD simulation with the absence of any ligand anywhere in the protein. Run 1 was 
allowed to proceed for 1,000 ns (1 µs). At the end, there was some kind of motion that 
involved the hinge region connecting the terminal β-barrel to the rest of TG2. The terminal 
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barrel showed the highest degree of fluctuation compared to other regions of TG2, and this 
is more clearly seen with the atomic fluctuations of the individual residues (Figure 5-8). 
 
Figure 5-7: Docking complexes for compounds i3 and i2 in the predicted allosteric site of TG2. At the top 
are the poses within the predicted site which is coloured red while the rest of the protein is dark green. 
At the bottom are the interactions of each compound with residues in the predicted site. Green dotted 
lines are hydrogen bonds, light purple lines are Pi-alkyl interactions, dark purple lines are Pi-Pi 
interactions, orange lines are Pi-ion interactions. 
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The fluctuation of the terminal barrel produced bending in TG2 structure. The bending was 
mainly to the outside of TG2 structure and not towards the catalytic core, although some 
degree of bending to the inside was also observed. A better appreciation for the type of 
bending in the terminal barrel during Run 1 can be obtained by analysing the PCs of the run. 
When the trajectory of Run 1 was analysed with pyPcazip, ten principal components were 
produced. The 1st PC accounted for 72% of all the motion in TG2, while the 2nd and 3rd 
highest PCs contributed only 15%. Those PCs are shown in the graph presented in Figure 
5-9. 
 
Figure 5-8: Atomic 
fluctuation values for TG2 
residues during Run 1. 
 
Figure 5-9: PCs obtained by 
pyPcazip for the trajectory of 
Run 1. 
The animation produced for pyPcazip for the 1st PC is presented in Figure 5-10 and shows 
that the motion to the side was of a similar magnitude to the motion towards the catalytic 
core. This indicates that it may be difficult for TG2 to achieve the full bending required for the 
closure of the conformation with the subsequent inactivation of the enzyme. In any case, the 
bending event was not observed until more than half of the simulation was done. This was 
confirmed by visual inspection of the trajectory as well as by measuring the RMSD for TG2 
backbone atoms for Run 1 (Figure 5-11). It was found that the 2nd β-barrel was oscillating 
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from the start of the simulation but the bending was not evident and permanent until around 
560 ns of simulation time. 
 
Figure 5-10: Animation of PC1 for Run 1 shown as a side view of TG2 (top) to view the bending towards 
that catalytic core and a back view (bottom) to view the bending to the sides. 
 
Figure 5-11: RMSD for TG2 
backbone atoms during Run 
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5.3.3.2 aMD on TG2 with 24 copies of GDP (Run 2) 
This aMD simulation involved the same TG2 open conformation used as the basis for the 
allosteric work surrounded by 24 copies of GDP. The rationale was to see whether one of 
the GDP molecules would find its way to the original allosteric binding site, and if a copy did, 
will it be able to induce the closure of TG2 conformation? A docking complex was not 
considered a possibility since it is difficult to define a binding site that is located on the 
surface of the protein, which is the case with GDP binding site when TG2 is in the open 
conformation. The simulation was allowed to run for a total of 635 ns of simulation time. In 
the simulation, again, it was the 2nd β-barrel that showed the greatest amount of atomic 
fluctuation as manifested by the RMSF values presented in Figure 5-12. 
 
Figure 5-12: Atomic 
fluctuation values for TG2 
residues during Run 2, when 
TG2 was surrounded by 24 
copies of GDP, and those 
from Run 1 (empty TG2). 
Visual inspection of the trajectory revealed that there was a considerable oscillation involving 
the terminal barrel at the start of the simulation, which did not result in any noticeable 
bending in the TG2 structure. Towards the end of the simulation, at ≈ 530 ns, a significant 
change in the conformation of TG2 was starting to develop. The change was manifested as 
a bending event that involved the hinge region connecting the two C-terminal β-barrels to 
TG2. There was not any noticeable change in the 2nd barrel with reference to the 1st. By the 
end of the simulation, the TG2 open conformation was transformed into a structure in which 
the two terminal barrels were straight with reference to each other and almost on a right 
angle with respect to the catalytic core and the N-terminal β-sandwich. A comparison 
between the structure at the start and the end of Run 2 is given in Figure 5-13, showing a 
clearer representation of the bending. 
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Figure 5-13: A comparison of 
TG2 structure at the end 
(blue and yellow) and start 
(red) of Run 2. The last two 
barrels are coloured yellow 
while the remainder of TG2 
is blue in the “end” 
structure. CYS277 is shown 
as space filling to appreciate 
the direction of bending. 
The RMSD of TG2 during Run 2 is given in Figure 5-14, and it can be used to explain the 
events that signified this run. In the first 100 ns there was a considerable oscillation that 
involved the 2nd barrel and resulted in high RMSD values for TG2 during this time. This was 
followed by a rather stable run for the next 400 ns. The bending event that resulted in the L-
shaped TG2 structure was not very clear on the RMSD graph, perhaps because it happened 
very smoothly. This was the rationale for measuring the RMSD for the terminal barrels only, 
which is also presented in the same graph. This graph more clearly shows the bending event 
which started at around 530 ns and continued until the simulation was stopped. 
 
Figure 5-14: RMSD for TG2 in Run 2, compared to that of the 2 terminal β-barrels during the same run. 
With regard to the behaviour of GDP copies, it was noted that 18 out of the 24 copies 
wandered around TG2 structure during the entire simulation, and that only six copies 
managed to settle themselves within different distinct regions of TG2 structure and remain in 
their spots for relatively long durations of time. No important positions were taken by the 6 
copies; the predicted allosteric site and the actual active site of TG2 did not attract any copy. 
The exception, however, was the original GDP binding site, to which one of the 24 copies of 
GDP was attracted (Figure 5-15). 
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Figure 5-15: The six GDP copies (in 
the stick form) that settled within 
distinct TG2 locations in Run 2. The 
predicted and original allosteric 
sites are shown in yellow and red 
respectively for reference, in 
addition to CYS277 (space filling). 
 
The copy of GDP within the GDP binding site started to settle in the area at around 400 ns, 
and since this was the only important event related to the movement of the copies, it can be 
assumed that the event ultimately led to the bending of TG2 structure from the middle. There 
were 14 TG2 residues lying within 5 Å of the GDP copy at the end of Run 2. Six of them 
were identical to those lying within the same distance in the closed TG2 conformation in 
1KV3 crystal structure (Liu et al. 2002). 
In addition to the induced bending, the GDP copy in Run 2 showed some of the 
characteristic interactions holding GDP in place in the 1KV3 crystal structure (Liu et al. 
2002), namely hydrogen bonds and electrostatic interactions between the phosphate groups 
of GDP and the positively charged side chains of ARG476 and ARG478 (Figure 5-16). An 
analysis of the hydrogen bonds in the region of the trajectory of Run 2 when GDP copy 
settled itself within the GDP binding site (from 400-635 ns of simulation time) showed very 
frequent hydrogen bonds with ARG476 and ARG478 (51% and 53% respectively of the 
analysed 235 ns). 
The TG2-bending event seen in Run 2, which could be a reasonable predecessor for the 
closure of TG2 conformation, and the pattern of interactions seen in the run can give an 
indication that the copy of GDP has managed a plausible binding within TG2 to induce a 
conformational change, and that the aMD run was able to simulate the induced 
conformational change in TG2 to some extent. 
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Figure 5-16: Interactions between GDP and TG2 residues, in 1KV3 crystal structure (left) and in the last 
frame in Run 2 (right), shown as dotted lines. Hydrogen bonds are green while electrostatic interactions 
are orange. 
5.3.3.3 aMD on compound i2 
5.3.3.3.1 aMD on i2 docking complex (Run 3) 
During the aMD run applied on the docking complex for compound i2 (Figure 5-7), the 
compound moved outside its starting position after about 100 ns of simulation time only. The 
compound did not leave the predicted pocket entirely but was not as deep as it was when 
the simulation started. This was confirmed by measuring the RMSD values for the 
compound on its own using the 1st frame as a reference (TG2 was aligned against the 1st 
frame) (Figure 5-17), which showed that there was a considerable movement of the 
compound at around 100 ns. The simulation was discontinued after 395 ns because of this 
motion of i2. A pose comparison for the compound at the start and end of the simulation 
within the predicted site is presented in Figure 5-18. 
 
Figure 5-17: RMSD values for 
compound i2 during Run 3. 
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Figure 5-18: A comparison between the pose of compound i2 at the start of Run 3 (left) and the pose after 
395 ns of simulation time (right). TG2 is dark green and the predicted allosteric site is red. 
When TG2 itself was examined, it was observed that the enzyme maintained its open 
conformation without any significant change. This also encouraged the discontinuation of the 
simulation. A comparison between the starting and the final conformations of TG2 in this 
simulation is shown in Figure 5-19. When the RMSD of TG2 was calculated, it gave a similar 
insight in that the protein was relatively stable (Figure 5-20). There appears to be, however, 
a slight shift in the 2nd β-barrel. This was verified by a calculation of the atomic fluctuations 
(root-mean-squared-fluctuations, RMSF) of the individual residues (Figure 5-21) which 
proved greater flexibility in the final ≈ 100 residues of TG2 (2nd β-barrel). 
 
Figure 5-19: A comparison between the structure of TG2 at the start (blue) and the end (red) of Run 3. 
Visual inspection of the trajectory with the VMD program showed that this movement was in 
the form of an oscillation affecting the 2nd β-barrel, where it moved to the inside of TG2 and 
then out again; sometimes very quickly between successive frames, which were 25 ps apart, 
and sometimes over extended periods such as the shift in the RMSD that happened around 
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the 100th ns. Because no permanent change in TG2 structure was observed, it may be 
assumed that i2, in the predicted site, does not have an influence on TG2 structure. 
 
Figure 5-20: RMSD for TG2 
during Run 3. 
 
Figure 5-21: Atomic 
fluctuation scores for TG2 
residues in Run 3. 
5.3.3.3.2 aMD on TG2 with 24 copies of i2 (Run 4) 
The rationale behind running this simulation was to examine the potential of the predicted 
allosteric site to be recognised by an allosteric inhibitor that is not in its immediate vicinity. 
Run 4 was allowed to continue for a total of 320 ns, at the end of which none of the copies 
was able to find its way into the predicted binding site, but 7 copies managed to locate 
themselves in the surrounding area of the site. It was also noticed that the terminal β-barrel 
was facing inwards, in the same direction of the folding in the closed conformation of TG2 
(Figure 5-22). 
The remaining copies were distributing themselves around the surface of the protein during 
the simulation, and none achieved a pose in which it was embedded within any region of the 
protein. One copy, however, (orange, Figure 5-22) was located in the section of the GDP 
binding site that is on the 1st β-barrel (Figure 5-23). This started to happen early in the 
course of the aMD simulation, where the copy started to move into the vicinity of the GDP 
binding site at around the 1st nanosecond of the production phase (6th nanosecond of 
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simulation time). The copy stayed in the vicinity for about 120 ns and then started to move in 
and out of GDP binding site for about 30 ns, at the end of which the copy settled within the 
pose shown in Figure 5-23. It is at this time that the 2nd β-barrel of TG2 started to fold toward 
the catalytic core. These events are better appreciated by inspecting the RMSD graph for 
this i2 copy (Figure 5-24). 
 
Figure 5-22: TG2 with the 24 
copies of i2 at the end of Run 4. 
The 7 copies that came close to 
the predicted site are coloured 
green, the predicted site is red 
and the 2nd β-barrel is coloured 
yellow. i2 copy residing in GDP 
binding site is coloured orange. 
 
Figure 5-23: Another angle for TG2 from Figure 5-22 
showing i2 copy (orange) on the GDP binding site 
within the 1st barrel (coloured red). 
 
Figure 5-24: RMSD graph for 
i2 copy that positioned itself 
in the GDP binding site 
during Run 4. 
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The shift in RMSD that occurred at around 225 ns (Figure 5-24) was caused by the copy of 
i2 leaving the GDP binding site, but it went back in and stayed there for the rest of the 
simulation, where it was adopting the pose seen in Figure 5-23. The bending in TG2 
structure was not affected by this motion and did not change once it was there. 
To further confirm that the i2 copy was residing in GDP binding site, DS Visualizer 4.0 was 
used to inspect the residues that are within 5 Å of GDP in 1KV3 crystal structure (Liu et al. 
2002), and those that are within 5 Å of i2 in the last frame of Run 4. There are 16 residues 
within 5 Å of GDP in 1KV3, 14 of them are located on the 1st barrel and 2 are on the catalytic 
core. There were 20 residues within 5 Å of i2 copy in the last frame of Run 4, 12 of which are 
identical to those that surround GDP in 1KV3, confirming that i2 was actually within a site 
that very much resembles that of GDP binding (Figure 5-25). When the atomic fluctuations of 
TG2 residues were measured, the residues for the 2nd β-barrel were found to have moved 
more when compared to the remaining residues in TG2 and when compared to the same 
region during the simulation applied on i2 docking complex (Run 3) (Figure 5-26). This is 
consistent with the 2nd barrel moving towards the inside of TG2 and attempting to produce 
the closed inactive conformation of the enzyme. Although the end result was not a fully 
closed conformation as that in 1KV3, it was a move in the right direction. 
 
Figure 5-25: Left: Residues within 5 Å of i2 copy at the end of Run 4. Right: Residues within 5 Å of GDP in 
1KV3 crystal structure. i2 and GDP are coloured by element and TG2 residues are shown as stick and 
coloured green if they are common and red if they are not. 
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Figure 5-26: Atomic 
fluctuation values for TG2 
residues during runs 3 and 
4. 
The results from the 1st simulation applied on the i2 docking complex (Run 3) indicate that 
compound i2 may not be a suitable binder in the predicted allosteric site or that the predicted 
site is not a true allosteric binding site. The results from the 2nd simulation give an indication 
that i2 has the potential to reside within the binding site of GDP and by doing this, the 
compound triggered a conformational change in TG2 that, to some extent, resembles what is 
induced by the binding of GTP or GDP. This was the inspiration that motivated the 
application of an aMD simulation starting from the last frame of Run 4 after removing all i2 
copies with the exception of the copy located within the GDP binding site (next section). 
5.3.3.3.3 aMD on TG2 with 1 copy of i2 
i2 copies from the previous simulation (Run 4), with the exception of the copy in the GDP 
binding site, were deleted for 2 reasons; the first was to reduce the computational cost by 
reducing the size of the system and the associated water box, and the second was to 
examine whether the TG2 bending was actually triggered by the binding of i2 in this site and 
not from the presence of another copy elsewhere. To further confirm that the bending was 
triggered by the binding of i2 copy in the GDP binding site, another aMD simulation was 
started which was identical to the one described here with the deletion of all the i2 copies 
including the one in the GDP binding site. 
The simulation with i2 copy (Run 5) was allowed to continue for 1,000 ns (1 µs), and at its 
end, the conformation of TG2 did not change much from that at the end of the previous run 
(Run 4) (Figure 5-27). The copy of i2 that started in the GDP binding site did not stay there 
for the entire simulation. i2 molecule left the binding site after about 850 ns and was 
wandering around the surface of TG2 until it settled itself at some point on the surface in the 
middle of TG2 molecule. This event of i2 leaving the GDP binding site did not affect the 
conformation of TG2 in terms of the bending. The RMSD of i2 molecule on its own is shown 
in Figure 5-28, in which it can be clearly seen that there was a major motion involving i2 
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molecule. This motion was confirmed to be involving the exit of i2 molecule from the GDP 
binding site by visual inspection of the trajectory with VMD. 
 
Figure 5-27: TG2 
structure at the 
end of Run 5 (red) 
compared to that 
at the end of Run 4 
(blue).
 
Figure 5-28: RMSD for i2 
during Run 5. 
When the atomic fluctuations (RMSF) values for TG2 residues during this run were 
measured, the graph in Figure 5-29 was produced. The movement of the terminal barrel was 
much lower in Run 5 when compared to Run 4. This indicates that this barrel did not move 
much in this aMD simulation, and that the bent shape of TG2 produced during Run 4 was 
maintained during this run. 
Another aMD run was applied on the same starting structure used for Run 5 (the last frame 
from the simulation on TG2 with 24 copies of i2, with only one i2 copy which is the one 
positioned in the GDP binding site) without the i2 copy (Run 6) and was also continued for 
1,000 ns. The bending of TG2 at the junction between the 1st and the 2nd β-barrels changed 
during this simulation; instead of having the barrel facing towards the catalytic core and 
CYS277, the direction of bending was towards the outside of TG2. This was similar to the 
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orientation of the section involving the 2nd β-barrel seen during Run 1. A comparison in the 
direction of bending for this run with that of Run 1 and Run 4 is presented in Figure 5-30. 
 
Figure 5-29: Atomic 
fluctuation values for TG2 
residues in Run 5 compared 
to those from Run 2. 
 
Figure 5-30: Conformation at the end of Run 6 (red) compared to that at the end of Run 4 (green), and the 
one at the end of Run 1 (blue), showing CYS277 to appreciate the direction of bending of the 2nd β-barrel. 
This conformational change started to happen at around the 350th nanosecond, and the new 
form of TG2 was maintained for the remainder of the aMD simulation. The conformational 
change in TG2 observed during Run 6 may be better appreciated by examining the RMSD 
graph for the run. The graph is presented in Figure 5-31. RMSD for Run 5 is also presented. 
In Run 5, TG2 structure was mostly stable as the bent conformation of TG2 was preserved 
throughout the simulation. This has been confirmed by measuring the atomic fluctuations for 
the individual residues (Figure 5-29). For Run 6, the time and magnitude of the 
conformational change can be clearly seen in Figure 5-31. To confirm that the change in 
TG2 conformation mainly affected the 2nd β-barrel, atomic fluctuations for Run 6 were 
calculated. RMSF values are presented in Figure 5-32, which show that the residues of the 
terminal region of TG2 in Run 6 moved more than their counterparts in Run 5, and more 
than those in the remainder of TG2. 
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Figure 5-31: RMSD for Run 6, 
compared to that of Run 5. 
 
Figure 5-32: Atomic 
fluctuations for TG2 residues 
in Run 6 compared to those 
in Run 5. 
Although the final result of Run 6 did not have TG2 in the open conformation, the change in 
the direction of the bending of the 2nd β-barrel towards the outside of the catalytic core and 
the persistence of this change throughout the simulation indicates that it was no longer 
possible for TG2 to be folded into the correct closed form. The same bending orientation has 
been noticed when aMD was applied on empty TG2 in Run 1, possibly indicating that it is a 
possible orientation active TG2 can adopt, but that cannot progress into a fully closed 
inactive structure. 
The results from the 4 aMD simulations applied with i2 can be used to draw some 
observations. No change in the conformation of TG2 was observed after Run 3, in which i2 
was docked into the predicted allosteric site. This, combined with the fact that the i2 
molecule did not maintain its pose within the predicted site, may indicate that the predicted 
site is not a suitable binding site for i2, or that i2 is not an allosteric inhibitor. The latter is 
actually consistent with the research in which i2 was first mentioned (Pardin, Roy, et al. 
2008), where the compound was presented as a reversible competitive inhibitor of TG2. The 
aMD simulation with the 24 copies of i2 (Run 4) showed something different. There was one 
copy that managed to position itself within the section of the GDP binding site that is located 
on the 2nd β-barrel of TG2. This positioning of the i2 copy was associated with a change in 
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the general conformation of TG2, manifested as the bending of the terminal barrel towards 
the catalytic core of TG2. 
Run 5 was performed to test whether the pose of i2 within the GDP binding site could induce 
further bending in TG2 to result ultimately in closure of the enzyme conformation after 
removing the other 23 copies of i2. The simulation finished with the same general 
conformation of TG2 with which it started; no further bending was observed. Furthermore, 
the i2 molecule left the GDP binding site, although this did not take place until late in the 
simulation. Run 6, which was identical to Run 5 minus the i2 copy, resulted in a change in 
the direction of bending of the terminal barrel; in Run 5 the possibility of complete closure of 
TG2 conformation was still there, while in Run 5, further bending in the same direction would 
have resulted in a totally unrealistic enzyme structure. Since the only different parameter 
between Run 5 and Run 6 was the presence of the i2 copy, it could be said that i2 has the 
potential to induce large conformational change in TG2 structure, similar to that produced by 
GTP and/or GDP by binding to a similar site. 
5.3.3.4 aMD on compound i3 
5.3.3.4.1 aMD on i3 docking complex (Run 7) 
This aMD run started with compound i3 docked into the predicted allosteric binding site and 
the run was continued for a total of 1,000 ns of simulation time. The i3 pose within the 
predicted site did not change much during this simulation; although it appeared to have been 
more deeply embedded in the site at the start of the simulation than it was at its end (Figure 
5-33). The RMSD graph for i3 in Run 7 is shown in Figure 5-34. In the same figure, there is 
a comparison with the RMSD for compound i2 during Run 3, and it can be observed that i3 
was more stable in its simulation than was i2. This indicates that i3 is a more suitable binder 
in the predicted allosteric site than i2. 
With regard to TG2 behaviour in Run 7, it was detected that there was a bending in the 
enzyme structure, also involving the hinge between the 1st and 2nd β-barrels. It was similar to 
the bending observed during aMD on TG2 with 24 copies of i2 (Run 4). The barrel was 
bending towards the inside of TG2 to close on the catalytic core and CYS277. Figure 5-35 
presents the structure of TG2 at the end of Run 7, superimposed on TG2 structure at the 
start of the run, and it is clear from the figure that there was considerable bending in TG2 
structure. The bending event started to appear in TG2 after about 320 ns of the simulation 
time, and persisted in the same form for the remainder of the simulation time. This is 
confirmed by inspecting the RMSD graph for TG2 during Run 7 (Figure 5-36), which 
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demonstrates that there was an increase followed by stabilisation in RMSD after 320 ns of 
simulation time. 
 
Figure 5-33: A comparison of the pose of i3 within the predicted site (red) between the docking complex 
(left) and the conformation at the end of the Run 7 (right). 
  
Figure 5-34: RMSD graphs, the Y-axis represents RMSD values in Å. On the left is RMSD of i3 during Run 
7 and on the right is the RMSD of i3 in Run 7 compared to that of i2 in Run 3 for the same length of the 
simulation time. 
To further confirm that the bending event was the major general motion of TG2 during Run 
7, the atomic fluctuations of the individual residues of TG2 were recorded. The results are 
presented in Figure 5-37 where the RMSF values are shown in comparison with those from 
Run 4. The relatively large motion of terminal barrel during the simulation is obvious and can 
be easily be compared to that observed in Run 4. 
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Figure 5-35: TG2 structure at the start of Run 7 (blue) and after 1 µs (red), showing the bending of the 
terminal barrel (green for start and yellow for the end of the simulation), and showing CYS277 to 
appreciate the direction of bending. 
 
Figure 5-36: RMSD graph for 
TG2 residues in Run 7. 
 
Figure 5-37: Atomic 
fluctuations for TG2 residues 
during Run 7, compared to 
those of Run 4. 
Additional confirmation for the bending event was performed using PCA. pyPcazip was able 
to extract 10 PCs from this aMD simulation representing the most important modes of motion 
observed in the trajectory. These PCs are presented in Figure 5-38, which shows the 
percentage contribution of the major 3 PCs to the total motion in TG2 structure. The first PC 
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accounts for about two thirds of the motion performed by TG2 during Run 7 aMD simulation, 
and the second major PC contributes only ≈ 15%. The animation produced by pyPcazip for 
the first and most important PC of Run 7 is presented in Figure 5-39 which shows that the 
PC mainly involved the terminal barrel of TG2. When the frames are coloured by time step, 
the result is an open conformation of TG2 at the beginning of the simulation and a bent 
conformation involving the hinge connecting the 2nd β-barrel to the rest of TG2 at the end. 
The bending is the most important component of this PC since, as can be seen from the 
figure, the rest of the protein is mostly stable and have the same structure at the start and 
the end of the simulation. 
 
Figure 5-38: PCs produced 
for Run 7 and the 
contribution of each to the 
total motion of TG2 during 
the run. 
 
Figure 5-39: The animation 
produced by pyPcazip for 
the first PC of Run 7, 
showing the 20 frames, and 
the frames are coloured by 
time step, where red 
represent the start and blue 
the end of the simulation. 
Figure 5-39 cleary shows that the motion that accounted for 64% of total TG2 motion during 
Run 7 involved the terminal β-barrel and was in the direction that resulted in the bending of 
the TG2 in a manner that could result in the closure and subsequent inactivation of the 
enzyme. It should be noted, however, that there was a considerable oscillation involving the 
barrel and it is the frame with the darkest blue colour that represents the final form of TG2 in 
this simulation. This means that the bending did not go all the way in the fashion presented 
in Figure 5-39, rather to the frame with the darkest blue colour. 
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When the second PC was considered, it was noted that the motion represented by this PC 
also involved the terminal β-barrel. The difference was in the direction and intensity, where 
with the 2nd PC, the motion was in the form of oscillation of the terminal barrel to the sides of 
TG2 rather than towards the catalytic core of the enzyme. A visual inspection of the 
associated animation (shown in Figure 5-40) gives a clearer understanding of the mode of 
motion of TG2 terminal barrel presented by this PC; most importantly, its direction and the 
locations of the starting and end frames which were essentailly in the same position at the 
middle of TG2 with reference to the direction of motion within this PC. This confirms that the 
2nd PC involved only oscillation affecting the terminal β-barrel. 
 
Figure 5-40: The animation produced by pyPcazip for the second PC of Run 7, showing the 20 frames 
(left) coloured by time step. The first and final frames are shown to the right. 
The analysis of the animations from the top two PCs was followed by investigating the 
projections of each PC into the general subspace as a function of time. The graph in Figure 
5-41 was produced from which two important observations can be drawn. The first is the 
magnitude of PC1 when compared to PC2, especially in the first 300 ns of simulation time, 
from which the percentage contributions of the two PCs in Figure 5-38 can be better 
appreciated. The second observation is the time during the simulation at which PC1 started 
to stabilise, which is roughly the same time at which the bending event started to happen as 
shown in the RMSD for TG2 in this run (Figure 5-36). The latter observation confirms that 
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the bending event was actually presented by PC1 and it corresponds to the most important 
motion of TG2 during Run 7. 
 
Figure 5-41: The projections 
of the top 2 PCs from Run 7 
into the general subspace as 
a function of simulation time. 
To examine the difference between the bending events observed in this run and in Run 1 
(empty TG2), a comparison was made between the first and most important PC from the 2 
runs. The result is displayed in Figure 5-42, which shows that the motion in Run 7 was more 
evident. The graph additionally shows that the bending in Run 7 lead to a stabilisation of the 
associated PC while in Run 1, the bending was associated with increased motion in the 
terminal barrel. This further confirms that the bending observed in Run 1 was not going to 
result in any further closure of TG2 conformation. 
 
Figure 5-42: PC1 as a 
function of time for Run 1 
and Run 7. 
5.3.3.4.2 aMD on TG2 with 24 copies of i3 (Run 8) 
This simulation was identical to the aMD simulation in Run 4, except that the 24 copies were 
for compound i3, and the simulation was allowed to continue for 1,000 ns. There was no 
significant alteration in the general structure of TG2; the enzyme maintained its open, active 
conformation for the entire length of the aMD simulation, and this can be easily seen from 
the RMSD graph for the run which is presented in Figure 5-43. 
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Figure 5-43: RMSD graph for 
TG2 during Run 8. 
Although there was fluctuation in the RMSD graph, the values were generally ranging 
between 4 and 8 Å and averaged around 6 Å. A comparison of the TG2 general structure at 
the start and the end of this run is shown in Figure 5-44, and is compatible with the RMSD of 
the enzyme by stating that the run did not affect the general structure, specifically the 
conformation at the junction between the terminal β-barrel and the rest of TG2 structure. 
 
Figure 5-44: A comparison of TG2 structure at the start and the end of Run 8, showing the preservation of 
the open form of the enzyme. 
Regarding the behaviour of the 24 copies of i3, no general pattern could be observed, and 
the motions were mostly random. In the final 200 ns of the simulation time, some copies 
were settling themselves within 2 major regions of TG2. Eight copies positioned themselves 
randomly within the N-terminal β-sandwich, distributing between the beta sheets of the 
sandwich. Six copies of i3 were in the region of the catalytic core, specifically above the area 
between the catalytic tunnel and the hydrophobic loop of the active site of TG2. No copy, 
however, was close to CYS277, nor positioned in a manner similar to that of irreversible 
inhibitors (Figure 5-45). Neither the predicted allosteric site nor the GDP binding site were 
among the popular attractions for i3 copies. 
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Figure 5-45: i3 copies in the final frame in Run 8. Green copies are those within the N-terminal β-
sandwich, and yellow copies are those close to TG2 active site. CYS277 is show as space filling and the 
hydrophobic loop as blue tube for reference to the active site. 
The results obtained from Run 7 (aMD on i3 docking complex in the predicted site) can be 
used to draw the conclusion that i3 has the potential to act as an allosteric inhibitor and to 
induce a conformational change in TG2, and that the predicted site could function as an 
alternative allosteric site within TG2. Run 8 (TG2 with 24 copies of i3) may not necessarily 
contradict Run 7, if it was explained on the basis of the nature of the predicted site; the site 
is not readily accessible and the approach of the ligand to the interior of the site may require 
an enhanced sampling technique. In addition, it may be argued that i3, unlike i2, cannot bind 
at the original allosteric site at which GDP binds. 
The energy and the temperature change was followed during each of the discussed aMD 
simulations, and the results showed that all the simulations were stable with reference to 
these parameters. Example measurements of energy and temperature for Run 5 and Run 7 
are presented in Figure 5-46. 
5.4 Conclusions 
During the work with the allosteric inhibitors, aMD was able to simulate some relatively large 
conformational changes in the structure of TG2 molecule. It was proven that these changes 
were induced by the binding of the allosteric inhibitors. The structure of the inhibitor had an 
effect on the preferred binding site, where i2 did not produce any change in TG2 structure 
when it was bound at the predicted site, but triggered bending in the terminal β-barrel when 
it was bound at the section of the GDP binding site located in the terminal barrel after the 
compound was allowed to select a binding site during Run 4 (TG2 with 24 copies of i2). i3 
appeared to be a better binder within the predicted site in Run 7, where it induced a similar 
bending effect to that induced by i2 during Run 4. GDP produced the best bending effect 
when compared to the other tested allosteric inhibitors, and the effect was induced by 
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binding at the original GDP binding site. This may mean that GDP has better potential of 
inducing the conformational change required for inactivating TG2 than i2 or i3. 
  
  
Figure 5-46: Energy and temperature during Run 5 (top) and Run 7 (bottom). 
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6 General Discussion and Conclusions 
In the first chapter (General Introduction), TG2 was thoroughly discussed in terms of its 
biological functions and its role in diseases, in addition to the available inhibitors. The facts 
that TG2 is not a vital enzyme and its possible role in a variety of pathological conditions 
present the enzyme as an attractive target for drug discovery efforts. To this end, the work 
that was presented in this thesis was performed with the aim of developing computational 
methods to help in the prediction of potential irreversible inhibitors for TG2. In the first part of 
the work, active site models of TG2 were developed and tested rigorously, and the same 
models were used in the second part of the work to study the mechanism of TG2 inhibition 
by irreversible inhibitors. The last part was independent of the previous parts and involved 
studying TG2 allosterism. 
Molecular dynamics can be used to account for receptor flexibility during docking, either by 
supplying multiple structures of the protein or by relaxing a ligand docked structure (Hospital 
et al. 2015; B-Rao et al. 2009; Huang & Zou 2010). As shown in Chapter 3, MD was 
successful in improving the structure of TG2 at its active site to be able to achieve plausible 
docking complexes for a set of known inhibitors. This was particularly true for the active site 
models extracted from the MD simulations applied on the initial docking complexes for 
compounds 1a and 1b. The MD trajectories for the complexes themselves gave some useful 
information about the interactions between the compounds and TG2 active site, especially 
with regard to hydrogen bonding, where it has been shown that a hydrogen bond with 
ASN333 is essential for the maintenance of a good pose for an active inhibitor (bent 
conformation) within the active site of TG2. 
The active site models extracted from MD trajectories were tested using the 6 most active 
TG2 inhibitors from the work by Badarau et al. (2015) (section 3.3). The criteria selected at 
this stage to define an appropriate docking complex were sufficient to judge the ability of the 
active site models to dock active TG2 inhibitors. The criteria were reasonable and all were 
important as proven during the later stages of the work. The most important is the bent pose; 
it is this pose that prompted the design of irreversible inhibitors with lipophilic and 
electrophilic ends connected by a linker. An ideal active irreversible TG2 inhibitor would 
adopt a bent pose within the active site of TG2, with the electrophilic end pointing in the 
direction of CYS277 and the lipophilic end being embedded within the hydrophobic loop of 
TG2 active site. Hydrogen bonds connecting the linker of the inhibitor to active site residues 
such as ASN333, PHE334 and others are important for maintaining the bent pose within the 
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active site. Similarly, lipophilic interactions stabilising the lipophilic end of the inhibitor within 
the hydrophobic loop of TG2 active site are also important. 
The selected 6 active site models were validated in the next stage by multiple experiments 
(section 3.4). These experiments started with the docking of 3 inactive compounds plus the 
original 6 active compounds, in which the models were able to distinguish between the 
compounds according to their inhibitory effect on TG2. The model performance proved to be 
similarly good when the test set was extended using more active and inactive compounds 
(validation processes 3 and 4), and the criteria for defining a plausible docking complex 
sustained their usefulness at this stage as well. There were differences in the performance 
of the individual models, where some models were better in capturing the bent pose for 
active compounds. Other models were superior in preventing the inactive compounds from 
docking appropriately into the active site. In any case, the docking scores failed to provide 
any useful information in ranking the compounds according to their biological activities. The 
scores even failed with the discrimination between active and inactive compounds. This, 
however, was achievable through the application of the docking criteria set at the beginning 
of the process, which again proved successful and manged to further validate the selected 
active site models. It should be noted here that when using GOLD, GoldScore, and to a 
lesser extent CHEMPLP, were able to rank the bent pose of TG2 inhibitors within the top 4 
solutions for the active compounds, and this top ranking was one of the criteria used to 
define a plausible docking complex. Similar model performance results were achieved when 
5-ns MD simulations were applied on docking complexes. 
The selection of GoldScore as the primary scoring function during all the dockings performed 
with GOLD was validated through experiments in which the other scoring functions available 
in GOLD were tried. The 3 other functions (ASP, ChemScore and CHEMPLP) failed to 
produce results comparable to those of GoldScore in posing the active compounds correctly 
within the active site of TG2. The success of GoldScore was attributed to the importance of 
hydrogen bonding in the dockings of TG2 inhibitors and the relatively high molecular weights 
of the tested TG2 inhibitors (more van der Waals contribution), which are both important 
parameters in GoldScore (Verdonk et al. 2003). Forcing a covalent bond to be formed 
between the inhibitors and CYS277 during covalent docking and MD (section 3.7) proved 
that it is the ability of the compound to place itself in the correct pose within the active site 
that would ultimately determine its activity. This was determined from the similar results 
obtained for active and inactive compounds during docking as well as MD. No water 
molecules could be found near the formed covalent bond, and the water density around the 
bond could not be used to differentiate between active and inactive compounds. 
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When the 6 validated models were analysed, some differences in the observed docking 
results could be explained; namely, the slightly better performance for the models extracted 
from the trajectory of 1a. These have been attributed, for example, to the orientation of the 
added loop between residues 319 and 327, where the orientation of the loop was acting as a 
determinant of the space available for the lipophilic part of the inhibitors within the active site 
of TG2. Another example for the difference between the 2 sets of models was the 
arrangement of the bridging tryptophan residues (241 and 332), which showed the stacking 
parallel shape in the trajectory of 1a that is characteristic of their orientation in the original 
crystal structure. 
The 3 independent MD runs applied on empty TG2 for 500 ns showed a similar behaviour 
for TG2 residues, with the most mobile parts being the loops composed of the residues that 
had been missing in the original TG2 crystal structure (2Q3Z). This was confirmed through 
measuring RMSD, atomic fluctuations and the principal components. Regarding the 
behaviour of water, it was observed that when TG2 is simulated on its own, water molecules 
usually reside within the active site close to the catalytic cysteine residues, and their highest 
density was recorded to be at a 2-Å distance from SG atom of CYS277. The number of 
water molecules as well as their density was found to decrease when there was an inhibitor 
within the active site during the simulation, as was the case with the trajectory of 1b. Within 
the hydrophobic loop of TG2 active site, the likelihood of finding water molecules was much 
lower, and this probably explains why it was relatively easier to keep the lipophilic part of the 
inhibitor within the loop than keeping the warhead within the catalytic tunnel. 
The results from Chapter 3 have shown in different ways that the selected 6 active site 
models are valid for discriminating between active and inactive TG2 inhibitors, if the set 
criteria were considered properly. The work performed within the chapter, however, could 
not produce appropriate correlations between many of the measured quantities and 
biological activity expressed as TG2 IC50 values. The best and most easily accessible 
example was the docking score obtained from different scoring functions. This failure was 
attributed to the fact that the activity of the different inhibitors is triggered by a covalent bond 
formation with TG2 active site cysteine residue, and most of the techniques used in the 
chapter cannot account for bond formation. The production of an informative correlation with 
biological activity and curiosity behind the possible mechanisms of inhibition of TG2 by the 
studied inhibitors motivated the work in Chapter 4. Furthermore, the work in Chapter 4 
added to the validity of the models by showing that their complexes can represent the actual 
chemical reactions behind the inhibition. 
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The two classes of inhibitors, acrylamide- and sulfonium ion-bearing TG2 inhibitors, were 
subjected to two different methods to investigate the inhibition mechanism. Both of the 
methods involved quantum mechanical (QM) treatment of the reaction centre. Inhibition with 
acrylamide inhibitors was investigated through umbrella sampling simulations using the 
QM/MM approach of AMBER, while the CAChe intrinsic reaction coordinate (IRC) reaction 
path tactic was employed when studying the inhibition by sulfonium ion inhibitors. 
The inhibition by the acrylamide compounds was proposed to proceed according to one of 
two possibilities; as a single concerted step (where the nucleophilic SG from TG2 reacts with 
the electrophilic carbon of the inhibitor and at the same time a proton from HIS335 of TG2 
saturates the alpha carbon of the acrylamide or C2) or as a two-step process (the 
nucleophile and the electrophile react first and the protonation follows). In the concerted 
mechanism, PM3, as the QM method, was able to drive the reaction to completion and to 
produce a reasonable correlation between the resultant PMF values and TG2 IC50 values of 
the inhibitors. A certain level of desolvation was also observed in this method, where 1 or 2 
water molecules have left the vicinity of the reaction centre just before the formation of the 
two bonds. The pattern of the change in the charges of the reacting atoms, however, was 
not uniform across the compounds and could not be used to devise a distinct mechanism for 
the inhibition. This happened because two intermediates were suggested based on the 
charge distribution and each intermediate supports a different mechanism. 
For the 2-step mechanism, SCC-DFTB performed better than PM3 as the QM method. A 
good correlation was obtained between the PMF values and TG2 IC50 values for the 
compounds in the 2 steps, and the correlation was better for the second step (R2 of 0.71 and 
0.89 for the 1st and 2nd steps respectively). The charge distribution for the atoms participating 
in the reaction was uniform throughout the compounds and could be used to suggest a 
mechanism for the inhibition. Such a mechanism would involve the formation of an oxyanion 
intermediate having a negative charge on the oxygen atom of the acrylamide carbonyl 
group. The behaviour of water molecules did not show an obvious desolvation event during 
the 2-stage approach. To sum up with umbrella sampling, the concerted mechanism could 
show some desolvation effect while the charges agreed more with the 2 stages. Since 
CYS277 lies in a tunnel in the TG2 active site and since there were no water molecules in 
the vicinity of this residue in the original crystal structure, the water effect may not be very 
important. With that, and the charge pattern, the 2-stage approach may give a better 
representation for the inhibition of TG2 with acrylamide-based inhibitors. 
The CAChe based experiments adopted a different approach. They started by locating a 
transition state structure, refining and verifying it and then using the verified structure as a 
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starting point for a reaction path experiment. The latter follows the IRC to the reactants and 
the products. The TS structures produced for the 8 studied sulfonium ion-based TG2 
inhibitors had very similar structure parameters, such as the lengths of the bond to be 
formed and the bond to be broken and the angle at the reaction point. They had similar 
values for the charges of the 2 sulphur atoms and the orders of the formed and broken 
bonds. All these indicate a similar TS structure for inhibitors having the same sulfonium ion 
warhead. Nevertheless, the produced activation energies correlated very well with the 
biological activities, especially when only the compounds with IC50 values of ≤ 1 µM were 
considered. This difference in activation energy despite the similar mechanism was 
attributed to the starting conformation of the compounds with respect to CYS277, and this in 
turn was dependent on the compound’s ability to dock into the active site. A backside attack 
SN2 mechanism for this reaction was proposed and the values for the angle at the reaction 
centre and the bond orders agree with such mechanism. 
With regard to the work that involved allosteric inhibition, the allosteric binding site predicted 
by the University of Strathclyde group has been preferred over the original GDP binding site 
during docking, for more than one reason. The relatively buried location of the predicted site 
at the end of the catalytic core, compared to the totally exposed, and torn apart (part on the 
catalytic core and part on the 1st β-barrel in the open conformation of TG2) GDP binding site 
was the main reason. The fact that the binding site for GDP has not been actually confirmed 
as the binding site for the reported allosteric inhibitors (Case & Stein 2007; Caron et al. 
2012) was another reason. Both chosen allosteric inhibitors attained a plausible pose within 
the predicted site in terms of their settlement within the site as well as the rank their poses 
achieved with the GoldScore scoring function. 
The predicted site did not prove very useful for the binding of i2 molecule, where the 
compound failed to maintain the docked pose during the aMD run applied, in addition to the 
lack of any significant and noticeable conformational change within TG2 structure. For i3, the 
predicted site was better; the compound maintained more stable pose within the site and 
could induce a relatively significant conformational change in TG2, manifested as the 
movement of the hinge region connecting the terminal β-barrel towards the catalytic core, in 
the same direction as the actual bending in the inactive closed form of TG2. The bending 
event did not end in the closed form of TG2, but it produced a distinctly different 
conformation from the starting structure of TG2, and the direction of the bending was correct. 
It can, therefore, be assumed that this hinge movement was a first step towards complete 
closure of TG2 conformation to achieve the inactive form. 
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The aMD run performed with 24 copies of i2 distributed around TG2 (Run 4) showed that i2 
has the potential to bind at the GDP binding site to induce a conformational change in TG2 
similar to that produced by i3 in the predicted site. This has been confirmed by Run 5 (in 
which all i2 copies have been deleted from the last frame in Run 4, save the one in the GDP 
binding site) and Run 6 (the final frame from Run 4 in which all i2 copies have been deleted). 
The conformational change brought about in Run 4 was preserved in Run 5, while TG2 in 
Run 6 adopted a structure similar to that produced by empty TG2 in Run 1, in which there 
was a bending but in the wrong direction. “Wrong direction” was used to describe a TG2 
bending event where the terminal barrel was pointing towards the outside of TG2 relative to 
the catalytic core and CYS277, making it difficult to achieve the TG2 inactivating closure. 
The most significant change in the conformation of TG2, and the closest change to the 
complete closure of TG2 confrontation was observed during Run 2 when TG2 was 
surrounded by 24 copies of GDP. One of the copies found its way to the original GDP 
binding site where it induced a bending that involved the connection between the 2 terminal 
β-barrels and the catalytic core of TG2, in a manner that would be expected to end in the 
closed inactive TG2 conformation, considering the direction of the bending. The magnitude 
of the bending was more easily noticeable when compared with the bending events obtained 
from the other runs. This run confirms the ability of GDP to inactivate TG2 by closing its 
structure and that the aMD was capable of simulating this effect to some extent. 
As a final remark, the aim set at the start of the thesis is expected to have been achieved, 
where several computational methods have been employed for the purpose of the analysis 
of the activities of known TG2 inhibitors. As a result, these methods could be applied when 
the objective is to predict the activity of new potential inhibitors for the enzyme. 
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